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Abstract
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Objective: To determine the clinical effectiveness and cost-effectiveness of active 
conservative treatment, compared with standard management, in regaining urinary 
continence at 12 months in men with urinary incontinence at 6 weeks after a radical 
prostatectomy or a transurethral resection of the prostate (TURP).
Background: Urinary incontinence after radical prostate surgery is common immediately 
after surgery, although the chance of incontinence is less after TURP than following 
radical prostatectomy.
Design: Two multicentre, UK, parallel randomised controlled trials (RCTs) comparing 
active conservative treatment [pelvic floor muscle training (PFMT) delivered by a specialist 
continence physiotherapist or a specialist continence nurse] with standard management in 
men after radial prostatectomy and TURP.
Setting: Men having prostate surgery were identified in 34 centres across the UK. If they 
had urinary incontinence, they were invited to enrol in the RCT.
Participants: Men with urinary incontinence at 6 weeks after prostate surgery were eligible 
to be randomised if they consented and were able to comply with the intervention.
Interventions: Eligible men were randomised to attend four sessions with a therapist 
over a 3-month period. The therapists provided standardised PFMT and bladder training 
for male urinary incontinence and erectile dysfunction. The control group continued with 
standard management.
Main outcome measures: The primary outcome of clinical effectiveness was urinary 
incontinence at 12 months after randomisation, and the primary measure of cost-
effectiveness was incremental cost per quality-adjusted life-year (QALY). Outcome data 
were collected by postal questionnaires at 3, 6, 9 and 12 months.iv Abstract
Results: Within the radical group (n = 411), 92% of the men in the intervention group 
attended at least one therapy visit and were more likely than those in the control group 
to be carrying out any PFMT at 12 months {adjusted risk ratio (RR) 1.30 [95% confidence 
interval (CI) 1.09 to 1.53]}. The absolute risk difference in urinary incontinence rates at 12 
months between the intervention (75.5%) and control (77.4%) groups was –1.9% (95% 
CI –10% to 6%). NHS costs were higher in the intervention group [£181.02 (95% CI £107 
to £255)] but there was no evidence of a difference in societal costs, and QALYs were 
virtually identical for both groups. Within the TURP group (n = 442), over 85% of men 
in the intervention group attended at least one therapy visit and were more likely to be 
carrying out any PFMT at 12 months after randomisation [adjusted RR 3.20 (95% CI 2.37 
to 4.32)]. The absolute risk difference in urinary incontinence rates at 12 months between 
the intervention (64.9%) and control (61.5%) groups for the unadjusted intention-to-treat 
analysis was 3.4% (95% CI –6% to 13%). NHS costs [£209 (95% CI £147 to £271)] and 
societal costs [£420 (95% CI £54 to £785)] were statistically significantly higher in the 
intervention group but QALYs were virtually identical.
Conclusions: The provision of one-to-one conservative physical therapy for men with 
urinary incontinence after prostate surgery is unlikely to be effective or cost-effective 
compared with standard care that includes the provision of information about conducting 
PFMT. Future work should include research into the value of different surgical options in 
controlling urinary incontinence.
Trial registration: Current Controlled Trials ISRCTN87696430.
Funding: This project was funded by the NIHR Health Technology Assessment programme 
and will be published in full in Health Technology Assessment; Vol. 15, No. 24. See the HTA 
programme website for further project information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Executive summary
Background
Successive Cochrane reviews have shown that, although conservative treatment based on pelvic 
floor muscle training (PFMT) may be offered to men with urinary incontinence after prostate 
surgery, there is insufficient evidence to evaluate its effectiveness and cost-effectiveness. Men 
After Prostate Surgery (MAPS) was a multicentre, UK, randomised controlled trial (RCT), 
the aim of which was to supply that evidence for men undergoing radical prostatectomy or 
transurethral resection of the prostate (TURP).
Radical prostatectomy is carried out for men suffering from early prostate cancer. The operation 
is usually carried out through an open incision in the abdomen, which may damage the urinary 
bladder sphincter, or its nerve supply, and other pelvic structures. Urinary incontinence occurs in 
around 90% of men initially but the long-term prognosis varies from 2% to 60%, depending on 
how incontinence is measured and time after surgery. TURP is carried out using an endoscope 
through the urethra: the aim is to remove enlarged prostate tissue from the lumen of the 
urethra. Damage to the distal urinary bladder sphincter or its nerve supply is less common than 
with radical surgery, and fewer men remain incontinent (an estimated 11% of men wear pads 
3 months after surgery).
The two types of surgery were considered in two parallel but separate trials because the rates of 
incontinence and the chance of regaining continence were expected to differ between the two 
clinical populations.
Objectives
The following question was addressed, primarily in terms of regaining urinary continence 
at 12 months after recruitments for both types of surgery: what are the clinical effectiveness 
and cost-effectiveness of active conservative treatment delivered by a specialist continence 
physiotherapist or a specialist continence nurse compared with standard management?
The hypothesis tested in each group of men was that active conservative management would 
result in a difference of 15% between the groups in the proportion of incontinent men at 1 year 
after recruitment.
Methods
Men having prostate surgery were identified in 34 centres across the UK. Men were invited to 
receive a screening questionnaire after their operation. Those who reported at screening that they 
were incontinent were invited to enrol in MAPS.
Inclusion criteria were full informed consent; ability to comply with intervention; and urinary 
incontinence at 6 weeks after prostate surgery. Incontinence was defined as a ‘positive’ response 
to either of two questions in the screening questionnaire: (‘how often do you leak urine?’ and 
‘how much urine do you leak?’).xii Executive summary
Exclusion criteria were formal referral for physiotherapy or teaching of PFMT related to prostate 
surgery; radiotherapy planned or given during the first 3 months after surgery for men with 
prostate cancer; resection of prostate as palliation for outflow obstruction in advanced prostate 
cancer (known as ‘channel TURP’); and inability to complete study questionnaires.
Men completed a questionnaire at 6 weeks after surgery and signed a consent form. Baseline 
information included sociodemographic and clinical characteristics including type of operation. 
Eligible men were randomised to attending four sessions with a therapist over a period of 
3 months (intervention group). The therapists were either specialist continence physiotherapists 
or specialist continence or urology nurses. All therapists were provided with standardised 
training in the management of male urinary incontinence and erectile dysfunction. The control 
group received standard management. Both groups received a lifestyle advice leaflet.
Randomisation was by remote computer allocation using the randomisation service of the 
Centre for Healthcare Randomised Trials (CHaRT, Health Services Research Unit, University of 
Aberdeen). Allocation was stratified by type of operation (radical prostatectomy or TURP), and 
minimised using centre, age and pre-existing urinary incontinence. The process was independent 
of all clinical collaborators.
The primary clinical effectiveness outcome was urinary incontinence at 12 months after 
randomisation, and the primary cost-effectiveness outcome was incremental cost per QALY. 
Outcome data were collected by postal questionnaires at 3, 6, 9 and 12 months. At each time 
point, men also completed a urinary diary for 3 days. Data collected included: urinary outcomes 
(presence, frequency and severity of incontinence, effect of incontinence on quality of life, use 
of pads and catheters, type of incontinence, urinary frequency and nocturia); bowel outcomes 
(faecal incontinence, constipation, bowel urgency); sexual function (erectile function, ejaculation, 
change in sexual function); quality of life (EQ-5D and SF-12); use of health services (contact 
with community, hospital and private staff, use of alternative treatments such as pads, catheters, 
surgery, drugs or mechanical devices, and their costs); participants’ costs (self-purchased health 
care, costs of accessing health care, cost of time away from usual activities); QALYs derived from 
responses to the EQ-5D and SF-12; and effect of the intervention in changing health-related 
behaviour and practice of PFMT and bladder training or urge suppression.
Results
We approached 1158 men having a radical prostatectomy and 5986 having TURP in 34 centres. 
The response rate for the screening questionnaire was 95% (742/780) of the eligible men in the 
radical prostatectomy group and 91% (2590/2838) in the TURP group.
Amongst the radical prostatectomy group, of 472 eligible men who returned a questionnaire after 
surgery, 411 entered the radical prostatectomy RCT: 205 in the intervention group and 206 in the 
control group. Follow-up rates were high (95% of all men in each arm, 97% and 98% respectively 
after accounting for withdrawals and deaths).
Ninety-two per cent of the men allocated to the intervention group attended at least one therapy 
visit. Men in the intervention group were more likely to be carrying out any PFMT at 12 months 
(67%) than those in the control group (50%, adjusted risk ratio (RR) 1.30, 95% confidence 
interval (CI) 1.09 to 1.53).
Among the men who had a radical prostatectomy, the difference in urinary incontinence rates 
at 12 months between the intervention and control groups (148/196, 75.5%, vs 151/195, 77.4%) © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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was not statistically significant: the absolute risk difference for the unadjusted intention-to-treat 
analysis was –1.9% (95% CI –10% to 6%), which ruled out the prespecified target difference of 
15%. Adjusting for minimisation factors or performing a ‘treatment received’ analysis did not 
change these results.
NHS costs were higher in the intervention group (£181, 95% CI £107 to £255), but costs to the 
NHS and the participant were on average lower (–£588, 95% CI –£1330 to £153). On average, 
QALYs were virtually identical in both the intervention and the control groups (–0.002, 95% CI 
–0.027 to 0.023). When the perspective was the NHS there was only a 20% chance that PFMT 
would be cost-effective. However, from a societal perspective, there was an 80% chance that it 
would be cost-effective. The findings from the societal perspective were driven by a trend towards 
more time away from usual activities in the control group. These data are counter-intuitive when 
considered alongside the rest of the trial data and so should be treated cautiously.
Amongst those who had TURP, of 512 eligible men who returned a questionnaire at 6 weeks 
after surgery, 442 entered the TURP RCT: 220 in the intervention group and 222 in the control 
group. Follow-up rates were high (88% and 92% respectively of all men, 97% in both arms after 
accounting for withdrawals and deaths).
Over 85% of the men allocated to the intervention group attended at least one therapy visit. 
Men in the intervention group were more likely to be carrying out any PFMT at 12 months 
after randomisation (65%) than those in the control group (20%, adjusted RR 3.20, 95% CI 2.37 
to 4.32).
Following a TURP, the difference between the intervention and control groups in the proportion 
of men who had urinary incontinence at 12 months (126/194, 64.9% vs 125/203, 61.5%) was not 
statistically significantly different: the absolute risk difference for the unadjusted intention-to-
treat analysis was 3.4% (95% CI –6% to 13%), which rules out the prespecified target difference 
of 15%. Adjusting for minimisation factors or performing a ‘treatment received’ analysis did not 
change these results.
The differences in NHS costs (£209, 95% CI £147 to £271) and NHS and participant costs (£420, 
95% CI £54 to £785) were higher in the intervention group. On average, QALYs were virtually 
identical in the intervention and control groups (–0.00003, 95% CI –0.026 to 0.026). From 
both a societal and an NHS perspective there was little chance that physical therapy would be 
considered cost-effective.
Conclusions
The provision of one-to-one conservative physical therapy for men with urinary incontinence 
after prostate surgery is unlikely to be effective or cost-effective compared with standard care 
(which includes the provision of information about conducting PFMT). 
Implications for research
  ■ Physical therapy of the type used in this trial is not worthwhile, but the continuing burden of 
incontinence suggests that research into other treatments is worthwhile, for example research 
on the value of surgery in controlling symptoms. Specifically, an RCT comparing different 
surgical options for men with severe persistent urinary incontinence is needed.xiv Executive summary
  ■ MAPS has not tested whether the provision of any PFMT advice is an effective and efficient 
way of reducing incontinence. Further research into the effectiveness of any other method of 
delivery of PFMT would be worthwhile.
  ■ Of the men in the radical prostatectomy trial, 80% still had erectile dysfunction at the 
12-month follow-up, and over 60% had tried various treatments. As PFMT was of no value 
to these men, research into effective and efficient treatments for this condition would be 
worthwhile. Such a study should also include a wider population of men following radical 
surgery and not just those with urinary incontinence.
  ■ The MAPS data set can be used to improve the quality of further research and to improve 
other aspects of management. Specifically, MAPS data can be used to further validate the 
outcome measures for use in future research and clinical settings. The further analysis of the 
epidemiological data will inform the debate about different methods of prostatectomy and 
provide prognostic information for counselling men.
Trial registration
This trial is registered as ISRCTN87696430.
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Chapter 1  
Introduction
I
n 2003, the National Institute for Health Research (NIHR) Health Technology Assessment 
(HTA) programme called for a randomised controlled trial (RCT) to determine the 
effectiveness and cost-effectiveness of pelvic floor muscle exercises, with and without 
biofeedback, for men with urinary incontinence at 6 weeks after prostate surgery. This report 
describes the research that was commissioned.
The Men After Prostate Surgery (MAPS) study was a major multicentre UK trial that aimed 
to establish whether a structured programme of conservative physical treatment, delivered 
personally by a trained health professional (therapist), resulted in better urinary and other 
outcomes compared with standard management with no professionally delivered pelvic floor 
muscle exercise regimen in men who were incontinent after prostate surgery. Men having (1) 
transurethral resection of the prostate (TURP) for benign prostatic hypertrophy and (2) radical 
prostatectomy for prostate cancer were randomised independently in separate trials but using 
common outcome measures.
Description of the underlying health problem
Urinary incontinence after prostate surgery and effect on well-being
Urinary incontinence is a debilitating condition that can be an iatrogenic consequence of prostate 
surgery.1 The effect of urinary incontinence on quality of life can be profound. The economic 
costs can be personal (such as the need to use pads or devices and the deleterious effect on quality 
of life) and societal (use of health services and the need for residential or nursing home care). 
The effect on quality of life of urinary incontinence is greater than that of erectile dysfunction, 
another possible iatrogenic consequence of prostate surgery.2
Continence mechanisms in men
Urinary continence in men is achieved by the interaction of anatomical structures (bladder, 
urinary sphincter, urethra and the pelvic floor muscles; Figure 1) and neurological control. 
Continence is maintained by contraction of the sphincter and pelvic floor muscles and relaxation 
of the bladder muscle (detrusor muscle), while controlled, appropriate urination requires the 
relaxation of the sphincter and pelvic floor muscles at the same time as the bladder muscle 
contracts. This process is under neurological control. Failure in either muscle or neurological 
function or both will result in incontinence or urinary retention.
The male urinary sphincter may be divided into two functionally separate units, the proximal 
sphincter (nearest the bladder, consisting of the bladder neck, prostate and the portion of the 
urethra that passes through the prostate) and the distal sphincter (further away from the bladder, 
just below the prostate at the level of the pelvic floor muscles). The pelvic floor muscles contribute 
to the ability of the distal sphincter to keep the urethra closed.
Radical prostatectomy physically disrupts the integrity of both the muscles and the nerves, thus 
resulting in urinary incontinence. The proximal sphincter is removed during prostatectomy, and 2 Introduction
may also be damaged by radiation to the prostate. After prostatectomy, men achieve continence 
using the distal sphincter and the pelvic floor muscles that surround it. Thus, following 
prostatectomy, continence depends on the distal sphincter mechanism, which includes soft 
tissue supporting structures, the muscles of both the sphincter and the pelvic floor, and their 
intact innervation (both autonomic via the pelvic nerve and somatic via the pudendal nerve). In 
addition, the disruption of the nerve supply to the penis can interfere with normal erectile and 
hence sexual function.
Transurethral surgery for benign prostatic hypertrophy, while theoretically not disrupting 
the distal sphincter or the nerve supply to the pelvic floor muscles, does remove the proximal 
urethral sphincter. Such sphincter injury can result in incontinence.
Thus, urinary incontinence can be an iatrogenic outcome of prostate surgery. However, 
incontinence may also result from bladder dysfunction, which may persist from before surgery 
or be of new onset. Before surgery, men with benign prostatic hypertrophy have difficulty in 
emptying their bladders owing to bladder outlet obstruction. This may manifest as the lower 
urinary tract symptoms of frequency, urgency and urgency urinary incontinence. Detrusor 
overactivity may be demonstrated by urodynamic studies. While these symptoms are relieved by 
prostatectomy in over 75% of men,3,4 residual overactivity or incontinence may be accounted for 
by a variety of mechanisms, including persistent obstruction (38%), impaired contractility of the 
bladder detrusor muscle (25%) and sphincter deficiency (8%).3
For a detailed description of the continence mechanisms and incontinence resulting from 
prostatic disease and its treatment see Koelbl et al.,5 pp. 299–308.
Definition of urinary incontinence
The MAPS study has used methods, definitions and units that conform to the standards jointly 
recommended by the International Continence Society and the International Urogynaecology 
Association, except where specifically noted.6 These replace those formerly in use.7
FIGURE 1  Anatomy of the pelvic organs in men (see Appendix 4.3).
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Urinary incontinence is defined as the ‘complaint of involuntary loss of urine’.6 This can be 
subcategorised as follows:
Stress urinary incontinence (SUI)  Complaint of involuntary loss of urine on effort or physical 
exertion (e.g. sporting activities) or on sneezing or coughing.
Urgency urinary incontinence (UUI)  Complaint of involuntary loss of urine associated 
with urgency.
Mixed urinary incontinence (MUI)  Complaint of involuntary loss of urine associated with 
urgency and also with effort or physical exertion or on sneezing or coughing.
Postmicturition leakage  Complaint of a further involuntary passage of urine following the 
completion of micturition.
Urgency  Complaint of a sudden compelling desire to pass urine that is difficult to defer.
In the MAPS study these were differentiated according to the men’s responses to questionnaires. 
Men could also categorise their incontinence as ‘other’ if they were incontinent under other 
circumstances, but we did not ask for clarification of the type of incontinence.
Incontinence can be further categorised according to the results of urodynamic studies 
(cystometry). These are:
Urodynamic stress incontinence (USI)  Involuntary leakage of urine during filling cystometry, 
associated with increased abdominal pressure, in the absence of a detrusor contraction.
Detrusor overactivity (DO)  Involuntary detrusor contractions occurring during filling 
cystometry. The symptoms of urgency and/or urgency incontinence may or may not occur.
However, we did not require the type of incontinence to be defined using urodynamics in MAPS.
Prevalence and natural history
The prevalence of urinary incontinence after radical prostatectomy is widely reported, ranging 
from 2% to 60%, albeit at varying times after operation.8 The wide range in estimates of the 
incidence of postprostatectomy urinary incontinence may be explained by factors such as 
differences in populations, type of study, type of operation, definition of incontinence and time 
of assessment relative to surgery. Estimates of incontinence soon after radical operation are much 
higher (e.g. 82% in 1013 men9). The technique of radical prostatectomy also affects continence 
rates: the perineal approach,1 use of laser,10 preservation of the neurovascular bundle11 and 
bladder neck preservation12 have all been shown to be associated with lower urinary incontinence 
rates. The incidence also varies according to who measures it: doctors may underestimate urinary 
incontinence rates by as much as 75%.13 The incidence of urinary incontinence decreases with 
time, and seems to plateau at 1 to 2 years after surgery,14 emphasising the need for long-term 
follow-up.8 Other factors sometimes associated with postprostatectomy urinary incontinence 
include older age, previous TURP, preoperative lower urinary tract symptoms, obesity, clinical 
stage, race and ethnic differences.8
In contrast, the prevalence of urinary incontinence after TURP is less widely reported. Based 
on a population audit of over 3000 men, an estimated 11% needed to use pads at 3 months after 
endoscopic resection of the prostate.154 Introduction
Significance in terms of ill health
Extent of problem in the UK
The number of men undergoing surgery for prostate disease is changing: in 2000–1, the number 
of TURPs in NHS hospitals in England was just under 30,000, while there were about 2000 open 
excisions of prostate (of which the majority would have been for prostate cancer).16 By 2008–9, 
the number of TURPs had fallen to just over 25,000 (of which 2700 were with laser), while 
over 4000 open operations were performed. Thus, prostate surgery and its sequelae represent a 
considerable use of health resources and a health burden to men.
Description of standard management
Existing guidelines
For men who have undergone prostate cancer treatment, the current National Institute for Health 
and Clinical Excellence (NICE) guidelines acknowledge that urinary incontinence has been 
reported as a result, most especially stress incontinence (which is mentioned as either temporary 
or permanent). NICE highlights that incontinence may be a problem after brachytherapy and 
external beam radiotherapy, as well as in those men who have also had a TURP.
NICE guidelines highlight some of the treatments available to men, including physical (pelvic 
floor muscle re-education, bladder retraining), medical (drug therapy) or surgical (injection 
of bulking agents, artificial urinary sphincters or perineal sling) interventions, and they give 
the following recommendations for urinary incontinence management following prostate 
cancer treatment.17
Current recommendations from NICE
  ■ Men experiencing troublesome urinary symptoms before treatment (of their prostate 
problem) should be offered a urological assessment.
  ■ Men undergoing treatment for prostate cancer should be warned of the likely effects of the 
treatment on their urinary function.
  ■ Health-care professionals should ensure that men with troublesome urinary symptoms after 
treatment should have access to specialist continence services for assessment, diagnosis and 
conservative treatment. This may include coping strategies, along with pelvic floor muscle 
re-education, bladder retraining and pharmacotherapy.
  ■ Health-care professionals should refer men with intractable stress incontinence to a specialist 
surgeon for consideration of an artificial urinary sphincter.
  ■ The injection of bulking agents into the distal urinary sphincter is not recommended to treat 
stress incontinence after prostate surgery in men.
No guidelines could be found for the treatment of urinary incontinence associated with either 
benign prostatic hypertrophy or TURP.
Treatment options
Treatment options for men with urinary incontinence after prostate surgery include:
  ■ containment using continence products, including absorbent products, sheaths, urine 
drainage bags, mechanical devices such as penile occlusive devices or clamps, and catheters 
(see Cottenden et al.18 for a comprehensive review)
  ■ conservative options such as advice to modify lifestyle factors and pelvic floor muscle 
training (PFMT) (see Hay-Smith et al.19 for a comprehensive review)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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  ■ surgery using injectable urethral bulking agents, a male sling, an adjustable balloon device or 
an artificial urinary sphincter or, as a last resort, creation of a catheterisable continent stoma 
by bladder neck closure or urinary diversion into a rectal reservoir or ileocaecal pouch with a 
catheterisable stoma (see Herschorn et al.20 for a comprehensive review).
However, few of these options are supported by reliable research evidence.
The decision to test conservative treatment
One of these options, PFMT, was the subject of a Cochrane review first published in 1999.21 
The review found that, although conservative treatment based on PFMT is offered to men with 
urinary incontinence after either type of prostate surgery, there was insufficient evidence to 
evaluate its effectiveness, cost-effectiveness and effect on quality of life. In the first version of 
that review, data from three small trials involving a total of 232 men provided estimates of the 
effects of PFMT on the chance of having incontinence after radical prostatectomy at 1 year: 
the relative risk of incontinence, comparing PFMT plus biofeedback versus control, was 0.55 
[95% confidence interval (CI) 0.24 to 1.23].22–24 However, some of the men in two of these trials 
were not incontinent at baseline, and the trials were all small. Thus, the data did not provide 
conclusive evidence about whether conservative treatment might reduce incontinence at 1 year 
after operation.
As a consequence, the NIHR HTA programme commissioned primary research (the MAPS trial) 
to provide reliable evidence about the effectiveness of PFMT in this population.
In three subsequent updates of the Cochrane review (in 2001, 2004 and 2007), there was still 
insufficient evidence to guide the practice of providing men with PFMT after prostate surgery. 
The current (as yet unpublished) update (2011) will have an additional 16 included RCTs, but 
even after inclusion of data from these trials, no clear conclusions can be drawn.
The questions addressed by this study
The following questions were addressed, primarily in terms of regaining urinary continence at 
12 months after recruitment:
1.  For men with urinary incontinence 6 weeks after radical prostatectomy, what is the clinical 
effectiveness and cost-effectiveness of active conservative treatment delivered by a specialist 
continence physiotherapist or a specialist continence nurse compared with standard 
management?
2.  For men with urinary incontinence 6 weeks after TURP, what is the clinical effectiveness 
and cost-effectiveness of active conservative treatment delivered by a specialist continence 
physiotherapist or a specialist continence nurse compared with standard management?
The hypothesis tested in each group of men (in two parallel but separate trials) was that active 
conservative management would result in a difference of 15% between the groups in the 
proportion of incontinent men at 1 year after recruitment. The two groups were considered 
independently because the underlying pathological mechanisms, the rates of incontinence and 
the chance of regaining continence were expected to be different in the two clinical populations. 
We recognised that standard management for the control arm in both trials was likely to include 
non-specialist advice about pelvic floor exercises, including leaflets. Men also had access to any 
normal care provided locally for men with urinary incontinence, such as pads and advice from 
continence nurse specialists on continence aids.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Chapter 2  
Methods of study
T
his chapter will describe the methods used to identify and enrol the men in the two trials, 
and describe the methods of statistical and economic analysis.
Study design and populations
The MAPS study involved men who had urinary incontinence after prostate surgery. Two parallel 
but separate RCTs were conducted, amongst:
1.  men having a radical prostatectomy, usually for prostate cancer
2.  men having TURP, usually for benign prostatic hypertrophy.
Approval for this UK study was obtained from the Scottish Multicentre Research Ethics 
Committee (reference number MREC/04/10/01) and confirmed by each centre’s local research 
ethics committee and research and development department. The study was conducted according 
to the principles of good practice provided by research governance guidelines.
Local clinical centres
Centres willing to participate in MAPS were identified from a survey of members of the British 
Association of Urological Surgeons (BAUS), through personal communication [with urological 
surgeons and with staff from the Radiotherapy and Androgen Deprivation in Combination After 
Local Surgery (RADICALS) trial] and through the inclusion of the study on the National Cancer 
Research Network (NCRN). Each centre had a local principal investigator (lead urologist), 
who co-ordinated the activities of the local recruitment officer(s) and the local therapist(s). All 
men from all consultants providing prostate surgery in each centre were eligible, but there were 
some centres that agreed only to the recruitment of men having radical surgery, while others 
agreed only to the inclusion of those having TURP. Four centres recruited only to the radical 
prostatectomy trial: three of these sites recruited during the last 6 months of the recruitment 
period and included only men recruited to the radical prostatectomy trial at the request of the 
central office, in order to maximise the numbers in that trial. The fourth site had such a large 
throughput of men having radical prostatectomies that it did not have the capacity to recruit to 
the TURP trial as well. Seven centres recruited only men having TURP. This was due, in five of 
these seven, to existing local services for all men having radical surgery that included explicit 
teaching of PFMT: the staff were reluctant to ‘unpick’ this element of their service for fear of 
delivering lower-quality care than before (despite the service not being evidence based). Men 
were not recruited to the radical prostatectomy trial in the other two sites because of lack of 
capacity and low numbers of prostate procedures being undertaken locally.
Therapists and training
The therapists could be either specialist continence physiotherapists or nurses with specialist 
continence or urology training. All therapists received standardised bespoke instruction in the 8 Methods of study
use of PFMT and bladder training for the conservative treatment of male urinary incontinence 
and PFMT for erectile dysfunction. Therapists used MAPS study instruction materials and 
documentation to further ensure standardisation of the intervention (see Chapter 3).
Participants
Men were approached at the time of admission for their prostate surgery or at pre-operative 
assessment clinics. They were initially asked for their consent to receive a screening survey 
questionnaire sent by post 3 weeks after their operation. Men who indicated in that questionnaire 
that they were incontinent were invited to participate in the appropriate RCT. Their eligibility was 
reviewed against the following criteria.
Inclusion criteria
  ■ Urinary incontinence at 6 weeks after prostate surgery (incontinence was defined as a 
response indicating a loss of urine to either of two questions in the screening questionnaire: 
‘how often do you leak urine?’ and ‘how much urine do you leak?’.
  ■ Full informed consent.
  ■ Ability to comply with intervention.
Exclusion criteria
  ■ Formal referral for physiotherapy or teaching PFMT related to prostate surgery.
  ■ Radiotherapy planned or given during the first 3 months after surgery for men with 
prostate cancer.
  ■ Transurethral/endoscopic resection of prostate carried out as palliation for outflow 
obstruction in advanced prostate cancer (known as ‘channel TURP’).
  ■ Inability to complete study questionnaires.
Men with prostate cancer diagnosed at transurethral resection of the 
prostate
The literature suggested that approximately 15% of men have incidental prostate cancer when 
the prostatic chips removed at TURP are examined for pathology.25 Within MAPS, men were 
still considered eligible for randomisation if the initial management plan did not include formal 
treatment (a wait and see policy). If the cancer was identified before randomisation, and either 
radiotherapy or radical prostatectomy was planned within the following 3 months, the man 
was not eligible for the TURP trial. However, men who were not randomised but subsequently 
readmitted for radical prostatectomy were eligible to be recruited as new participants to the 
radical prostatectomy group (after signing a new consent form and completing a new screening 
questionnaire after surgery). If cancer was diagnosed after randomisation, the men remained in 
the group to which they had been allocated even if radiotherapy or radical prostatectomy was 
carried out subsequently. These men could still have the MAPS intervention, if the timing of the 
new treatment allowed, and were followed up as per the MAPS protocol.
Thus, the MAPS study consisted of two stages: stage 1, the screening survey (used to identify 
eligible men), and stage 2, the two RCTs.
Screening for postoperative urinary incontinence (stage 1, the 
screening survey)
Potential MAPS participants were identified by recruitment officers in each clinical centre from 
amongst all men admitted to the urological ward(s) for prostate surgery. A log was kept of © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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potentially eligible men, categorising reasons if they subsequently became ineligible or did not 
consent to receive a screening questionnaire. Each man was given a MAPS hospital information 
sheet (see Appendix 1.1) by the recruitment officer, and then, if interested in the study, each 
man was asked for his consent to be sent the screening questionnaire at 3 weeks after surgery. 
The hospital patient information sheet, the screening consent form (see Appendix 2.1) and the 
screening questionnaire (see Appendix 3.1) all included information about being contacted about 
further research.
The screening questionnaire was sent to men from the study office in Aberdeen at 3 weeks after 
the date of operation. A reminder letter with a second copy of the questionnaire was sent after 
2 weeks to non-responders. If the returned questionnaire indicated that a man had urinary 
incontinence, he became eligible for stage 2 of MAPS.
Recruitment to the randomised controlled trial of conservative 
treatment (stage 2, the randomised controlled trials)
Each man who indicated on his screening questionnaire that he had urinary incontinence 
was sent an RCT patient information sheet (see Appendix 1.2), a baseline questionnaire (see 
Appendix 3.2), a urinary diary (see Appendix 3.5) and an RCT consent form (see Appendix 2.2) 
by the study office in Aberdeen. Men who were willing to be contacted by telephone were 
telephoned around a week later by a dedicated recruitment co-ordinator based at the MAPS 
study office in Aberdeen. The purpose of this call was to answer the men’s questions about the 
trial, to confirm eligibility and to obtain verbal consent to randomisation. Upon receipt of the 
signed RCT consent form, men were randomised to the intervention or standard care group. 
Men who did not respond within 14 days after the initial mailing-out were reminded by post 
and/or telephone.
Withdrawal
Men were free to withdraw from the study at any point without giving a reason. Verbal consent 
was obtained from men who initially agreed to enter the trial, but later decided to withdraw, to 
enable relevant data to be retained or collected through central NHS resources.
Randomisation and allocation to group
When the baseline questionnaire and the consent form were received, the Aberdeen MAPS study 
office randomised the man to the intervention or standard care group.
Randomisation was by computer allocation using the randomisation service of the Centre for 
Healthcare Randomised Trials (CHaRT, in the Health Services Research Unit, University of 
Aberdeen). Allocation was stratified by type of operation (radical prostatectomy or TURP) and 
minimised using centre, age and pre-existing urinary incontinence. The process was independent 
of all clinical collaborators.
The study office informed all men of their allocation by post. All groups received a lifestyle 
advice leaflet (see Appendix 4.2). For men allocated to the intervention group, the study office 
arranged for the local therapist (physiotherapist or continence nurse) to send out the necessary 
appointments. A letter and GP information sheet were sent to each participant’s GP. Copies of the 
GP’s letter and the consent form were sent to the hospital urological consultant for filing in the 
man’s hospital notes.
A flow chart summarising the trial recruitment processes and procedures is shown in Figure 2.10 Methods of study
Interventions
Intervention arm
The men in the intervention group attended for a MAPS therapist assessment of their symptoms 
after randomisation (see Chapters 6 and 11). The first appointment, for an hour, consisted of 
assessment and training, including customised goal setting for home practice of exercises. The 
men then attended a further three appointments, each lasting approximately 45 minutes, at 
around 2, 6 and 12 weeks after the first appointment. They were taught PFMT, with bladder 
FIGURE 2  Flow chart of the trial recruitment processes and procedures. Q, questionnaire.
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training for men with urgency or urge incontinence.26 This was supplemented by a booklet 
containing reminder instructions for PFMT and bladder training (see Pelvic Floor Exercises for 
Men Taking Part in the MAPS Study; Appendix 4.3). Men also received the lifestyle advice leaflet 
sent to the men in the standard care arm (see Appendix 4.2).
Biofeedback using digital anal examination was used to teach correct contraction technique and 
to monitor the strength of contractions. Although biofeedback used for diagnosis or training 
(repetitive exercising with machine-led feedback on the effectiveness of contractions) was not 
used routinely in the trial, therapists could use this at their discretion in individual cases. Further 
details of the intervention are given in Chapter 3.
Control arm
Men in the control group received standard care and a booklet containing supportive lifestyle 
advice only (without reference to PFMT) by post after randomisation (see Appendix 4.2). Men 
did not receive any formal assessment or treatment but were able to access usual care and routine 
NHS services if they felt they needed help with incontinence. This could include written advice if 
this was part of routine hospital care (such as leaflets containing instructions on PFMT).
Both arms
Use of NHS services, use of pads and practice of PFMT were documented in both groups using 
information from questionnaires (see Appendix 3.4) and 3-day urinary diaries (see Appendix 3.5) 
issued at baseline and 3, 6, 9 and 12 months after randomisation.
Data collection and processing
Men were recruited between January 2005 and September 2008. Follow-up continued 
with 3-monthly questionnaires and urinary diaries for 12 months from the date of the last 
randomisation, at which time the primary end point (incontinent or not) was measured using the 
International Consultation on Incontinence (ICI) Short Form questionnaire (ICI-SF).27 Consent 
was sought to continue follow-up into the future. The men were also asked to consent to be 
contacted about other relevant research studies.
Questionnaires (see Appendices 3.1–3.4)
Men were sent postal questionnaires at baseline and 3, 6, 9 and 12 months. An additional 
health-care unit cost questionnaire was sent only at 6 months. The short questionnaires 
at 3 and 9 months contained only brief urinary incontinence, exercise and health-care 
utilisation questions.
Urinary diaries (see Appendix 3.5)
Men were asked to keep diaries at baseline and 3, 6, 9 and 12 months after randomisation, kept 
for 3 days at each time period.
Data processing
Data from the various sources outlined above were sent to the study office in Aberdeen for 
processing. Staff in the study office carried out extensive range and consistency checks to enhance 
the quality and accuracy of the data. Essential missing data were sought from the recruitment 
officers at the centres, or the men, by post, telephone or email as appropriate.
Outcomes
The primary clinical outcome was subjective report of urinary continence at 12 months.2712 Methods of study
Incontinence was defined as a response indicating a loss of urine to either of two questions in 
the screening questionnaire, ICI-SF: ‘how often do you leak urine?’ and ‘how much urine do 
you leak?’
The primary measure of cost-effectiveness was incremental cost per quality-adjusted life-year 
(QALY).
Secondary outcome measures were as follows.
Clinical
  ■ Subjective report of continence or improvement of urinary incontinence at 3, 6 and 9 months 
after randomisation, and improvement at 12 months.
  ■ Number of incontinent episodes in previous week (objective, from diary).
  ■ Use of absorbent pads, penile collecting sheath, bladder catheter or bed/chair pads.
  ■ Number and type of incontinence products used.
  ■ Coexistence, cure or development of urgency or urge incontinence.
  ■ Urinary frequency.
  ■ Nocturia.
  ■ Faecal incontinence (passive or urge).
  ■ Other bowel dysfunction (urgency, constipation, other bowel diseases).
  ■ Sexual function at 12 months (including information about erection, ejaculation, retrograde 
ejaculation, pain, change in sex life and reason for change).
Quality of life
  ■ Incontinence-specific quality of life outcome measure (10-point scale, ICI-Q).27
  ■ General health measures (Short Form questionnaire-12 items, SF-12, and European Quality 
of Life-5 Dimensions, EQ-5D).
Use of health services for urinary incontinence
  ■ Need for alternative management for incontinence (e.g. surgery, drugs).
  ■ Use of GP, nurse, consultant urologist, physiotherapist.
  ■ Satisfaction with treatment of incontinence after prostate surgery.
Other use of health services
  ■ Visits to GP.
  ■ Visits to practice nurse.
Effects of interventions
  ■ Use of PFMT.
  ■ Lifestyle changes (weight, constipation, lifting, coughing, exercise).
Economic measures
  ■ Patient costs [e.g. self-care (e.g. pads, laundry), travel to health services, sick leave].
  ■ Cost of conservative trial treatment.
  ■ Cost of alternative or additional NHS treatments [e.g. pads, catheters, drugs (e.g. adrenergic 
agonists, anticholinergics, oral medication for erectile dysfunction), hospital admissions or 
further surgery].
  ■ Other measures of cost-effectiveness (e.g. incremental cost per additional man continent at 
12 months).
Table 1 provides a summary of which study measures and outcomes were collected at each time 
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Blinding
As the trial arm to which men were allocated could not be concealed after randomisation had 
occurred from either the man or the therapist, blinding of participants to intervention was not 
possible. However, outcome measures were assessed using questionnaires that were processed by 
MAPS study office staff who were not aware of the randomisation.
The statistician responsible for the final analyses was not the same as the one who performed 
the interim analyses for the Data Monitoring Committee. All statistical coding and results were 
agreed before the allocation was revealed.
Sample size
Based on the aim of detecting an absolute difference between intervention and control groups of 
15% (30% to 15%) in the number of men who are still incontinent at 12 months, we calculated 
that we would need 174 men per arm of each trial to give 90% power to detect a significant 
difference at the 5% level. This would allow detection of a difference of 0.30 of a standard 
deviation (SD) at 80% power for continuous measures such as quality of life. Should the 
proportion of men who are incontinent be more than 30%, we would still have 80% power to 
detect a 15% change from 40% to 25%.
Allowing for a 13% dropout rate after enrolment in the RCT, we planned to recruit 200 men per 
arm. This would amount to 400 men in each of the two parallel trials, who would come from 615 
incontinent men, assuming that 65% agree to join the trial. Based on conservative assumptions 
of 50% and 5% incontinent at 6 weeks after radical prostatectomy and endoscopic resection of 
prostate, respectively, and 80% response rates to the screening questionnaire, 1540 and 15,400 
men would need to be approached. If a typical centre undertook 30 radical prostatectomies and 
TABLE 1  Principal study measures and timing of data collection 
Study measure Screening Baseline Month 3 Month 6 Month 9 Month 12
Consent/randomisation  
Sociodemographic characteristics 
Operative details  
Clinical characteristics  
Follow-up (outcome) questionnaires    
Urinary diaries     
Urinary outcomes (primary)      
Other urinary outcomes   
Health-care utilisation questions     
SF-12, EQ-5D   
Exercise, including practice of PFMT      
Bowel outcomes    
Participant cost questionnaire 
Sexual function outcomes 
Lifestyle change outcomes 
Satisfaction with treatment for incontinence  
Further treatment for incontinence  14 Methods of study
300 endoscopic resections of prostate each year, about 26 centres would be required for each trial 
recruiting over an average of 2 years.
Table 2 shows the number of men whom we estimated we would need to approach and hence 
the number of ‘typical sized’ clinical centres that would be required. In summary, we needed to 
screen around 17,000 men in stage 1 of the study, making conservative assumptions about likely 
response and participation rates. Based on these figures, a 2-year recruitment period in 26 centres 
would have been needed.
However, towards the end of planned recruitment (end September 2007), it became apparent 
that we would fall short of our minimum targets for men randomised. We therefore applied for 
a 9-month extension to recruitment, based on more accurate estimates of recruitment rates. In 
consultation with the Data Monitoring Committee and representatives of the HTA programme, 
recruitment was extended to July 2008 and, as a result, randomisation finished on 23 September 
2008. There were no changes to the effective sample size sought (174 in each group at 12-month 
follow-up).
Statistical methods
Trial analyses
The principal comparisons in each trial were between men allocated to active therapy (up to 
four visits to a therapist plus the lifestyle advice leaflet) and men allocated to the control group 
(lifestyle advice leaflet only). The two populations of men (having radical prostatectomy or 
TURP) were analysed as separate trials. The primary outcome measure (urinary incontinence 
at 12 months) and secondary outcome measures were analysed using general linear models 
that adjusted for the minimisation covariates (age and pre-existing urinary incontinence) and, 
when possible, the baseline measure of the outcome. For the primary outcome only, unadjusted 
analyses were also reported. All analyses used 95% CIs. For the binary outcomes, a Poisson link 
function was used to estimate relative risks (instead of estimating odds ratios from a logistic 
model) and robust standard errors were used to estimate the CIs.28 For illustrative purposes, the 
relative risk of the primary outcome was also transformed to a risk difference.
The primary statistical analysis was based on all men as randomised, irrespective of subsequent 
compliance with the treatment allocated (intention to treat). The intention-to-treat approach 
gives the least biased estimate of effectiveness of the two interventions. Given that it was likely 
TABLE 2  Initial estimate of recruitment numbers and centres needed
Estimate Radical prostatectomy TURP
Men needed per arm (minimum) 174 174
Allowing for 13% dropout 200 200
Total men needed in two arms 400 400
Assuming 65% willing to enter RCT, no. of incontinent men needed 615 615
Percentage incontinent at 6 weeks (stage 2) 50% 5%
No. of men needed to reply to survey 1230 12,300
Assuming 80% response to survey, no. needed for survey (stage 1) 1540 (approx.) 15,400 (approx.)
No. of operations per typical centre 30 300
No. of typical centres needed in 2 years 26 26
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that some of the participants would not attend the therapy sessions (e.g. because they were 
continent), a secondary comparison was conducted to estimate the efficacy of the treatment 
received (i.e. what is the effect if the participants actually received the treatment they were 
allocated to?). The so-called ‘per-protocol’ approach for estimating efficacy of treatment, in which 
compliers with treatment in each group are compared with each other, can have substantial 
selection bias. A more robust method is to use a latent variable approach.29 We used the method 
of adjusted treatment received as described by Nagelkerke et al.30 The method used a two-stage 
least squares approach, whereby treatment received and the residuals from that model were used 
as an independent variable in a second model together with the treatment received to estimate 
the effects on the primary outcome.
Missing items in the health-related outcome measures were treated as per the instructions for 
that particular measure. No further imputation for missing values was undertaken. The ways in 
which the data were analysed were prespecified in the statistical analysis plan, which was agreed 
in advance with the MAPS Trial Steering Committee.
Timing and frequency of analyses
A single principal analysis was carried out at 15 months after the last man was recruited. The 
Data Monitoring Committee considered confidential interim analyses of data on three occasions 
during the data collection period (January 2006 – 31 randomised to radical prostatectomy 
and 48 randomised to TURP; January 2007 – 180 randomised to radical prostatectomy and 
200 randomised to TURP; January 2008 – 297 randomised to radical prostatectomy and 364 
randomised to TURP). The Data Monitoring Committee did not recommend any amendments 
to the protocol on any occasion.
Planned secondary subgroup analyses
Subgroup analyses (separately for the two populations) explored the effect on urinary 
incontinence at 12 months after randomisation of:
1.  pre-existing urinary incontinence (before prostate surgery)
2.  age (up to 60 years, 61 years and over for radical prostatectomy; up to 70 years, 71 years and 
over for TURP)
3.  body mass index (BMI) (up to 30 kg/m2, 30–34.9 kg/m2, 35 kg/m2 or greater)
4.  type of incontinence at trial entry (SUI, UUI, MUI, postmicturition leakage)
5.  other morbidity
6.  type of therapist (physiotherapist or nurse)
7.  centres with and without biofeedback machines.
Stricter levels of statistical significance (2p < 0.01) were sought, reflecting the exploratory nature 
of these analyses.
Ancillary analyses
Screening data
Descriptive statistics were tabulated to describe the derivation of the trial groups from the 
screening procedures, and included comparison of those who responded versus those who did 
not respond to the screening.
Therapist data
Descriptive data were tabulated to describe how the therapy intervention was implemented in 
each of the trials. This included a comparison across therapy visits (one to four) on incontinence, 
bowel and sexual problems and pelvic floor muscle performance.16 Methods of study
Economics methods
Introduction
The economic evaluation was based on a within-trial analysis at 12 months after recruitment 
for men with urinary incontinence 6 weeks after radical prostatectomy or TURP. The question 
addressed was: what is the clinical effectiveness and cost-effectiveness of active conservative 
treatment delivered by a specialist continence physiotherapist or a specialist continence nurse 
compared with usual management? The perspective of the study was based on a societal 
viewpoint and included both the costs of the health service provider (the NHS) and those of 
the patients.
Measurement of resource use
The use of health services as a consequence of being incontinent was recorded prospectively 
for every participant in the study. Resource utilisation data were collected using questionnaires 
and urinary diaries. These data were collected using questionnaires sent to the participants 
at baseline, and 3, 6, 9 and 12 months. Resource utilisation data collected also included the 
intervention, i.e. the number of visits to the therapists, who were either specialist continence 
physiotherapists or continence nurse specialists. According to the protocol, PFMT intervention 
comprised four sessions. Details of the intervention are provided in Chapter 3. The first session of 
PFMT was 1 hour and the other three sessions were approximately 45 minutes each. Each session 
was conducted in a hospital department. The consumables required per session were gloves, K-Y 
Jelly, wipes and paper towels. No additional resources were required for the biofeedback as no 
equipment was used; verbal biofeedback was used to teach the men how to contract their muscles 
optimally and advise them on improvement from previous appointments.
Primary care and outpatient resource use included visits to the GP as well as to the outpatient 
department. The number of GP visits and the contact (doctor or nurse) were obtained from the 
3-, 9- and 12-month follow-up questionnaires. Number of outpatient visits was obtained from the 
3-, 6-, 9- and 12-month follow-up questionnaires. For the length of stay, the number of days the 
men were admitted was recorded. Other resource use included the number and type of drugs the 
patients were prescribed for their incontinence problems, the number of pads used and, finally, 
the number of bed and chair protectors used. The data reported by the patients were used to 
calculate the average and total resource use per patient.
The information generated from these questionnaires entailed manipulation of the data to 
perform the comparative analysis. Details of methods used to estimate resource use collected are 
included in Table 3.
Identification of unit costs
As described above, costs focused on the direct health service costs associated with each 
treatment. Unit cost data were extracted from the literature or from relevant sources such as 
manufacturers’ price lists (British National Formulary, BNF)31 and NHS Reference Costs.32 The 
year of the cost data is 2008 and the currency is pounds sterling (£).
The costs of the intervention included the cost of PFMT sessions. These comprised the costs of 
the staff involved, consumables and overheads. The costs of producing the leaflets for the trial 
were not included in the analysis as all the men in the trial received leaflets. Men in both groups 
received a booklet containing supportive lifestyle advice (without reference to PFMT) by post 
after randomisation (see Appendix 4.2). Men in the intervention group also received a MAPS 
pelvic floor exercise leaflet (see Appendix 4.3) from the therapist at the first visit. The booklet © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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aimed both to support and to reinforce the anatomy teaching received during MAPS therapy 
appointments, as well as the exercise programme that had been set. It was therefore assumed that 
the costs would be the same for both groups. The cost of training that therapists received (1-day 
course) was included in the intervention costs because it was low and was not likely to impact on 
the overall costs.
The cost of the follow-up management comprised the cost per visit to both primary (GP and 
nurse appointments) and secondary (outpatient appointments and number of inpatient days) 
health-care providers. Unit costs for GP’s visits were obtained from the Personal Social Services 
Research Unit (PSSRU) unit costs of community care.33 Unit costs for outpatient services were 
obtained from the Scottish Health Service Costs (SHCS) (Information and Statistics Division 
website34) for the primary analysis and the national reference costs in a sensitivity analysis 
(Department of Health website35). The inpatient costs were those of the wards to which the men 
were admitted.
Other costs considered included containment products. These comprised all the products that 
participants used, such as absorbent pads, penile collecting sheaths, bladder catheters and bed 
and chair protectors. The unit costs of these items were taken from the providers of these items 
or from the NHS suppliers, where available. The unit cost of sheaths is based on a weekly cost 
of sheaths, estimated assuming that one sheath is used each day, the reusable leg bag is used for 
3 days and one night bag is used each night. The unit costs of the catheter were based on the 
assumption that the catheter was used over a 3-month period, and similar assumptions were 
made for the leg and night bags. The unit cost of the medications was taken from the BNF,31 and 
the cost per patient in terms of medication use was calculated by multiplying the unit cost by 
each number of units consumed for each patient. The costs considered were those of the drugs, 
not the prescription charges. Table 4 provides a summary of the unit costs for the resources used.
The data describing the resource utilisation of participants were combined with estimates of unit 
costs for each of the areas of management considered. This allowed for estimation of total cost for 
each participant, as well as the average cost for each area of resource utilisation and average total 
cost. The results are reported in Chapters 8 and 13.
TABLE 3  NHS resource use in the last 12 months
Resource Relevant variables Source Reported outcome
Patient management Physiotherapist 1st visit DA Number attending
Physiotherapist 2nd–4th visit DA Number attending
GP visits  PQ Number
Primary care Nurse visits PQ Number
Outpatient visits  PQ Number
Secondary care Inpatients days  PQ Number
Physiotherapy  PQ Number
Medications, e.g. tolterodine tartrate  PQ Type and number
Other Pads PQ Type and number
Chair/bed protectors PQ Type and number
Catheters PQ Type
External sheaths  PQ Type
DA, data abstraction of patient notes; PQ, patient questionnaire.18 Methods of study
Participant costs of urinary incontinence
As the perspective of the study was the NHS and patient, those costs borne by participants and 
their families were also considered. Participants’ resource use was taken as time taken to access 
services (e.g. attend GP, physiotherapist, outpatient or inpatient appointments), travel costs and 
the time taken off usual activities owing to poor health. Similar costs were included for spouses, 
relatives or friends who accompanied them to their appointments. Travel costs to patients and 
their families were based on actual fares when public transport was used and published mileage 
rates in the case of those who used their own vehicles (HM Revenue and Customs website36). 
These data were collected through postal questionnaires administered at 12 months.
In the case of patients who would have been engaged in employed work, the value of their 
time was taken as the gross average full-time wage rate for men (Office for National Statistics 
website37). The value for those who were not in formal employment was based on 57% of the 
average national rate and 43% for those who may have been involved in leisure activities.38 The 
costs of friends/relatives accompanying patients to hospital were estimated in the same way. 
These unit time costs, measured in terms of their natural and monetary terms, were combined 
with estimates of number of health-care contacts derived from the health-care utilisation 
questions. Self-purchased health care included items such as pads bought by the participant, 
prescription medicines and over-the-counter medications. Information about these was collected 
through the health-care utilisation questions. Patients’ time and travel costs were based on the 
information collected, and are described in Table 5.
Quality of life
Effectiveness within the trial was measured in terms of QALYs and subjective continence at 
12 months (assessed using data from the ICI-SF). Quality of life data were collected at baseline 
and 6 and 12 months. This was generated using generic health status measurement tools, the 
EQ-5D and SF-12, included in the questionnaires. The EQ-5D measure divides health status into 
five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). 
Each of these dimensions has three levels, therefore 243 possible health states exist.39 Responses 
of the patient EQ-5D questionnaires were transformed using a standard algorithm to produce a 
health state utility at each time point for each patient. The utility scores obtained at baseline and 
6 and 12 months were used to estimate the mean QALY score for each group. The estimation 
of QALYs took account of the mortality of study participants. Participants who died within the 
TABLE 4  Average unit costs
Resource use Unit cost (£) Notes
Staff costs 67 Based on cost per hour of patient contact for Band 6 of the October–December 2007 NHS 
staff earnings estimates for qualified nurses33
Cost of consumables  0.90 Based on cost of gloves, K-Y Jelly, couch roll, paper towels, wipes for four visits
Medications  Various Cost based on recommended dosage
GP doctor visit 36 Per surgery consultation lasting 11.7 minutes33
GP nurse visit 11 Based on cost per consultation33
Physiotherapist visit 31 Based on cost of nurse-led clinic33
Outpatient visit  75 Based on cost34
Inpatient visit 157 Based on the average cost per day in a urology specialty ward34
Pads  0.17 Cost per pad
Chair/bed protector 0.15 Cost per protector 
Sheath 8.46 Weekly cost of sheath (condom) catheter, reusable leg bag and disposable night bag
Catheter 2.73 Weekly cost of catheter, reusable leg bag and disposable night bag© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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study follow-up were assigned a zero utility weight from their death until the end of the study 
follow-up. QALYs before death were estimated using linear extrapolation between the QALY 
scores at baseline and all available EQ-5D scores up to death.
As described below in the section on the sensitivity analysis, the responses from the SF-12 
questionnaire were also used as the basis of QALYs, and were mapped on to the existing Short 
Form questionnaire-6 Dimensions (SF-6D) measure using the algorithm by Brazier et al.40 to 
allow utility values to be estimated for each time point. These utility scores were transformed 
into QALYs using the methods described above to provide an alternative measure of QALYs for 
each patient.
Incremental cost-effectiveness
Data collected on costs and effects of the interventions were combined to obtain an incremental 
cost-effectiveness ratio (ICER). This was performed by calculating the mean difference in 
costs between the interventions and control groups over the difference in effect between the 
interventions and control groups. This gives us the cost per additional QALY gained for the new 
interventions relative to standard practice.
The primary analysis was based on the 1-year follow-up of the trial and the outcome was the 
incremental cost per QALY. This outcome was chosen to reflect a societal decision-making 
perspective. The results are presented as point estimates of mean incremental costs, proportion of 
men continent, QALYs and cost per QALY. Measures of variance were based upon bootstrapped 
estimates of costs, QALYs and incremental cost per QALY. Incremental cost-effectiveness data are 
presented in terms of cost-effectiveness acceptability curves (CEACs).
Data analysis (economics)
As data were collected over a 1-year period, discounting was not carried out. The numbers of 
missing data for each variable used in the analyses of cost were quite low, and data that were 
missing were considered to be missing completely at random. Data reported as mean costs for 
both cases and controls were derived for each item of resource use and then compared using 
unpaired t-tests and linear regression adjusted for baseline values. As the data were not normally 
distributed, non-parametric bootstrapping was used to estimate confidence limits around the 
difference in cost for each area of resource use and total costs.
Sensitivity analysis
With all parameter estimates there are elements of uncertainty owing to the lack of available 
information. In order to explore the importance of such uncertainties and assumptions, various 
sensitivity analyses were conducted by varying some of the assumptions or estimates used in 
the analysis. Two types of sensitivity analyses were performed: one-way sensitivity analysis and 
threshold analysis.
TABLE 5   Patient and companion resource use and costs
Resource Resource use  Unit cost
Use of personal car to GP  Distance travelled Cost per mile/km 
Use of personal car to hospital  Distance travelled Cost per mile/km 
Use of public transport to GP  Ticket Return cost of ticket 
Use of public transport hospital  Ticket Return cost of ticket 
Medication purchased Type and number  Cost of medicines 
Loss of earnings Number of days off work Daily wage20 Methods of study
The base-case analyses in terms of utilities were adjusted for patient outcomes at baseline to 
account for variability that might be present amongst the intervention groups. An unadjusted 
analysis was also performed to highlight the importance of this base-case assumption.
There is uncertainty around the QALY estimates as they were derived using one generic 
instrument, the EQ-5D. There is some debate over whether the dimensions in the EQ-5D are 
sensitive enough to capture the loss in quality of life for chronic health states of which the worst 
effects occur during acute episodes. Therefore, the responses from the SF-12 questionnaire 
were mapped on to the existing SF-6D measure using the algorithm by Brazier et al.40 to allow 
utility values to be estimated for each time point. These utility scores were then transformed into 
QALYs using the same methods as used for the EQ-5D scores to provide an alternative measure 
of QALYs for each patient.
Modelling
Additional information for policy-makers was derived from a simple economic model that 
considers what difference in continence rates would result in a change in the conclusions about 
which treatment would be cost-effective. This analysis was performed from the perspective of 
the NHS.
The data used to populate the model were based on the trial patient data, to inform on the 
probability of being incontinent at the end of 12 months, and the cost data. The data also 
included QALYs and costs derived for each participant, based on the group they were allocated to 
(intervention or control) The model is illustrated in Figure 3.
Management of the study
The MAPS study office, working in conjunction with our trials unit, and CHaRT in the Health 
Services Research Unit, University of Aberdeen, provided support for the clinical centres, 
randomisation, management of data collection, follow-up, data processing and analysis. The 
MAPS Project Management Group (grant holders and representatives from the study office) met 
formally at least monthly during the course of the study to discuss key trial issues.
The study was overseen by an independent Trial Steering Committee with an independent 
chairman and three other independent members. The remaining members were the grant 
holders. The Trial Steering Committee met annually on six occasions. An independent Data 
Monitoring Committee was also established, comprising an independent chairman and three 
FIGURE 3  Structure of the model used in economic analyses.
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other independent members, who met on three occasions. The trial statistician supplied, in strict 
confidence, interim analysis results for their consideration.
The University of Aberdeen assumed the role of sponsor for the study.
Table 6 shows the substantive changes to the MAPS study protocol since its first approval by the 
MREC: they were approved on the dates shown.
TABLE 6  Changes to MAPS study protocol
Change to protocol Date approved
Nomenclature: the operation types for the two groups of men are referred to as ‘radical’ and ‘TURP’ 31 May 2005
Nomenclature: intervention will be delivered by ‘therapists’ rather than ‘physiotherapists’ 31 May 2005
Formal referral to a therapist delivering PFMT before or after operation added as a specific exclusion criterion 31 May 2005
Multiple sclerosis or Parkinson’s disease no longer a specific exclusion criterion 31 May 2005
Trial Steering Committee concluded that the study should still aim to enrol 25–30 centres as this would allow for sites 
withdrawing and rates dropping off
30 November 2005
Amendment relating to the diagnosis of unsuspected prostate cancer in men undergoing TURP, and how this would be 
handled in the MAPS study
30 November 2005
New sponsor: University of Aberdeen 30 November 2007
Revised extension timings 30 November 2007© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
23   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
Chapter 3  
Intervention design, centres, therapists 
and therapy
I
n this chapter, the rationale for the intervention, the methods used to train the therapists in 
order to standardise the intervention and the types of therapists at each centre are described.
Introduction
The purpose of the MAPS trial was to compare return to continence with or without a structured 
PFMT programme, delivered by a trained therapist, in men after TURP or radical prostatectomy. 
Both groups received written information on recovery after surgery. The primary outcome was 
self-reported urinary incontinence at 12 months after randomisation.
Following radical prostatectomy, some degree of iatrogenic urinary incontinence is a recognised 
complication in up to 90% of men.9 Following TURP for benign prostatic hypertrophy, the figure 
is around 10%.15
Some physiotherapists already use PFMT and bladder training (BT) or urge suppression (US) 
techniques to treat men with urinary incontinence following prostate surgery, despite Cochrane 
reviews clearly showing that there is currently insufficient evidence to confirm whether or not 
these are effective.26,41 Uncertainty also surrounds the most effective PFMT and BT/US protocols 
for specific clinical indications.
MAPS control protocol
All participants received a lifestyle advice leaflet (see Appendix 4.2) (control and intervention 
groups). Face and content validity were established by review of the literature,19 with a consumer 
representative of men who had urinary incontinence, and with health-care professionals. The 
final copy contained information about moderating fluid intake (avoiding too much or too little), 
and information on caffeine, cranberry juice, diet and obesity, constipation, general fitness, 
lifting, smoking, chest problems and urinary tract infections and was based on clinical practice 
recommendations. The control group had no further contact with the research team, apart from 
follow-up by questionnaires.
MAPS intervention protocol
In addition to the leaflet described above, all men in the intervention group received a structured 
PFMT intervention. The protocol was based on one used in a previous trial using PFMT to 
increase pelvic floor muscle strength for men with erectile dysfunction.42 The BT/US techniques 
were based on those typically used in clinical practice for UUI and summarised in a Cochrane 
review.43 The advice on fluid intake was based on standard clinical practice.4424 Intervention design, centres, therapists and therapy
Constituent elements of the intervention protocol
Assessment of pelvic floor strength
During each therapy appointment, pelvic floor muscle contraction strength was evaluated 
by a digital anal examination using the Oxford score (graded 0–5).45 An additional grade (6) 
was added to define a very strong anal squeeze.46 The new grading system was used to assess 
separately the strength of both the external anal sphincter and the deeper puborectalis muscle 
(taken to represent the pelvic floor muscles). The external anal sphincter was assessed at 1–2 cm 
from the anal meatus, and the puborectalis at 3–4 cm from the anal meatus.
Verbal biofeedback from this examination was used to teach the men how to contract their 
muscles optimally, and advise them on improvement from previous appointments. At each 
assessment, the maximum duration of each contraction was timed by counting.
Pelvic floor muscle therapy regimen
PFMT was aimed at improving the strength of the pelvic floor muscles to allow effective 
contraction during exertion to prevent urinary leakage. PFMT consisted primarily of three 
maximum-strength contractions with a 10-second break between each one, practised in three 
positions (lying, sitting and standing) twice daily (see Appendix 4.3). Targets were set for 
the duration of each contraction, up to a maximum of 10 seconds, and revised in successive 
appointments if progress had been made. In addition, men were taught to carry out a sustained 
submaximal contraction of the pelvic floor muscles during walking and to perform a strong 
contraction before and during any event that might cause leakage, such as coughing or rising 
from sitting (‘the knack’).47 Men were advised to eliminate urine remaining in the bulbar urethra 
by using a strong contraction after urination was finished, in order to prevent postmicturition 
dribble.42 Contracting the pelvic floor muscles during sexual activity was also recommended to 
achieve, maintain or improve erectile strength.
Bladder training/urge suppression
Men with urgency or UUI were taught urge suppression techniques in order to avoid rushing to 
the toilet when the bladder was starting to contract (see Appendix 4.3). Fluid advice, including 
avoiding or reducing caffeine, was also offered.
Written supplementary guidance
The MAPS PFMT leaflet (see Appendix 4.3) aimed both to support and to reinforce the anatomy 
teaching received during appointments, as well as the exercise programme that had been set. To 
maximise understanding, careful consideration was given to the language and terminology used 
in this leaflet, taking into account the sensitive nature of incontinence and erectile dysfunction. 
The use of medical and anatomical terms was minimised in favour of a plain English approach 
(‘urine leakage’ for incontinence).48
Drafts of the leaflets were reviewed for face and content validity by lay persons and health-care 
professionals with knowledge of men’s health and continence issues.
Understanding strategies selected for the MAPS intervention
In order to clarify key aspects of the rationale behind elements of the MAPS standardised 
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Rationale for performing a digital anal examination
A digital anal examination was undertaken to assess the strength and endurance of, firstly, the 
external anal sphincter and, secondly, the puborectalis muscles. Wyndaele and Van Eetvelde49 
demonstrated the reproducibility of assessing the puborectalis by anal assessment using grades 
0–5. By assessing puborectalis muscle strength, the strength of the surrounding pelvic floor 
muscles would also be graded. The muscles were graded from 0 to 6, with 0 being ‘no flicker or 
contraction’ and 6 being ‘very strong, unable to withdraw finger.42 Repeating the examination at 
subsequent visits enabled therapists to provide verbal feedback to men that their exercises were 
effective in building up muscle strength and to monitor progress.
Rationale for asking men to perform pelvic floor exercises in three 
positions
Pelvic floor muscles support the abdominal contents and prevent urinary leakage. The three 
positions provided a graded method of increasing the effect of gravity, in order to provide extra 
muscle work load. The pelvic floor muscles were recruited initially in a lying position, without 
the effect of gravity. As strengthening occurred, pelvic floor muscles were subject to a higher 
load by recruiting them in a sitting position, where the downwards descent of the pelvic floor 
would be partly prevented by the seat of the chair. A greater load would be placed on the pelvic 
floor during standing, when gravitational forces opposed the elevation of the pelvic floor during 
exercise. MAPS adopted this regimen for the intervention supported by evidence from four 
previously documented trials, which found it to be convenient, acceptable and comfortable for 
patients.24,50–52 It was believed that men needed to be able to tighten their pelvic floor muscles in a 
number of positions, so that they could recruit them speedily during coughing and sneezing.
Rationale for performing three pelvic floor muscle contractions
The PFMT programme was aimed at increasing pelvic floor muscle strength in order to 
counteract increases of abdominal pressure during exertion. Based on clinical research of 
quadriceps strengthening using a progressive resistance machine, repeated computerised 
readings showed that the first contraction gave the patient the feel of the movement but failed 
to achieve maximum power. The second contraction attained maximum power, whilst the third 
failed to reach maximum power owing to fatigue.53 Kegel54 stated that maximum power was a key 
element to gaining increased muscle strength. These principles informed the PFMT programme, 
considering that the maximum power of pelvic floor contraction would be attained using three 
muscle contractions in each position held for up to 10 seconds. The target was individually 
adjusted as performance improved.
Rationale for performing the regimen twice a day
Kegel54 recommended 300–400 pelvic floor muscle contractions a day to treat SUI in women.
However, clinical practice has shown that patients find this level of commitment to be too 
arduous, resulting in attrition and demotivation. The principles of muscle building show that it is 
the quality of the contraction that is more important than the quantity.53,55
The MAPS intervention was therefore designed to provide targets that were achievable in order 
to motivate men to maintain the regimen within the constraints of the protocol. In a previous 
trial,42 55 men were asked to perform their exercise sets only twice a day. After 3 months, all 
except one (who had severe back pain) showed a statistically significant increase in pelvic floor 
muscle strength. We therefore felt that this regimen had a proven ability to increase pelvic floor 
muscle strength.
Rationale for contracting the muscles as strongly as possible
The pelvic floor muscles consist of two-thirds slow-twitch continually tonic muscle fibres and 
one-third fast-twitch muscle fibres, which can be speedily recruited when extra support is needed 26 Intervention design, centres, therapists and therapy
during activities that increase intra-abdominal pressure.56 Both fibre types are recruited during 
maximum contraction of the pelvic floor muscles. In order to achieve an increase in muscle bulk, 
the MAPS intervention used maximum voluntary effort, which was expected to result in the 
hypertrophy of muscles and an increase in local blood supply.53,55
Rationale for functional use of muscles
Pelvic floor muscles need to be recruited to prevent leakage of urine during activities that increase 
intra-abdominal pressure. ‘The Knack’ is the technique, or learned skill, of tightening just before 
and during these activities.47 Owing to its significant role in contributing to continence, teaching 
of ‘the Knack’ was therefore included as an element in the MAPS intervention.
Reasons for increasing pelvic floor muscle endurance
Slow-twitch muscle fibres fulfil a number of important functions: pelvic floor support, bladder 
and bowel control, sexual activity, posture and respiration. The upright posture stimulates the 
pelvic floor reflex, which results in contraction of the slow-twitch fibres in response to the weight 
of the abdominal contents.57 In order to meet this demand, the pelvic floor muscles need to have 
sufficient muscle endurance to prevent urinary leakage. By encouraging the patient to tighten the 
pelvic floor muscles slightly during walking (as taught in the MAPS intervention), a functional 
method of potentially increasing the use of slow-twitch fibres and hence muscle endurance 
was achieved.
Rationale for tightening the pelvic floor muscles after urinating
One of the superficial pelvic floor muscles, the bulbocavernosus muscle, encircles the proximal 
50% of the penis and tightens by reflex action at the end of micturition to facilitate emptying of 
the bulbar portion of the urethra.58 Teaching men to contract their pelvic floor muscles strongly 
after they have completed micturition will result in the recruitment of the bulbocavernosus 
muscle along with the other pelvic floor muscles.42 This muscle contraction will then facilitate 
the evacuation of residual urine from the bulbar urethra. This may restore or develop the reflex 
postvoid milking mechanism identified by Wille et al.58 and termed the ‘urethrocavernosus reflex’ 
by Shafik and El-Sibai.59 Thus, as an additional strategy to attain continence, participants were 
taught to perform consciously a pelvic floor muscle contraction immediately after micturition.
Rationale for tightening the pelvic floor muscles during sexual activity
The superficial bulbocavernosus and ischiocavernosus muscles are active during penile erection.60 
The bulb of the penis sits on the inferior aspect of the deeper layer of the pelvic floor muscles, 
which form a firm base for the erect penis. The bulbocavernosus muscle prevents blood from 
escaping through the deep dorsal vein during an erection. One study has shown that pelvic floor 
exercises can restore erectile function in 40% of men and improve it in a further 36%.42 As this is 
another potential benefit of PFMT, it was decided that it would be appropriate to include erectile 
function in the MAPS intervention materials and be measured as a secondary outcome. However, 
it is not yet clear whether men will benefit after radical prostatectomy as the amount and degree 
of nerve damage caused by surgery is likely to be variable. Erectile function was a secondary 
outcome of the study.
Rationale for choice of urge suppression techniques
A detrusor contraction produces a desire (urge) to empty the bladder. If urgency sensations 
cannot be overcome, urinary incontinence may occur. The resulting fear of leakage can cause 
anxiety, breath-holding and descent of the diaphragm, which, coupled with abdominal muscle 
contraction, can produce early inappropriate micturition. A retrospective study in women 
has reported that effective urge suppression techniques include keeping calm, sitting down or 
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used to strengthen the pelvic floor musculature and, together with urge suppression techniques, 
can help to restore bladder control.
Rationale for giving fluid, dietary and lifestyle advice
All men received fluid, dietary and relevant lifestyle advice as part of the therapy appointments, 
supplemented by written information (see Appendix 4.2). Advice included information that 
reducing fluid intake (underdrinking) to avoid leakage may lead to urinary tract infections, 
constipation and dehydration.61 Conversely, drinking excessive amounts (in the belief that this 
is beneficial for health) may have adverse effects such as an increased risk of leakage.62 However, 
men experiencing nocturia were advised that avoiding fluids 2 hours before bedtime may 
be helpful.
Drinks containing caffeine or alcohol may cause increased risk of urgency and men were advised 
to reduce or avoid them.61 Anecdotal evidence has shown that certain foods (e.g. onions, spicy 
foods and curries) can cause increased gut peristalsis, which may also have an effect on the 
bladder, causing it to be overactive and contractile. Other risk factors for an overactive bladder 
were highlighted, including the effect of constipation, smoking and obesity.63 Information on all 
these elements was included in the MAPS lifestyle advice leaflet (see Appendix 4.2).
Rationale for four appointments in 12 weeks
The value of psychological support for men following radical prostatectomy has been stressed 
in the literature,52 as has the intrinsic value of therapist contact in order to maintain patient 
motivation.64 Within MAPS, therefore, a schedule of four appointments (at baseline, 2 weeks, 
6 weeks and 12 weeks) was considered sufficient to monitor postsurgical muscle strength 
development and maintain motivation but not be too burdensome on patients or costly in terms 
of resources (chiefly therapist time).
Pelvic floor muscle strength can improve over a 3-month period of PFMT.42 Men in the study 
received four appointments and were encouraged to continue their exercise regimen for life, 
with particular emphasis on functional work (e.g. contracting during activity or counteracting 
increases in intra-abdominal pressure by use of ‘the Knack’). A previous trial by van Kampen et 
al.24 using pelvic floor exercises and functional use of these muscles showed significant reduction 
in urinary incontinence at 1, 6, and 12 months after radical prostatectomy, demonstrating that 
improvement was maintained while men continued to perform their exercises.
Summary of rationale for design of intervention
The MAPS intervention, combining PFMT, BT/US and fluid advice, was evidence based wherever 
possible. Where evidence was lacking, the intervention was based on expert clinical practice. The 
rationale underpinning the intervention was published in 2009.65
The trial compared the structured PFMT intervention with standard care, in order to add to 
the current evidence base. This, in turn, should inform practice and treatment decisions for 
therapists, men with incontinence after prostate surgery, and providers of care.
Training for the therapists
Therapists were either specialist continence physiotherapists or specialist continence nurses. 
The intervention protocol was standardised by systematically training all the therapists during 
a bespoke training day programme, and by use of common trial forms for recording assessment 28 Intervention design, centres, therapists and therapy
and treatment data. Some therapists were trained on a one-to-one basis if they joined the study 
late. During the training day, an overview provided information on the anatomy and physiology 
of the lower urinary tract, the pelvic floor muscles and the abdominal muscles, together with 
information on how prostate surgery affects normal urine control. Therapists received instruction 
on the MAPS PFMT protocol including:
  ■ assessment and examination of men in a systematic manner
  ■ the diagnosis of SUI, UUI, postmicturition dribble and erectile dysfunction by history
  ■ grading the strength of the pelvic floor muscles during a digital anal examination by 
evaluating the anal sphincter and also the puborectalis sling at each visit
  ■ affirmation that all the pelvic floor muscles (including the transversus abdominis) should 
tighten during a maximum contraction and that, if the contraction was strong, they would 
see a scrotal lift and the penis moving slightly into the body
  ■ description of the MAPS-approved method of teaching PFMT
  ■ instruction in BT/US techniques
  ■ advice about fluid intake and other lifestyle advice corresponding to the leaflet
  ■ the role of PFMT in the treatment of erectile dysfunction
  ■ graded goal-setting for the men in terms of gradually increasing endurance of pelvic floor 
muscle contractions
  ■ documenting the treatment given at each visit.
Summary of the MAPS intervention
At the baseline assessment visit, the men were taught PFMT. BT/US techniques were included if 
men described urgency or UUI. The men had reinforcement sessions on three further occasions 
over 3 months – at around 2 weeks, 6 weeks and 12 weeks after the first appointment. Anal 
examination was repeated at each visit to document changes in pelvic floor muscle strength, and 
to provide feedback to the men on their progress.
Pelvic floor muscle training
Men in the intervention group were instructed:
  ■ to carry out three maximum pelvic floor contractions in three positions (lying supine with 
knees bent and feet on the couch, sitting with knees apart and standing with feet apart) twice 
per day
  ■ to ‘lift’ their pelvic floors slightly while walking
  ■ to tighten their pelvic muscles before activities that might cause them to leak, such 
as coughing
  ■ to tighten after urinating to eliminate the last few drops.
Biofeedback
Biofeedback involved monitoring the strength of a pelvic floor contraction (by digital anal 
assessment) and verbally relaying the information back to the men in order to confirm that they 
were performing contractions correctly (lifting up in a cranial direction) and to inform them 
when they were increasing the strength or duration of their contractions. Therapists were trained 
to consistently grade the pelvic floor muscle strength and endurance by digital anal assessment 
at each session. The findings were used to set progressive targets for the men. Treatment was 
therefore individualised and could be progressively increased for each man.
If it was felt clinically indicated, in addition to digital anal assessment, therapists used machine-
mediated biofeedback with an anal biofeedback probe in centres where this was available (see 
Table 7), both for diagnosis and for teaching of correct muscle contraction.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
29   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
Bladder training/urge suppression
BT/US involved advice to gradually delay urination (by pelvic floor muscle contraction or 
calming/distracting activities) to teach the bladder to hold increasing volumes of urine. Men 
were instructed to relax for 1 minute when they first felt an ‘urge’, then walk calmly to the toilet or 
delay urination until the next ‘urge’.
Written information
All participants received the lifestyle advice booklet (see Appendix 4.2), and those in the 
intervention group also received the pelvic floor exercise booklet (see Appendix 4.3).
Ensuring standardisation of intervention
All staff delivering the intervention received exactly the same training in order to ensure 
consistency of their method of teaching and delivery of the PFMT, BT/US and biofeedback. Both 
specialist continence physiotherapists and specialist continence nurses were eligible to deliver the 
intervention, thus increasing the generalisability of the trial.
The therapists recorded their assessments and treatment programmes on standard study forms 
(see Appendix 4.1). Data were stored locally in case notes but collected and analysed centrally (see 
Chapters 6 and 11).
Centres, resources and therapists
Because physiotherapists were not available at every centre, and to increase the generalisability 
of the intervention to the NHS, we chose to train both specialist continence physiotherapists 
and specialist continence nurses (as above). There were 17 centres with therapists from a 
physiotherapy background, and 17 with a nursing background (Table 7).
Machine-led biofeedback was available in 13 centres (Table 7). Therapists were asked to declare 
whether they felt that biofeedback would be clinically indicated (whether or not a biofeedback 
machine was available) and also whether it was actually used. In five centres that had access to a 
biofeedback machine, and in four without such access, therapists reported that they would like to 
use one. A biofeedback machine was actually used in 5 of the 13 centres with access, for 17 men 
after radical surgery and 10 after TURP (Table 7).
TABLE 7  Types of therapists at each centre, availability of biofeedback, and use of biofeedback for men in each centre
Centre Physiotherapist
Specialist 
continence 
nurse
Biofeedback 
available in the 
centre 
Biofeedback 
clinically indicateda
Number of 
men receiving 
biofeedback
Aberdeen No Yes No  No  0
Ipswich Yes No Yes Yes (3R) 2R
Dundee No Yes No  No  0
Stockport Yes No No  Yes (2R, 1T) 0
Tameside Yes No Yes  Yes (3R, 8T) 3R, 4T
Middlesbrough Yes No No  Yes (8R) 0
Falkirk Yes No No  No  0
Newcastle upon Tyne Yes No No  No  1R
Airedale Yes No Yes  Yes (4R) 4R
Reading No Yes No  No  0
Wakefield Yes No Yes  No  0
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Centre Physiotherapist
Specialist 
continence 
nurse
Biofeedback 
available in the 
centre 
Biofeedback 
clinically indicateda
Number of 
men receiving 
biofeedback
Ayr Yes No Yes  Yes (1T) 0
Bristol No Yes Yes Yes (7R, 6T) 7R, 6T
Stevenage No Yes No  No  0
Inverness No Yes No  No  0
Leeds No Yes No  Yes (8R, 6T) 0
Inverclyde Yes No No  No  0
Wolverhampton Yes No No  No  0
Swansea No Yes No  No  0
Sheffield No Yes No  No  0
Ilford No Yes Yes No  0
Bolton Yes No Yes  No  0
Taunton No Yes No  No  0
Norwich Yes No Yes  No  0
Yeovil Yes No Yes  No  0
Edinburgh Yes No No  Yes (5R, 1T) 0
Dunfermline Yes No Yes  No  0
Cardiff No Yes  No  No  0
Macclesfield No Yes No  No  0
Southmead No Yes No  No  0
Crewe Yes No Yes  No  0
Hillingdon No Yes No  No  0
St Mary’s, London No Yes  Yes  No  0
Hope, Salford No Yes No  No  0
a  Numbers in brackets indicate the number of men for whom biofeedback was clinically indicated for men having radical prostatectomy (R) and 
TURP (T) at each site.
TABLE 7  Types of therapists at each centre, availability of biofeedback, and use of biofeedback for men in each centre 
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Chapter 4  
Centres and recruitment to the two 
trials
T
his chapter describes how the two trial groups were identified from the men admitted 
for radical prostatectomy and TURP at the recruiting hospitals. It reports the baseline 
comparability of the men in hospital, the response to the screening survey, and the characteristics 
of the study groups up to the point of entry to the RCTs.
Study recruitment
Men who were having prostate surgery were approached during their hospital stay by 
recruitment officers in each of the 34 centres. Men were asked to consent to being sent a 
screening questionnaire at 3 weeks after their surgery. If their response indicated that they were 
incontinent, they were invited to participate in the RCT of PFMT.
Centre screening and recruitment
Table 8 shows the number of men approached in each centre, and how many were eventually 
eligible for screening and randomisation. In total, 780 men having radical prostatectomy and 
2836 men who had TURP were sent a screening questionnaire, 742 and 2590 responded, and 
429 and 442 were eventually randomised. However, 18 of the ‘radical’ men from one centre were 
subsequently excluded after randomisation (postrandomisation exclusion) as therapy was not 
available during some of the period of screening in that centre, leaving 411 randomised to the 
radical prostatectomy trial.
Reasons for not completing a screening questionnaire
Table 9a describes the reasons given for ineligibility for receiving a screening questionnaire. 
The most common reasons for ineligibility were that the men were missed (no contact with 
recruitment officer), they refused, they were unable to give informed consent or they were having 
radiotherapy or palliative surgery, or that the operation was not carried out or changed to another 
operation. Table 9b shows that the men having TURP who were ineligible for screening were 
older than those who consented to screening.
Table 10a describes the reasons why men who were eligible for screening (signed consent forms 
received at the study office in Aberdeen) were in the event not sent a screening questionnaire. 
The most common reason was that the planned operation was changed or cancelled after the men 
had signed a consent form. Only men who actually had a radical prostatectomy or TURP were 
eligible to be screened. Table 10b shows that there were no significant differences in age between 
those who were eligible and screened and those who were eligible and not screened.32 Centres and recruitment to the two trials
TABLE 8  Centres with numbers of men recruited to each trial
Centre
Radical prostatectomy TURP
n screened/N 
approached
n responded/N 
screened
n randomised/N 
responded to 
screening
n screened/N 
approached
n responded/N 
screened
n randomised/N 
responded to 
screening
Aberdeen 76/85 74/76 55/74 320/467 302/320 60/302
Ipswich 40/49 39/40 15/39 146/511 138/146 17/138
Dundee 1/1 1/1 1/1 27/37 27/27 4/27
Stockport 70/97 68/70 37/68 191/476 173/191 27/173
Tameside 30/32 26/30 18/26 145/203 125/145 19/125
Glasgow Southern 4/45 3/4 0/3
Middlesbrough 49/60 47/49 36/47
Falkirk 4/22 4/4 2/4 6/62 6/6 1/6
Newcastle 45/61 42/45 23/42 491/661 448/491 63/448
Airedale 5/15 5/5 2/5 19/109 18/19 3/18
Reading 69/98 68/69 32/68 144/408 131/144 18/131
Wakefield 15/23 15/15 6/15 59/150 57/59 11/57
Ayr 109/225 101/109 17/101
Bristol 26/51 26/26 16/26 110/244 104/110 24/104
Stevenage 0/3 27/108 26/27 8/26
Inverness 38/41 36/38 18/36 108/144 98/108 15/98
Leeds 118/168 113/118 77/113 205/623 180/205 24/180
Inverclyde 20/30 16/20 3/16
Wolverhampton 38/115 36/38 9/36
Swansea 31/36 30/31 15/30 43/63 38/43 6/38
Sheffield 63/67 61/63 27/61 112/143 102/112 22/102
Ilford 20/22 18/20 4/18
Bolton 8/12 6/8 3/6 51/155 43/51 8/43
Taunton 4/5 4/4 2/4 71/82 62/71 14/62
Norwich 12/24 12/12 5/12 18/72 17/18 1/17
Yeovil 1/2 1/1 0/1 40/63 39/40 10/39
Edinburgh 10/81 10/10 6/10 23/220 21/23 4/21
Dunfermline 5/6 5/5 2/5 91/108 82/91 14/82
Cardiff 107/194 97/107 19/97
Macclesfield 0/1 14/45 13/14 1/13
Southmead 29/86 24/29 15/24 44/150 38/44 8/38
Crewe 33/51 31/33 8/31
Hillingdon 1/1 1/1 1/1
St Mary’s, London 28/28 22/28 13/22
Hope, Salford 2/3 2/2 2/2
Total (34) 780/1158 742/780 429/742 2836/5986 2590/2836 442/2590© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
33   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
TABLE 9a  Number of men admitted for prostate surgery, and numbers eligible for screening survey 
Radical prostatectomy TURP
Approached 1158 5986
[Consented, N] [804] [2985]
Not consented  354/1158 (31) 3001/5986 (50)
Reasons for no consent
No reason given 15 (4) 65 (2)
Refused 75 (21) 601 (20)
Not approached/missed 154 (44) 1078 (36)
Unable to give informed consent 20 (6) 537 (18)
Referred for formal physiotherapy 10 (3) 3 (0)
Radiotherapy planned or palliative surgery 6 (2) 485 (16)
Surgery cancelled or changed (e.g. BNI) 17 (5) 198 (7)
On other trial (e.g. ProtecT) 47 (13) 3 (0)
Unclear/other reason 10 (3) 31 (1)
BNI, bladder neck incision.
n/N (%)
TABLE 9b  Baseline comparability of men eligible and not eligible for screening survey
Radical prostatectomy TURP
Eligible Ineligible Eligible Ineligible
Age, years [mean (SD) n] 62.5 (5.9) 802 63.1 (6.5) 347 69.9 (8.3) 2972 73.4 (9.1) 2971
TABLE 10a  Number of men eligible for screening survey and reasons for not screening some of them
Radical prostatectomy TURP
Consented n/N (%) 804/1158 (69.4) 2985/5986 (49.9)
Consented and screened n/N (%) 780/804 (97) 2838/2985 (95)
Consented but not screened n/N (%) 24/804 (3) 147/2985 (5)
Reasons for not screening (n)
No reason given 0 (0) 3 (3)
Refused 0 (0) 11 (8)
Referred for formal physiotherapy 1 (4) 0
Radiotherapy planned or palliative surgery 1 (4) 17 (12)
Surgery cancelled or changed (e.g. BNI) 12 (50) 106 (72)
On other trial (e.g. ProtecT) 0 (0) 1 (1)
Unclear/other reason 10 (42) 11 (6)
TABLE 10b  Baseline comparability of men screened and not screened by screening questionnaire
Radical prostatectomy TURP
Screened  Not screened Screened Not screened
Age, years  [mean (SD) n] 62.4 (6.0) 778 63.5 (5.2) 24 70.0 (8.2) 2825 69.3 (10.0) 14734 Centres and recruitment to the two trials
Recruitment of men to the randomised controlled trial
Each man who indicated on his screening questionnaire that he had urinary incontinence was 
sent a baseline questionnaire and contacted around a week later by a dedicated recruitment 
officer based at the MAPS study office in Aberdeen. Eligibility was confirmed and, upon receipt of 
the signed RCT consent form, men were randomised to the intervention or standard care groups. 
Figures 4 and 5 show the flow of the number of patients who were approached to take part in the 
screening through to randomisation into the radical prostatectomy and TURP trials respectively.
FIGURE 4  Flow chart of men from operation to recruitment to RCT: radical prostatectomy. a, Postrandomisation 
exclusion: therapy was not available during some of the period of screening in one centre (18 men).
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Reasons for screened patients not to be subsequently 
randomised
Table 11 describes the reasons why screened men were not randomised into the trials. The most 
common reason was that the men were continent at the screening questionnaire or subsequently 
continent by the time the baseline questionnaire or telephone recruitment call was conducted.
FIGURE 5  Flow chart of men from operation to recruitment to RCT: TURP.
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Recruitment rates
The original projections were based on assumptions from the literature that around 50% of men 
would be wet after a radical prostatectomy, and that 65% of these would be willing to enter an 
RCT of conservative treatment (see Table 2). For the men having TURP, we expected around 5% 
of men to be wet, and that a similar proportion (65%) would agree to randomisation. The sample 
size calculation had indicated that we would need to recruit 400 men per trial in order to achieve 
our prespecified difference, and that 26 centres would be sufficient to achieve this.
In the event, the numbers of men having operations at each centre varied widely (see Table 8) but 
the proportions of men responding, incontinent and willing to enter the RCT were much higher 
than our assumptions, especially in the TURP group. Despite this, a review of actual accrual rates 
led us to anticipate a shortfall in recruitment. We therefore prepared revised projections, based 
on more realistic assumptions and recruitment of extra centres, and were granted a 9-month 
extension in order to achieve our initial target sample size.
By the end of recruitment, 7144 men had been approached regarding the screening survey 
in 34 sites, and 853 men from these sites had been randomised. Figure 6 shows a graphical 
representation of recruitment against revised targets as agreed for the extension period. The jump 
in the projected recruitment line after December 2006 reflects the change after implementing the 
extension. The last men were approached in July 2008 and recruitment to the RCT ended on 23 
September 2008.
TABLE 11  Reasons why men did not progress during the study, or withdrew before randomisation
Radical prostatectomy TURP
Number of men responding at screening but not sent a baseline questionnaire 
Dry at screening 51 1387
Dry before baseline 1 5
Declined further contact 26 122
Referred for PFMT 2 1
Referred for radiotherapy 1  –
Moving away/unable to attend therapy 1 1
Permanently catheterised  – 1
No reason given 2 25
Number of men responding at baseline but not randomised
Dry before randomisation 61 274
Declined participation in RCT 15 16
Unable/unwilling to travel to therapy appointments 11 32
Dry after baseline 8 18
Attending PFMT training 2  –
Having radiotherapy 5  –
Medical problems 1 4
In another study 1  –
Postrandomisation exclusions
Therapy not available during some of the period of screening in one centre 18  –© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Chapter 5  
Radical randomised controlled 
trial: derivation and description of 
participants
T
his chapter describes the men derived from the screening survey in terms of their clinical 
characteristics and presents the baseline comparability between the randomised groups in 
the group having radical prostatectomy.
Comparison between those responding and not responding to 
screening survey
Table 12 shows the comparability at baseline of those responding and not responding to the 
screening survey in terms of their demographic and clinical characteristics. There were no 
clinically important differences between the responders and non-responders. The majority of 
men (around 80%) had a traditional abdominal retropubic prostatectomy, 2% had a perineal 
approach and just under 20% had a laparoscopic procedure. One or both nerve bundles were 
spared in just over 60% of operations amongst the responders.
Findings from screening survey
The average time of completion of the screening survey was at around 5 weeks after surgery 
(mean days since operation 38.1, SD 14.9).
TABLE 12  Screening survey responders and non-responders
Radical prostatectomy Responder  Non-responder 
Number screened [n/N (%)] 742/780 (95) 38/780 (5)
Age [mean years (SD) n] 62.5 (5.9) 740 61.1 (7.4) 38
Weight [mean kg (SD) n] 82.8 (12.2) 704 84.2 (12.7) 35
Height (mean cm (SD) n] 173.9 (13.1) 664 173.9 (8.4) 34
Current smoker (yes) [n/N (%)] 81/742 (11) 7/38 (18)
Nights in hospital [mean (SD) n] 6.2 (2.9) 687 5.7 (3.2) 33
Type of operation  N = 740 N = 38
Abdominal retropubic prostatectomy [n/N (%)] 585/740 (79) 31/38 (82)
Perineal radical prostatectomy [n/N (%)] 15/740 (2) 0
Laparoscopic radical prostatectomy [n/N (%)] 140/740 (19) 7/38 (18)
Nerve bundle sparing  N = 708 N= 36
One nerve bundle spared [n/N (%)] 133/708 (19) 10/36 (28)
Both nerve bundles spared [n/N (%)] 302/708 (43) 9/36 (25)
Neither nerve bundles spared [n/N (%)] 90/708 (13) 2/36 (6)
Unknown nerve bundle sparing [n/N (%)] 183/708 (26) 15/36 (42)
Numbers as reported.40 Radical randomised controlled trial: derivation and description of participants
Radical prostatectomy can be performed using three main routes: open abdominal, perineal, 
and laparoscopically. The last two are thought to be associated with less postoperative urinary 
incontinence and sexual dysfunction.1,66 In addition, urinary incontinence is thought to be 
reduced in operations in which it is possible to spare one or both nerve bundles.11,67,68 The 
majority of men had a traditional open abdominal prostatectomy, with only a few having a 
perineal approach (n = 15). Table 13 shows that, at screening, there was little difference in the 
chance of immediate incontinence according to the route of operation. Nor did the chance 
of incontinence differ according to the surgeon’s ability to spare one or both nerve bundles 
(Table 13). Long-term follow-up will be needed to confirm whether these findings persist. The 
most common type of incontinence was SUI (76%).
Summary information for progress from screening questionnaire 
to randomisation
Of 691 men wet at screening, 33 were not eligible to be sent a baseline questionnaire (see 
Table 11 for reasons). Of the 658 men sent a baseline questionnaire, 533 (81%) responded, of 
whom 472 (89%) were still wet and 61 dry. A further 43 were excluded as they were ineligible for 
randomisation despite still being incontinent (see Table 11 for reasons). Finally, 429 men were 
randomised but 18 were excluded after randomisation as there was no therapy available during 
TABLE 13  Results of screening survey 3 weeks after operation (responders only, n = 742)
Radical prostatectomy
All responders 
to screening 
questionnaire
(n = 742)a
Abdominal route
(n = 585)
Perineal route
(n = 15)
Laparoscopic route
(n = 140)
Days since operation
[mean (SD) n]
38.1 (14.9) 732 33.0 (14.6) 578 30.0 (7.9) 15 34.5 (14.5) 139
Number of men with any urine loss at 
screening questionnaire [n/N (%)]
691/742 (93) 543/585 (93) 15/15 (100) 131/140 (94)
Nerve bundle sparing: number of men with any 
urine loss [n/N (%)]
658/708 (93) 514/555 (93) 15/15 (100) 128/137 (93)
  One nerve bundle spared [n/N (%)] 126/133 (95) 98/103 (95) 5/5 (100) 23/25 (92)
  Both nerve bundles spared [n/N (%)] 280/302 (93) 212/230 (92) 4/4 (100) 64/68 (94)
  Neither spared [n/N (%)] 87/90 (97) 71/74 (96) 1/1 (100) 15/14 (100)
  Unknown sparing [n/N (%)] 165/183 (90) 133/148 (90) 5/5 (100) 26/29 (90)
ICI-QoL score owing to UIb [mean (SD) n] 4.6 (5.6) 726 4.4 (3.2) 572 5.1 (3.3) 15 5.5 (3.3) 139
ICI-Q scorec [mean (SD) n] 10.8 (5.6) 740 10.4 (5.5) 585 11.9 (4.7) 15 12.3 (5.8) 140
Number of men with urine loss before surgery 
[n/N (%)]
47/740 (6) 45/585 (8) 0 2/140 (1)
Number of men with faecal incontinence after 
surgery [n/N (%)]
18/742 (2) 14/585 (2) 1/15 (8) 3/140 (2)
Type of incontinence 
  SUI [n/N (%)] 559/740 (76) 427/585 (73) 14/15 (93) 118/140 (84)
  UUI [n/N (%)] 297/740 (40) 227/585 (39) 9/15 (60) 61/140 (44)
  MUI [n/N (%)] 242/740 (33) 175/585 (30) 9/15 (60) 58/140 (41)
  Postmicturition leakage [n/N (%)] 253/740 (34) 185/585 (32) 7/15 (47) 61/140 (44)
  Other incontinence [n/N (%)] 334/740 (45) 266/585 (45) 6/15 (40) 62/140 (44)
a  Type of operation unknown for two participants.
b  ICI-QoL score: 0 = none, 10 = maximum (worst) score. Derived from question 3 of the ICIQ-UI Short Form Questionnaire.
c  ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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their recruitment period, leaving 411 men properly randomised, 205 in the intervention group 
and 206 in the control group (see Figure 4).
Men who recorded that they were wet at the screening survey were sent a further baseline 
questionnaire to confirm persistent leakage. Those who were still wet and consented were 
randomised to intervention or control. The average time to randomisation from the date of 
surgery was 8 weeks (mean 7.9, SD 2.7).
Comparability on baseline characteristics at trial entry
Table 14 shows that the men in the two randomised groups were comparable at baseline on the 
clinical and demographic characteristics recorded.
Prior knowledge of pelvic floor exercises
Many men had been counselled before surgery about the possibility of urinary incontinence 
and sexual dysfunction after surgery.69 Table 15 shows that almost all of the men (97% and 99% 
TABLE 14  Baseline comparability at trial entry between men in randomised groups 
Radical prostatectomy Intervention (n = 205) Control (n = 206)
Age in years [mean (SD) n, (min–max)] 62.4 (5.8) 205, (47–76) 62.3 (5.6) 206, (47–75)
BMI (kg/m2) [mean (SD) n, (min–max)] 25.9 (2.9) 197, (19.4–39.5) 26.3 (3.3) 202, (18.0–36.2)
Type of operation [n/N (%)]a 204 205
 Abdominal  157/204 (77) 161/205 (79)
 Perineal  6/204 (3) 4/205 (2)
 Laparoscopic  41/204 (20) 40/205 (20)
TURP before surgery [n/N (%)] 12/205 (6) 4/201 (2)
Number of men not able to achieve erection before prostate surgery [n/N (%)] 17/205 (8) 18/202 (9)
Leakage of urine before operation [n/N (%)] 14/205 (7) 13/206 (6)
ICI-Q score at baseline [mean (SD) n]b 11.2 (4.3) 205 11.5 (4.5) 206
Number of men with severe incontinence at baseline [n/N (%)]c 188/205 (92) 189/206 (92)
Urinary frequency at baseline (per day) [mean (SD) n] 7.4 (2.9) 187 7.9 (3.7) 192
Nocturia at baseline (per night) [mean (SD) n] 2.2 (1.2) 199 2.5 (1.6) 202
Type of incontinence [n/N (%)] 205 206
 SUI  195/205 (95) 195/206 (95)
 UUI  135/205 (66) 156/206 (76)
  MUI (both) 132/205 (64) 151/206 (73)
  Postmicturition leakage 166/205 (81) 170/206 (83)
  Other incontinence 72/205 (35) 91/206 (44)
Pad use  180/205 (88) 176/205 (86)
Other health problems  89/204 (44) 94/204 (46)
EQ-5D [mean (SD) n] 0.8 (0.2) 200 0.8 (0.2) 206
SF-12 mental [mean (SD) n] 50.8 (10.5), 201 49.3 (10.7), 201
SF-12 physical [mean (SD) n] 42.7 (9.9), 201 41.8 (10.6), 201
Numbers as reported. 
a  Information missing in two cases.
b  ICI-Q score: 0=none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
c  Severe incontinence defined as at least once a day and a moderate or large amount of leakage.42 Radical randomised controlled trial: derivation and description of participants
in the two groups) had prior knowledge of pelvic floor exercises for these problems. The most 
common sources of information were from nurses or continence advisors or from leaflets or 
books (Table 15).
TABLE 15  Number of men with prior knowledge of pelvic floor exercises
Source of information  Intervention Control
From a doctor 79/195 (41) 72/191 (38)
From a nurse/continence advisor 147/195 (75) 136/191 (71)
From a physiotherapist 21/195 (11) 23/191 (12)
From leaflets or books 127/195 (65) 129/191 (68)
From the internet 22/195 (11) 34/191 (18)
From friends or family 42/195 (22) 43/191 (23)
From another source 2/195 (1) 2/191 (1)
At least one source of information  190/195 (97) 190/191 (99)
Figures are n/N (%) answering yes. Respondents could cite more than one source of information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Chapter 6  
Radical randomised controlled trial: 
management received
T
his chapter describes how the intervention was implemented in the therapy arm of the 
radical RCT, and the progress of men through the intervention period (n = 205). The 
information in this chapter is derived from the therapy documentation (see Appendix 4.1), which 
was used primarily to guide the therapists while delivering the standardised intervention.
Compliance with therapy
Of the 205 men who were randomised to the intervention, 189 attended at least one visit (92%), 
and 85% attended every time (Table 16). The non-attenders were younger and lighter, but these 
differences were not clinically important (Table 17). Only 5 of the 16 men who did not attend 
were dry. The other main reason was that, after they were allocated to therapy, five men found 
it to be inconvenient or impossible to attend appointments, often owing to work commitments 
(Table 18).
TABLE 16  Number of visits attended (n = 205)
Radical prostatectomy First visit Second visit  Third visit Fourth visit
Number of men attending [n (%)] 189 (92) 186 (91) 177 (86) 175 (85)
TABLE 17  Number of attenders/non-attenders, comparability on age and BMI [mean (SD) n]
Radical prostatectomy Attenders Non-attenders 
Age (years) 62.6 (5.7) 189 59.8 (6.6) 16
BMI (kg/m2) 26.0 (3.0) 181 25.8 (1.5) 16
TABLE 18  Reasons for non-compliance (not attending any visits at all) (n = 16)
Radical prostatectomy Non-attenders (n)
Dry 5
Ill 1
Unable to attend 5
Declined 0
No reason given 5
Total 1644 Radical randomised controlled trial: management received
Relationship between type of therapist and outcomes during 
therapy period
Half of the centres (17) used a physiotherapist to deliver the MAPS intervention, while in the 
other 17 the therapist had a nursing background (Table 19). There was no significant difference 
in the number of visits men made to physiotherapists or nurse therapists (Table 19). During the 
3-month intervention period, there were no statistically significant differences in the mean ICI 
scores (a composite score reflecting urinary incontinence and its effect on quality of life) between 
therapists (Table 19).
Urinary incontinence during therapy period
Incidence of urinary incontinence
The therapists asked the men at each visit to rate their incontinence (in the previous week). 
This allowed the therapists to monitor the change in reported incontinence. They used the same 
form of question as the questionnaires, based on the ICI-SF instrument, which were also used to 
measure the primary outcome. The proportion of men with incontinence fell from 92% to 73%, 
while the mean ICI score decreased (improved) from around 8 at the start of treatment to around 
4 afterwards (Table 20 and Figure 7).
Type of urinary incontinence during therapy period
The distribution of type of incontinence reported by the men did not vary with time across 
the therapy visits (Table 21 and Figure 8) except that the proportion with stress incontinence 
alone decreased slightly (from 84% to 72%), and postmicturition leakage also decreased 
(from 63% to 25%).
TABLE 20  Number of men incontinent at each time point and mean ICI-Q score at each therapy visit 
Radical prostatectomy Visit 1 Visit 2 Visit 3  Visit 4
Men incontinent [n/N (%)] 172/187 (92) 165/182 (91) 143/171 (84) 123/169 (73)
ICI-Q scorea [mean (SD) n] 7.9 (4.3) 189 6.8 (4.1) 186 5.6 (3.9) 177 4.3 (3.7) 175
a  ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
TABLE 19  Relationship between type of therapist and attendance rates (mean number of attendances) and effect on ICI 
composite incontinence score at each visit
Radical prostatectomy Physiotherapist Continence nurse Mean difference (95% CI), p-value
Number of attendances 3.7 (1.0) 79, (3.5 to 3.9) 3.4 (1.3) 126, (3.2 to 3.7) 0.26 (–0.06 to 0.59), 0.113
ICI-Q score
  Visit 1 8.3 (4.7) 75, (7.2 to 9.4) 7.6 (4.0) 114, (6.8 to 8.3) 0.71 (–0.55 to 1.98), 0.267
  Visit 2 7.1 (4.1) 75, (6.2 to 8.1) 6.6 (4.0) 111, (5.9 to 7.4) 0.54 (–0.65 to 1.74), 0.372
  Visit 3 5.7 (4.1) 72, (4.8 to 6.7) 5.5 (3.8) 105, (4.7 to 6.2)  0.26 (–0.94 to 1.45), 0.674
  Visit 4 4.6 (3.8) 71, (3.7 to 5.5) 4.1 (3.6) 104, (3.4 to 4.8) 0.49 (–0.64 to 1.61), 0.396
Figures are mean (SD) n, (95% CI), unless shown otherwise.
ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Incidence and type of bowel problems during therapy period
Therapists also enquired at each visit about whether the men experienced any bowel dysfunction 
in the previous week. The proportions of men with three different types of bowel dysfunction 
(faecal incontinence, faecal urgency and constipation) were low, and did not vary during the 
therapy period (Table 22 and Figure 9).
Incidence and type of sexual problems during therapy period
The questions relating to sexual problems were those used in routine clinical practice. They were 
not based on the questions men were asked at 12 months to assess their sexual function and 
activity 70 (see section G, 12-month questionnaire, Appendix 3.3).
The proportion of men with sexual dysfunction (‘difficulty gaining or maintaining an erection 
in the last week’) after radical surgery was high (85–90%) and this did not change during the 
therapy period. The corresponding proportion with premature ejaculation was very low and also 
did not vary with time (Table 23 and Figure 10).
FIGURE 7  Trend analysis of the proportion (%) of men incontinent at each visit: men having had radical prostatectomy. 
ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
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TABLE 21  Type of incontinence at each therapy visit and change over time
Radical prostatectomy Visit 1 Visit 2 Visit 3 Visit 4
Number of men 189 186 177 175
SUI  152/181 (84) 145/175 (83) 118/162 (73) 110/152 (72)
UUI  35/173 (20) 31/159 (19) 33/154 (21) 22/145 (15)
MUI (both SUI and UUI) 28/182(15) 26/174(15) 24/162(15) 17/155(11)
Postmicturition leakage 113/179 (63) 68/163 (42) 49/157 (31) 36/145 (25)
Other UI 47/162 (29) 35/148 (24) 34/146 (23) 27/135 (20)
Figures are n/N (%). 46 Radical randomised controlled trial: management received
FIGURE 8  Type of incontinence at each visit and change over time: men having had radical prostatectomy.
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Examination of pelvic floor muscle performance during therapy 
visits
Therapists assessed the strength of the pelvic floor muscle contractions and their endurance 
(length of time men were able to hold a contraction) at each visit using digital anal assessment 
(see Chapter 3). The external anal sphincter and the internal puborectalis muscle were assessed 
separately. The internal puborectalis muscle strength was taken to be a measure of pelvic floor 
muscle strength.
TABLE 22  Type of bowel problems at each therapy visit and change over time
Radical prostatectomy Visit 1 Visit 2 Visit 3 Visit 4
Faecal incontinence 4/187 (2) 3/183 (2) 2/172 (1) 2/171 (1)
Faecal urgency 13/187 (7) 11/183 (6) 13/172 (8) 6/171 (4)
Constipation 23/187 (12) 10/181 (5) 11/171 (6) 13/169 (8)
Figures are n/N (%).
FIGURE 9  Type of bowel problems at each visit and change over time: men having had radical prostatectomy.
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Constipation at each visit48 Radical randomised controlled trial: management received
For both the sphincter and the puborectalis, both strength and endurance improved during 
the therapy period (Table 24 and Figure 11). At baseline, only 15% of men had a strength of 5 
or more, whereas by the fourth visit around 50% of men were able to contract strongly (5) or 
very strongly (6), and 85% had good muscle strength (4 or better). The therapists were trained 
to ask men to hold the pelvic floor muscle contraction for up to 10 seconds during the digital 
anal examination. This is in line with functional use of these muscles. However, some therapists 
assessed the maximum length of time for which men could hold a contraction. Of these men, 
some held the contraction for over 1 minute.
TABLE 23  Type of sexual problems at each therapy visit and change over time 
Radical prostatectomy Visit 1 Visit 2 Visit 3 Visit 4
Difficulty gaining erection 156/176 (89) 153/170 (90) 142/159 (89) 144/161 (89)
Difficulty maintaining erection 148/169 (88) 144/165 (87) 128/148 (86) 145/157 (92)
Premature ejaculation 4/154 (3) 4/150 (3) 4/139 (3) 2/143 (1)
Figures are n/N (%).
FIGURE 10  Type of sexual problems at each visit and change over time: men having had radical prostatectomy.
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Examination and functional use of pelvic floor muscles
Therapists examined men at each visit to assess skin damage, skin infection, ability to tighten the 
anus, perform penile retraction and testicular lift, evidence of leakage on coughing and (for those 
who did leak) ability to prevent leakage on coughing. Very few men showed evidence of skin 
damage or infection (data not shown).
Four different aspects of functional use of pelvic floor muscles were assessed (ability to tighten 
anus; ability to perform penile retraction; leakage on coughing; ability to prevent leakage on 
coughing). While most men (around 95%) were able to contract well enough to tighten the anal 
sphincter at least a little from baseline onwards, the proportion able to demonstrate a testicular 
lift increased slightly with time (from 80% to 90%; Figure 12). The proportion who leaked when 
coughing decreased from about 18% to 9% during the therapy period. Around 80% of these men 
were able to contract their pelvic floor muscles sufficiently to prevent leakage when coughing at 
the first visit, and this improved only slightly to around 85% by the fourth visit.
Use of machine-led biofeedback
Biofeedback was available in 13 of 34 MAPS centres, and was used clinically for MAPS men in 
five of them (see Table 7). Therapists would have liked access to this facility in four other centres 
where biofeedback was not available. Biofeedback can be used in two ways:
TABLE 24  Ability to contract anal sphincter and puborectalis muscle (pelvic floor) over time 
Radical prostatectomy Visit 1 Visit 2 Visit 3 Visit 4
A: External anal sphincter strength 
[mean (SD) n]a
3.3 (1.0) 170 3.6 (0.9) 153 4.0 (1.0) 127 4.3 (1.0) 129
0 1/170 (0.5) 0 0 0
1 1/170 (0.5) 2/153 (1) 1/127 (1) 1/129 (1)
2 29/170 (17) 11/153 (7) 9/127 (7) 4/129 (3)
3 71/170 (42) 54/153 (35) 20/127 (16) 17/129 (13)
4 48/170 (28) 62/153 (41) 57/127 (45) 45/129 (35)
5 19/170 (11) 23/153 (15) 38/127 (30) 51/129 (39)
6 1/170 (0.5) 1/153 (1) 2/127 (1) 11/129 (8)
A: External anal sphincter endurance (seconds) 
[mean (SD) n]b
6.1 (2.7) 170 7.6 (2.8) 153 9.3 (6.0) 127 10.6 (8.4) 129
B: Puborectalis muscle strength [mean (SD) n]a 3.4 (1.0) 169 3.7 (0.9) 153 4.1 (1.0) 126 4.4 (1.0) 128
0 0 0 0 0
1 4/169 (2) 3/153 (2) 2/126 (2) 1/128 (1)
2 24/169 (14) 8/153 (5) 5/126 (4) 3/128 (2)
3 68/169 (40) 43/153 (28) 23/126 (18) 19/128 (15)
4 51/169 (30) 71/153 (46) 48/126 (38) 39/128 (30)
5 22/169 (13) 28/153 (18) 44/126 (35) 52/128 (41)
6 0 0 4/126 (3) 14/128 (11)
B: Puborectalis muscle endurance (seconds) 
[mean (SD) n]b
6.5 (3.0) 169 7.7 (2.7) 153 9.4 (6.1) 126 10.7 (8.5) 128
Figures are n/N (%) unless otherwise indicated.
a  External anal sphincter and puborectalis muscle strength were measured on a 0–6 modified Oxford scale: 0 = no flicker; 1 = flicker; 2 = weak 
contraction, no movement; 3 = moderate contraction with movement; 4 = good contraction against resistance; 5 = strong contraction against 
strong resistance; 6 = maximal contraction, very strong, unable to remove finger.
b  Endurance was measured as the duration in seconds for which the man could maintain an anal squeeze contraction.50 Radical randomised controlled trial: management received
  ■ to feed back information to men that they are actually performing a correct pelvic floor 
contraction, and at what strength
  ■ as part of a repetitive training regimen when men are asked to use the machine to enable 
them to monitor their exercise function for a period of time (such as 20 minutes).
It was unclear which type of biofeedback was practised in the centres where this was available, 
but therapists from five centres recorded its use in 16 men (see Table 7) from the radical 
prostatectomy group (the number at each time point is shown in Table 25). In some cases men 
may have preferred anal examination using a machine rather than digital examination by the 
therapist for teaching of correct contractions. As it was most often used on the first visit, this 
suggests that suggests that biofeedback was used in a diagnostic rather than in a training capacity.
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FIGURE 11  Ability to contract anal sphincter and puborectalis muscle (pelvic floor) over time: men having had radical 
prostatectomy. (a) External anal sphincter strength/endurance. (b) Puborectalis muscle strength/endurance. 0 = No 
flicker; 1 = flicker; 2 = weak; 3= moderate movement; 4 = good resistance; 5 = strong resistance; 6 = very strong, unable to 
withdraw finger. Endurance of contraction in seconds: median, minimum, maximum and mean duration.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 12  Aspects of ability to use pelvic floor muscles at each visit and change over time: men having had radical 
prostatectomy.
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Cough leak Ability to prevent cough leak
Testicular lift Able to tighten anus
TABLE 25  Use of biofeedback for any men
Radical prostatectomy Biofeedback indicated  Biofeedback actually implemented
Visit 1  12/123 (10) 8/124 (6)
Visit 2  5/110 (4) 5/110 (4)
Visit 3  5/94 (5) 5/94 (5)
Visit 4  4/106 (4) 4/106 (4)
Figures are n/N (%).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 7  
Radical randomised controlled trial: 
outcomes and results
T
his chapter describes the results of the intervention amongst the men recruited to the radical 
prostatectomy RCT.
Patient flow
The derivation of the trial study groups and their progress through the trial is summarised in 
Figure 13. This is in the form of a CONSORT (Consolidated Standards of Reporting Trials) flow 
diagram. In total, 411 participants were recruited to the randomised trial: 205 randomly allocated 
to the intervention group and 206 to the control group. Nine men had withdrawn from follow-up 
by 12 months (although some information was available before their withdrawal in some cases). 
One of these nine, in the intervention group, subsequently died. His death was not attributed 
to the trial intervention. Sixteen participants (8%) in the intervention group did not attend any 
therapy sessions and were considered non-compliers with the intervention (see Chapter 6).
Response rates
Over 90% of all participants returned completed questionnaires. As shown in Figure 13, by the 
time of each follow-up some participants had formally withdrawn (five from the intervention 
group and four from the control group; Table 26), and so were not sent questionnaires. Of the 
participants for whom it was appropriate to send a follow-up questionnaire, over 95% returned it 
at each time point (Table 27a).
For return of urinary diaries, the response rate was slightly lower, but still approximately 90% at 
each time point (Table 27b).
TABLE 26  Reasons for withdrawal
Reason
Radical prostatectomy RCT
Intervention Control
Ill 1 1
Dry 1 1
Catheterised permanently 0 0
No reason 2 0
Other 1 2
Total 5 454 Radical randomised controlled trial: outcomes and results
Primary outcome: urinary incontinence at 12 months
The primary outcome was incontinence in men at 12 months after randomisation, measured by a 
positive response to one of two questions from the ICI-SF questionnaire (‘How often do you leak 
urine’ or ‘How much urine do you usually leak?’). Table 28 shows that the difference between the 
intervention and control groups in urinary incontinence at 12 months (75.5% vs 77.4%) was not 
statistically significant:
354
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FIGURE 13  Radical CONSORT diagram (men randomised n = 411). a, Postrandomisation exclusion: therapy was not 
available during some of the period of screening in one centre (18 men).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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  ■ either when analysed by intention to treat (all men analysed in the groups to which they 
were randomised but results as given in the outcome questionnaires without adjustment for 
missing values)
  ■ or when analysed by ‘treatment received’, which adjusts the result by a factor related to the 
men who actually attended a therapist versus those who did not.
TABLE 27b  Urinary diary response rates (n = 205 in intervention group, 206 in control group)
Radical prostatectomy Number sent Number returned (%) Percentage of all men
Baseline
 Intervention 205 194 (95) 95
 Control 206 199 (97) 97
3 months
 Intervention 204 188 (92) 92
 Control 206 187 (91) 91
6 months
 Intervention 202 185 (92) 90
 Control 205 182 (89) 88
9 months
 Intervention 201 178 (89) 87
 Control 203 181 (89) 88
12 months
 Intervention 200 183 (92) 89
 Control 202 181 (90) 88
The first returned column is percentage out of all diaries sent (to men continuing in the study); the second is the percentage out of the total 
number of men randomised to each trial group.
TABLE 27a  Patient questionnaire response rates (n = 205 in intervention group, 206 in control group)
Radical prostatectomy Number sent Number returned (%) Percentage of all men
Baseline
 Intervention 205 205 (100) 100
 Control 206 206 (100) 100
3 months
 Intervention 204 200 (98) 98
 Control 206 198 (96) 96
6 months
 Intervention 202 199 (99) 97
 Control 205 197 (96) 95
9 months
 Intervention 201 191 (95) 93
 Control 203 194 (95) 94
12 months
 Intervention 200 196 (98) 95
 Control 202 195 (97) 95
The first returned column is the percentage out of all questionnaires sent (to men continuing in the study); the second is the percentage out of the 
total number of men randomised to each trial group.56 Radical randomised controlled trial: outcomes and results
The above analyses were then repeated adjusting for the minimisation factors, but this did not 
alter the findings (Table 28). The corresponding risk difference for the unadjusted intention-to-
treat analysis was –1.9% (95% CI –10% to 6%), thereby ruling out the likelihood that the trial 
prespecified difference of 15% in proportion incontinent between intervention and control group 
could have been missed.
Secondary outcomes
Urinary outcomes
Urinary incontinence was also measured at 3, 6 and 9 months after randomisation together with 
other urinary outcomes. Table 29a describes the various urinary outcomes at each follow-up and 
Table 29b shows the formal statistical testing of the differences at each time point. Figure 14 is 
a pictorial representation of the percentage of men incontinent at each follow-up and Figure 15 
shows the change in mean ICI-score over time. The data show that there were no statistically 
significant differences between the intervention and control groups at any of the time points in 
terms of urinary incontinence and the other urinary outcomes measured.
Type of incontinence
Table 30 and Figure 16 show the type of incontinence at baseline, and at 6 and 12 months after 
randomisation. Men could report more than one type of incontinence. At all time points the 
majority (70%) of men had (any) stress incontinence: this did not vary much after the first 
6 months, and the proportions were not significantly different between the intervention and 
control groups (see Table 30 and Figure 16a). Around half of the men had urgency or mixed 
incontinence. The proportions of men with other types of urinary incontinence (urgency, 
Figure 16b; mixed, Figure 16c; postmicturition leakage, Figure 16d; and other types of 
incontinence) decreased over the first 6 months, but there was little further improvement, or 
difference between the groups.
Use of aids or protection for urinary incontinence
Table 31a shows the men’s use of aids to protect them from urinary leakage: this did not differ 
significantly according to the randomised groups at any of the follow-up time points. Table 31b 
presents the statistical analyses of these outcomes. About 40% of the men were still using pads at 
12 months to protect themselves from leakage accidents, although in some cases this might have 
been more of a precaution than because they actually leaked.
TABLE 28  Urinary incontinence at 12 months
Radical prostatectomy Intervention Control RR (95% CI), p-value
Urinary incontinence at 12 months 
[n/N (%)]
148/196 (75.5) 151/195 (77.4) Absolute risk difference (95% CI) 
–1.9% (–10% to 6%)
Intention to treat
Unadjusted analysis 0.980 (0.879 to 1.094), 0.719
Analysis adjusted for 
minimisation factors
0.97 (0.87 to 1.09), 0.637
Adjusted treatment received
Unadjusted analysis 0.979 (0.877 to 1.093), 0.702
Analysis adjusted for 
minimisation factors
0.977 (0.876 to 1.090), 0.676© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 29b  Urinary outcomes at each 3-month interval: statistical analyses 
Radical prostatectomy
Effect size (95% CI), p-value
3 months 6 months 9 months 12 months
Incontinence
Men incontinent [RR (95% 
CI), p-value]
0.97 (0.90 to 1.04), 0.366 1.00 (0.91 to 1.10), 
0.990
0.93 (0.84 to 1.03), 
0.174
0.97 (0.87 to 1.09), 
0.637
Men with severe 
incontinence [RR (95% CI), 
p-value]a
0.95 (0.79 to 1.15), 0.595 1.02 (0.80 to 1.29), 
0.875
0.86 (0.67 to 1.09), 
0.208
0.93 (0.73 to 1.19), 
0.582
ICI-Q scoreb –0.66 (–1.37 to 0.05), 0.068 –0.15 (–0.86 to 0.55), 
0.674
–0.49 (–1.22 to 0.24), 
0.188
–0.34 (–1.05 to 0.38), 
0.355
Frequency of daytime 
urinary incontinence from 
diaries
–0.47 (–1.30 to 0.37), 0.274 –0.09 (–1.03 to 0.85), 
0.855
–0.17 (–1.03 to 0.68), 
0.690
0.04 (–0.65 to 0.12), 
0.919
Effect of UI on QoL  –0.37 (–0.79 to 0.05), 0.086 –0.22 (–0.61 to 0.17), 
0.266
–0.24 (–0.63 to 0.15), 
0.233
0.14 (–0.51 to 0.24), 
0.476
Urinary frequency
Daytime urinary frequency  0.01 (–0.49 to 0.52), 0.958 0.02 (–0.43 to 0.46), 
0.944
–0.61 (–1.44 to 0.22), 
0.149
–0.24 (–0.73 to 0.26), 
0.346
Daytime urinary frequency 
from diaries
0.15 (–0.38 to 0.69), 0.577 –0.02 (–0.66 to 0.62), 
0.939
–0.11 (–0.42 to 0.65), 
0.679
–0.07 (–0.89 to 0.73), 
0.861
Nocturia  –0.23 (–0.42 to –0.04), 
0.020
–0.09 (–0.25 to 0.07), 
0.280
–0.14 (–0.39 to 0.10), 
0.248
–0.04 (–0.21 to 0.14), 
0.683
Nocturia from diaries –0.31 (–0.52 to –0.09), 
0.005
–0.18 (–0.41 to 0.04), 
0.113
–0.13 (–0.35 to 0.10), 
0.277
–0.15 (–0.35 to 0.06), 
0.167
Frequency of nocturnal 
incontinence from diaries
–0.18 (–0.44 to 0.07), 0.159 –0.07 (–0.30 to 0.15), 
0.516
–0.07 (–0.31 to 0.18), 
0.593
–0.05 (–0.27 to 0.16), 
0.617
Effect size is mean difference unless indicated as RR (risk ratio) adjusted for age, urinary incontinence before surgery and baseline value. 
a  Severe incontinence defined as at least once a day and a moderate or large amount of leakage, as defined by the men in 
questionnaire responses.
b  ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
FIGURE 14  Per cent of men incontinent at each time point.
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FIGURE 15  Mean ICI-Q score at each time point. ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from 
questions 1–3 of the ICIQ-UI Short Form Questionnaire.
12
11
10
9
8
7
6
5
4
3
2
1
Baseline
Intervention
Control
Group
3 months 6 months 9 months 12 months
Time point
M
e
a
n
 
I
C
I
-
Q
 
s
c
o
r
e
TABLE 30  Type of incontinence 
Radical 
prostatectomy
Baseline 6 months 12 months
Intervention Control Intervention Control
RR (95% 
CI), p-value Intervention Control
RR (95% 
CI), p-value
SUI 195/205 
(95)
195/206 
(95)
136/197 
(69)
135/197 
(69)
1.002 (0.88 
to 1.14), 
0.972
138/196 
(70)
128/195 
(66)
1.071 (0.94 
to 1.22), 
0.314
UUI 135/205 
(66)
156/206 
(76)
58/197 (29) 87/197 (44) 0.735 (0.57 
to 0.94), 
0.015
61/196 (31) 83/195 (43) 0.782 (0.61 
to 1.00), 
0.054
Urgency  131/205 
(64)
160/206 
(78)
76/197 (39) 105/197 
(53)
0.827 (0.68 
to 1.01), 
0.066
80/196 (41) 100/195 
(51) 
0.879 (0.72 
to 1.08), 
0.218
MUI (both SUI 
and UUI) 
132/205 
(64)
151/206 
(73)
55/197 (28) 81/197 (41) 0.752 (0.58 
to 0.98), 
0.033
59/196 (30) 74/195 (38) 0.843 (0.65 
to 1.10), 
0.208
Postmicturition 
leakage 
166/205 
(81)
170/206 
(83)
87/197 (44) 106/197 
(54)
0.831 (0.69 
to 1.01), 
0.059
102/196 
(52)
106/195 
(54)
0.924 (0.73 
to 1.17), 
0.512
Other UI  72/205 (35) 91/206 (44) 38/197 (19) 52/197 (26) 0.777 (0.54 
to 1.12), 
0.181
39/196 (20) 39/195 (20) 1.099 (0.74 
to 1.63), 
0.640
RR adjusted for age, urinary incontinence before surgery and baseline value.
Figures are n/N (%), unless stated otherwise.
Note: men could have more than one type of incontinence; hence the numbers are higher than the total number of men.60 Radical randomised controlled trial: outcomes and results
Bowel function
In addition to urinary outcomes, men were also asked to describe some aspects of bowel 
function. Few men (< 10%) had faecal incontinence or constipation by the end of follow-up at 
12 months, although rather more reported faecal urgency occasionally or more often. Table 32 
and Figure 17 show that there were no differences in any aspect of bowel function between the 
men in the randomised groups.
Sexual function
Table 33 compares the men in the randomised groups in terms of sexual function outcomes. Over 
90% of men had normal erectile function before their operation. Although around one-third had 
an active sex life at 12 months, the majority said that this was less satisfactory than before their 
operation. There were, however, no differences at 12 months according to the randomised groups 
in terms of the proportion of men with an active sex life [RR 0.94 (95% CI 0.73 to 1.22); adjusted 
for age, urinary incontinence before surgery and baseline value, p = 0.661] or the proportion 
of men who rated their sex life as worse after the operation [RR 0.79 (95% CI 0.47 to 1.34); 
p = 0.391].
FIGURE 16  Type of incontinence at baseline and at 6 and 12 months after randomisation. Men could report more 
than one type of incontinence. (a) Stress urinary incontinence. (b) Urgency urinary incontinence. (c) Mixed urinary 
incontinence (proportion of men reporting both stress and urgency urinary incontinence). (d) Postmicturition leakage 
(defined as ‘urine leaking when urination finished’).
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.62 Radical randomised controlled trial: outcomes and results
Table 34 compares the randomised groups in terms of problems with sexual function. There were 
no significant differences in sexual function outcomes between the intervention and control 
groups (Table 34 and Figure 18). Only about 20% of the men were able to achieve a normal 
erection or one with slightly reduced stiffness by 12 months after surgery, and almost all reported 
a lack of semen or no ejaculation. Of those men, few reported more than slight pain. Around 60% 
of men used drugs and about 20% used a vacuum device to help with sexual function. Only 20% 
reported urinary incontinence during intercourse.
Quality of life
General health outcomes were measured using the EQ-5D and SF-12, the latter subdivided into 
role – mental (SF-12M) and role – physical (SF-12P) scores. The slight increase in the scores 
over time represents recovery from the operation but there were no differences between the 
randomised groups at any time point in EQ-5D or SF-12 scores (Table 35 and Figure 19).
Pelvic floor muscle training
All men were asked to report on their practice of carrying out pelvic floor exercises at baseline 
and 6 and 12 months after randomisation. Initially a high proportion of men (over 80%) reported 
practising them, of whom around 80% carried them out every day. As this occurred before 
randomisation, it must reflect the high profile given to PFMT in the standard care of men after 
radical prostate surgery.
The prevalence of exercising in the control group had fallen by 6 months (to 62%), while men 
in the therapy group were more likely than controls still to be performing exercises (83%). 
This difference was maintained at 12 months: a significantly higher proportion of men from 
the intervention group were carrying out any PFMT at 12 months after randomisation (67%) 
compared with those in the control group (50%; see Table 36). Significantly more were practising 
for at least 3–4 days each week in the intervention group than in the control group (56% vs 36%). 
Although men in the intervention group were performing fewer daily contractions by 12 months 
TABLE 32  Type of bowel problems at baseline and 6 and 12 months 
Radical 
prostatectomy
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI),
p-value Intervention Control
Effect size 
(95% CI),
p-value
Faecal 
incontinencea
6/205 (3) 15/206 (7) 11/190 (6) 14/195 (7) 0.97 (0.41 
to 2.29), 
0.968
16/193 (8) 11/193 (6) 1.56 (0.74 
to 3.29), 
0.241
Faecal urgencya 76/204 (37) 92/205 (45) 65/190 (34) 80/195 (41) 0.93 (0.73 
to 1.18), 
0.549
70/193 (36) 86/193 (45) 0.88 (0.70 
to 1.10), 
0.244
Constipation  31/205 (15) 23/206 (11) 12/189 (6) 16/194 (8) 0.60 (0.29 
to 1.23), 
0.165
11/193 (6) 14/193 (7) 0.69 (0.28 
to 1.58), 
0.359
Any bowel 
dysfunctionb
97/205 (47) 110/206 
(53)
80/190 (42) 94/195 (48) 0.92 (0.75 
to 1.13), 
0.419
80/193 (42) 98/193 (51) 0.84 (0.69 
to 1.03), 
0.102
Figures are n/N (%), unless stated otherwise.
Effect size is RR adjusted for age, urinary incontinence before surgery and baseline value.
a  Faecal incontinence and urgency were defined as present when the problem was rated as occurring ‘occasionally or more often’.
b  Any bowel dysfunction includes faecal urgency, ulcerative colitis, Crohn’s disease, irritable bowel syndrome or constipation, but not faecal 
incontinence.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 17  Type of bowel problems at baseline and 6 and 12 months.
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TABLE 33  Description of sex life variables before and 12 months after prostate surgery
Radical prostatectomy Intervention Control
Number of men not able to achieve erection before prostate surgerya  17/205 (8) 18/202 (9)
Number of men with active sex life at 12 months 68/184 (37) 73/184 (40)
Reasons for not having an active sex life
  Because of urinary symptoms 13/116 (11) 10/113 (9)
  Because of bowel symptoms 0/116 0/111
  Because of prostate operation 112/136 (82) 106/132 (80)
  Because of medical treatment 1/116 (1) 1/112 (1)
  For another reason 27/118 (23) 30/112 (27)
Comparison of sex life with before prostate operation 12 months ago 
  Stayed the same 22/163 (13) 24/162 (15)
 Better 0/163 (0) 3/162 (2)
 Worse 141/163 (87) 135/162 (83)
Figures are n/N (%), unless otherwise stated.
a  This information was collected at baseline but was retrospective, based on men’s recall of their sexual function before their operation.64 Radical randomised controlled trial: outcomes and results
TABLE 34  Type of sexual problems at 12 months after prostate surgery 
Radical prostatectomy Intervention Control
Difficulty with achieving erection
  Normal stiffness 6/189 (3) 3/190 (2)
  Reduced stiffness 29/189 (15) 38/190 (20)
  Severely reduced stiffness 49/189 (26) 44/190 (23)
  No erection possible 105/189 (56) 105/190 (55)
  Bother with erection [mean (SD) n]a  6.0 (3.3) 183  6.5 (3.1) 183
Ejaculation
  Normal quantity of semen 0/187 (0) 1/184 (1)
  Reduced quantity of semen 1/187 (1) 2/184 (1)
  Significantly reduced quantity of semen 3/187 (2) 3/184 (2)
  Ejaculation but without semen 65/187 (35) 69/184 (38)
  No ejaculation 118/187 (63) 109/184 (59)
  Bother with ejaculation [mean (SD) n]a  3.8 (3.7) 172 4.4 (3.7) 171
Pain or discomfort with ejaculation 
  No pain  94/117 (80) 98/124 (79)
  Slight pain 14/117 (12) 17/124 (14)
  Moderate pain 5/117 (4) 5/124 (4)
  Severe pain 4/117 (3) 4/124 (3)
  Bother with pain or discomfort [mean (SD) n]a  2.5 (3.4) 49 2.3 (3.1) 55
Number of men using medication for sexual problems  104/186 (56) 110/189 (58)
Number of men using vacuum device for sexual problems  47/185 (25) 39/183 (21)
Number of men using either medication or a vacuum device for sexual problems 116/188 (62) 123/189 (65)
Number of men leaking urine during intercourse 26/135 (19) 30/139 (22)
Figures are n/N (%) except where stated otherwise.
a  Bother scale: 0 = not at all to 10 = a great deal.
FIGURE 18  Quality of erectile function at 12 months after prostate surgery: Radical prostatectomy.
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than they had previously, the difference between randomised groups at this time point did not 
reach statistical significance (mean contractions 11.7 intervention vs 19.4 control) (see Table 36). 
This is likely to reflect the taught exercise regimen in the intervention group (aiming for 18 strong 
contractions every day) compared with recommendations from NICE,71,72 which are to perform 
eight contractions three times a day.
TABLE 35  Quality of life outcomes measured by EQ-5D and SF-12 
Radical 
prostatectomy
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI), 
p-value Intervention Control
Effect size 
(95% CI), 
p-value
EQ-5D  0.797 
(0.216) 200
0.783 
(0.225) 206
0.884 
(0.205) 184
0.875 
(0.189) 189
0.006 
(–0.027 
to 0.039) 
0.725
0.879 
(0.209) 187
0.887 
(0.176) 189
–0.013 
(–0.047 
to 0.021), 
0.460
SF-12M 50.8 (10.5) 
201
49.3 (10.7) 
201
53.6 (8.3) 
188
53.2 (8.1) 
191
0.4 (–1.3 to 
2.1) 0.615
52.9 (9.1) 
190
53.6 (7.9) 
191
–0.9 (–2.6 
to 0.9), 
0.321
SF-12P 42.7 (9.9) 
201
41.8 (10.6) 
201
50.9 (9.4) 
188
49.6 (9.9) 
191
1.1 (–0.7 to 
2.8) 0.246
51.4 (8.3) 
190
51.2 (8.4) 
191
0.0 (–1.6 to 
1.6), 0.967
SF-12M, SF-12 role – mental; SF-12P, SF-12 role – physical.
Figures are mean (SD) n, unless stated otherwise.
A higher score on the EQ-5D and the SF-12 represents better health.
Effect size is mean difference adjusted for age, urinary incontinence before surgery and baseline value.
FIGURE 19  Graphical representations of EQ-5D and SF-12 scores over time. SF-12M, SF-12 role – mental; SF-12P, 
SF-12 role – physical.
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Men in the intervention group were also significantly more likely to perform contractions while 
walking. Differences between groups in performing a pelvic floor muscle contraction prior to 
increases in intra-abdominal pressure such as coughing or lifting (also known as ‘the Knack’) did 
not quite reach statistical significance (Table 36). There were no differences between the groups 
in terms of ‘the Knack’ reducing or stopping urinary leakage (although this analysis includes only 
the men using this technique).
Lifestyle outcomes
Men were also advised, in the lifestyle advice leaflet sent to both groups but reinforced by the 
therapists in the intervention group, about the benefits of general health strategies such as taking 
more exercise. There were few differences between the groups in terms of other types of exercise 
practised (Table 37) and no statistically significant difference in the proportion taking general 
exercise [RR 0.94 (95% CI 0.87 to 1.02); p = 0.151].
TABLE 36  Practice of PFMT at 12 months after randomisation: results from 6- and 12-month questionnaires
Radical 
prostatectomy
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI), 
p-value Intervention Control
Effect size 
(95% CI), 
p-value
Any PFMT in 
last week 
 Yes 176/205 
(86)
170/206 
(83)
156/188 
(83)
117/190 
(62)
1.329 (1.17 
to 1.51), 
0.001
128/191 
(67)
95/189 (50) 1.296 (1.09 
to 1.53), 
0.003
 No 22/205 (11) 21/206 (10) 32/188 (17) 70/190 (36) 63/191 (33) 91/189 (48)
  Don’t know 7/205 (3) 15/206 (7) 0/188 (0) 3/190 (2) 0/191 (0) 3/189 (2)
Days carrying 
out PFMT 
  Every day 145/205 
(71)
139/206 
(67)
96/188 (51) 64/190 (34) 67/192 (35) 51/190 (27)
  5–6 days 8/205 (4) 8/206 (4) 17/188 (9) 10/190 (5) 13/192 (7) 5/190 (3)
  3–4 days 9/205 (4) 16/206 (8) 19/188 (10) 13/190 (7) 26/192 (14) 12/190 (6)
  1–2 days 13/205 (6) 6/206 (3) 20/188 (11) 28/190 (15) 18/192 (9) 28/190 (15)
 None 30/205 (15) 37/206 (18) 36/188 (19) 75/190 (39) 68/192 (35) 94/190 (49)
Average 
contractions 
[mean (SD) 
n; mean 
difference]
18.2 (29.4) 
188
21.1 (45.0) 
190
–2.9 (–10.7 
to 4.8), 
0.457
11.7 (20.0) 
192
19.4 (79.2) 
189
–7.8 (–19.4 
to 3.9), 
0.189
Deliberate 
contractions 
whilst walkinga 
150/187 
(80)
118/184 
(64)
1.25 (1.10 
to 1.42), 
0.001
148/192 
(77)
121/186 
(65)
1.18 (1.04 
to 1.35), 
0.011
Deliberate 
contractions 
before you do 
somethinga
128/185 
(69)
111/184 
(60)
1.15 (0.98 
to 1.33), 
0.078
134/192 
(70)
113/187 
(60)
1.16 (1.00 
to 1.34), 
0.052
Contracting 
reduces or 
stops leaking
113/130 
(87)
105/125 
(84)
1.09 (0.96 
to 1.24), 
0.197
117/137 
(85)
97/126 (77) 1.16 (1.00 
to 1.34), 
0.046
Figures are n/N (%), unless indicated otherwise.
Effect size is RR, unless indicated as mean difference, adjusted for age, urinary incontinence before surgery and baseline value. 
a  Coded as positive if man responded ‘sometimes’ or more often.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Finally, men in both groups were given (via the lifestyle advice leaflet) other general advice on 
lifestyle changes they could make that might help both with incontinence and with general 
health. Again, this advice was reinforced by the therapists for men in the intervention group. 
There were few differences between the groups in terms of changes made to lifestyle factors 
(Table 38).
Prespecified subgroup analyses
Preplanned subgroup analyses were carried out on the primary outcome (urinary incontinence at 
12 months) according to factors that we thought would be prognostic. These factors were:
1.  pre-existing urinary incontinence (before prostate surgery)
2.  age (up to 60 years, 61 years and over)
3.  BMI (up to 30 kg/m2, 30–34.9 kg/m2, 35 kg/m2 or greater)
4.  type of incontinence at trial entry
i.  SUI
ii.  UUI
iii.  MUI
iv.  postmicturition leakage
5.  other morbidity
6.  type of therapist (physiotherapist or nurse).
Whilst a subgroup analysis on the use of biofeedback machines was also prespecified, there were 
insufficient numbers of centres with biofeedback machines to do such an analysis (see Table 7).
Figure 20 shows the effect of subgroup analysis on the primary outcome (urinary incontinence at 
12 months) according to the prespecified factors. The dotted line reflects the overall main effect 
of the intervention on incontinence rates. Stricter levels of statistical significance (2p < 0.01) were 
sought (99% CIs), reflecting the exploratory nature of these analyses. There were no apparent 
clinically relevant differences according to any subgroup and none of the formal tests for 
statistical interaction effects were significant.
TABLE 37  Practice of other exercise at 12 months after randomisation: results from 12-month questionnaire 
Radical prostatectomy
12 months [n/N (%)]
Intervention  Control 
General exercise (yes)a 160/189 (85) 168/188 (89)
Exercise type
 Walking 150/189 (79) 148/188 (78)
 Swimming 25/189 (13) 19/188 (10)
 Gardening 101/189 (53) 119/188 (63)
 Running 9/189 (5) 14/188 (7)
  Going to gym 20/189 (11) 20/188 (11)
 Other 36/189 (19) 36/188 (19)
Changed exercise since prostate operation
  No changes 142/191 (74) 121/191 (63)
  I do less 27/191 (14) 39/191 (20)
  I do more 22/191 (12) 31/191 (16)
a  Number of men responding ‘yes’ to question: ‘Have you done any general exercise or fitness activity in the last week?’.68 Radical randomised controlled trial: outcomes and results
Satisfaction with treatment for urinary incontinence
Men were asked to score their satisfaction with the treatment they received for urinary 
incontinence (0 = ‘very unsatisfied’ to 10 = ‘very satisfied’) at 12 months after randomisation. Men 
in the intervention group were significantly more satisfied than those in the control group (see 
Appendix 5, Table 88). Thus, the therapy intervention did increase satisfaction rates despite the 
lack of difference in urinary outcomes.
TABLE 38  Compliance with lifestyle advice and changes to lifestyle at 12 months
Radical prostatectomy Intervention [n/N (%)] Control [n/N (%)]
Weight
No need to lose weight  75/190 (39) 77/187 (41)
Haven’t tried to lose weight  78/190 (41) 73/187 (39)
Extra exercise to lose weight  27/190 (14) 29/187 (16)
Diet to lose weight  12/190 (6) 11/187 (6)
Other ways of losing weight  15/190 (8) 9/187 (5)
Fluid intake
Number of men making no changes to fluid intake  90/191 (47) 88/192 (46)
Drink more fluids  55/191 (29) 61/192 (32)
Drink more cranberry juice  39/191 (20) 36/192 (19)
Drink fewer caffeinated drinks 49/191 (26) 58/192 (30)
Drink less fluid in evenings  49/191 (26) 59/192 (31)
Other changes to fluid intake  14/191 (7) 18/192 (9)
Diet
Number of men making no changes to diet or food  130/189 (69) 133/191 (70)
More balanced diet  36/189 (19) 35/191 (18)
More fruit and vegetables  49/189 (26) 53/191 (28)
More fibre  31/189 (16) 35/191 (18)
Less fats or sugars  45/189 (24) 37/191 (19)
Other changes to food intake  7/189 (4) 7/191 (4)
Lifting
Number of men who reduce lifting  81/193 (42) 76/190 (40)
Smoking
Number of men who smoked  16/193 (8) 17/189 (9)
Number of men stopping smokinga  1/16 (6) 1/17 (6)
Number of men reducing smokinga  8/16 (50) 9/17 (53)
Chest or respiratory symptoms
Number of men who did have chest symptoms 17/188 (9) 19/184 (10)
Taking correct medicationa 12/17 (71) 6/19 (32)
Consulted GP about medicationa  6/17 (35) 8/19 (42)
Other changes to reduce respiratory symptomsa  0/17 (0) 1/19 (5)
a  Responses limited to number of men who did smoke or had chest symptoms respectively.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 20   Forest plot of subgroup analyses: urinary incontinence at 12 months. PML, postmicturition leakage.
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Chapter 8  
Resource use and cost-effectiveness 
in the radical randomised controlled 
trial
This chapter describes the economic analyses for the radical prostatectomy RCT.
Description of the data available
Table 39 describes the number of men who contributed data for each of the areas of resource 
use and quality of life at each time point. Fewer data were available at the later data collection 
time points. For some areas of resource use (for example number of NHS pads at 12 months), 
only three-quarters of men indicated the quantity used. For other areas, for example hospital 
physiotherapist visits, nearly 90% of men provided data on the use of that resource even at 
12 months. The difference between these two rates cannot be explained by the mode of data 
collection, as both were collected by participant-completed questionnaire. An alternative 
explanation might be the limited use of these services by 12 months, which meant that men did 
not answer the questions because they did not think they were relevant. Other explanations could 
be advanced, but there is no information to determine what the reasons are for men providing 
information for some areas of resource use but not for others.
Analysis of resource use and costs
Resource use
Table 40 details the average total resource use for the intervention and subsequent use of health 
services over the 12-month follow-up period after randomisation. The pattern of resource use 
was similar across both groups and there were few statistically significant differences between 
the two groups. In addition to differences in costs of the intervention (incurred only by those 
randomised to the intervention group), these costs included the use of pads paid for by the NHS, 
incontinence-related GP doctor and nurse visits, hospital physiotherapist visits and the number 
of days that participants were off work. The use of resources in each of these areas was higher for 
the control group, apart from the subsequent number of hospital physiotherapy visits, which was 
higher for the intervention group. A detailed description of the use of NHS and private provider 
health services is provided in Appendix 5.
Costs
Participant time and travel costs
The average time and costs to participants and their companions (families or carers) of a contact 
with a GP, an outpatient consultation or an inpatient admission are reported in Table 41. These 
data were combined with the information on number of contacts (e.g. hospital doctor visits) that 
the trial participants had reported (Table 40) to estimate a monetary cost per patient for both 
intervention and control groups.72 Resource use and cost-effectiveness in the radical randomised controlled trial
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Estimation of societal costs
Table 42 details the mean cost per participant of the two interventions. The unit cost information 
in Tables 4 and 41 was combined with the resource use information reported in Table 40 to 
provide estimates of the total cost per participant. For the base-case analysis, based on societal 
costs, the mean total cost per participant in the intervention group was £1509 (SD £2802) and 
TABLE 40  Mean resource use per patient during 12-month period after randomisation: radical prostatectomy
Area of resources use
Mean (SD)
Difference (95% CI)a Intervention Control
Intervention 3.55 (1.61) 0 3.55
Subsequent resource use
NHS-supplied pads usedb 2.46 (3.86) 3.53 (5.71) –0.90 (–1.74 to –0.07)
NHS-supplied bed/chair protectors used 0.18 (0.64) 0.26 (1.41) –0.08 (–0.29 to 0.12)
GP doctor incontinence-related visitb 0.33 (1.17) 0.63 (1.94) –0.34 (–0.63 to –0.05)
GP doctor other visit 4.17 (4.03) 4.53 (4.03) –0.24 (–1.00 to 0.52)
GP nurse incontinence-related visit 0.16 (0.94) 0.37 (1.50) –0.17 (–0.40 to 0.06)
GP nurse other visit 1.85 (2.21) 2.16 (3.43) –0.32 (–0.88 to 0.23)
Number of men using catheters  1.17 (1.29) 1.26 (1.29) –0.09 (–0.34 to 0.16)
Number of men using sheaths  0.20 (0.59) 0.24 (0.61) –0.03 (–0.14 to 0.08)
Hospital doctor visits 0.44 (1.13) 0.44 (1.14) –0.01 (–0.23 to 0.21)
Hospital nurse visitsb 0.62 (1.49) 0.31 (0.88) 0.32 (0.08 to 0.55)
Hospital physiotherapist visitsb 0.79 (1.44) 0.18 (1.17) 0.62 (0.38 to 0.87)
Inpatient days 0.04 (0.26) 0.06 (0.29) –0.02 (–0.07 to 0.04)
Number taking incontinence drugs  0.29 (0.85) 0.33 (0.86) –0.05 (–0.21 to 0.11)
Self-purchased use of health care
Pads used 1.61 (3.18) 2.37 (4.60) –0.62 (–1.34 to 0.09)
Bed/chair protector used 0.25 (0.72) 0.48 (2.18) –0.17 (–0.47 to 0.14)
Private doctor visits 0.13 (0.47) 0.14 (0.53) –0.02 (–0.12 to 0.07)
Private nurse visits 0.15 (0.53) 0.09 (0.35) 0.07 (–0.02 to 0.15)
Private physiotherapist visits 0.16 (0.60) 0.08 (0.68) 0.07 (–0.05 to 0.19)
Number of days off workb 7.62 (24.71) 15.20 (42.93) –6.54 (–13.08 to –0.01)
Note: the number of days off work refers only to the number of days absent from paid employment after randomisation. 
a  Differences adjusted for baseline costs.
b  Statistically significantly different at 5%.
TABLE 41  Cost to the patient and their companion of a single visit or admission: radical prostatectomy
Resource use Time or monetary cost Mean (SD)
Primary care consultation visit Time spent going to and attending a primary care consultation (hours) 0.67 (0.30)
Companion’s time off work (£) 0.80 (2.40)
Average cost to participant and companion of a primary care consultation (£) 17.30 (36.75)
Secondary care visit Time spent attending a secondary care visit (hours) 2.07 (1.51)
Companion’s time off work (£) 9.05 (14.46)
Average cost to participant and companion of travelling to a secondary care 
department (£)
36.43 (49.17)
Inpatient visit Visits to participant during admission (number)  4.04 (5.42)
Companion’s time off work (£) 23.46 (73.12)
Average cost to participant and companion of travelling to admission (£) 82.78 (136.38)74 Resource use and cost-effectiveness in the radical randomised controlled trial
TABLE 42  Cost per participant for each area of resource use: radical prostatectomy
Area of resource use 
Mean cost [£ (SD)]
Difference (95% CI)a Intervention Control
NHS costs
Intervention 198.30 (63.89) 0 193.30
Subsequent resource use
NHS-supplied padsb 38.03 (59.71) 54.67 (88.32) –13.97 (–26.88 to –1.06)
NHS-supplied bed/chair protectors  2.40 (8.74) 3.58 (19.21) –1.15 (–3.96 to 1.66)
GP doctor incontinence-related visitsb 11.77 (42.11) 22.54 (69.78) –12.18 (–22.55 to –1.80)
GP doctor other visit 150.15 (144.90) 163.05 (145.08) –8.72 (–36.09 to 18.66)
GP nurse incontinence-related visit 1.72 (10.30) 4.11 (16.55) –1.85 (–4.38 to 0.68)
GP nurse other visit 20.34 (24.29) 23.76 (37.76) –3.57 (–9.65 to 2.51)
Catheter  0.46 (6.55) 0.23 (3.27) 0.24 (–0.77 to1.24)
Sheath 22.00 (81.06) 21.89 (74.81) 0.73 (–12.33 to 13.80)
Hospital doctor visits 32.93 (84.42) 32.77 (85.22) –0.72 (–17.19 to 15.75)
Hospital nurse visitsb 19.20 (46.16) 9.48 (27.19) 9.83 (2.49 to 17.17)
Total hospital physiotherapy visitsb 24.35 (44.72) 5.57 (36.25) 19.32 (11.79 to 26.85)
Inpatient days 13.80 (46.65) 20.07 (48.83) –5.67 (–14.73 to 3.39)
Prescribed drugs 28.96 (98.77) 28.20 (86.21) –2.99 (–19.96 to 13.98)
Total subsequent use cost 358.42 (381.02)  378.99 (399.45) –17.31 (–89.81 to 55.19)
Total NHS cost 556.72 (396.07) 378.99 (399.45) 181.02 (107.06 to 254.97)
Patient costs
Self-supplied pads  35.17 (58.52) 49.11 (82.18) –12.88 (–26.58 to 0.81)
Self-supplied bed/chair protector  0.87 (5.59) 2.85 (21.74) –1.14 (–4.03 to 1.76)
Private doctor visits 4.02 (44.68) 2.91 (29.49) 0.03 (–7.01 to 7.07)
Private nurse visits 0.00 (0)  0.00 (0) 0 
Private physiotherapist visits 0.91 (9.66) 0.30 (4.32) 0.36 (–0.63 to 1.36)
Participant number of days off workb 809.19 (2624.53) 1614.14 (4558.83) –694.77 (–1388.71 to –0.83)
Total patient costs 832.72 (2628.03) 1657.67 (4554.01) –714.57(–1408.16 to –20.97)
Participant travel and companion travel and time off work costs
Intervention 132.70 (43.43) 0.00 (0)
GP doctor incontinence-related visitsb 5.66 (20.25) 10.84 (33.55) –5.85 (–10.84 to –0.87)
GP doctor other visit 72.20 (69.67) 78.40 (69.76) –4.19 (–17.36 to 8.97)
GP nurse incontinence-related visit 2.70 (16.21) 6.47 (26.05) –2.91 (–6.90 to 1.08)
GP nurse other visit 32.00 (38.22) 37.39 (59.42) –5.62 (–15.19 to 3.95)
Total GP visits 112.56 (97.54) 133.10 (131.13) –18.92 (–40.46 to 2.61)
Hospital doctor visits 16.43 (42.12) 16.35 (42.52) –0.35 (–8.58 to 7.86)
Hospital nurse visitsb 23.18 (55.72) 11.44 (32.82) 11.89 (3.01 to 20.73)
Hospital physiotherapy visitsb 29.39 (53.98) 6.72 (43.76) 23.32 (14.23 to 32.41)
Total outpatient visitsb 201.70 (118.93) 34.51 (81.09) 167.06 (147.36 to 188.77)
For inpatient visits 3.23 (21.44) 4.82 (24.05) –1.30 (–5.61 to 3.02)
Total participant and companion travel 
and time off work costb
450.19 (200.28) 172.44 (180.86) 272.74 (225.08 to 320.40)
Total participant and companion cost  1150.21 (2671.60) 1830.11 (4627.01) –567.96 (–1274.10 to 138.15)
Total societal costs 1508.63 (2802.37) 2209.10 (4835.12) –588.23 (–1329.83 to 153.37)
a  Differences adjusted for baseline costs.
b  Statistically significantly different at 5% level.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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the mean cost in the control group was £2209 (SD £4835). The trend towards higher costs in the 
control group, –£588 (95% CI –£1330 to £153), was not statistically significant. The difference in 
mean societal cost was mainly due to the high number of days taken off work by the participants 
in the control arm of the trial.
Estimation of NHS costs
In terms of NHS costs incurred after the intervention was delivered, the mean total cost per 
patient in the intervention group was £358 (SD £381) and the mean cost in the control group 
was £379 (SD £399). There was, however, no evidence of a statistically significant difference in 
the cost of subsequent NHS services used. Intervention costs were, as would be expected, greater 
in the intervention group. Combining information on the cost of the interventions and the cost 
of subsequent NHS care resulted in a statistically significantly higher total cost per participant 
in the intervention group. This difference was driven almost entirely by the cost of the PFMT 
intervention itself.
Quality-adjusted life-years
Table 43 shows the EQ-5D scores for each arm of the trial at baseline and 6 and 12 months. 
Also reported is the mean difference between arms in EQ-5D score at 6 and 12 months. From 
these data it was estimated that the mean QALYs were 0.86 (SD 0.16, median 0.796) for the 
intervention arm and 0.86 (SD 0.19, median 0.796) for the control arm. The mean difference in 
QALYs after adjusting for minimisation and baseline EQ-5D scores was –0.002 (95% CI –0.027 to 
0.023) higher for the intervention group, which was not statistically significant.
Imputation was not performed on missing values in the base-case analysis. Simple plausible 
extreme value imputation on EQ-5D scores taking the 25th and 75th percentile values indicated 
that the mean difference in EQ-5D scores did not differ from that reported in Table 43.
Estimation of cost-effectiveness
Societal perspective
The cost-effectiveness of the intervention compared with control is dependent on whether the 
differences in QALYs are considered to be important to people with incontinence. Taking the 
mean difference in the total societal costs from Table 42 (–£588) and the mean difference in 
TABLE 43  Quality of life measures: radical prostatectomy
Mean (SD)
Difference
(95% CI) Intervention Control
Baseline EQ-5D 0.80 (0.22)
n = 200
0.78 (0.23)
n = 206
6-month EQ-5D 0.88 (0.21)
n = 184
0.87 (0.19)
n = 189
0.009
12-month EQ-5D 0.88 (0.21)
n = 187
0.89 (0.18)
n = 189
–0.008
QALYs 0.86 (0.19)
n = 170
0.86 (0.16)
n = 179
–0.002
(–0.027 to 0.023)a 
a  Difference adjusted for baseline EQ-5D score.76 Resource use and cost-effectiveness in the radical randomised controlled trial
QALYs from Table 43 (–0.002) it can be seen that the intervention is, on average, more effective 
and less costly (Table 44).
Uncertainty around the estimates of QALYs and costs was derived using 1000 bootstrap 
simulations. The bootstrap estimates in Figure 21 indicate that in most of the instances the 
intervention group had lower costs than the control; however, there was a relatively wide 
distribution in the difference in QALYs and costs.
At a cost-effectiveness threshold of £20,000 per QALY, the intervention has a likelihood of 89% 
of being cost-effective, and at a threshold of £30,000 per QALY the intervention is 84% likely to 
be cost-effective (Figure 22). However, these results have to be interpreted cautiously as they are 
driven almost entirely by differences in time away from usual activities.
NHS perspective
Taking the mean difference in total NHS costs from Table 42 (£181) and the mean difference 
in the QALY estimate after adjusting for baseline EQ-5D scores from Table 43, the mean 
incremental cost per QALY is £90,510 (Table 45).
As with the societal perspective, bootstrap simulations were undertaken to estimate the 
uncertainty around the benefit and costs. The bootstrap estimates in Figure 23 indicate that 
the intervention group had higher costs than the control. However, there was a relatively wide 
distribution in the difference in QALYs.
At a cost-effectiveness threshold of £20,000 per QALY, the intervention has a probability of 19% 
of being cost-effective, and at a threshold of £30,000 per QALY the intervention is 27% more 
likely to be cost-effective (Figure 24). At no point does the probability of being cost-effective 
reach 50%. This indicates that it is unlikely that PFMT is cost-effective.
Sensitivity analysis
As mentioned in Chapter 2, sensitivity analysis is necessary to assess the robustness of the 
qualitative conclusion and identify areas where research is needed to more precisely estimate 
the values of those variables to which the result is sensitive. The variables that were considered 
uncertain in this study related to the costs and QALYs of the different services used.
Incremental cost per quality-adjusted life-year when differences are not 
adjusted for baseline differences
An unadjusted analysis was performed as a sensitivity analysis to highlight the importance of 
the assumption that the characteristics of the groups were not the same at baseline. The results 
of this analysis, from the perspective of the NHS, indicate that at a cost-effectiveness threshold 
of £20,000 per QALY the intervention has a probability of 45.3% of being cost-effective, and 
TABLE 44  Cost-effectiveness results from the societal perspective: radical prostatectomy
Difference in mean NHS costs [mean (95% CI)a] –588.23 (–1329.83 to 153.37)
Difference in QALYs [mean (95% CI)] –0.002 (–0.027 to 0.023)
ICER (£/QALY) Organised PFMT is dominant 
Probability intervention is cost-effective when threshold is £20,000 per QALY 89.4%
Probability intervention is cost-effective when threshold is £30,000 per QALY 83.7%
a  Adjusting for baseline before randomisation.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 21  Representation of the uncertainty in differential mean costs and QALYs: societal perspective (radical 
prostatectomy).
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FIGURE 22  Cost-effectiveness acceptability curve for intervention versus control: societal perspective (radical 
prostatectomy).
Willingness to pay per QALY (£000)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 10 20 30 40 50 60 70 80 90 100
P
r
o
b
a
b
i
l
i
t
y
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
TABLE 45  Cost-effectiveness results from the perspective of the NHS: radical prostatectomy
Difference in mean NHS costs [mean (95% CI)] 181.02 (107.06 to 254.97)
Difference in QALYs [mean (95% CI)] –0.002 (–0.027 to 0.023)
ICER (£/QALY) 90,510
Probability intervention is cost-effective when threshold is £20,000 per QALY 19.2%
Probability intervention is cost-effective when threshold is £30,000 per QALY 27.3%78 Resource use and cost-effectiveness in the radical randomised controlled trial
at a threshold of £30,000 per QALY the intervention is 50.2% more likely to be cost-effective 
(Figures 25 and 26).
Basing quality-adjusted life-year estimates on SF-6D values
Table 46 reports the SF-6D scores for each arm of the trial at baseline and 6 and 12 months. 
These scores were slightly lower than those reported using the EQ-5D. From these data it was 
estimated that the mean QALYs were 0.80 (SD 0.11, median 0.806) for the intervention arm and 
0.79 (SD 0.11, median 0.818) for the control arm. The mean difference in QALYs after adjusting 
for minimisation and baseline SF-6D scores was 0.005 (95% CI –0.022 to 0.012) higher for the 
intervention group, which was not statistically significant.
FIGURE 23  Representation of the uncertainty in differential mean costs and QALYs: NHS perspective (radical 
prostatectomy).
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FIGURE 24  Cost-effectiveness acceptability curve for intervention versus control: NHS perspective (radical 
prostatectomy).
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The results of the analysis using the SF-6D data when estimating incremental cost-effectiveness 
from the societal perspective were similar to those of the EQ-5D. Taking the mean difference in 
the total societal costs from Table 42 (–£588) and the mean difference in QALYs from Table 46 
(–0.005); it can be seen that the intervention is, on average, more effective and less costly 
(Table 47).
At a cost-effectiveness threshold of £20,000 per QALY, the intervention has a likelihood of 85% of 
being cost-effective, and at a threshold of £30,000 per QALY the intervention is 79.8% likely to be 
cost-effective (Figures 27 and 28). Based on the societal perspective, these estimates indicate that 
the intervention is likely to be cost-effective. However, as with the base-case analysis, these results 
FIGURE 25  Representation of the uncertainty in differential mean costs and QALYs: using unadjusted data (radical 
prostatectomy).
FIGURE 26  Cost-effectiveness acceptability curve for intervention versus control: using unadjusted data (radical 
prostatectomy).
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TABLE 46  SF-6D quality of life measures: radical prostatectomy
Mean (SD)
Difference (95% CI)a Intervention Control
Baseline SF-6D 0.71 (0.12)
n = 201 (98%)
0.69 (0.13)
n = 200 (97%)
6-month SF-6D 0.82 (0.14)
n = 188 (92%)
0.81 (0.14)
n = 189 (92%)
0.012
12-month SF-6D 0.82 (0.13)
n = 189 (92%)
0.84 (0.12)
n = 189 (92%)
–0.014
QALYs 0.80 (0.11)
n = 172 (78%)
0.79 (0.11)
n = 166 (75%)
–0.005 (–0.022 to 0.012)
a  Differences adjusted for baseline costs.
TABLE 47  Cost-effectiveness results from the societal perspective: radical prostatectomy
Difference in mean NHS costs [mean (95% CI)a] –588.23 (–1329.83 to 153.37)
Differences in QALYs [mean (95% CI)a] –0.005 (–0.022 to 0.012)
ICER (£/QALY) Organised PFMT is dominant 
Probability intervention is cost-effective when threshold is £20,000 per QALY 85.0%
Probability intervention is cost-effective when threshold is £30,000 per QALY 79.8%
a  Differences adjusted for baseline costs.
FIGURE 27  Representation of the uncertainty in differential mean costs and QALYs: societal perspective using 
SF-6D data (radical prostatectomy).
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have to be interpreted cautiously as they are driven almost entirely by differences in time away 
from usual activities for which there is no obvious trial-related explanation.
Taking the mean difference in total NHS costs from Table 42 and the mean difference in the 
QALY estimate after adjusting for baseline SF-6D scores from Table 46, the mean incremental 
cost per QALY from the NHS perspective is reduced to £36,204 (Table 48).
The probability of the intervention being cost-effective in this analysis was lower than that 
estimated when using the EQ-5D data. At a cost-effectiveness threshold of £20,000 per QALY 
the intervention has a probability of 6% of being cost-effective, and at a threshold of £30,000 per 
QALY the intervention is 11% likely to be cost-effective (Figures 29 and 30). At no point does the 
probability of being cost-effective reach 50%.
Threshold analysis around the cure rates
Further sensitivity analysis was performed by reanalysing the data by patient group for 
differences in costs and QALYs by continence status. A simple model was used to determine at 
what reduction in the rate of incontinence in the intervention group compared with the control 
the physical therapy would be cost-effective. Details of the parameters used in the model are 
given in Table 49.
Figure 31 shows that when the rate of incontinence was reduced below 0.66 in the treatment 
group (while that of the control group was 0.77), the incremental cost per QALY would reduce 
to the level that society might be willing to pay. Reductions in the rates of incontinence are 
consistent with the reported CIs surrounding differences in continence rates. This suggests that, 
if smaller differences are clinically important, then, should these reductions be achieved, they 
would be potentially cost-effective.
Conclusions
For men having radical prostatectomy, QALYs were similar in both groups, and the costs of those 
who received the intervention were higher, but not statistically significantly so, than the costs 
of those who did not. The costs of the intervention were less than those of the control when the 
analysis was performed from a societal perspective. However, these results need to be interpreted 
FIGURE 28  Cost-effectiveness acceptability curve for intervention versus control: societal perspective using 
SF-6D data (radical prostatectomy).
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TABLE 48  Cost-effectiveness results from the perspective of the NHS: radical prostatectomy
Difference in mean NHS costs [mean (95% CI)a] 181.02 (107.06 to 254.97)
Differences in QALYs [mean (95% CI)a] –0.005 (–0.012 to 0.022)
ICER (£/QALY) 36,204
Probability intervention is cost-effective when threshold is £20,000 per QALY 6.0%
Probability intervention is cost-effective when threshold is £30,000 per QALY 11.0%
a  Differences adjusted for baseline costs.
FIGURE 29  Representation of the uncertainty in differential mean costs and QALYs: NHS perspective using SF-6D data 
(radical prostatectomy).
FIGURE 30  Cost-effectiveness acceptability curve for intervention versus control: NHS perspective using SF-6D data 
(radical prostatectomy).
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cautiously as they were largely influenced by the number of days that the participants said they 
were off work. The results of the analysis performed from the NHS perspective had lower costs 
for the control group, as anticipated. The cost-effectiveness results from a societal perspective 
favoured the intervention, and those from the NHS perspective favoured the control.
The model-based sensitivity analysis showed that a reduction in continence rates that is 
consistent with the CIs surrounding the relative risk of incontinence between treatment and 
control might be cost-effective. A judgement is required whether the smaller differences in 
incontinence are clinically significant. If they are, then a further judgement is required whether a 
larger trial would be worthwhile to identify these differences.
TABLE 49  Data used in analysis based on random allocation and state of incontinence at 12 months: 
radical prostatectomy
Parameter
Participants in 
intervention group who 
were continent 
Participants in 
intervention group 
who were incontinent
Participants in control 
group who were 
continent
Participants in control 
group who were 
incontinent
Cost of intervention (£) 196.34 (223.00) [66.82] 204.56 (223.00) [56.00] 0.00 (0.00) [0.00] 0.00 (0.00) [0.00]
Total subsequent resource use 
costs (£)
291.17 (239.19) 
[209.46]
518.59 (365.39) 
[485.15]
253.63 (214.21) 
[174.01]
291.17 (239.19) 
[209.46]
Total NHS costs (£) 487.51 (442.09) 
[212.57]
723.16 (565.42)
[495.26]
253.63 (214.21) 
[174.01]
291.17 (239.19) 
[209.46]
QALY 0.92 (0.95) [0.08] 0.84 (0.92) [0.21] 0.91 (0.94) [0.10] 0.84 (0.89) [0.18]
Probability of being continent/
incontinent
0.23 0.77
Relative risk of being incontinent 0.85–1 0.85–1
Figures are mean (SD) [median].
FIGURE 31  Probability that intervention is likely to be cost-effective: radical prostatectomy.
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Chapter 9  
Discussion of results of randomised 
controlled trial after radical 
prostatectomy
This chapter summarises the discussions relating to the radical prostatectomy RCT.
Summary of main findings
In the men who had a radical prostatectomy, there were no statistically significant differences in 
urinary, bowel or sexual function outcomes between the intervention and control groups, despite 
evidence of extra performance of PFMT and improvement in pelvic floor muscle strength over 
time in the intervention group. The estimated additional cost to the NHS was on average £181 
(95% CI £107 to £255) higher in the intervention group than in the control group.
Recruitment and screening of men in hospital
We approached 1158 men having a radical prostatectomy in NHS hospitals and obtained consent 
to screen 804 of these men. Of those, 95% returned their screening survey, and over 90% of 
the responders were incontinent of urine at about 6 weeks after surgery (see Table 13). This 
prevalence was similar to that found by Kao et al. (82% in 1013 men).9 The majority of the men 
(around 80%) had a traditional open retropubic radical prostatectomy, and around 55% had a 
procedure in which one or both nerve bundles were spared. Only 6% of the men had urinary 
incontinence before surgery, and 2% reported faecal incontinence (see Table 13). The average age 
of the men was 62 years.
Recruitment to randomised controlled trial and response rates
Of the 742 men who were incontinent at screening, 411 agreed to be randomised to a controlled 
trial of conservative treatment (PFMT and lifestyle advice) for urinary incontinence (205 in the 
intervention group and 206 in the control group). The groups were comparable at baseline on all 
the epidemiological and clinical characteristics measured (see Table 14). Almost all of the men 
had heard of pelvic floor exercises at some time prior to randomisation (see Table 15).
Conduct of the intervention
Compliance (attendance at therapy visits) with the intervention was high, with 92% of the men 
allocated to the intervention group attending at least one therapy visit and 85% attending all 
four of them. The most common reasons for not attending were becoming dry and finding it 
inconvenient to attend.
Association with type of therapist
Half of the centres used physiotherapists as the provider of the intervention, while the rest used 
nurse therapists (although all therapists received the same standardised training). About 40% of 
the men attended a physiotherapist while 60% attended a nurse therapist. However, there were no 
significant differences in the number of visits or the chance of urinary incontinence during the 
treatment period according to type of therapist (see Table 19).86 Discussion of results of randomised controlled trial after radical prostatectomy
At follow-up, no statistically significant association was demonstrated between the chance of 
incontinence at 12 months and type of therapist (see Figure 20).
Clinical symptoms during the therapy period
During the therapy period, the proportion of men with incontinence fell from 92% to 73% by the 
fourth visit (see Table 20 and Figure 7). Few men reported bowel problems, and these numbers 
did not vary much over time (see Table 22 and Figure 9). Around 90% of the men had problems 
with sexual function and these did not decrease with time (see Table 23 and Figure 10).
Clinical findings during the therapy period
Anal sphincter and pelvic floor muscle contraction strength increased over time in the 
intervention group: 40% of men rated their strength as good or better at the beginning of 
the therapy period, rising to 85% by the fourth visit (see Table 24 and Figure 11). However, 
around 15% still had only moderate or poor contraction strength at the end of the 3-month 
therapy period.
Machine-led biofeedback was available in only 13 of the 34 MAPS centres (see Table 7), and 
was used clinically in only five centres in 16 men (see Table 25). It was not clear whether this 
was for diagnosis or for repeated use to assist with training. However, almost all men had verbal 
biofeedback from their therapist following digital anal assessment of muscle contraction, to teach 
them to perform contractions correctly and to monitor improvement at each successive visit.
Practice of pelvic floor muscle training after end of therapy period
While over 80% of men in both the intervention and the control groups were practising PFMT 
at baseline (before they were randomised and before the intervention), this fell to 67% in the 
intervention group and 50% in the control group at the 12-month follow-up.
Findings of the randomised controlled trial
The primary outcome of the RCT was the proportion of men with urinary incontinence at 
12 months after randomisation. This was measured using the ICI-SF questionnaire, and was 
also ascertained at 3, 6 and 9 months after randomisation. In addition, urinary outcomes were 
obtained from 3-day diaries completed by the men at each of these time points. The response 
rates were over 95% for the questionnaires and over 80% for the diaries (see Table 27).
Urinary outcomes
While the proportion of men with urinary incontinence fell from 100% at baseline to around 
75% by 12 months, the majority of the decrease occurred in the first 3 months (to around 87%) 
with a further fall (to 80%) at 6 months. There was no statistically significant difference in the 
proportion of men with urinary incontinence between the intervention and control group at 
12 months [75.5% vs 77.4%, absolute risk difference –1.9% (95% CI –10% to 6%) (see Table 28) or 
at any other time point (see Table 29 and Figure 14)].
These findings (of no statistically significant differences between the trial groups) were similar 
for all the urinary outcomes regardless of how (by questionnaire or diary) or when they were 
measured (see Table 29).
Severity of incontinence
If severe incontinence is defined as incontinence at least once a day and a moderate or large 
amount of leakage, around 40% of the men were still experiencing severe leakage at 12 months 
(see Table 29a) and 40% were also using pads (see Table 31a). Using the ICI score as a composite 
measure of severity and effect on quality of life, the same picture emerged: the majority of the © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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improvement (decrease) in the score occurred in the first 3 months after randomisation with a 
further small improvement at 6 months (see Table 29 and Figure 15).
Types of incontinence
The most common type of incontinence was SUI (around 70%; see Table 30), while UUI and 
MUI affected around 40% of men. The prevalence of these and the other types of urinary 
symptoms was no different between the randomised groups (see Table 30 and Figure 16).
Subgroup analyses
Prespecified subgroup analyses were carried out on the primary outcome (urinary incontinence 
at 12 months). There were no significant differences between randomised groups in any of the 
subgroups (see Figure 20).
Other clinical outcomes
Men were also asked to report on bowel and sexual problems.
Bowel outcomes
Bowel problems that might be expected to be ameliorated by therapy or lifestyle advice included 
faecal incontinence, urgency and constipation. Men were also asked about bowel conditions such 
as ulcerative colitis, Crohn’s disease and irritable bowel syndrome. There were no differences at 
any time point in any aspect of bowel function or disease between the men in the randomised 
groups (see Table 32 and Figure 17).
Sexual function outcomes
Over 90% of men had normal erectile function before operation. Although around one-third had 
an active sex life at 12 months, the majority said that this was worse than before their operation 
(see Table 33). There were, however, no differences at 12 months according to the randomised 
groups in any of the aspects of sexual function measured (see Tables 33 and 34). Even at 
12 months, 82% of intervention group men and 78% of control group men reported severely 
reduced or no erectile function (see Table 34 and Figure 18). Neither were there differences 
between the groups in the proportions of men with an active sex life [RR 0.94 (95% CI 0.73 to 
1.22); p = 0.661] or the proportions of men whose sex life had become worse after the operation 
[RR 0.79 (0.47 to 1.34); p = 0.391; see Table 33].
Over half of the men had used a vacuum device or medication to improve sexual function 
(see Table 34). NICE guidelines17 suggest that phosphodiesterase type 5 (PDE5) inhibitors 
could be offered to men who experience loss of erectile function. If PDE5 inhibitors fail or are 
contraindicated, men could be offered vacuum devices, intraurethral inserts, penile injections or 
prostheses. 
Quality of life outcomes
General health outcomes were measured using the EQ-5D and SF-12 (the latter subdivided 
into role – mental and role – physical scores). The slight increase in the scores over time can 
be assumed to represent recovery from operation, but there were no differences between the 
randomised groups at any time point in EQ-5D or SF-12 scores (see Table 35 and Figure 19).
Knowledge of pelvic floor muscle training in trial groups before 
intervention
Nearly all of the men in both groups (97% and 99% respectively) had received information about 
the use of pelvic floor exercises before starting the trial intervention (see Table 15). The most 
common sources were from nurses or continence advisors (over 70%), or from leaflets or books 
(around 65%; see Table 15).88 Discussion of results of randomised controlled trial after radical prostatectomy
Practice of pelvic floor muscle training in intervention and control 
groups
It is not surprising, given the prior knowledge of pelvic floor exercises, that over 80% of men in 
both groups reported carrying out some exercises before randomisation (see Table 36). However, 
by 6 months the men in the intervention group were more likely to be still carrying them out and 
this difference persisted at the 12-month follow-up (see Table 36).
Changes in lifestyle factors
Men in both groups were given written information about lifestyle changes that might improve 
aspects of both their general health and incontinence. In the intervention group, this advice was 
reinforced and individualised by the therapists. However, there were no significant differences in 
the uptake of any aspect of this advice at 12 months after randomisation (see Tables 37 and 38).
Economic outcomes
Costs to the NHS
Total costs to the NHS were on average £181 (95% CI £107 to £255) higher in the intervention 
group than in the control group. This difference was entirely due to the cost of providing the 
PFMT training in the intervention group. The use of other health services, and hence cost, was, 
on average, slightly lower in the control group, but this difference was not statistically significant.
Costs to the participants
Costs to the participants related to three broad elements: (i) the cost of private health care; (ii) 
the cost of accessing NHS care (in terms of time and out-of-pocket expenses); and (iii) the cost 
of time away from usual activities. On average, the costs of any private health care used were low 
and there was no evidence of any difference between groups. Similarly, the costs of accessing 
care other than the intervention were similar for the two groups. However, participants in the 
control arm appeared, on average, to have more days away from usual activities than participants 
in the intervention arm [mean difference –6.54 days (95% CI –13.08 days to –0.01 days)]. 
The mean cost of time away from usual activities was approximately £809 for the intervention 
group and £1614 for the control group. Given the assumptions made about valuing time away 
from usual activities, this difference was the key determinant of the differences in average total 
participant costs. It is not clear why there would be fewer days away from usual activities in the 
intervention group, given the lack of evidence for any treatment effect. Therefore, as these data 
are counterintuitive, they should be treated cautiously.
Overall costs to the NHS and participants
On average, the cost to the NHS and participants was £588 [–£1330 to £153] greater in the 
control group than in the intervention group. Although not statistically significant, the direction 
of effect was the result of differences in the mean time away from usual activities.
Quality-adjusted life-years
On average, QALYs were virtually identical in both the intervention and the control group [on 
average, QALYs were 0.002 higher in the intervention group (95% CI –0.027 to 0.023)].
Cost-effectiveness from the perspective of the NHS and participants
Based upon the point estimates of the mean difference in costs and QALYs the intervention is 
dominant. The point estimates are associated with considerable imprecision, so the probability 
that the intervention would be considered cost-effective at typical thresholds for society’s 
willingness to pay for a QALY were calculated (see Figure 22). This analysis suggested that there 
was over an 80% chance that organised PFMT training was cost-effective. As noted above, 
this result was almost entirely driven by the differences in days away from usual activities, and 
therefore should be treated with caution.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Cost-effectiveness from the perspective of the NHS
When the perspective of the economic evaluation was restricted to the NHS, the point estimate 
of the incremental cost per QALY was effectively dominated. Furthermore, there was less than a 
20% chance that the intervention would be cost-effective should the threshold value for society’s 
willingness to pay for a QALY be £20,000.
Sensitivity analyses
The majority of the sensitivity analyses conducted did not greatly alter the conclusions of the 
economic evaluation. In one sensitivity analysis, conducted from the perspective of the NHS, 
the reduction in the rate of incontinence that would make the intervention cost-effective was 
estimated. The results of this analysis suggested that, should the intervention reduce the rate 
of incontinence by approximately 10%, then the provision of physical therapy could be cost-
effective. This difference is similar to the lower end of the CIs surrounding the risk difference in 
incontinence rates. However, the trial was of sufficient size to rule out any but a small chance that 
this difference could exist.
Strengths and weaknesses (specific to the radical prostatectomy 
randomised controlled trial)
Recruitment
We approached 1158 men who were admitted to hospital for radical prostate surgery in order 
to identify and recruit our final population of 411 men who entered the RCT. Many of the 
men approached were ineligible or missed in hospital (354 men; see Table 9a) and 24 were 
subsequently found to be ineligible (see Table 10a). This scale of recruitment represented a large 
burden on the recruitment officers in the centres. However, we felt that this was the most efficient 
way of identifying our target population, which was men who had urinary incontinence after 
prostate surgery. Other methods, such as expecting local staff to identify incontinent men and 
recruit them to the RCT directly, might have been too burdensome and risked missing many men 
owing to pressure of routine work.
Generalisability of the trial population
Most of the men who agreed, when in hospital, to be screened 3 weeks later returned their 
screening questionnaire (742/780, 95%; Table 12). There were no significant differences in 
demographic or clinical characteristics when non-responders were compared with responders. 
Just over half (411/742, 55%) of the men who returned a screening questionnaire were eventually 
recruited into the RCT. Many of the remainder had become dry [53 (7%) at screening, 61 (8%) 
at baseline], and a further 125 (17%) were not eligible because they did not return their baseline 
questionnaire (see Figure 4 and Table 11). Of the 92 not accounted for, 26 (4%) declined further 
contact, 15 (2%) did not wish to be randomised, and the remainder had a variety of other 
reasons for not wishing to enter the trial (see Table 11). A further 18 (2%) were excluded after 
randomisation. Thus, our trial population represented 411/472 (87%) of the men who were 
incontinent and eligible to be randomised, but only 411/780 (53%) of men identified in hospital 
as having radical prostate surgery.
Response rates
Once randomised, participants were compliant in returning their questionnaires (over 90%) 
and urinary diaries (over 80%), while the withdrawal rates were very low. There was no evidence 
of differential dropout from the randomised groups, with outcome data available for 98% 
(intervention) and 97% (control) of the men continuing at 12 months (see Table 27a). This 
provides some reassurance that the outcome data are representative of the men in the RCT, and 
that bias from differential attrition was minimal.90 Discussion of results of randomised controlled trial after radical prostatectomy
Strengths and weaknesses of the economic analyses
The methods of the economic analysis were rigorous and reproducible, and efforts were made 
to assess the importance of uncertainty surrounding estimates of costs, effects and cost-
effectiveness. As the study was not powered to detect differences in economic outcomes, it was 
anticipated that differences in costs and effects would not reach statistical significance. For this 
reason, conclusions from the economic evaluation were based upon the consideration of the 
balance of probabilities.
The conclusions from the economic analysis are sensitive to the perspective taken. When the 
perspective was the NHS, it was unlikely that the intervention would be cost-effective. When 
the perspective was widened to the NHS and patients, there was over an 80% chance that the 
intervention would be cost-effective. The main driver of this difference in the conclusions was the 
trend towards more time away from usual activities in the control group. It is not clear whether 
this trend was real or not, given the lack of any meaningful trends in either health or use of health 
services. Therefore, the conclusion drawn on the basis of the NHS and patient perspective should 
be treated with caution.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Chapter 10  
Transurethral resection of the 
prostate: derivation and description of 
participants
T
his chapter describes the men derived from the screening survey in terms of their clinical 
characteristics and presents the baseline comparability between the randomised groups in 
the TURP group.
Comparison between those responding and not responding to the 
screening survey
Table 50 shows the comparability at baseline of those responding and not responding to the 
screening survey in terms of their demographic and clinical characteristics. There were no 
clinically important differences between responders and non-responders. The majority were 
standard TURPs, but 5% were laser TURPs, 15 were open abdominal procedures and two were 
transvesical. A further 16 men were all originally admitted for TURP but were subsequently 
found to need a different procedure. They were not randomised or followed up in MAPS. 
Findings from screening survey
The average time of completion of the screening survey was at around 5 weeks after surgery 
[mean days since operation 34.4 (SD 18.8)]. The majority of the men had a standard TURP, but 
laser was used for ablation in about 5%: this did not affect the chance of subsequent incontinence. 
Just under half of the men had urinary incontinence at the time of screening, and the most 
common type was UUI (Table 51).
TABLE 50  Screening survey responders and non-responders
TURP Responder  Non-responder 
Number screened [n/N (%)] 2590/2836 (91) 246/2836 (9))
Age [mean years (SD) n] 69.9 (8.2) 2578 70.6 (9.0) 246
Weight [mean kg (SD) n] 81.9 (31.4) 2399 81.5 (15.0) 222
Height [mean cm (SD) n] 172.6 (14.0) 2226 171.6 (22.0) 213
Current smoker [n/N (%)] 285/2590 (11) 44/246 (18)
Nights in hospital [mean (SD) n] 3.8 (2.2) 2457 4.2 (2.6) 231
Type of operationc n = 2587 n = 241
Standard TURP [n/N (%)]a 2431/2588 (94.0) 224/246 (93.1)
Laser TURP [n/N (%)] 140/2588 (5.4) 12/246 (4.9)
No TURP (had other procedure) [n/N (%)]b 16/2588 (0.6) 5/246 (2.0) 
a  Seventeen of the prostatectomies were carried out as open simple retropubic (n = 15) or transvesical (n = 2) procedures.
b  The other procedures included BNI, cystoscopy, cystolithopaxy, circumcision and urethral dilatation. One man had a subcapsular orchidectomy. 
These men were all originally admitted for TURP but were subsequently found to need the other procedure.
c  Data on type of operation missing for 10 men.92 Transurethral resection of the prostate: derivation and description of participants
Summary information for progress from screening questionnaire 
to randomisation
Of 1203 men wet at screening, 155 were not eligible to be sent a baseline questionnaire (see 
Table 11 for reasons). Of the 1048 men sent a baseline questionnaire, 786 (75%) responded, of 
whom 512 (89%) were still wet and 274 dry. A further 70 were excluded as they were ineligible 
for randomisation despite still being incontinent (see Table 11 for reasons). Finally, 442 men were 
randomised, 220 in the intervention group and 222 in the control group (see Figure 5).
Men who recorded that they were wet at the screening survey were sent a further baseline 
questionnaire to confirm persistent leakage. Those who were still wet and consented were 
randomised to intervention or control. The average time to randomisation from the date of 
surgery was 8 weeks (mean 8.4, SD 3.4).
Comparability on baseline characteristics at trial entry
Table 52 shows that the men in the two randomised groups were comparable at baseline on the 
clinical and demographic characteristics recorded.
Prior knowledge of pelvic floor exercises
Many men had been counselled before surgery about the possibility of urinary incontinence and 
sexual dysfunction after surgery, although this was less common in the men undergoing TURP 
than in those undergoing radical surgery.69 Table 53 shows that the most common sources of 
information about pelvic floor exercises were leaflets or books or nurses or continence advisors: 
around 80% of men had some prior knowledge of pelvic floor exercises for these problems.
TABLE 51  Results of screening survey 3 weeks after operation (responders to screening questionnaire who had TURP 
only, N = 2587)
TURP
All responders 
to screening 
questionnaire
(n = 2587)
Standard TURP
(n = 2431)
Laser TURP
(n = 140)
No TURP
(n = 16)
Days since operation [mean (SD) n] 34.4 (18.8) 2518 34.1 (19.1) 2368 32.7 (12.5) 134 34.1 (9.8) 13
Number of men with any urine loss at 
screening questionnaire 
1203/2585 (47) 1129/2433 (46) 66/140 (47) 6/16 (38)
ICI-QoL score due to UI [mean (SD) n]a 1.3 (2.4) 2414 1.3 (2.4) 2269 1.5 (2.7) 129 0.9 (2.0) 16
ICI-Q score [mean (SD) n]b 3.42 (4.7) 2568 3.4 (4.7) 2415 3.7 (4.9) 137 2.6 (3.9) 16
Number of men with urine loss before surgery 883/2588 (36) 839/2432 (37) 38/140 (29) 6/16 (43)
Number of men with faecal incontinence after 
surgery
112/2585 (4) 105/2433 (4) 7/140 (5) 1/16 (6)
Type of incontinence 
SUI  303/2585 (12) 292/2433 (12) 11/140 (8)  1/16 (6)
UUI  733/2585 (28) 697/2433 (29) 36/140 (26) 1/16 (6)
MUI 135/2585 (5) 131/2433 (5) 5/140 (4) 0
Postmicturition leakage 446/2585 (17) 413/2433 (17) 29/140 (21) 4/16 (25)
Other incontinence 295/2585 (11) 270/2433 (11) 24/140 (17) 1/16 (6)
Figures are n/N (%), unless stated otherwise.
a  ICI-QoL score: 0 = none, 10 = maximum (worst) score. Derived from question 3 of the ICIQ-UI Short Form Questionnaire.
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TABLE 52  Baseline comparability at trial entry between men in randomised groups 
TURP Intervention (n = 220) Control (n = 222)
Age in years [mean (SD) n, (min–max)] 68.2 (7.7) 220, (47–90) 67.9 (8.1) 222, (45–86)
BMI (kg/m2) [mean (SD) n, (min–max)] 27.1 (4.1) 217, (15–48) 27.1 (4.7) 215, (17–44)
Type of operation 220 222
  Standard TURP  199/220 (90) 199/222 (90)
  Laser TURP 10/220 (5) 15/222 (7)
  TURP + other procedure  11/220 (5) 8/222 (4)
TURP before surgery  23/217 (11) 26/218 (12)
Number of men not able to achieve erection before prostate surgery  67/214 (31) 71/215 (33)
Leakage of urine before operation 95/195 (49) 102/205 (50)
ICI-Q scorea at baseline [mean (SD) n, (0–21 max)]  8.6 (4.1) 219 8.7 (4.3) 222
Number of men with severe incontinence at baselineb 145/220 (66) 144/222 (65)
Urinary frequency at baseline (per day) [mean (SD) n]  8.6 (5.2) 205  7.9 (3.1) 199
Nocturia at baseline (per night) [mean (SD) n] 2.7 (1.6) 215  2.5 (1.5) 212
Type of incontinence  220 222
 SUI  148/220 (67) 136/222 (61)
 UUI  186/220 (85) 183/222 (82)
  MUI (both) 129/220 (59) 112/222 (50)
  Postmicturition leakage 151/220 (69) 156/222 (70)
  Other incontinence  57/220 (26) 44/222 (20)
Pad use 71/220 (32) 70/217 (32)
Other health problems  138/220 (63) 145/222 (65)
EQ-5D [mean (SD) n] 0.8 (0.3) 213 0.8 (0.3) 208
SF-12M [mean (SD) n] 49.9 (10.4) 216 50.3 (10.4) 212
SF-12P [mean (SD) n]  42.7 (11.0) 216 43.2 (11.9) 212
Numbers as reported. Figures are n/N (%), unless stated otherwise.
a  ICI-Q score: 0 = none to 21 = maximum (worst) score.
b  Severe incontinence defined as at least once a day and a moderate or large amount of leakage.
TABLE 53  Number of men with prior knowledge of pelvic floor exercises
Source of information  Intervention Control
A doctor 13/106 (12) 13/119 (11)
A nurse/continence advisor 34/106 (32) 40/119 (34)
A physiotherapist 6/106 (6) 5/119 (4)
Leaflets or books 46/106 (43) 54/119 (45)
The internet 2/106 (2) 7/119 (6)
Friends or family 18/106 (17) 16/119 (13)
Another source 10/106 (9) 6/119 (5)
At least one source of information 94/106 (89) 89/119 (75)
Figures are n/N (%) answering yes. Respondents could cite more than one source of information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
95   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
Chapter 11  
Transurethral resection of the prostate: 
management received
T
his chapter describes how the intervention was implemented in the therapy arm of the TURP 
RCT, and the progress of men through the intervention period (n = 220). The information 
in this chapter is derived from the therapy documentation (see Appendix 4.1), which was used 
primarily to guide the therapists while delivering the standardised intervention.
Compliance with therapy
Of the 220 men who were randomised to the intervention, 189 attended at least one visit (86%), 
and 72% attended every time (Table 54). The non-attenders were slightly older and lighter, 
although these differences were not clinically important (Table 55). Only 7 of the 31 men who did 
not attend were dry. The other main reasons were that, after they were allocated to therapy, four 
men became ill and six men found it to be inconvenient or impossible to attend appointments, 
often because of work. The remainder simply declined or did not give a specific reason (Table 56).
Relationship between type of therapist and outcomes during 
therapy period
Half of the centres (17) used a physiotherapist to deliver the MAPS intervention, while in the 
other 17 the therapist had a nursing background (Table 57). There was no significant difference 
in the number of visits men made to physiotherapist or nurse therapists (Table 57). During the 
3-month intervention period, there were no statistically significant differences in the mean ICI 
scores (a composite score reflecting urinary incontinence and its effect on quality of life) between 
therapists (Table 57).
TABLE 54  Number of visits attended 
TURP First visit Second visit  Third visit Fourth visit
Number of men attending 189 (86%) 173 (79%) 163 (74%) 158 (72%)
TABLE 55  Number of non-attenders/attenders, comparability on age and BMI 
TURP Attenders Non-attenders
Age [mean years (SD) n] 68.0 (7.9) 189 69.2 (6.9) 31
BMI [mean kg/m2 (SD) n] 27.2 (4.1) 187 26.3 (4.5) 3096 Transurethral resection of the prostate: management received
Urinary incontinence during therapy period
Incidence of urinary incontinence
The therapists asked the men at each visit to rate their incontinence (in the previous week). 
This allowed the therapists to monitor the change in reported incontinence. They used the same 
form of question as the questionnaires, based on the ICI-SF instrument, which were also used to 
measure the primary outcome. During the 3-month intervention period, the proportion of men 
with incontinence fell from 82% to 52%, while the mean ICI score decreased (improved) from 
around 6.5 at the start of treatment to 3 afterwards (Table 58 and Figure 32).
Type of urinary incontinence during therapy period
The distribution of type of incontinence reported by the men did not vary with time across the 
therapy visits, except that the proportion with SUI decreased slightly (from 36% to 21%), the 
proportion with UUI decreased (from 57% to 20%) and the proportion with postmicturition 
leakage decreased (from 57% to 33%) (Figure 33 and Table 59).
TABLE 57  Relationship between type of therapist and attendance rates (mean number of attendances) and effect on 
incontinence rates (composite ICI score) 
TURP Physiotherapist  Continence nurse
Significance [mean difference 
(95% CI), p-value 
Number of attendances  3.1 (1.5) 111, (2.8 to 3.4) 3.1 (1.5) 109, (2.8 to 3.4) 0.02 (–0.4 to 0.4), 0.901
ICI-Q score
Visit 1 6.7 (4.7) 95, (5.7 to 7.7) 6.4 (3.7) 94, (5.6 to 7.1) 0.3 (–0.9 to 1.5), 0.602
Visit 2 5.0 (3.8) 87, (4.2 to 5.8) 4.5 (3.9) 86, (3.6 to 5.3) 0.5 (–0.7 to 1.7), 0.387
Visit 3 4.3 (3.6) 82, (2.7 to 4.3) 3.8 (3.5) 81, (3.0 to 4.6) –0.2 (–1.3 to 0.9), 0.691
Visit 4  2.9 (3.9) 81, (2.0 to 3.8) 3.1 (3.3) 77, (2.3 to 3.8) –0.2 (–1.3 to 1.0), 0.775
Figures are mean (SD) n, (95% CI), unless shown otherwise.
ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
TABLE 58  Number of men incontinent at each time point, and mean ICI score at each clinic visit
TURP Visit 1 Visit 2 Visit 3 Visit 4
Men incontinent [n/N (%)] 154/188 (82) 118/172 (69) 97/162 (60) 82/157 (52)
ICI-Q score [mean (SD) n] 6.5 (4.23) 189 4.8 (3.87) 173 3.7 (3.53) 163 3.0 (3.58) 158
ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
TABLE 56  Reasons for non-compliance (not attending any visits at all) (n = 31)
TURP Non-attenders (n)
Dry 7
Ill 4
Unable to attend 6
Declined 9
No reason given 5
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Incidence and type of bowel problems during therapy period
Therapists also enquired at each visit about whether the men experienced any bowel dysfunction 
in the previous week. The proportions of men with three different types of bowel dysfunction 
(faecal incontinence, faecal urgency and constipation) were low and did not vary during the 
therapy period (Table 60 and Figure 34).
Incidence and type of sexual problems during therapy period
The questions relating to sexual problems were those used in routine clinical practice. They were 
not based on the questions men were asked at 12 months to assess their sexual function and 
activity70 (see section G, 12-month questionnaire, Appendix 3.3).
Just over half of the men reported sexual dysfunction (‘difficulty gaining or maintaining an 
erection in the last week’) (52–62%) and this did not change during the therapy period. The 
corresponding proportion with premature ejaculation was low (around 6%) and also did not vary 
with time (Table 61 and Figure 35).
TABLE 59  Type of incontinence at each visit and change over time 
TURP Visit 1 Visit 2 Visit 3 Visit 4
Number of men 189 173 163 158
SUI  59/162 (36) 50/151 (33) 42/146 (29) 28/134 (21)
UUI  95/166 (57) 47/150 (31) 38/144 (26) 27/135 (20)
MUI (both SUI and UUI) 34/170 (20) 15/155(10) 9/148 (6) 5/138 (4)
Postmicturition leakage 97/171 (57) 67/154 (44) 52/144 (36) 45/136 (33)
Other UI 28/146 (19) 22/131 (17) 24/123 (20) 21/127 (17)
Figures are n/N (%).
FIGURE 32  Trend analysis of the proportion (%) men incontinent at each visit: TURP. ICI-Q score: 0 = none, 
21 = maximum (worst) score. Derived from questions 1–3 of the ICIQ-UI Short Form Questionnaire.
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FIGURE 33  Type of incontinence at each visit and change over time: TURP.
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Examination of pelvic floor muscle performance during therapy 
visits
Therapists assessed the strength of the pelvic floor muscle contractions and their endurance 
(length of time men were able to hold a contraction) at each visit using digital anal assessment 
(see Chapter 3). The external anal sphincter and the internal puborectalis muscle were assessed 
separately. The internal puborectalis muscle strength was taken to be a measure of pelvic floor 
muscle strength.
TABLE 60  Type of bowel problems at each therapy visit and change over time
TURP Visit 1 Visit 2 Visit 3 Visit 4
Faecal incontinence 6/184 (3) 3/170 (2) 3/159 (2) 2/156 (1)
Faecal urgency 17/185 (9) 9/170 (5) 7/159 (4) 11/156 (7)
Constipation 30/184 (16) 18/165 (11) 21/156 (13) 10/155 (6)
Figures are n/N (%).
FIGURE 34  Type of bowel problems at each visit and change over time: TURP.
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For both the sphincter and the puborectalis, both strength and endurance improved during the 
therapy period (Table 62 and Figure 36). At baseline, only 4–6% of men had a strength of 5 or 
more, but by the fourth visit around 35–40% of men were able to contract strongly (5) or very 
strongly (6), while over 80% had good muscle strength (4 or better). The therapists were trained 
to ask men to hold the pelvic floor muscle contraction for up to 10 seconds during the digital 
anal examination. This is in line with functional use of these muscles. However, some therapists 
assessed the maximum length of time for which men could hold a contraction. Of these men, 
some held the contraction for over 1 minute.
TABLE 61  Type of sexual problems at each visit and change over time 
TURP Visit 1 Visit 2 Visit 3 Visit 4
Difficulty gaining erection 95/173 (55) 77/149 (52) 79/142 (56) 71/137 (52)
Difficulty maintaining erection 97/168 (58) 86/146 (59) 85/138 (62) 80/134 (60)
Premature ejaculation 8/152 (5) 9/137 (7) 8/130 (6) 7/121 (6)
Figures are n/N (%).
FIGURE 35  Type of sexual problems at each visit and change over time: TURP.
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Examination and functional use of pelvic floor muscles
Therapists examined men at each visit to assess skin damage, skin infection, ability to tighten the 
anus and perform penile retraction and testicular lift, evidence of leakage on coughing and (for 
those who did leak) ability to prevent leakage on coughing. Very few men showed evidence of 
skin damage or infection (data not shown).
Four different aspects of functional use of pelvic floor muscles were assessed: ability to tighten 
anus; ability to perform penile retraction; leakage on coughing; ability to prevent leakage on 
coughing. While most men (over 95%) were able to contract well enough to tighten the anal 
sphincter at least a little from baseline onwards, the proportion able to demonstrate a testicular 
lift increased slightly with time (from 73% to 89%; Figure 37). The proportion who leaked when 
coughing was low (< 5%) and decreased very slightly during the therapy period. Around 77% of 
these men were able to contract their pelvic floor muscles sufficiently to prevent leakage when 
coughing at the first visit, and this improved to around 86% by the fourth visit.
Use of machine-led biofeedback
Biofeedback was available in 13 of 34 MAPS centres, and was used clinically for men after TURP 
in two of them (see Table 7). Therapists would have liked access to this facility in four other 
centres where biofeedback was not available. Biofeedback can be used in two ways:
TABLE 62  Ability to contract anal sphincter and puborectalis muscle (pelvic floor) over time 
TURP Visit 1 Visit 2 Visit 3 Visit 4
A: External anal sphincter strength [mean (SD) n]a 3.1 (0.9), 153 3.5 (0.9), 125 3.9 (0.9), 119 4.2 (1.0), 108
0 1(1) 0 0 0
1 6/153 (3) 1/125 (1) 1/119 (1) 0
2 28/153 (18) 17/125 (14) 7/119 (6) 5/108 (7)
3 63/153 (41) 34/125 (27) 29/119 (24) 16/108 (15)
4 50/153 (33) 59/125 (47) 55/119 (46) 48/108 (44)
5 6/153 (4) 14/125 (11) 24/119 (20) 29/108 (27)
6 0 0 3/119 (2) 10/108 (9)
A: External anal sphincter endurance (seconds) 
[mean (SD) n]b
6.0 (2.9) 153 7.4 (3.0) 125 8.4 (3.3) 119 10.2 (5.3) 108
B: Puborectalis muscle strength [mean (SD) n]a 3.1 (1.0) 153 3.5 (0.9) 125 3.9 (0.9) 119 4.3 (1.0) 108
0 1/153 (1) 0 0 0
1 8/153 (5) 4/125 (3) 1/119 (1) 1/108 (1)
2 23/153 (15) 13/125 (10) 7/119( 6) 4/108 (4)
3 67/153 (44) 42/125 (34) 30/119 (25) 13/108 (12)
4 44/153 (29) 53/125 (42) 52/119 (44) 45/108 (42)
5 8/153 (5) 12/125 (10) 25/119 (21) 37/108 (34)
6 2/153 (1) 1/125 (1) 4/119 (3) 8/108 (7)
B: Puborectalis muscle endurance (seconds) 
[mean (SD) n]b
6.0 (2.8) 153 7.6 (3.1) 125  8.5 (3.2) 119 10.2 (5.5) 108
Figures are n/N (%), unless stated otherwise.
a  Anal sphincter and puborectalis muscle strength are measured on a 0–6 modified Oxford scale: 0 = no flicker; 1 = flicker; 2 = weak 
contraction, no movement; 3 = moderate contraction with movement; 4 = good contraction against resistance; 5 = strong contraction against 
strong resistance; 6 = maximal contraction, very strong, unable to remove finger.
b  Endurance is measured as the duration in seconds for which the man can maintain an anal squeeze contraction.102 Transurethral resection of the prostate: management received
  ■ to feed back information to men that they are actually performing a correct pelvic floor 
contraction, and at what strength
  ■ as part of a repetitive training regimen when men are asked to use the machine to enable 
them to monitor their exercise function for a period of time (such as 20 minutes).
It was not clear which type of biofeedback was practised in the centres where it was available, 
but therapists from two centres recorded its use in 11 men (see Table 7) from the TURP group 
(Table 63). In some cases men may have preferred anal examination using a machine rather than 
digital examination by the therapist for teaching of correct contractions.
FIGURE 36  Ability to contract anal sphincter and puborectalis muscle (pelvic floor) over time:TURP. (a) External anal 
sphincter strength/endurance. (b) Puborectalis muscle strength/endurance.
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FIGURE 37  Aspects of ability to use pelvic floor muscles at each visit and change over time: TURP.
TABLE 63  Use of biofeedback for any men
TURP Biofeedback indicated  Biofeedback actually implemented
Visit 1  10/92 (11) 0/90 (0)
Visit 2  7/87 (8) 5/85 (6)
Visit 3  3/81 (4) 3/78 (4)
Visit 4  3/85 (3) 3/85 (3)
Figures are n/N (%).
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Chapter 12  
Transurethral resection of the prostate: 
randomised controlled trial outcomes 
and results
T
his chapter describes the results of the intervention amongst the men recruited to the 
TURP RCT.
Patient flow
The derivation of the trial study groups and their progress through the trial is summarised 
in Figure 38. This is in the form of a CONSORT flow diagram. In total, 442 participants were 
recruited to the randomised trial: 220 randomly allocated to the intervention group and 222 
to the control group. Twenty-five men had withdrawn from follow-up by 12 months (although 
some information was available prior to the time of their withdrawal in some cases). Ten men, 
three in the intervention group and seven in the control group, died before 12-month follow-up 
was reached. These deaths were not attributed to the trial intervention. Thirty-one men (14%) in 
the intervention group did not attend any therapy sessions and were considered non-compliers 
with the intervention (see Chapter 6) but were retained in their allocated group for the purpose 
of analysis.
Response rates
Over 90% of all participants returned completed questionnaires. As shown in Figure 38, by the 
time of each follow-up some participants had formally withdrawn or died, and so were not sent 
questionnaires (Table 64). Of the participants for whom it was appropriate to send a follow-up 
questionnaire, over 90% returned it at each time point (Table 65a). For return of urinary diaries, 
the response rate was slightly less, but still approximately 90% at each time point (Table 65b).
TABLE 64  Reasons for withdrawal
Reason
TURP
Intervention Control
Ill 6 2
Dry 6 1
Catheterised permanently 2 0
No reason 2 1
Other 4 1
Total 20 5106 Transurethral resection of the prostate: randomised controlled trial outcomes and results
Primary outcome: urinary incontinence at 12 months
The primary outcome was incontinence in men at 12 months after randomisation, measured by a 
positive response to one of two questions from the ICI-SF questionnaire (‘How often do you leak 
urine’ or ‘How much urine do you usually leak?’). Table 66 shows that the difference between the 
intervention and control groups in urinary incontinence at 12 months (64.9% vs 61.6%) was not 
statistically significant:
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  ■ either when analysed by intention to treat (all men analysed in the groups to which they 
were randomised but results as given in the outcome questionnaires without adjustment for 
missing values)
  ■ or when analysed by ‘treatment received’, which adjusts the result by a factor related to the 
men who actually attended a therapist versus those who did not.
TABLE 65b  Urinary diary response rates (n = 220 in intervention group, n = 222 in control group)
TURP Number sent Number returned (%) Percentage of all men
Baseline
 Intervention 220 207 (94) 94
 Control 222 203 (91) 91
3 months
 Intervention 216 183 (85) 83
 Control 220 186 (85) 84
6 months
 Intervention 208 184 (88) 84
 Control 219 183 (84) 82
9 months
 Intervention 203 177 (87) 80
 Control 215 184 (86) 83
12 months
 Intervention 199 176 (88) 80
 Control 211 181 (86) 82
The first returned column above is percentage out of all questionnaires sent (to men continuing in the study); the second is the percentage out of 
the total number of men randomised to each trial group.
TABLE 65a  Patient questionnaire response rates (n = 220 in intervention group, n = 222 in control group)
TURP Number sent Number returned (%) Percentage of all men 
Baseline
 Intervention 220 220 (100) 100
 Control 222 222 (100) 100
3 months
 Intervention 216 206 (95) 94
 Control 220 208 (95) 94
6 months
 Intervention 208 201 (97) 91
 Control 219 203 (93) 91
9 months
 Intervention 203 198 (98) 90
 Control 215 202 (93) 91
12 months
 Intervention 199 194 (97) 88
 Control 211 203 (97) 92
The first returned column above is percentage out of all questionnaires sent (to men continuing in the study); the second is the percentage out of 
the total number of men randomised to each trial group.108 Transurethral resection of the prostate: randomised controlled trial outcomes and results
The above analyses were then repeated adjusting for the minimisation factors, but this did not 
alter the findings (Table 66). The corresponding risk difference for the unadjusted intention-
to-treat analysis was 3.4% (95% CI –6% to 13%), thereby ruling out the likelihood that the trial 
prespecified difference of 15% in the proportion incontinent between intervention and control 
group could have been missed.
Secondary outcomes
Urinary outcomes
Urinary incontinence was also measured at 3, 6 and 9 months after randomisation, together with 
other urinary outcomes. Table 67a describes the various urinary outcomes at each follow-up, and 
Table 67b shows the formal statistical testing of the differences at each time point. Figure 39 is a 
pictorial representation of the percentage of men incontinent at each follow-up, and Figure 40 
shows the change in mean ICI-Q score over time. The data show that there were no statistically 
significant differences between the intervention and control groups at any of the time points in 
urinary incontinence and the other urinary outcomes measured.
Type of incontinence
Table 68 and Figure 41 show the type of incontinence at baseline and at 6 and 12 months after 
randomisation. Men could report more than one type of incontinence. About two-thirds of 
men had SUI at baseline, reducing to about one-third over time. More men had urgency and 
UUI (than stress incontinence) at baseline. The proportions of men with the other types of 
urinary incontinence (mixed, Figure 41c; postmicturition leakage, Figure 41d; and other types 
of incontinence) decreased over time but there was little difference between the groups for any 
specific type of incontinence.
Use of aids or protection for urinary incontinence
Table 69a shows the men’s use of aids to protect them from urinary leakage: this did not vary 
according to the randomised groups at any of the follow-up time points. Table 69b presents 
the statistical analyses of these outcomes. Just under 20% of the men were still using pads at 
12 months to protect themselves from leakage accidents, although in some cases this might have 
been more of a precaution than because they actually leaked.
Bowel function
In addition to urinary outcomes, men were also asked to describe some aspects of bowel 
function. Few men (< 20%) had faecal incontinence or constipation occasionally or more often by 
the end of follow-up at 12 months, although rather more (around 50%) reported faecal urgency. 
TABLE 66  Urinary incontinence at 12 months
TURP Intervention Control RR (95% CI), p-value
Urinary incontinence at 12 months [n/N (%)] 126/194 (64.9) 125/203 (61.6) Absolute risk difference 3.4% 
(95% CI –6% to 13%)
Intention to treat
  Unadjusted analysis 1.055 (0.908 to 1.225), 0.486
  Analysis adjusted by minimisation factors 1.057 (0.910 to 1.227), 0.471
Adjusted treatment received
  Unadjusted analysis 1.048 (0.900 to 1.221), 0.546
  Analysis adjusted by minimisation factors 1.049 (0.901 to 1.222), 0.538© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Table 70 and Figure 42 show that there were no differences in any aspect of bowel function 
between the men in the randomised groups.
Sexual function
Table 71 compares the men in the randomised groups in terms of sexual function outcomes. 
One-third of men had difficulty with erection before surgery. Although just over one-third had 
an active sex life at 12 months, about half said that it was the same as before their operation. 
There were, however, no differences at 12 months according to the randomised groups in terms 
of the proportion of men with an active sex life [RR 1.04 (95% CI 0.80 to 1.36); adjusted for age, 
urinary incontinence before surgery and baseline value, p = 0.768] or the proportion of men who 
rated their sex life as worse after the operation [RR 0.99 (0.80 to 1.22), p = 0.912].
Table 72 compares the randomised groups in terms of problems with sexual function. There were 
no significant differences in sexual function outcomes between the intervention and control 
FIGURE 39  Per cent of men incontinent at each time point.
FIGURE 40  Mean ICI-Q score at each time point. ICI-Q score: 0 = none, 21 = maximum (worst) score. Derived from 
questions 1–3 of the ICIQ-UI Short Form Questionnaire.
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groups (Table 72, Figure 43). About half of the men were able to achieve a normal erection or 
one with slightly reduced stiffness by 12 months after surgery, and almost all reported a reduced 
quantity of semen or no ejaculation. Of those men, few reported more than slight pain. Around 
15% of men used drugs, and about 1% used a vacuum device to help with sexual function. Only 
2% reported urinary incontinence during intercourse.
Quality of life
General health outcomes were measured using the EQ-5D and SF-12 (the latter subdivided into 
role – mental and role – physical scores). The slight increase in the scores over time probably 
represents recovery from the operation, but there were no differences between the randomised 
groups at any time point in EQ-5D or SF-12 scores (Table 73 and Figure 44).
Pelvic floor muscle training
All men were asked to report on their practice of carrying out pelvic floor exercises at baseline 
and 6 and 12 months after randomisation. Initially around 20% of the men reported practising 
PFMT, of whom around 80% did it every day. The men in the control group continued with 
FIGURE 41  Type of incontinence at baseline, and at 6 and 12 months after randomisation: TURP. Men could report 
more than one type of incontinence. (a) Stress urinary incontinence. (b) Urgency urinary incontinence. (c) Mixed urinary 
incontinence (proportion of men reporting both stress and urgency urinary incontinence). (d) Postmicturition leakage 
(defined as ‘urine leaking when urination finished’).
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TABLE 70  Type of bowel problems at baseline and 6 and 12 months
TURP
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI),
p-value Intervention Control
Effect size 
(95% CI), 
p-value
Faecal 
incontinencea
40/216 (19) 29/218 (13) 35/195 (18) 29/194 (15) 1.13 (0.74 to 
1.73), 0.563
40/192 (21) 36/199 (18) 1.06 (0.74 to 
1.52), 0.745
Faecal 
urgencya
130/216 
(60)
116/218 
(53)
96/195 (49) 105/194 
(54)
0.86 (0.72 to 
1.03), 0.094
107/192 
(56)
106/198 
(54)
1.00 (0.85 to 
1.17), 0.966
Constipation  44/216 (21) 35/218 (16) 29/195 (15) 24/191 (13) 1.03 (0.66 to 
1.59), 0.910
32/190 (17) 28/196 (14) 1.03 (0.69 to 
1.53), 0.877
Any bowel 
dysfunctionb
146/216 
(68)
128/218 
(59)
113/195 
(58)
116/194 
(60)
0.91 (0.78 to 
1.06), 0.226
121/191 
(63)
118/196 
(60)
0.97 (0.85 to 
1.11), 0.640
Figures are n/N (%), unless otherwise stated. Effect size is RR adjusted for age, urinary incontinence before surgery and baseline value.
a  Faecal incontinence and urgency were defined as present when the problem was rated as occurring ‘occasionally or more often’.
b  Any bowel dysfunction includes faecal urgency, ulcerative colitis, Crohn’s disease, irritable bowel syndrome or constipation but not faecal 
incontinence.
FIGURE 42  Type of bowel problems at baseline and 6 and 12 months: TURP.
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TABLE 71  Description of sex life variables before and 12 months after prostate surgery
TURP Intervention Control
Number of men not able to achieve erection before prostate surgerya 67/214 (31) 71/215 (33)
Number of men with active sex life at 12 months 65/173 (38) 66/184 (36)
Reasons for not having an active sex life at 12 months 
  Because of urinary symptoms 7/108 (6) 7/118 (6)
  Because of bowel symptoms 3/108 (3) 1/118 (1)
  Because of prostate operation 42/113 (37) 38/127 (30)
  Because of medical treatment 29/109 (27) 25/119 (21)
  For another reason 51/110 (46) 60/123 (49)
Sex life compared now with before prostate operation 12 months ago
  Stayed the same 76/145 (52) 75/145 (52)
 Better 3/145 (2) 5/145 (3)
 Worse 66/145 (46) 65/145 (45)
Figures are n/N (%).
a  This information was collected at baseline but was retrospective, based on men’s recall of their sexual function before operation.
TABLE 72  Type of sexual problems at 12 months after prostate surgery 
TURP Intervention Control
Difficulty with achieving erection 
  Normal stiffness 37/177 (21) 36/178 (20)
  Reduced stiffness 48/177 (27) 48/178 (27)
  Severely reduced stiffness 40/177 (23) 51/178 (29)
  No erection possible 52/177 (29) 43/178 (24)
Bother with erection [mean (SD) n]a 4.2 (3.7) 152 4.6 (3.9) 154
Ejaculation 
  Normal quantity of semen 7/174 (4) 5/179 (3)
  Reduced quantity of semen 22/174 (13) 27/179 (15)
  Significantly reduced quantity of semen 25/174 (14) 27/179 (15)
  Ejaculation but without semen 62/174 (36) 54/179 (30)
  No ejaculation  58/174 (33) 66/179 (37)
Bother with ejaculation [mean (SD) n]a 3.6 (3.7) 155 3.8 (3.7) 153
Pain or discomfort with ejaculation 
  No pain  121/142 (85) 127/150 (85)
  Slight pain 15/142 (11) 15/150 (10)
  Moderate pain 5/142 (4) 7/150 (5)
  Severe pain 1/142 (1) 1/150 (1)
Bother with pain or discomfort [mean (SD) n]a 2.4 (3.6) 54 2.3 (3.4) 68
Number of men using medication for sexual problems  25/177 (14) 20/186 (11)
Number of men using vacuum device for sexual problems  2/175 (1) 2/185 (1)
Number of men using either medication or a vacuum device for sexual problems 26/177 (15) 20/186 (11)
Number of men leaking urine during intercourse  3/135 (2) 3/133 (2)
Figures are n/N (%), unless otherwise indicated.
a  Bother scale: 0 = not at all to 10 = a great deal.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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this frequency, while those in the intervention group were more likely to be carrying out 
PFMT at 6 and 12 months (75% and 65% respectively, Table 74). Significantly more, 64%, were 
practising for 3–4 days or more each week in the intervention group than in the control group at 
6 months (14%). Men in the intervention group were also more likely to perform contractions 
while walking (81% vs 41%) or before a stress situation such as coughing or lifting by performing 
a pelvic floor muscle contraction before an increase in intra-abdominal pressure, also known as 
‘the Knack’ (40% vs 28%). ‘The Knack’ was also more likely to reduce or stop urinary leakage in 
the intervention group (77% vs 62%).
Men in the therapy group were performing more contractions every day (11.5 vs 4.3) by 
12 months (Table 74). This is likely to reflect the taught exercise regimen in the therapy group 
(aiming for 18 strong contractions every day). Recommendations from NICE72 suggest that 
men should perform eight contractions three times a day (24 per day). The low mean number of 
FIGURE 43  Quality of erectile function at 12 months after prostate surgery: TURP.
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TABLE 73  Quality of life outcomes measured by EQ-5D and SF-12
TURP
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI), 
p-value Intervention Control
Effect size 
(95% CI), 
p-value
EQ-5D 0.752 (0.270) 
213
0.781 (0.251) 
208
 0.800 
(0.257) 188
0.826 (0.235) 
185
–0.005 
(–0.040 to 
0.031), 0.789
0.784 (0.249) 
177
 0.791 
(0.266) 189
–0.005 
(–0.040 to 
0.031), 0.789
SF-12M 49.9 (10.4) 
216
50.3 (10.4) 
212
51.5 (9.5) 
188
51.5 (10.5) 
189
–0.039 
(–1.708 to 
1.630), 0.964
52.6 (9.2) 
188
51.7 (10.5) 
193
–0.039 
(–1.708 to 
1.630), 0.964
SF-12P 42.7 (11.0) 
216
43.2 (11.9) 
212
45.0 (11.6) 
188
45.4 (12.6) 
189
0.385 
(–1.216 to 
1.986), 0.636
44.5 (11.1) 
188
44.0 (13.3) 
193
0.385 
(–1.216 to 
1.986), 0.636
Figures are mean (SD) n, unless stated otherwise.
A higher score on the EQ-5D and the SF-12 represents better health.
Effect size is mean difference adjusted for age, urinary incontinence before surgery and baseline value.118 Transurethral resection of the prostate: randomised controlled trial outcomes and results
contractions reflects the high proportion of men in the control group (80%) not carrying out any 
exercises at all.
Lifestyle outcomes
Men were also advised, in the lifestyle advice leaflet sent to both groups and reinforced by the 
therapists in the intervention group, about the benefits of general health strategies such as taking 
more exercise. There were few differences between the groups in terms of other types of exercise 
practised (Table 75) except that men in the intervention group were more likely to practise 
walking [RR 1.18 (95% CI 1.02 to 1.35); p-value 0.024] or go swimming [RR 2.44 (95% CI 1.19 to 
4.98); 0.014].
Finally, men in both groups were given (via the lifestyle advice leaflet) other general advice on 
lifestyle changes they could make that might help both with incontinence and general health. 
Again, this advice was reinforced by the therapists for men in the intervention group. There were 
no significant differences between the groups in terms of changes made to lifestyle factors after 
TURP (Table 76).
Prespecified subgroup analyses
Preplanned subgroup analyses were carried out on the primary outcome (urinary incontinence at 
12 months) according to factors that we thought would be prognostic. These factors were:
1.  pre-existing urinary incontinence (before prostate surgery)
2.  age (up to 70 years, 71 years and over)
3.  BMI (up to 30 kg/m2, 30–34.9 kg/m2, 35 kg/m2 or greater)
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FIGURE 44  Graphical representations of EQ-5D and SF-12 scores over time: TURP. SF-12M, SF-12 role – mental; SF-
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TABLE 74  Practice of PFMT at 12 months after randomisation: results from 12-month questionnaire
TURP
Baseline 6 months 12 months
Intervention Control Intervention Control
Effect size 
(95% CI), 
p-value Intervention Control
Effect size 
(95% CI), 
p-value
Yes 47/213 (22) 46/220 (21) 146/194 (75) 36/183 (20) 3.93 (2.90 to 
5.31), 0.001
122/188 (65) 39/193 (20) 3.20 (2.37 to 
4.32), 0.001
No 104/213 (49) 124/220 
(56)
44/194 (23) 129/183 
(70)
65/188 (35) 133/193 
(69)
Don’t know 62/213 (29) 50/220 (23) 4/194 (2) 18/183 (10) 1/188 (1) 21/193 (11)
Days carrying 
out PFMT 
  Every day 26/213 (12) 28/220 (13) 75/194 (39) 14/183 (8) 51/188 (27) 15/193 (8)
  5–6 days 1/213 (0) 1/220 (0) 17/194 (9) 0/183 (0) 9/188 (5) 4/193 (2)
  3–4 days 12/213 (6) 9/220 (4) 32/194 (16) 11/183 (6) 38/188 (20) 11/193 (6)
  1–2 days 8/213 (4) 8/220 (4) 19/194 (10) 10/183 (5) 20/188 (11) 9/193 (5)
 None 166/213 (78) 174/220 
(79)
51/194 (26) 149/183 
(81)
70/188 (37) 155/194 
(80)
Average 
contractions 
[mean (SD) n]
12.4 (19.2) 
194
2.7 (10.6) 
183
9.6 (6.5 
to 12.8), 
< 0.001
11.5 (22.8) 
188
4.3 (16.4) 
193
7.1 (3.1 to 
11.1), 0.001
Deliberate 
contractions 
whilst 
walkinga
156/186 (84) 67/163 (41) 2.04 (1.68 
to 2.48), 
<0.001
151/186 (81) 71/175 (41)  1.98 (1.64 
to 2.40), 
< 0.001
Deliberate 
contractions 
before doing 
somethinga
74/179 (41) 35/157 (22) 1.85 (1.32 
to 2.60), 
<0.001
74/183 (40) 48/173 (28)  1.47 (1.09 to 
1.98), 0.012
Contracting 
reduces or 
stops leaking
77/92 (80) 37/62 (60) 1.32 (1.05 to 
1.66), 0.016
79/103 (77) 58/78 (62)  1.24 (1.01 to 
1.52), 0.043
Figures are n/N (%), unless stated otherwise.
Effect size is RR unless indicated as mean difference, adjusted for age, urinary incontinence before surgery and baseline value.
a  Coded as positive if man responded ‘sometimes’ or more often.
TABLE 75  Practice of other exercise at 12 months after randomisation: results from 12-month questionnaire
TURP Intervention Control 
General exercise (yes) 148/184 (80) 139/192 (72)
Exercise type
 Walking 134/184 (73) 122/192 (62)
 Swimming 23/184 (13) 10/192 (5)
 Gardening 98/184 (53) 89/192 (45)
 Running 6/184 (3) 5/192 (3)
  Going to gym 12/184 (7) 10/192 (5)
 Other 23/184 (13) 30/192 (16)
Changed exercise
 No 137/190 (72) 142/197 (72)
 Less 17/190 (9) 26/197 (13)
 More 36/190 (19) 29/197 (15)
Figures are n/N (%).120 Transurethral resection of the prostate: randomised controlled trial outcomes and results
4.  type of incontinence at trial entry
i.  SUI
ii.  UUI
iii.  MUI
iv.  postmicturition leakage
5.  other morbidity
6.  type of therapist (physiotherapist or nurse).
Whilst a subgroup analysis on the use of biofeedback machines was also prespecified, there were 
insufficient numbers of centres with biofeedback machines to do so (see Table 7).
Figure 45 shows the effect of subgroup analysis on the primary outcome (urinary incontinence at 
12 months) according to the prespecified factors. The dotted line reflects the overall main effect 
TABLE 76  Compliance with lifestyle advice and changes to lifestyle at 12 months
TURP Intervention Control
Weight
  No need to lose weight  68/184 (37) 75/192 (39)
  Haven’t tried to lose weight  67/184 (36) 83/192 (43)
  Extra exercise to lose weight  33/184 (18) 19/192 (10)
  Diet to lose weight  23/184 (13) 15/192 (8)
  Other ways of losing weight  16/184 (9) 11/192 (6)
Fluid intake
  Number of men making no changes to fluid intake  66/189 (35) 86/196 (44)
  Drink more fluids  84/189 (44) 85/196 (43)
  Drink more cranberry juice  34/189 (18) 36/196 (18)
  Drink fewer caffeinated drinks  52/189 (28) 47/196 (24)
  Drink less fluid in evenings  67/189 (35) 59/196 (30)
  Other changes to fluid intake  9/189 (5) 6/196 (3)
Diet
  Number of men making no changes to diet or food  104/186 (56) 109/193 (56)
  More balanced diet  47/186 (25) 41/193 (21)
  More fruit and vegetables  67/186 (36) 77/193 (40)
  More fibre  44/186 (24) 42/193 (22)
  Less fats or sugars  50/186 (27) 56/193 (29)
  Other changes to food intake  3/186 (2) 6/193 (3)
Lifting
  Number of men who reduce lifting  90/191 (47) 86/196 (44)
Smoking
  Number of men who smoked  25/186 (13) 23/195 (12)
  Number of men stopping smokinga  1/25 (4) 1/23 (4)
  Number of men reducing smokinga  14/25 (56) 11/23 (48)
Chest or respiratory symptoms
  Number of men who did have chest symptoms  50/189 (26) 41/189 (22)
  Taking correct medicationa 36/50 (72) 24/41 (59)
  Consulted GP about medicationa 34/50 (68) 23/41 (56)
  Other changes to reduce respiratory symptomsa 4/50 (8) 3/41 (7)
Figures are n/N (%).
a  Responses limited to number of men who had chest symptoms.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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of the intervention on incontinence rates. Stricter levels of statistical significance (2p < 0.01) were 
sought (99% CIs), reflecting the exploratory nature of these analyses. There were no apparent 
clinically relevant differences according to any subgroup and none of the formal tests for 
statistical interaction effects was significant.
Satisfaction with treatment for urinary incontinence
Men were asked to score their satisfaction with the treatment they received for urinary 
incontinence (0 = ‘very unsatisfied’ to 10 = ‘very satisfied’) at 12 months after randomisation. Men 
in the intervention group were significantly more satisfied than those in the control group (see 
Appendix 5, Table 93). Thus, the therapy intervention did increase satisfaction rates despite the 
lack of difference in urinary outcomes.
FIGURE 45  Forest plot of subgroup analyses: urinary incontinence at 12 months.
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Chapter 13  
Resource use and cost-effectiveness 
in transurethral resection of the 
prostate randomised controlled trial
This chapter describes the economic analyses for the TURP RCT.
Description of the data available
Table 77 describes the number of men who contributed data for each of the areas of resource use 
and quality of life at each time point. Fewer data were available at the later data collection time 
points. For some areas of resource use (for example number of NHS pads at 12 months), only 
two-thirds of men indicated the quantity used. For other areas, for example inpatient admissions, 
88% of men provided data on use of that resource even at 12 months. The difference between 
these two rates cannot be explained by the mode of data collection, as both were collected by 
participant-completed questionnaire. An alternative explanation might include the limited use of 
these services by 12 months, which meant that participants did not answer the questions because 
they did not think they were relevant. Other explanations could be advanced but there is no 
information to determine what the reasons are for men providing information for some areas of 
resource use but not others.
Analysis of resource use and costs
Resource use
Table 78 details the average resource use for the intervention and subsequent use of health 
services over the 12-month follow-up period after randomisation. Resource utilisation was 
slightly higher across most areas in the intervention group than in the control group but the 
differences were very small and were not statistically significant, apart from nurse and hospital 
physiotherapy visits and the number of private physiotherapy visits. A detailed description of the 
use of NHS and private provider health services is provided in Appendix 5.
Costs
Participant time and costs
The average time and costs to participants and their companions (families or carers) of a contact 
either with a primary care service provider or as an outpatient consultation or an inpatient 
admission are reported in Table 79. These data were combined with the information on number 
of contacts (e.g. hospital doctor visits) that the trial participants had reported (Table 78) to 
estimate a monetary cost per participant for both intervention and control.
Estimation of societal cost
Table 80 details the mean costs per participant of the two interventions. The unit cost information 
in Tables 4 and 79 was combined with the resource use information reported in Table 78 to 
provide estimates of the total cost per participant. For the base-case analysis based on societal 
costs the mean total cost per participant in the intervention group was £984 (SD £2626) and the 124 Resource use and cost-effectiveness in transurethral resection of the prostate randomised controlled trial
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mean cost in the control group was £566 (SD £1285). There was evidence of higher costs in the 
intervention group: mean difference £420 (95% CI £55 to £785). The difference in mean societal 
cost was mainly due to the higher number of days taken off work by the participants in the 
intervention arm of the trial and the cost of the intervention itself.
TABLE 78  Mean resource use per participant during 12-month period after randomisation: TURP
Area of resource use Intervention [mean (SD)] Control [mean (SD)] Difference (95% CI)a
Intervention visits 3.10 (1.51) 0 –3.10
Subsequent resource use
  NHS-supplied pads used 1.09 (3.28) 0.77 (2.33) 0.21 (–0.24 to 0.66)
  NHS-supplied bed/chair protectors used 0.14 (0.83) 0.29 (1.54) –0.18 (–0.40 to 0.04)
  GP doctor incontinence-related visits 0.38 (1.32) 0.37 (0.98) –0.02 (–0.23 to 0.20)
  GP doctor other visit 4.25 (4.32) 4.00 (4.04) 0.34 (–0.43 to 1.11)
  GP nurse incontinence-related visit 0.20 (1.00) 0.20 (1.15) 0.00 (–0.19 to 0.19)
  GP nurse other visit 2.47 (4.00) 2.61 (4.56) 0.01 (–0.75 to 0.76)
  Number of men using catheters  0.45 (0.92) 0.34 (0.78) 0.10 (–0.06 to 0.26)
  Number of men using sheaths  0.15 (0.52) 0.15 (0.54) –0.01 (–0.10 to 0.09)
  Hospital doctor visits 0.33 (1.48) 0.37 (1.04) –0.04 (–0.28 to 0.20)
  Hospital nurse visitsb 0.46 (1.33) 0.15 (0.60) 0.31 (0.12 to 0.51)
  Hospital physiotherapy visitsb 0.82 (1.68) 0.06 (0.39) 0.76 (0.53 to 0.99)
  Inpatient days 0.06 (0.44) 0.05 (0.35) 0.01 (–0.06 to 0.08)
  Number taking incontinence drugs  0.22 (0.66) 0.36 (0.95) –0.13 (–0.28 to 0.02)
  Participant resource use
  Self-supplied pads used 1.10 (3.86) 0.84 (3.58) 0.26 (–0.42 to 0.94)
  Self-supplied bed/chair protector used 0.22 (1.51) 0.36 (2.42) –0.15 (–0.52 to 0.23)
  Private doctor visits 0.05 (0.28) 0.10 (0.34) –0.05 (–0.11 to 0.01)
  Private nurse visits 0.10 (0.62) 0.05 (0.27) 0.05 (–0.03 to 0.14)
  Private physiotherapist visitsb 0.26 (0.87) 0.18 (2.29) 0.22 (0.10 to 0.34)
Number of days off work 4.14 (23.32) 1.50 (11.48) 2.63 (–0.58 to 5.84)
Note: the number of days off work refers only to the number of days off paid employment.
a  Differences adjusted for baseline costs.
b  Statistically significantly different at 5% level.
TABLE 79  Cost to the participant and their companion of a single visit or admission: TURP
Resource use Time or monetary cost Mean (SD)
Primary care consultation visit Time spent going to and attending a primary care consultation (hours) 0.68 (0.29)
Companion’s time off work (£) 1.10 (2.68)
Average cost to participant and companion of a primary care consultation (£) 11.29 (13.38)
Secondary care visit Time spent attending a secondary care visit (hours) 1.73 (1.11)
Companion’s time off work (£) 5.81 (9.69)
Average cost to participant and companion of travelling to a secondary care department (£) 25.25 (25.31)
Inpatient visit Number of visits to participant during admission  2.10 (4.47)
Companion’s time off work (£) 6.59 (31.69)
Average cost to participant and companion of admission (£) 30.21 (55.84)126 Resource use and cost-effectiveness in transurethral resection of the prostate randomised controlled trial
TABLE 80  Cost per participant for each area of resource use: TURP
Area of resources use Intervention [mean cost, £ (SD)] Control [mean cost, £ (SD)] Difference (95% CI)a
NHS costs
Intervention 174.47 (82.89) 0 174.47
Subsequent resource use
NHS-supplied pads  16.88 (50.74) 11.85 (35.99) 3.27 (–3.70 to 10.24)
NHS-supplied bed/chair protectors  1.92 (11.32) 3.94 (21.05) –2.50 (–5.56 to 0.51)
GP doctor incontinence-related visits 13.58 (47.53) 13.46 (35.42) –0.57 (–8.27 to 7.11)
GP doctor other visit 153.16 (155.65) 143.84 (145.32) 12.13 (–15.53 to 39.79)
GP nurse incontinence-related visit 2.20 (11.01) 2.18 (12.63) 0.12 (–2.12 to 2.14)
GP nurse other visit 27.20 (44.04) 28.74 (50.17) 0.06 (–8.22 to 8.35)
Catheter  1.28 (13.36) 0.42 (4.44) 0.87 (–1.030 to 2.73)
Sheath 13.50 (62.93) 13.38 (55.23) 1.41 (–0.26 to 0.80)
Hospital doctor visits 24.89 (111.12) 27.70 (77.78) –2.70 (–20.66 to 15.26)
Hospital nurse visits 14.37 (41.19) 4.75 (18.74) 9.67 (3.68 to 15.67)b
Hospital physiotherapy visits 25.36 (52.11) 1.82 (12.20) 23.52 (16.45 to 30.59)b
Inpatient days 7.15 (47.89) 6.89 (44.15) 0.26 (–8.36 to 8.88)
Prescribed drugs 14.51 (50.33) 24.97 (76.77) –7.24 (–18.84 to 4..36)
Total subsequent use cost 318.13 (333.42) 284.81 (315.07) 34.43(–25.53 to 94.38)
Total NHS cost 492.59 (355.95) 284.81 (315.07) 208.88 (146.69 to 271.07)b
Participant costs
Self-supplied pads  19.41 (61.51) 11.22 (36.97) 8.22 (–1.17 to 17.60)
Self-supplied bed/chair protector  0.31 (2.42) 3.75 (29.81) –3.45 (–7.38 to 0.48)
Private doctor visits 0.00 (0.00) 1.35 (15.90) –1.35 (–3.46 to 0.76)
Private nurse visits 0.00 (0.00) 0.00 (0) 0
Private physiotherapist visits 0.14 (2.09) 4.75 (70.74) –0.52 (–1.72 to 0.68)
Number of days off work 439.76 (2476.70) 158.82 (1219.55) 279.32 (–61.62 to 620.28)
Total participant costs 462.30 (2519.18) 184.00 (1222.49) 277.74 (–68.71 to 624.18)
Participant travel and companion travel and time off work costs
Intervention  78.39 (38.18) 0 78.39
GP doctor incontinence-related visits 4.26 (14.90) 4.22 (11.11) 0.18 (–2.59 to 2.23)
GP doctor other visit 48.03 (48.81) 45.11 (45.57) 3.81 (–4.87 to 12.48)
GP nurse incontinence-related visit 2.26 (11.30) 2.24 (12.96) 0.01 (–2.17 to 2.20)
GP nurse other visit 27.92 (45.20) 29.50 (51.49) 0.06 (–8.44 to 8.57)
Total GP travel and time off work 82.47 (85.60) 81.06 (88.75) 2.93 (–12.81 to 18.67)
Hospital doctor visits 8.38 (37.41) 9.33 (26.19) –0.91 (–6.96 to 5.14)
Hospital nurse visits 11.71 (33.55) 3.87 (15.27) 7.88 (3.00 to 12.76)
Hospital physiotherapy visits 20.66 (42.44) 1.48 (9.94) 19.16 (13.40 to 24.92)b
Total outpatient travel and time off work 
costs
197.52 (118.68) 14.67 (41.33) 13.65 (–4.99 to 32.29)
Total inpatient visits 1.79 (13.27) 1.50 (10.45) 0.29 (–1.94 to 2.52)
Total participant travel and companion 
travel and time off work costs
360.17 (187.89) 97.23 (104.11) 70.06 (39.73 to 100.39)b
Total participant and companion cost 665.68 (2540.26) 281.24 (1224.41)  385.11 (35.21 to 35.01)b
Total societal costs 983.81 (2626.28) 566.05 (1284.97) 419.50 (53.67 to 785.31)b
a  Adjusting for use of health services before randomisation.
b  Statistically significant at 5% level.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Estimation of NHS costs
In terms of NHS costs incurred after the intervention was delivered, the mean total cost per 
patient in the intervention group was £493 (SD £356) and the mean cost in the control group was 
£285 (SD £315). There was, however, no evidence of a statistically significant difference in the 
cost of subsequent NHS services used. Intervention costs were, as would be expected, greater in 
the intervention group. Combining information on the cost of the interventions and the cost of 
subsequent NHS care resulted in a statistically significantly higher total cost per participant in 
the intervention group. The mean difference was £209 (95% CI £147 to £271). This difference was 
driven almost entirely by the cost of the PFMT intervention itself.
Quality-adjusted life-years
Table 81 reports the EQ-5D scores for each arm of the trial at baseline and 6 and 12 months. 
Also reported is the difference between arms in EQ-5D score at 6 and 12 months. From these 
data it was estimated that the mean QALYs were 0.78 (SD 0.24, median 0.85) for the intervention 
arm and 0.82 (SD 0.22, median 0.89) for the control arm. The mean difference in QALYs after 
adjusting for minimisation and baseline EQ-5D scores was –0.00003 (95% CI –0.026 to 0.026). 
The mean difference is equivalent to 0.011 days in full health over the 1-year time horizon.
Imputation was not performed on missing values in the base-case analysis. Simple plausible 
extreme value imputation on EQ-5D scores, taking the 25th and 75th percentile values, suggested 
that only if it is assumed that all missing values were equal to the 75th percentile range of 
EQ-5D scores would the mean difference in EQ-5D scores differ from that reported in Table 81. 
However, this mean difference still would not be significantly different.
Estimation of cost-effectiveness
Societal perspective
Taking the mean difference in costs from Table 80, and assuming that the mean difference in 
the QALYs from Table 81 is 0, then on average the intervention is both more costly and no more 
effective than the control and hence the intervention is dominated by the control (Table 82). 
Arithmetically, the ICER was 14 million because the difference in QALYs was just negative. 
However, this has been interpreted as being effectively 0 as the difference was so small as to 
be meaningless.
One thousand bootstrap simulations were undertaken to estimate the uncertainty around the 
benefits and costs. At a willingness to pay threshold of £20,000 per QALY the intervention 
has a probability of 11% of being cost-effective, and at a threshold of £30,000 per QALY the 
TABLE 81  Quality of life measures: TURP
Intervention [mean (SD)] Control [mean (SD)] Difference (95% CI)a
Baseline EQ-5D 0.75 (0.27)
n = 213 (97%)
0.78 (0.25)
n = 208 (94%)
6-month EQ-5D 0.80 (0.26)
n = 188 (85%)
0.83 (0.24)
n = 185 (83%)
–0.03
12-month EQ-5D 0.78 (0.25)
n = 177 (80%)
0.79 (0.27)
n = 189 (85%)
–0.01
QALYs 0.78 (0.24)
n = 162 (74%)
0.82 (0.22)
n = 163 (73%)
–0.00003 (–0.026 to 0.026)
a  Adjusting for baseline EQ-5D before randomisation.128 Resource use and cost-effectiveness in transurethral resection of the prostate randomised controlled trial
TABLE 82  Cost-effectiveness results from the societal perspective: TURP
Difference in mean costs [mean (95% CI)a] 419.50 (53.67 to 785.31)
Difference in QALYs [mean (95% CI)a] –0.00003 (–0.026 to 0.026)
ICER (£/QALY) Dominated
Probability intervention is cost-effective when threshold is £20,000 11.2%
Probability intervention is cost-effective when threshold is £30,000 17.3%
a  Adjusting for baseline before randomisation.
FIGURE 46  Representation of the uncertainty in differential mean costs and QALYs: societal perspective (TURP).
FIGURE 47  Cost-effectiveness acceptability curve for intervention versus control: societal perspective (TURP).
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intervention is 17% likely to be cost-effective (Figures 46 and 47). At no point does the probability 
of being cost-effective reach 50%.
NHS perspective
Taking the mean difference in total NHS costs from Table 80 and assuming that the mean 
difference in QALYs is effectively zero means that the provision of PFMT is on average both more 
costly and no more effective than the control and hence dominated (Table 83). Arithmetically, the 
ICER was 6.9 million because the difference in QALYs was just negative. However, this has been 
interpreted as being effectively 0 as the difference was so small as to be meaningless.
As with the societal perspective, bootstrap simulations were undertaken to estimate the 
uncertainty around the benefit and costs. The bootstrap estimates in Figure 48 indicate that 
the intervention group had higher costs than the control; however, there was a relatively wide 
distribution in the difference in QALYs.
At a cost-effectiveness threshold of £20,000 per QALY, the intervention has a probability of 20% 
of being cost-effective and at a threshold of £30,000 per QALY the intervention is 29% likely to be 
cost-effective (Figure 49). At no point does the probability of being cost-effective reach 50%. This 
indicates that it is unlikely that PFMT is cost-effective.
TABLE 83  Cost-effectiveness results from the perspective of the NHS: TURP
Difference in mean NHS costs [mean (95% CI)a] 208.88 (146.69 to 271.07)
Difference in QALYs [mean (95% CI)a] –0.00003 (–0.026 to 0.026)
ICER (£/QALY) Dominated
Probability intervention is cost-effective when threshold is £20,000 per QALY 20.0%
Probability intervention is cost-effective when threshold is £30,000 per QALY 29.4%
a  Adjusting for baseline before randomisation.
FIGURE 48  Representation of the uncertainty in differential mean costs and QALYs: NHS perspective (TURP).
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Sensitivity analysis
As mentioned in Chapter 2, sensitivity analysis is necessary to assess the robustness of the 
qualitative conclusion and identify areas where research is needed to more precisely estimate 
the values of those variables to which the result is sensitive. The variables that were considered 
uncertain in this study related to the cost of the different services used.
Incremental cost per quality-adjusted life-year when differences are not 
adjusted for baseline differences
An unadjusted analysis was performed as a sensitivity analysis to highlight the importance of 
the assumption that the characteristics of the groups were not the same at baseline. The results 
of this analysis, from the perspective of the NHS, indicate that at a cost-effectiveness threshold 
of £20,000 per QALY the intervention has a probability of 41.1% of being cost-effective, and at 
a threshold of £30,000 per QALY the intervention is 47.4% likely to be cost-effective (Figures 50 
and 51).
Basing quality-adjusted life-year estimates on SF-6D values
Table 84 reports the SF-6D scores for each arm of the trial at baseline and 6 and 12 months. 
These scores were slightly lower than those reported using the EQ-5D at the same time points. 
From these data it was estimated that the mean QALYs were 0.75 (SD 0.13, median 0.800) for the 
intervention arm and 0.77 (SD 0.15, median 0.783) for the control arm. The mean difference in 
QALYs, after adjusting for minimisation and baseline EQ-5D scores, was 0.004 (95% CI –0.012 to 
0.022) higher for the control group, which was not statistically significant.
The results of the analysis using the SF-6D data when estimating incremental cost-effectiveness 
from the societal perspective were similar to those of the EQ-5D. Taking the mean difference 
in the total societal costs from Table 80 (£420) and the mean QALY difference from Table 85 
(–0.004) it can be seen that the intervention is on average less effective and more costly, 
indicating that it is dominated.
At a cost-effectiveness threshold of £20,000 per QALY, the intervention has a likelihood of 2% 
of being cost-effective, and at a threshold of £30,000 per QALY the intervention has only a 4% 
likelihood of being cost-effective (Figures 52 and 53). Based on the societal perspective, these 
estimates indicate that the intervention is unlikely to be cost-effective.
FIGURE 49  Cost-effectiveness acceptability curve for intervention versus control: NHS perspective (TURP).
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FIGURE 50  Representation of the uncertainty in differential mean costs and QALYs: using unadjusted data (TURP).
FIGURE 51  Cost-effectiveness acceptability curve for intervention versus control: using unadjusted data (TURP).
TABLE 84  SF-6D quality of life measures: TURP
Intervention [mean (SD)] Control [mean (SD)] Difference (95% CI)a
Baseline SF-6D 0.73 (0.14)
n = 217 (99%)
0.73 (0.15)
n = 209 (94%)
 
6-month SF-6D 0.76 (0.15)
n = 186 (85%)
0.77 (0.16)
n = 187 (84%)
–0.01
12-month SF-6D 0.77 (0.15)
n = 186 (85%)
0.76 (0.16)
n = 191 (86%)
0.01
QALYs 0.75 (0.13)
n = 172 (78%)
0.77 (0.15)
n = 166 (75%)
–0.004 (–0.020 to 0.012)
a  Adjusting for baseline EQ-5D before randomisation.132 Resource use and cost-effectiveness in transurethral resection of the prostate randomised controlled trial
Taking the perspective of the NHS resulted in similar findings (Table 86). The probability 
of the interventions being cost-effective in this analysis was lower than that estimated when 
using the EQ-5D data. At a cost-effectiveness threshold of £20,000 per QALY the intervention 
has a probability of 4.2% of being cost-effective, and at a threshold of £30,000 per QALY the 
intervention has a 9% chance of being cost-effective (Figures 54 and 55). At no point does the 
probability of being cost-effective reach 50%, and it is unlikely that the intervention would be 
cost-effective.
Threshold analysis around the cure rates
Further sensitivity analysis was performed by reanalysing the data by patient group for 
differences in costs and QALYs by continence status. A simple model was used to determine at 
what reduction in the rate of incontinence in the intervention group compared with the control 
group PFMT might be cost-effective. Details of the parameters used in the model are given 
in Table 87.
The results of the analysis indicate that the intervention was always dominated over the range 
of reductions in incontinence considered. Hence, it can be concluded that it is unlikely that the 
intervention could ever be considered cost-effective.
TABLE 85  Cost-effectiveness results from the societal perspective: TURP 
Difference in mean NHS costs [mean (95% CI)a] 419.50 (53.67 to 785.31)
Differences in QALYs [mean (95% CI)a] –0.004 (–0.020 to 0.012)
ICER (£/QALY) Dominated
Probability intervention is cost-effective when threshold is £20,000 per QALY 1.9%
Probability intervention is cost-effective when threshold is £30,000 per QALY 3.9%
a  Adjusting for baseline before randomisation.
FIGURE 52  Representation of the uncertainty in differential mean costs and QALYs: societal perspective using 
SF-6D data (TURP).
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FIGURE 53  Cost-effectiveness acceptability curve for intervention versus control: societal perspective using SF-6D 
data (TURP).
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TABLE 86  Cost-effectiveness results from the perspective of the NHS: TURP
Difference in mean NHS costs [mean (95% CI)a] 181.02 (107.06 to 254.97)
Differences in QALYs [mean (95% CI)a] –0.004 (–0.020 to 0.012)
ICER (£/QALY) Dominated
Probability intervention is cost-effective when threshold is £20,000 per QALY 4.2%
Probability intervention is cost-effective when threshold is £30,000 per QALY 8.9%
a  Adjusting for baseline before randomisation.
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FIGURE 54  Representation of the uncertainty in differential mean costs and QALYs: NHS perspective using SF-6D data 
(TURP).134 Resource use and cost-effectiveness in transurethral resection of the prostate randomised controlled trial
Conclusions
For men having TURP QALYs were similar in both groups, and costs for those who received 
the intervention were higher regardless of whether a societal or an NHS perspective was taken. 
Therefore, for both perspectives and over the range of sensitivity analyses conducted, it is 
unlikely that the provision of physical therapy for men who are incontinent after TURP would be 
cost-effective.
FIGURE 55  Cost-effectiveness acceptability curve for intervention versus control: NHS perspective using SF-6D data 
(TURP).
TABLE 87  Data used in analysis based on random allocation and state of incontinence at 12 months: TURP
Parameter
Participants in the 
intervention group who 
were continent
Participants in the 
intervention group who 
were incontinent
Participants in the 
control group who were 
continent
Participants in the 
control group who were 
incontinent
Cost of intervention (£) 178.81 (223.00) [75.85] 195.07 (223.00) [67.32] 0.00 (0.00) [0.00] 0.00 (0.00) [0.00]
Total subsequent resource 
use costs (£)
304.69 (223.19) [308.33] 425.02 (351.65) [351.14] 225.67 (141.00) [241.53] 433.08 (334.13) [368.07]
Total NHS costs (£) 483.51 (417.41) [331.26] 620.09 (572.00) [352.32] 225.67 (141.00) [241.53] 433.08 (334.13) [368.07]
QALYs 0.82 (0.87) [0.20] 0.77 (0.85) [0.26] 0.87 (0.95) [0.19] 0.79 (0.84) [0.23]
Probability of being 
continent/incontinent
0.35 0.65 0.38 0.62
Relative risk of being 
incontinent
Varied
between 0.85 and 1
Varied between 0.85 
and 1
Figures are mean (SD) [median]. 
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Chapter 14  
Discussion of results of transurethral 
resection of the prostate randomised 
controlled trial
This chapter summarises the discussions relating to the TURP RCT.
Summary of main findings
In the men who had TURP, there were no statistically significant differences in urinary, bowel or 
sexual function outcomes between men in the intervention and control groups, despite evidence 
of extra performance of PFMT and improvement in pelvic floor muscle strength over time in the 
intervention group. The estimated extra cost to the NHS was on average £209 (95% CI £147 to 
£271) higher in the intervention group than in the controls.
Recruitment and screening of men in hospital
We approached 5986 men having TURP in NHS hospitals and obtained consent to screen 2832 
of them. Of those, 91% returned their screening survey, and 46% were incontinent of urine at 
about 6 weeks after surgery (see Table 51). The majority of the men (around 94%) had a standard 
TURP, and a further 5% had a laser TURP. Around 36% of the men had urinary incontinence 
before surgery, and 4% reported faecal incontinence (see Table 51). The average age of the men 
was 70 years.
Recruitment to randomised controlled trial and response rates
Of the 1201 men who were incontinent at screening, 442 agreed to be randomised to a controlled 
trial of conservative treatment (including PFMT and lifestyle advice) for urinary incontinence 
(220 in the intervention group and 222 in the control group). The groups were comparable at 
baseline on all the epidemiological and clinical characteristics measured (see Table 52). Most men 
(around 80% in both groups) had heard of pelvic floor exercises at some point before starting the 
study (see Table 53).
Conduct of the intervention
Compliance with the intervention was high, with 86% of the men allocated to the intervention 
group attending at least one therapy visit and 72% attending all four of them. The most common 
reasons for not attending were becoming dry or ill, or finding it inconvenient to attend (see 
Table 56).
Association with type of therapist
Half of the centres used physiotherapists as the provider of the intervention, while the rest used 
nurse therapists (although all therapists received the same standardised training). About half 
of the men attended a physiotherapist while the other half attended a nurse therapist. However, 
there were no significant differences in the number of visits or the prevalence of urinary 
incontinence during the treatment period according to type of therapist (see Table 57).136 Discussion of results of transurethral resection of the prostate randomised controlled trial
At follow-up, no statistically significant association was demonstrated between the chance of 
incontinence at 12 months and type of therapist (Figure 57).
Clinical symptoms during the therapy period
During the therapy period, the proportion of men with incontinence fell from 82% to 52% 
by the fourth visit (see Table 58 and Figure 32). Few men reported bowel problems, and these 
numbers did not vary much over time (see Table 60 and Figure 34), although constipation was 
more common amongst the men who had a radical prostatectomy (who were around 10 years 
younger). Around half of the men had problems with sexual function and these did not improve 
with time (see Table 61 and Figure 35).
Clinical findings during the therapy period
Anal sphincter and pelvic floor muscle contraction strength increased over time in the 
intervention group: 37% of men had good or better strength at the beginning of the therapy 
period, rising to 80% by the fourth visit (see Table 62 and Figure 36). However, around 20% still 
had only moderate or poor contraction strength at the end of the 3-month therapy period.
Machine-led biofeedback was available in only 13 of the 34 MAPS centres, and was only actually 
used clinically in 10 men from two centres (see Table 63). When it was used it was not clear 
whether it was for diagnosis or for repeated use to assist with training. However, almost all 
men had verbal biofeedback from their therapist following digital anal assessment of muscle 
contraction, to teach them to perform contractions correctly and to monitor improvement at 
each successive visit.
Practice of pelvic floor muscle training after end of the therapy period
While around 20% of men in both the intervention and control groups were practising PFMT at 
baseline (before they were randomised and before the intervention), this increased to 65% in the 
intervention group at the 12-month follow-up, but remained at 20% in the control group.
Findings of the randomised controlled trial
The primary outcome of the RCT was the proportion of men with urinary incontinence at 
12 months after randomisation. This was measured using the ICI-SF questionnaire, and was 
also ascertained at 3, 6 and 9 months after randomisation. In addition, urinary outcomes were 
obtained from 3-day diaries completed by the men at each of these time points. The response 
rates were almost all over 95% for the questionnaires and over 80% for the diaries (see Table 65).
Urinary outcomes
While the proportion of men with urinary incontinence fell from 100% at baseline to around 
65% by 12 months, the majority of the decrease occurred in the first 3 months (to around 65%). 
There was no statistically significant difference between the intervention and control group in 
the proportion of men with urinary incontinence at 12 months [64.9% vs 61.6%, absolute risk 
difference 3.4% (95% CI –6% to 13%) at 12 months; see Table 66] or at any other time point (see 
Table 67 and Figure 39).
These findings (of no statistically significant differences between the trial groups) were similar 
for all the urinary outcomes regardless of how (by questionnaire or diary) or when they were 
measured (see Table 67).
Severity of incontinence
If severe incontinence is defined as leakage at least once a day and a moderate or large amount 
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(see Table 67a) and around 17% were also using pads at 12 months (see Table 69a). Using the ICI 
score as a composite measure of severity and effect on quality of life, the same picture emerged: 
the majority of the improvement (decrease) in the score occurred in the first 3 months after 
randomisation with little further improvement (see Table 67 and Figure 40).
Types of incontinence
The most common type of incontinence was UUI (around 80%, see Table 68), while SUI and 
MUI affected around 60% of men. These and the other types of urinary symptoms were not 
different in the randomised groups at any time point, although they all decreased in frequency 
with time (see Table 68 and Figure 41).
Subgroup analyses
Prespecified subgroup analyses were carried out on the primary outcome (urinary incontinence 
at 12 months). There were no significant differences between randomised groups in any of the 
subgroups (see Figure 45).
Other clinical outcomes
Men were also asked to report on bowel and sexual problems.
Bowel outcomes
Bowel problems that might be expected to be ameliorated by therapy or lifestyle advice included 
faecal incontinence, urgency and constipation. Men were also asked about bowel conditions such 
as ulcerative colitis, Crohn’s disease and irritable bowel syndrome. There were no differences at 
any time point in any aspect of bowel function or disease between the men in the randomised 
groups (see Table 70 and Figure 42).
Sexual function outcomes
Around 70% of men had normal erectile function before operation. Although around one-third 
had an active sex life at 12 months, about half said that this was much the same as before their 
operation and just under half said that it was worse than before their operation (see Table 71). 
There were, however, no differences at 12 months, according to the randomised groups in any 
of the aspects of sexual function measured (see Tables 71 and 72). Around a half of the men had 
severely reduced or no erectile function (see Table 72). There were no differences at 12 months 
according to the randomised groups in terms of the proportion of men with an active sex life [RR 
1.04 (95% CI 0.80 to 1.360), p = 0.768] or the proportion of men whose sex life had become worse 
after the operation [RR 0.99 (95% CI 0.80 to 1.22), p = 0.912] (see Table 71). Around 15% of men 
had used a vacuum device or medication to improve sexual function (see Table 72).
Quality of life outcomes
General health outcomes were measured using the EQ-5D and SF-12 (the latter subdivided 
into role – mental and role – physical scores). The slight increase in the scores over time can 
be assumed to represent recovery from operation, but there were no differences between the 
randomised groups at any time point in EQ-5D or SF-12 scores (see Table 73 and Figure 44).
Knowledge of pelvic floor muscle training in trial groups before 
intervention
Around four-fifths of the men in both groups had received information about the use of pelvic 
floor exercises before starting the trial intervention from at least one source (see Table 53). The 
most common sources were nurses or continence advisors (around 30%) or leaflets or books 
(over 40%, see Table 53).138 Discussion of results of transurethral resection of the prostate randomised controlled trial
Practice of pelvic floor muscle training in intervention and control 
groups
It is not surprising, given the level of prior knowledge of pelvic floor exercises, that 20% of men in 
both groups reported carrying out some exercises before randomisation (see Table 74). However, 
by 6 months the men in the intervention group were more likely to be still carrying them out and 
this difference persisted at the 12-month follow-up (see Table 74).
Changes in lifestyle factors
Men in both groups were given written information about lifestyle changes that might improve 
aspects of both their general health and incontinence. In the intervention group, this advice was 
reinforced and individualised by the therapists. However, there were no significant differences in 
the uptake of any aspect of this advice at 12 months after randomisation (see Tables 75 and 76).
Economic outcomes
Costs to the NHS
Total costs to the NHS were on average £209 (95% CI £147 to £271) higher in the intervention 
group than in the control group. This difference was primarily due to the cost of providing the 
PFMT training in the intervention group. The use of other health services, and hence cost, was 
similar between the groups.
Costs to the participants
On average, the costs of any private health care used were low and there was no evidence of any 
difference between groups. Similarly, the costs of accessing care other than the intervention were 
similar for the two groups. Participants in the intervention arm had on average more days away 
from usual activities than participants in the control arm and hence on average a higher cost. 
However, this difference was not statistically significant.
Overall costs to the NHS and participants
On average, the cost to the NHS and participants was greater in the intervention group than in 
the control group. This difference was not statistically significant.
Quality-adjusted life-years
On average, QALYs were virtually identical in both the intervention and the control group [mean 
difference –0.00003 (95% CI –0.026 to 0.026)].
Cost-effectiveness from the perspective of the NHS and participants
Based upon the point estimates of the mean difference in costs and QALYs, the intervention is 
dominated by the control intervention as it is on average more costly but associated with no more 
effectiveness. As there was considerable imprecision around the estimates of mean difference 
in costs and effects, the probability that the intervention would be cost-effective at the typical 
threshold for society’s willingness to pay for a QALY was calculated. This analysis suggested that 
there was less than an 18% chance that organised PFMT training was cost-effective.
Cost-effectiveness from the perspective of the NHS
When the perspective of the economic evaluation was restricted to the NHS, the intervention was 
dominated by the control intervention (it was more costly and no more effective). Furthermore, 
there was only a 20% chance that the intervention would be cost-effective if the threshold value 
for society’s willingness to pay for a QALY were £20,000.
Sensitivity analyses
The majority of the sensitivity analyses conducted did not greatly alter the conclusions of the 
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showed that, should the intervention reduce the rate of incontinence by approximately 15%, the 
provision of physical therapy might be cost-effective.
Strengths and weaknesses (specific to transurethral resection of 
the prostate randomised controlled trial)
Recruitment
We approached 5986 men who were admitted to hospital for TURP in order to identify and 
recruit our final population of 442 men who entered the RCT. Many of the men approached were 
ineligible or missed in hospital (3001 men, see Table 9a) and some were subsequently found to 
be ineligible (149 men; see Table 10a). This scale of recruitment represented a large burden on 
the recruitment officers in the centres. However, we felt that this was the most efficient way of 
identifying our target population, which was men who had urinary incontinence after prostate 
surgery. Other methods, such as expecting local staff to identify incontinent men and recruit 
them to the RCT directly, might have been too burdensome and risked missing many men owing 
to pressure of routine work.
Generalisability of the trial population
Most of the men who agreed, when in hospital, to be screened 3 weeks later, returned their 
screening questionnaire (2590/2838, 91%; Table 50): although the non-responders were older, 
more likely to smoke and spent more time in hospital, there were no clinically important 
differences in demographic or clinical characteristics when compared with responders. Just under 
one-fifth (442/2590, 17%) of the men who returned a screening questionnaire were eventually 
recruited into the RCT. Many of the remainder had become dry [1387 (54%) at screening, 274 
(11%) at baseline], and a further 262 (10%) were not eligible because they did not return their 
baseline questionnaire (see Figure 5 and Table 11). Of the 227 (9%) not accounted for, 122 
declined further contact, 16 did not wish to be randomised and the remainder had a variety 
of other reasons for not wishing to enter the trial (see Table 11). Thus, our trial population 
represents 442/512 (86%) of the men who were incontinent and eligible to be randomised, but 
only 442/2838 (15%) of men identified in hospital as having TURP.
Response rates
Once randomised, our participants were compliant in returning their questionnaires (over 90%) 
and urinary diaries (over 80%). While the withdrawal rates were slightly higher than from the 
radical prostatectomy RCT, there was no evidence of differential dropout from the randomised 
groups, with outcome data available for 97% (intervention) and 97% (control) of the men 
continuing at 12 months (see Table 65a). This provides some reassurance that the outcome data 
are representative of the men in the RCT, and that bias from differential attrition was minimal.
Strengths and weaknesses of economic analyses
The methods of the economic analysis were rigorous and reproducible, and efforts were made 
to assess the importance of uncertainty surrounding estimates of costs, effects and cost-
effectiveness. As the study was not powered to detect differences in economic outcomes, it was 
anticipated that differences in costs and effects would not reach statistical significance. For this 
reason, conclusions from the economic evaluation were based upon the consideration of the 
balance of probabilities.
Regardless of the perspective taken for the analysis, there was little chance that the intervention 
would be cost-effective. Furthermore, none of the sensitivity analyses conducted changed the 
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Chapter 15  
Overview of MAPS study
T
his chapter draws together the findings generated during the conduct of the MAPS study, 
discusses its strengths and weaknesses and sets the findings in context with those in 
the literature.
Summary of findings statement
Urinary incontinence
MAPS has shown that the provision of one-to-one conservative physical therapy for men with 
urinary incontinence after prostate surgery, either radical prostatectomy or TURP, does not 
result in better short- or long-term incontinence rates than standard management. The therapy 
intervention did, however, increase the number of men performing PFMT (compared with 
the control groups). From the perspective of the NHS, it is unlikely that, for either of the two 
patient groups considered, provision of one-to-one conservative physical therapy is cost-effective 
compared with standard care.
Pelvic floor muscle training
It seems that a great deal of information was available to men regarding PFMT in both the 
control and the intervention groups, for example from routine care in the NHS (from nurses, 
continence advisors, physiotherapists and doctors), books, leaflets, friends and the internet 
(Tables 15 and 53). It may be that this information was sufficient to allow men to manage their 
own incontinence. Therefore, this trial has not shown whether PFMT is effective or not; rather, 
it has shown that one-to-one sessions by a trained therapist are not necessary for instruction in 
PFMT and other aspects of conservative care such as bladder training and lifestyle advice. There 
was also no evidence to suggest that an intervention delivered by a trained continence nurse was 
more or less effective than that delivered by a trained physiotherapist.
Bowel function
Bowel dysfunction was uncommon. There was no evidence from MAPS that PFMT was effective 
in the treatment of faecal incontinence, constipation or bowel urgency.
Sexual function
There was no evidence from MAPS that PFMT was effective in the treatment of sexual 
dysfunction. Current NICE guidelines17 suggest that drugs or mechanical devices should be 
offered to men, and indeed around 60% of men had tried one or the other of these.
Quality of life
There was no difference between the intervention and control groups in either condition-specific 
or general measures of quality of life, in either of the clinical groups. The men did, however, show 
a gradual improvement in quality of life, consistent with a return to health after major surgery.142 Overview of MAPS study
Prevention of risk of bias
Selection bias at trial entry (generation of allocation sequence, quality of 
concealment of randomisation process)
The randomisation programme was computer generated and used prespecified minimisation 
factors that varied according to each participant, which provided protection from selection bias.
Attrition bias (accounting for missing data, withdrawals and deaths)
We accounted for all deaths and men withdrawing from the trial. We did not impute data for 
them after their withdrawal but did use the information they supplied up to the point of loss 
of contact. However, the loss to follow-up was low and similar in the randomised groups of 
both trials.
Performance bias (blinding of participants and care deliverers to allocated 
group)
Neither the men nor the therapists could be blinded to the intervention, as this would not have 
been possible.
Detection bias (blinding of outcome assessments)
The majority of the outcomes were obtained using self-reported data from questionnaires posted 
from the MAPS study office to the men at their homes. The data were entered without the clerks 
being aware of the randomised allocation.
Strengths and weaknesses
Reliability of findings
One of the main strengths of the MAPS study is the consistency and robustness of the findings. 
No matter which way we compared the groups, all the different outcome measures concurred in 
failing to find clinically or statistically significant differences between the randomised groups in 
the clinical outcomes. Where statistically significant differences in costs were identified, these 
could be attributed to the cost of providing the intervention rather than the consequences of 
the intervention.
Trial management
We deliberately chose to minimise the trial processes that needed to occur at local centres, as 
most of the staff involved were engaged in routine delivery of care in the NHS. Recruitment 
officers at each site were tasked with approaching men who were admitted for prostate surgery. 
Rather than ask them to explain the RCT to all men, we chose to ask them only to obtain the 
men’s contact details and consent to receive a postoperative (screening) questionnaire. In this 
way, staff at the MAPS study office in Aberdeen were able to carry out the administration of the 
survey and subsequent contact only with men with incontinence in an efficient and standardised 
manner. This also facilitated follow-up by post and telephone.
If a man was randomised to the intervention group, the MAPS study office contacted the local 
therapist to ask that an appointment should be set up with the participant in accordance with 
local conditions.
In this way the burden of participating in research was reduced to a minimum in participating 
centres. We feel that this contributed to the success of recruitment to both the study and the RCT.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Design and content of pelvic floor muscle training regimen
The design of the PFMT regimen could not be based on evidence as there is no consensus on 
the most effective types of treatment and frequency of follow-up. The frequency of therapy visits 
(four in a 3-month period) was chosen to reflect current practice in the NHS. It would potentially 
have been feasible to roll out this pattern of visits to NHS practice if it had been effective.
The rationale underlying the choice of components is given in Chapter 3. The underlying 
assumption was that any treatment programme would have to be acceptable to men and 
practical to incorporate into their daily lives without becoming a burden. The emphasis was 
that men should continue to practise the exercises both during and after the end of the therapy 
period. The choice of nine strong contractions twice a day is not far removed from the NICE 
recommendations of eight contractions three times a day.72
Standardisation of the therapy intervention
We tried to ensure standardisation in the delivery of the intervention by inviting all therapists to 
undertake a bespoke training programme. The programme and the intervention were formalised 
using standardised therapy documentation (see Appendix 4), which ensured a consistent content 
at each visit and between different therapists. The content of the documentation was based on 
similar documents used in a previous trial of PFMT for women with prolapse, and was also 
linked to that of the questionnaire (ICI-SF) that was used to obtain urinary outcome data from 
the men.
Prevalence of help and support services and information for men with 
urinary incontinence
Men in both groups had access to any standard care that would normally be provided locally for 
men with urinary incontinence. This would include the service provision of a continence nurse 
or a community nurse, who would provide continence aids, as well as general advice, which could 
include verbal instruction and leaflets on PFMT.
We recognised that this advice on PFMT might potentially dilute the measurable effect of our 
intensive PFMT intervention. Therefore, if a centre was to participate in MAPS, the staff had 
to agree that they would not provide specific instruction in pelvic floor anatomy, demonstrate 
PFMT or suggest a daily PFMT exercise regimen. However, they were permitted to provide a 
PFMT leaflet if this was part of their standard pattern of care. In addition, most men could and 
did access any care they needed, which included information on pelvic floor exercises from the 
literature, staff and elsewhere (see Tables 15 and 53). It might be that this would be sufficient 
for men to be able to perform adequate PFMT without the need for specialist advice from a 
trained therapist.
Effect of prior knowledge of pelvic floor exercises and provision of advice 
on practice of pelvic floor muscle training
It was clear that almost all of the men having a radical prostatectomy, and 80% of those having a 
TURP, were aware of the use of PFMT after operation, and they derived this information from a 
variety of sources (see Tables 15 and 53). Before randomisation to the intervention, in the radical 
RCT, 80% of the men in both the intervention and the control groups were initially performing 
at least some PFMT at baseline (see Table 36), compared with only 20% in each of the TURP 
groups (see Table 74). In the control groups, around 50% of the men in the radical trial were still 
performing some exercises at 12 months, while the proportion in the TURP trial remained the 
same as at baseline (20%). This could be regarded as an estimate of the background effect of the 
provision of PFMT advice outwith a specialist service.144 Overview of MAPS study
In both trials the proportion of men continuing to do the exercises at 12 months was greater 
in the intervention group (radical prostatectomy 67%, TURP 65%) than in the control groups 
(50% and 20% respectively). Therefore, the therapists had succeeded in motivating the men to 
carry out more exercises. Nevertheless, this did not result in any difference in urinary or other 
clinical outcomes.
Choice of clinical effectiveness outcome measures
Urinary incontinence
We started from the premise that the outcomes of importance were those that mattered to the 
men. Clinicians’ assessments of patients’ outcomes often underestimate the degree of bother 
perceived by patients, and tend to focus on issues of lesser importance to patients.73,74 The wide 
variety of different data collection methods and instruments limits the ability of researchers to 
compare similar clinical and research data. In the latest iteration of the ICI, Staskin et al. devote a 
chapter to the assessment of ‘patient-reported outcomes’ and provide grades of recommendation 
for a wide range of different instruments developed for this purpose.73
As a result of an ICI initiative after the first meeting in 1998, an international advisory board 
was tasked to develop modular ICI questionnaires on each of the clinical issues in incontinence. 
This was quickly expanded to include wider urinary symptoms, bowel symptoms and vaginal 
symptoms.18 The first fruit of this process was the ICI-SF urinary incontinence questionnaire, and 
we adopted this for our screening questionnaire. We felt that it was short and easy to complete 
and reliably assessed the aspects of urinary incontinence in which we were interested. This 
formed the basis for our assessment of male urinary incontinence at each time point.
The questionnaire has now been in use for about 5 years, but when MAPS was starting we felt 
that we needed another, more ‘objective’ (though still patient-reported), outcome measure. The 
most common method was to ask men to complete a urinary diary. In the past, researchers 
have experienced poor return rates for these diaries, which require participants to record fluid 
input and, worse, urine output for 3 or 5 days. We decided to reduce the burden of completion 
of diaries by simplifying it, and indeed obtained return rates of over 80%. There was good 
concordance between the men’s diary records and their questionnaire responses: for example, 
the two methods of recording daytime urinary frequency and nocturia agreed remarkably (see 
Table 29a).
Another aspect of the ICI-SF questions was the ability to generate a urinary incontinence score, 
as a composite of the amount of incontinence and the men’s assessment of its effect on quality of 
life. It was also possible to use the ‘quality of life’ question on its own as a measure of the effect 
of ‘leaking urine on everyday life’. Each separate method of measuring incontinence, however, 
gave the same general picture: of an improvement in the first 6 months and relatively little 
change thereafter.
Sexual function outcomes
We addressed this sensitive aspect of male function (symptoms of sexual dysfunction) by 
using the same outcome measures that were developed and piloted for the ProtecT trial,70 with 
permission from the study staff. The ICSmale and ICSsex questionnaires in ProtecT have already 
been used in related research.75 Use of common and standardised outcome measures will enable 
direct comparisons to be made between the outcomes of MAPS and those of ProtecT.
Choice of economic effectiveness outcome measures
Both the EQ-5D and SF-12 are recognised measures for the measurement of health-related 
quality of life. Furthermore, both can be used to provide utility scores that can be used to 
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as it is the preferred approach of NICE.17 However, the SF-12 can be converted into similar 
population-based scores using an algorithm developed by Brazier et al.,40 and this approach was 
used in a sensitivity analysis. The results of the cost-effectiveness analysis, based upon either the 
EQ-5D or SF-12 data, are, however, similar.
The perspective adopted for the economic analysis was that of both the NHS and the trial 
participant. This meant that the costs incurred by the NHS and by participants themselves were 
combined to produce an overall estimate of cost. While such an approach is not recommended 
by NICE,17 this methodological standpoint is contentious and it was felt that a more informed 
view about the desirability of the intervention would come from the consideration of a 
wider perspective.
For the TURP trial, the conclusions were sensitive to the choice of perspective (owing to a 
trend to more days away from usual activities in the control group). The trend towards fewer 
days away from usual activities following physical therapy was not consistent with the findings 
about quality of life or use of health services, so should be treated with caution. In the radical 
prostatectomy trial the conclusions were unaffected by the choice of perspective. A second 
analysis using an NHS-only perspective was also performed (i.e. only those costs that fell on 
the NHS were included and those that fell on the participants were excluded). For both trials 
combining information on the cost of the interventions and the cost of subsequent NHS care 
resulted in a statistically significantly higher total cost per participant in the intervention group. 
This difference was driven almost entirely by the cost of the PFMT intervention itself.
Long-term follow-up and potential for further research
When signing the original consent form in hospital, men also consented to being approached 
about other research in the future. This enabled us to apply to the ethics committee to commence 
long-term follow-up.
Two-year follow-up is ongoing. This will include information about persistent incontinence, the 
continuing need for treatment and whether the men have made use of any services (such as pads 
or surgery). The conclusions of the economic analysis will be reviewed in the light of longer-term 
follow-up data obtained.
We carried out a short survey to determine the level of provision of services at each site, both 
by asking the men about the services they used or needed and by asking the staff about what 
they provided.
Generalisability
Centres
The centres varied widely in size, with our largest centre approaching a total of 118 men having 
a radical prostatectomy and 661 having a TURP, while in the smallest, one man had a radical 
prostatectomy and 30 had a TURP. 
Some centres, however, did not agree to recruit men from one of the clinical groups. In seven 
centres, we were able to recruit only men having TURP. This occurred most often because a 
service was already in place for men after radical surgery that contained specific instruction 
in PFMT. Centre staff were reluctant to unpick this aspect of their service (which formed part 
of a larger service addressing other continence needs). In one centre we did not recruit men 
having TURP because they treated such a large volume of men that recruitment would have 
been impractical. In a further three centres, which joined MAPS only for the final few months, 146 Overview of MAPS study
we targeted recruitment for the radical prostatectomy group only as we needed to increase our 
sample size before the study finished.
Therapists
Because of the lack of physiotherapy availability in some centres, we allowed specialist continence 
or urology nurses to be trained as therapists: they delivered the intervention in about half of the 
centres and to just over half of the men. This would have increased the generalisability of the trial 
if the intervention were to be rolled out to the NHS. As specialist physiotherapists are in short 
supply, it would be possible to train other staff to deliver the PFMT intervention.
Men undergoing prostate surgery
Within each centre, we aimed to explain the research study to all the men admitted during the 
recruitment period. Owing to unavoidable local factors, such as holidays, some men were missed 
(154/1158 radical prostatectomies, 1078/5986 TURPs; see Table 9a), and a further 20% did 
not wish to participate in research. Many men also became ineligible when it became apparent 
that they did not meet the inclusion criteria (for example, almost 500 of the men admitted for 
TURP were in fact having a palliative ‘channel TURP’ for advanced local prostate cancer). The 
‘ineligible’ men were older than those who were eligible for screening (see Table 9b). Some men 
were also not screened as, after consenting before operation, they became ineligible because 
in the event they did not undergo a prostatectomy (24/804 radical prostatectomies, 147/2985 
TURPs; see Table 10a). Thus, apart from the men who declined participation in screening, we felt 
that we avoided systematic biases in recruiting our sample, and that we screened a representative 
sample of the population of eligible men undergoing prostate surgery.
Our trial was aimed at men who were still incontinent at 6 weeks after surgery. A considerable 
proportion of the men were known to be dry by the time they could have been randomised 
(113/742 radical prostatectomies, 1661/2590 TURPs) and a further number explicitly declined 
randomisation, did not return their baseline questionnaire or had another reason why they 
could not participate (218/742 and 489/2590 respectively). Thus, the men entering the two trials 
represented 411/742 (55%) of men undergoing radical surgery and 442/2590 (17%) undergoing 
TURP. These figures compare with our original estimates before the trial started that 50% of the 
men after radical prostatectomy and 5% after TURP would be randomised.
Timing of the intervention
Nearly all of the improvement in incontinence happened within the first 8 months after surgery 
for the radical prostatectomies (see Table 29a and Figures 14 and 15) and 5 months for the 
TURPs (see Table 67a and Figures 39 and 40). In retrospect, it might have been better to wait 
until at least 6 months after surgery before randomising men who were then still incontinent to 
specialist therapy. This would then have been targeted at men with a persistent problem (avoiding 
unnecessary treatment of men who recovered spontaneously). The MAPS findings cannot 
be extrapolated to this group of men, and we know of no evidence to suggest that a delayed 
intervention would have been more effective. However, it is clear that a substantial proportion of 
men remain wet with or without specific instruction.
Need for further treatment
At the end of follow-up at 12 months, around 14 months after surgery, a substantial proportion 
of men were still incontinent. Based on the original populations, 299/742 (40%) in the radical 
group and 251/2590 (10%) in the TURP group were still incontinent a year after surgery. For men © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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with severe urinary incontinence (defined as incontinence at least once a day and a moderate or 
large amount of urine loss), the equivalent figures were radical prostatectomies, 152/742 (20%); 
and TURPs, 97/2590 (4%). Forty per cent of the men who had radical prostatectomy and 20% of 
those who had TURP were still using pads.
Although we are still carrying out follow-up at 2 years for these men, it seems likely that this 
provides a reasonable estimate of the men who are likely to have a continuing problem. We have 
now shown that four specialised sessions of conservative therapy have not benefited the men and 
are not likely to be cost-effective, but a considerable number of men are still severely affected 
by urinary incontinence. It is important to consider what further treatment can be offered to 
these men.
Need for further research
Surgical treatment for men with persistent urinary incontinence
For some men it may be appropriate to consider a surgical intervention. The options include 
an artificial sphincter that can be inflated and deflated to permit continence and micturition 
respectively. More recently, a mesh sling analogous to the minimally invasive slings used in 
women (such as tension-free vaginal tape and transobturator tape) has been introduced. A 
new RCT comparing these two options might be an appropriate way of evaluating their relative 
effectiveness and cost-effectiveness.
While NICE recommends surgery for men with intractable and bothersome SUI,17 there is no 
consensus on which surgery is most effective and cost-effective. The recommendation was based 
on case series evidence only. The MAPS study has shown that, based on the original number of 
men having prostate surgery, the proportion of men with severe urinary incontinence (defined 
as incontinence at least once a day and a moderate or large amount) amongst the radical 
prostatectomy group was 152/742 (20%) and amongst the TURP group 97/2590 (4%).
The type of incontinence in the radical group was mostly SUI, for which surgery might be 
appropriate. Current management advice from NICE17 is in favour of the artificial urinary 
sphincter. This operation has been available for SUI after prostatectomy for several years. 
Recently, transobturator ‘minimally invasive’ slings have been marketed for men,76 extrapolated 
from their use to treat SUI in women. Published evidence for these male slings is sparse and 
usually single-centre, uncontrolled case series. Men with SUI are increasingly aware of the sling 
option and often enquire about it in clinic.
NICE interventional procedure guidance suggests that current evidence (from case series only) 
on the safety and efficacy of suburethral synthetic sling insertion appears adequate to support 
the use of this procedure under normal arrangements for consent and audit.76 However, this 
suggests that such male sling surgery ‘should only be undertaken by units that specialise in the 
investigation and treatment of postprostatectomy incontinence and that can offer alternative 
treatments, including the insertion of artificial urinary sphincters’.76 Adverse effects of male slings 
were reported, and there was no evidence comparing them with other procedures.
Relative efficacy and adverse effects of the male sling are thus uncertain, and therefore a 
randomised trial comparing the artificial urinary sphincter with the male sling would be a high 
priority. Based on a population of 4000 men having radical prostatectomy annually in England, 
and 20% of those men having severe persistent SUI, up to 800 men per year might be available for 
a trial. Such a trial should include an economic evaluation.148 Overview of MAPS study
As artificial urinary sphincter is normally performed only in tertiary centres, only a limited 
number of urological surgeons would be available to collaborate in such a trial but they would 
already be treating the majority of eligible men. A collaboration amongst these urologists might 
feasibly result in a rigorous RCT, which would in turn guide future management of men with 
persistent and severe urinary incontinence after prostate surgery.
Another possibility that could be tested is the addition of an anti-incontinence procedure such as 
a sling during the initial radical prostatectomy operation.
Validation of ICI-SF and other outcome measures
A large number of longitudinal data were collected on a variety of measures of urinary, bowel and 
sexual function outcomes, largely using the instruments developed, or being developed, by the 
ICI initiative.27 Quantitative analysis, and work comparing the data with those from the urinary 
diaries, will allow further validation of these outcome measures for use in future research and 
clinical settings.
Long-term epidemiology after different types of prostate surgery
The men who agreed to be screened in MAPS also agreed to be contacted in the future about 
other research related to men’s health after prostate surgery. Some valuable epidemiological 
information was provided in the short term by their responses to the screening survey. We could 
capitalise on this by carrying out further epidemiological research in this cohort of men. We 
have detailed information on their clinical characteristics and baseline level of incontinence. 
This might inform the debate about different methods of prostatectomy and provide valuable 
prognostic information for counselling men in the future.
In addition, long-term follow-up of the men enrolled in the MAPS RCT would provide useful 
clinical and epidemiological information about the consequences of urinary incontinence, in 
particular the need for and use of NHS services, use of products such as pads and catheters, the 
need for admission to residential or nursing home care and the chance of receiving surgery.
Meaning of the study/relationship to other work in the field
The data from the MAPS study will be added to the Cochrane review in order to supplement 
the existing body of knowledge. The MAPS trial, however, will more than double the number 
of existing data on the treatment of men with incontinence after a radical prostatectomy, and 
provides unique data on men having a TURP.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
149   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
Chapter 16  
Implications for the NHS and further 
research
Implications for the NHS and patients
Incontinence is a major complication of prostate surgery. It does, however, resolve in a proportion 
of those initially affected. For those for whom incontinence does not quickly resolve, additional 
physical therapy for incontinence is unlikely to be effective or cost-effective compared with the 
current practice of provision of information about PFMT. This suggests that, in centres routinely 
offering specific PFMT therapy in one-to-one consultations with a trained physiotherapist or 
continence nurse for all men who are incontinent after prostate surgery, it may be possible to 
reallocate resources with potentially no loss of benefit.
Incontinence that persists into the longer term represents a considerable continuing burden to 
both the NHS and the men affected. Further management of these men is necessary.
Unanswered questions and further research
Treatment for men with urinary incontinence after prostate surgery
  ■ Physical therapy of the type used in this trial is not worthwhile, but the continuing burden 
of incontinence suggests that research into other treatments would be, for example research 
on the value of surgery in controlling symptoms. Specifically, an RCT comparing different 
surgical options for men with severe persistent urinary incontinence is needed (see 
Chapter 15).
  ■ While the MAPS study has demonstrated that specific instruction in PFMT from a therapist 
is not more effective than standard management, nevertheless many men are advised to 
carry out PFMT and indeed do so. However, MAPS did not test whether any other method 
of provision of advice about PFMT would be an effective and efficient way of reducing 
incontinence. If not, this would represent a waste of resources in teaching men or providing 
leaflets, and a waste of their own time in practising the exercises. Further research into the 
effectiveness of any other method of delivery of PFMT would be worthwhile.
Treatment for men with erectile dysfunction after prostate surgery
  ■ Of the men in the radical prostatectomy trial, 80% still had erectile dysfunction at the 
12-month follow-up, and over 60% had tried various treatments. As PFMT was of no value 
to these men, research into effective and efficient treatment would be worthwhile. While men 
who did not also have urinary incontinence were not included in the RCT, it is possible that 
erectile dysfunction is equally prevalent in that group and might also merit further research 
and evaluation of treatment.
Validation of ICI-SF and other outcome measures
  ■ The MAPS data set can be used to improve the quality of further research and to improve 
other aspects of management. The data collected within MAPS can be used to further 
validate the ICI outcome measures for use in future research and clinical settings. These will 150 Implications for the NHS and further research
support the work on standardised outcome measures being developed by the ICI initiative.27 
This would include quantitative analysis and work comparing the data with those from the 
urinary diaries.
Long-term consequences of different types of prostate surgery
  ■ Detailed epidemiological data gathered within MAPS can be analysed and will allow 
prospective follow-up of the men. This will inform the debate about different methods of 
prostatectomy and provide valuable prognostic information for counselling men in the 
future. Issues include the consequences of urinary incontinence, in particular the need for 
and use of NHS services, use of products such as pads and catheters, the need for admission 
to residential or nursing home care and the chance of receiving surgery.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Appendix 1.1  Hospital information sheet for Men After 
Prostate Surgery: research information leaflet 
for men having prostate surgery
Men After Prostate Surgery
MAPS
Who has approved this study?
The Multicentre Research Ethics Committee, your Local Research
Ethics Committee and your Consultant Urologist have approved this
study.
What do I need to do now if I think I might like to take part?
If you think you might like to take part, please sign the consent form
and fill in your contact details. You can return this to the MAPS
researcher in hospital.
How do I get in touch with the research team if I want any further
information about the study?
If you have any questions about the study please speak to your
MAPS hospital researcher or contact the MAPS Study Office on
01224 551103.
Thank you for reading this.
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
Version 5 November 2004
MEN’S HEALTH AFTER
PROSTATE SURGERY
RESEARCH INFORMATION LEAFLET
for men having prostate surgery
Please take time to read this information leaflet and discuss it
with your family and friends if you wish. Do not hesitate to
contact us if there is anything you do not understand
or if you would like more information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Your Health After Prostate Surgery
Introduction
You are being invited to take part in a research study. This leaflet tells
you why the research is being done and what it will involve.We hope you
will find this information helpful.
What is the purpose of the study?
We would like to find out more about men’s health after prostate surgery.
We are undertaking a large study of treatment to see if it will help men
who lose control of their urine (urinary incontinence) after prostate
surgery. There is not enough evidence to tell us how many men suffer
from such incontinence, and if they do, whether simple (non-drug, non-
surgery) treatment helps.
We are inviting men to complete a short questionnaire three weeks after
their prostate surgery asking them about their health, and especially any
experience of urinary incontinence. Later, we may also contact some of
the men to ask if they would be interested in helping with further
research, for example, into treatment.
Why are you inviting me?
We are inviting you, as we understand that you are about to have, or
have just had, prostate surgery.
Do I have to take part?
No. If you do not want to take part, that is fine.You do not have to give a
reason and your health care will not be affected by your decision. If you
decide to take part but later change your mind, you can withdraw at any
time without giving a reason. The information we already have will be
stored securely and confidentially, unless you request that we delete it.
What will I have to do if I decide to take part?
If you think you might like to take part we will ask you to sign a consent
form when you are in hospital and give us your name, address and
phone number.This information will be held in a secure database at the
MAPS Study Office in Aberdeen.We will send you a short questionnaire
in about three weeks. We would like you to fill this in and return it to
us. You are not obliged to answer every question if you do not want to.
If you do have urinary incontinence we would like to contact you again
after you have sent back your questionnaire to find out whether or not
you would be interested in helping with further research into treatment
for incontinence. Even if you are not incontinent, you might be able to
help us with further research. However, you do not have to take part in
more research after returning your questionnaire unless you want to at
that time.
We are happy to answer any questions you may have before deciding
whether you wish to take part in this study. If so, please contact the
MAPS Study Office on 01224 551103.
What are the risks and benefits for me if I take part ?
We believe that this study has no risks for your health.Your health care
will not be affected.We hope that you will enjoy taking part in the study.
You might find it helpful to fill in the questionnaire.
Will the information I give be kept confidential?
Yes. The information will be kept confidential. Your name will not be
written on the questionnaire. The information you give us will be kept
secure using passwords. Any information will be stored using a Study
Identity Number for confidentiality. The information you provide will be
seen by the research team only.
In order to increase their usefulness, we hope to link your answers with
data related to your health after prostate surgery from your medical
NHS records, but again this will be done confidentially and the
information will only be available to the research team.When the results
of the study are reported, individuals who have taken part will not be
identified in any way.
How will the information I provide be used?
The results will help us to understand the best ways to assess whether
treatments are helping men with urinary incontinence. We plan to
publish the results in a health journal so others can read about and learn
from the results of the study.162 Appendix 1
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Who has approved this study?
The Multicentre Research Ethics Committee, your Local Research
Ethics Committee and your Consultant Urologist have approved this
study.
What do I need to do now if I think I might like to take part?
If you think you might like to take part, please sign the consent form
and fill in your contact details. You can return this to the MAPS
researcher in hospital.
How do I get in touch with the research team if I want any further
information about the study?
If you have any questions about the study please speak to your
MAPS hospital researcher or contact the MAPS Study Office on
01224 551103.
Thank you for reading this.
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
Version 5 November 2004
MEN’S HEALTH AFTER
PROSTATE SURGERY
RESEARCH INFORMATION LEAFLET
for men having prostate surgery
Please take time to read this information leaflet and discuss it
with your family and friends if you wish. Do not hesitate to
contact us if there is anything you do not understand
or if you would like more information.164 Appendix 1
Appendix 1.2  Randomised controlled trial patient 
information sheet: simple treatment for urinary 
incontinence in Men After Prostate Surgery. 
Invitation to help with research
Men After Prostate Surgery
MAPS
If you have any questions or would like any more information,
please contact the MAPS Study Office
by phone: 01224 551103
or email: maps@abdn.ac.uk
You should keep this information sheet.
If you agree to enter the study, please sign the enclosed
consent form and we will return a copy to you
Thank you very much for reading
this information sheet.
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
Version 7 February 2005
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Simple treatment for urinary incontinence in
men after prostate surgery (MAPS)
1. Title of project
Conservative treatment for men with urinary incontinence after
prostate surgery: multicentre randomised controlled trial of pelvic
floor muscle training and biofeedback.
2. Invitation
You are being invited to take part in a research study. Before you
decide, it is important for you to understand why the research is
being done and what it will involve. Please take time to read the
following information carefully and discuss it with others if you wish.
Do feel free to ask us if there is anything that is not clear or if you
would like more information. Take as much time as you need to
decide whether or not you wish to take part.You do not have to give
a reason if you do not wish to take part.
Thank you for reading this.
3. What is the purpose of the study?
We want to find out if simple (physical and lifestyle) advice and
treatment help men with urinary incontinence after prostate
surgery. The study will take about 12 months and you will be
followed up at 3, 6, 9 and 12 months by being asked to fill in a
questionnaire and keep a short diary as explained in Section 7
below.
We have found out that up to 10% of men have urinary incontinence
after prostate surgery through the urethra and 50% after abdominal
surgery. Although the problem gets better with time, there is hardly
any information to show if treatment can also help.
4. Why have I been chosen?
When you kindly returned the questionnaire we sent you after your
prostate surgery, your answers showed that you might have this
problem and be suitable for our study of treatment. We hope to
study up to 800 men with the same problem.
All information which is collected about you during the course of the
research will be kept strictly confidential. The identification
information that you give us will be separated from your answers to
the questionnaires and will only be linked using a secret unique
study number. We may collect some information from your hospital
notes or NHS records about your surgery or use of NHS services,
but again this will be confidential to the research team. Any
information about you which leaves the hospital or research unit will
have your name and address removed so that you cannot be
recognised from it.
If we have any questions about your health as a result of you
participating in this study, this will be discussed with you in order to
find out what you would like to do about it. Any such information
would be entirely confidential, however, and would not be given to
anyone else (such as your GP) without your express permission.
17. What will happen to the results of the research study?
We shall publish the results of this study in the academic and
popular press, and present the information at academic meetings.
The information will also be sent to NHS policy makers. However,
you will not be identified personally in any report or publication.
18. Who is organising and funding the research?
The research is funded by the Health Technology Assessment
programme of the NHS.This study is being organised by staff at the
MAPS Study Office at the Health Services Research Unit,
University of Aberdeen.
The funds are only available for the expenses necessary for
running this study, including the salaries of the researchers and
staff employed. No-one will benefit financially from this research.
19. Who has reviewed the study?
This study has been approved by the Multi-centre Research Ethics
Committee and your Local Research Ethics Committee. The
science has been reviewed and approved by the NHS Health
Technology Assessment programme.166 Appendix 1
5. Do I have to take part?
No. If you do not want to take part, that is fine.You do not have to
give a reason and your health care will not be affected by your
decision.You can still have any treatment available locally whether
or not you take part.
If you decide to take part but later change your mind, you can
withdraw at any time without giving a reason. The information we
already have will be stored securely and confidentially, unless you
request that we delete it. If you agree, we may still collect NHS
information about you (such as from your hospital records), unless
you request that we do not. We will specifically seek your consent
(or not) to keeping this information if you choose to withdraw.
6. What will happen to me if I take part?
Sometimes because we do not know which way of treating patients
is best, we need to make comparisons. People will be put into
groups and then compared.The groups are selected by a computer
which has no information about the individual (i.e. by chance).
Patients in each group then have different treatments and these are
compared.
In this study, you will have a 1 in 2 chance of being either in the
active treatment group or in the standard treatment group.
If you are in the active treatment group, you will be invited to see a
hospital physiotherapist or nurse for advice about diet and exercise,
such as pelvic floor muscle training, four times in three months in
an outpatient clinic. They will assess you by asking questions and
examining you at the first visit, which will last for an hour. The
examinations at each visit will include gentle anal (back passage)
testing to measure your muscle strength. This could be with a
gloved finger and/or using a biofeedback machine with a small
sheathed anal probe. In the second, third and fourth visits, which
will each last for about three-quarters of an hour, they will find out
how you are getting on with following their advice, and may suggest
extra ways of helping.
12. What are the possible benefits of taking part?
We hope that the treatment you receive will help you. Even if you
are in the standard treatment group, you may find that your
problems improve. However, this cannot be guaranteed. The
information we get from this study will help us to treat men with
urinary incontinence better in the future.
13. What if new information becomes available?
Sometimes during the course of a research project, new
information becomes available about the treatment that is being
studied. If this happens, the MAPS Study Office staff will contact
you to let you know about the choices available to you.However, we
are not aware that any new information is likely to become available
before the end of this study.
14. What happens when the research study stops?
If this treatment works, we hope that the NHS will provide it in the
future for all men who might benefit. However, this cannot be
guaranteed and will depend on local resources.Your GP will be able
to refer you for any treatments which are available.
15. What if something goes wrong?
We do not expect any harm to come to you by taking part in this
study. However, if you are harmed by taking part in this research
project, there are no special compensation arrangements.If you are
harmed due to someone’s negligence, then you may have grounds
for a legal action but you may have to pay for it. Regardless of this,
if you wish to complain, or have any concerns about any aspect of
the way you have been approached or treated during the course of
this study, the normal National Health Service complaints
mechanisms (which includes professional indemnity insurance)
would be available to you.
16. Will my taking part in this study be kept confidential?
If you are willing to take part, we will let your GP and your hospital
Urology Consultant know that you have agreed and we will send
them information about what this study is about. However, we will
not send them any personal or research information about you or
your part in the study.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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If you are in the standard treatment group you will receive
information about lifestyle changes which may help your problem,
but otherwise you can continue with your normal activities.You can
still have any other treatment available locally if you want it.
In both groups, you are free to consult your GP or anyone else if
you feel you need extra help.
7. What do I have to do?
Before you enter the study, we would like you to fill in another
questionnaire and sign a consent form. In both groups you will be
asked to fill in two more questionnaires, at 6 and 12 months from
now.Each questionnaire should take less than half-an-hour to fill in.
You do not need to answer every question if you do not want to.
Even if you are in the control group, it would be very important to
return these questionnaires because otherwise we will not be able
to compare the effects of the study treatment with current standard
treatment.
We will also ask you to keep a short diary (just for three days) at
three monthly intervals (one now before you enter the study, and
the others at 3, 6, 9 and 12 months from now). The diary should
only take a few minutes a day to complete.There are also two short
questionnaires at 3 and 9 months. These are to keep a record of
how often you leak urine, and how much you use the health service.
There are no extra outpatient appointments other than the four
treatment appointments if you are in the active group.
We may wish to find out in the future how you are after the study
has finished, for example by checking your NHS records or by
sending you another questionnaire. To make sure we can contact
you again, we would be grateful if you could give us details of a
person we could contact who would know where you are if you have
moved.
8. What is the procedure that is being tested?
Simple (physical exercise and lifestyle) advice and treatment. We
do not propose that men in the study will have any operations,
drugs or blood tests.
9. What are the alternatives for diagnosis or treatment?
Alternative ways of managing your urinary incontinence include
drugs or an operation, but there is also very little information about
whether they work.The sorts of treatment available depend on how
severe the problem is. However, it is likely that (if they work) simple
methods would be recommended in the first instance, depending
on the results of this study.That is why we are running this study.
10. What are the side effects of any treatment received when
taking part?
Physiotherapists and doctors have been giving simple advice about
lifestyle and exercise for many years to individuals but we still do
not know how well this works. There are no known side effects. If
you do think that you suffer any symptoms, you could report them
in your questionnaires.
However, if you are concerned by any aspect of your treatment or
health, please do not hesitate to contact the MAPS Study Office on
01224 551103, or your GP, who will know you are in the study.In an
emergency please contact your GP or hospital Accident and
Emergency Department as usual.
11. What are the possible disadvantages and risks of taking part?
We do not think that there are any possible disadvantages or risks
to you.
If you have private medical insurance you should check with the
company before agreeing to take part in the study.We do not know
of a reason, however, why participation might affect your medical
insurance.168 Appendix 1
If you are in the standard treatment group you will receive
information about lifestyle changes which may help your problem,
but otherwise you can continue with your normal activities.You can
still have any other treatment available locally if you want it.
In both groups, you are free to consult your GP or anyone else if
you feel you need extra help.
7. What do I have to do?
Before you enter the study, we would like you to fill in another
questionnaire and sign a consent form. In both groups you will be
asked to fill in two more questionnaires, at 6 and 12 months from
now.Each questionnaire should take less than half-an-hour to fill in.
You do not need to answer every question if you do not want to.
Even if you are in the control group, it would be very important to
return these questionnaires because otherwise we will not be able
to compare the effects of the study treatment with current standard
treatment.
We will also ask you to keep a short diary (just for three days) at
three monthly intervals (one now before you enter the study, and
the others at 3, 6, 9 and 12 months from now). The diary should
only take a few minutes a day to complete.There are also two short
questionnaires at 3 and 9 months. These are to keep a record of
how often you leak urine, and how much you use the health service.
There are no extra outpatient appointments other than the four
treatment appointments if you are in the active group.
We may wish to find out in the future how you are after the study
has finished, for example by checking your NHS records or by
sending you another questionnaire. To make sure we can contact
you again, we would be grateful if you could give us details of a
person we could contact who would know where you are if you have
moved.
8. What is the procedure that is being tested?
Simple (physical exercise and lifestyle) advice and treatment. We
do not propose that men in the study will have any operations,
drugs or blood tests.
9. What are the alternatives for diagnosis or treatment?
Alternative ways of managing your urinary incontinence include
drugs or an operation, but there is also very little information about
whether they work.The sorts of treatment available depend on how
severe the problem is. However, it is likely that (if they work) simple
methods would be recommended in the first instance, depending
on the results of this study.That is why we are running this study.
10. What are the side effects of any treatment received when
taking part?
Physiotherapists and doctors have been giving simple advice about
lifestyle and exercise for many years to individuals but we still do
not know how well this works. There are no known side effects. If
you do think that you suffer any symptoms, you could report them
in your questionnaires.
However, if you are concerned by any aspect of your treatment or
health, please do not hesitate to contact the MAPS Study Office on
01224 551103, or your GP, who will know you are in the study.In an
emergency please contact your GP or hospital Accident and
Emergency Department as usual.
11. What are the possible disadvantages and risks of taking part?
We do not think that there are any possible disadvantages or risks
to you.
If you have private medical insurance you should check with the
company before agreeing to take part in the study.We do not know
of a reason, however, why participation might affect your medical
insurance.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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5. Do I have to take part?
No. If you do not want to take part, that is fine.You do not have to
give a reason and your health care will not be affected by your
decision.You can still have any treatment available locally whether
or not you take part.
If you decide to take part but later change your mind, you can
withdraw at any time without giving a reason. The information we
already have will be stored securely and confidentially, unless you
request that we delete it. If you agree, we may still collect NHS
information about you (such as from your hospital records), unless
you request that we do not. We will specifically seek your consent
(or not) to keeping this information if you choose to withdraw.
6. What will happen to me if I take part?
Sometimes because we do not know which way of treating patients
is best, we need to make comparisons. People will be put into
groups and then compared.The groups are selected by a computer
which has no information about the individual (i.e. by chance).
Patients in each group then have different treatments and these are
compared.
In this study, you will have a 1 in 2 chance of being either in the
active treatment group or in the standard treatment group.
If you are in the active treatment group, you will be invited to see a
hospital physiotherapist or nurse for advice about diet and exercise,
such as pelvic floor muscle training, four times in three months in
an outpatient clinic. They will assess you by asking questions and
examining you at the first visit, which will last for an hour. The
examinations at each visit will include gentle anal (back passage)
testing to measure your muscle strength. This could be with a
gloved finger and/or using a biofeedback machine with a small
sheathed anal probe. In the second, third and fourth visits, which
will each last for about three-quarters of an hour, they will find out
how you are getting on with following their advice, and may suggest
extra ways of helping.
12. What are the possible benefits of taking part?
We hope that the treatment you receive will help you. Even if you
are in the standard treatment group, you may find that your
problems improve. However, this cannot be guaranteed. The
information we get from this study will help us to treat men with
urinary incontinence better in the future.
13. What if new information becomes available?
Sometimes during the course of a research project, new
information becomes available about the treatment that is being
studied. If this happens, the MAPS Study Office staff will contact
you to let you know about the choices available to you.However, we
are not aware that any new information is likely to become available
before the end of this study.
14. What happens when the research study stops?
If this treatment works, we hope that the NHS will provide it in the
future for all men who might benefit. However, this cannot be
guaranteed and will depend on local resources.Your GP will be able
to refer you for any treatments which are available.
15. What if something goes wrong?
We do not expect any harm to come to you by taking part in this
study. However, if you are harmed by taking part in this research
project, there are no special compensation arrangements.If you are
harmed due to someone’s negligence, then you may have grounds
for a legal action but you may have to pay for it. Regardless of this,
if you wish to complain, or have any concerns about any aspect of
the way you have been approached or treated during the course of
this study, the normal National Health Service complaints
mechanisms (which includes professional indemnity insurance)
would be available to you.
16. Will my taking part in this study be kept confidential?
If you are willing to take part, we will let your GP and your hospital
Urology Consultant know that you have agreed and we will send
them information about what this study is about. However, we will
not send them any personal or research information about you or
your part in the study.170 Appendix 1
Simple treatment for urinary incontinence in
men after prostate surgery (MAPS)
1. Title of project
Conservative treatment for men with urinary incontinence after
prostate surgery: multicentre randomised controlled trial of pelvic
floor muscle training and biofeedback.
2. Invitation
You are being invited to take part in a research study. Before you
decide, it is important for you to understand why the research is
being done and what it will involve. Please take time to read the
following information carefully and discuss it with others if you wish.
Do feel free to ask us if there is anything that is not clear or if you
would like more information. Take as much time as you need to
decide whether or not you wish to take part.You do not have to give
a reason if you do not wish to take part.
Thank you for reading this.
3. What is the purpose of the study?
We want to find out if simple (physical and lifestyle) advice and
treatment help men with urinary incontinence after prostate
surgery. The study will take about 12 months and you will be
followed up at 3, 6, 9 and 12 months by being asked to fill in a
questionnaire and keep a short diary as explained in Section 7
below.
We have found out that up to 10% of men have urinary incontinence
after prostate surgery through the urethra and 50% after abdominal
surgery. Although the problem gets better with time, there is hardly
any information to show if treatment can also help.
4. Why have I been chosen?
When you kindly returned the questionnaire we sent you after your
prostate surgery, your answers showed that you might have this
problem and be suitable for our study of treatment. We hope to
study up to 800 men with the same problem.
All information which is collected about you during the course of the
research will be kept strictly confidential. The identification
information that you give us will be separated from your answers to
the questionnaires and will only be linked using a secret unique
study number. We may collect some information from your hospital
notes or NHS records about your surgery or use of NHS services,
but again this will be confidential to the research team. Any
information about you which leaves the hospital or research unit will
have your name and address removed so that you cannot be
recognised from it.
If we have any questions about your health as a result of you
participating in this study, this will be discussed with you in order to
find out what you would like to do about it. Any such information
would be entirely confidential, however, and would not be given to
anyone else (such as your GP) without your express permission.
17. What will happen to the results of the research study?
We shall publish the results of this study in the academic and
popular press, and present the information at academic meetings.
The information will also be sent to NHS policy makers. However,
you will not be identified personally in any report or publication.
18. Who is organising and funding the research?
The research is funded by the Health Technology Assessment
programme of the NHS.This study is being organised by staff at the
MAPS Study Office at the Health Services Research Unit,
University of Aberdeen.
The funds are only available for the expenses necessary for
running this study, including the salaries of the researchers and
staff employed. No-one will benefit financially from this research.
19. Who has reviewed the study?
This study has been approved by the Multi-centre Research Ethics
Committee and your Local Research Ethics Committee. The
science has been reviewed and approved by the NHS Health
Technology Assessment programme.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Men After Prostate Surgery
MAPS
If you have any questions or would like any more information,
please contact the MAPS Study Office
by phone: 01224 551103
or email: maps@abdn.ac.uk
You should keep this information sheet.
If you agree to enter the study, please sign the enclosed
consent form and we will return a copy to you
Thank you very much for reading
this information sheet.
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
Version 7 February 2005
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Appendix 2.1  Screening consent form: your health after 
prostate surgery
MAPS Study Number
Consent Form
Your Health After Prostate Surgery
Please tick the boxes, complete, sign and return this form to the researcher or ward staff if
you think you might like to take part in the study.
There is no need to sign or return anything if you do not want to take part.
I am willing to receive a short questionnaire after I go home.
I am willing for a researcher to contact me in the future to ask me if I would like to help with
further research into men’s health after prostate surgery.
I agree that information related to my health after prostate surgery may be collected from my
hospital and NHS records.
I agree that this information and my personal details will be held in a secure central database.
Signed ............................................................................................................................
Date ............................................................................................................................
Date of
operation ............................................................................................................................
Telephone ............................................................................................................................
E-mail ............................................................................................................................
Name ............................................................................................................................
Address ............................................................................................................................
............................................................................................................................
Date of birth ........................................Hospital number ........................................................
I confirm that I have explained the nature and purpose of the study and the procedures involved to
the person named above.
Signature ..................................................................................... Date ...................................
This form should be returned to
MAPS Study Office, Health Services Research Unit, University of Aberdeen,
Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD
4 Copies: Top copy for Study Office in Aberdeen; 1 for patient;
1 to be filed with hospital notes and 1 for recruitment officer.
The research is funded by the Health Technology Assessment programme of the NHS.
It is being organised by the MAPS Study Office at the Health Services Research Unit, University of Aberdeen.
Hospital Consent Form Version 4 03 11 2004
Men After Prostate Surgery
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Appendix 2.2  Randomised controlled trial consent form: 
simple treatment for urinary incontinence in 
Men After Prostate Surgery
Trial Consent Form
Simple treatment for urinary incontinence
in men after prostate surgery (MAPS)
Conservative treatment for men with urinary incontinence after prostate surgery:
multicentre randomised controlled trial of pelvic floor muscle training and biofeedback
By signing this form and ticking each box I agree that:
I have:
• been given the Information Sheet about the study (Version 7, February 2005)
• had the opportunity to discuss the study
• received satisfactory answers to questions
• been given enough information about the study
I understand that:
• taking part in the study may not benefit my own health
• I am free to withdraw from the study at any time without having to give a reason
• if I withdraw, this will not affect my care
• information relevant to the MAPS study may be collected from my hospital and
NHS records, including Office of National Statistics (ONS) and NHS central registers
I agree to take part in the study
I agree that my family doctor (GP), my hospital Urological Consultant and the person
I have nominated as my Best Contact may be told that I am taking part in this study
Your signature (participant).........................................................................................................
Your name in block capitals........................................................................................................
Date ............................................................................................................................................
I confirm that I have explained to the person named above, the nature and purpose of the study and
the procedures involved
Signature.....................................................................................................................................
Date ............................................................................................................................................
Study ID number of participant
Hospital number of participant
MAPS Study Office, Health Services Research Unit, University of Aberdeen,
Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD
Copies: 1 for patient; 1 for researcher in Aberdeen; 1 to be filed with hospital notes.
The research is funded by the Health Technology Assessment programme of the NHS.
It is being organised by the MAPS Study Office at the Health Services Research Unit, University of Aberdeen.
Trial Consent Form Version 7 August 2005
Men After Prostate Surgery
MAPS
Please
tick all
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Appendix 3.1  MAPS screening questionnaire
Study ID Number
MAPS Screening Questionnaire
CONFIDENTIAL
DAY MONTH YEAR
1 Please write in today’s date:
2 Please write in your date of birth:
3 Please write in the date of your prostate operation:
Many people leak urine some of the time. We are trying to find out how many people leak urine after prostate
surgery, and how much this bothers them. We would be grateful if you could answer the following questions,
thinking about how you have been, on average, in the LAST WEEK.
4 How often do you leak urine? (Cross one box only) never
about once a week or less often
two or three times a week
about once a day
several times a day
all the time
5 We would like to know how much urine you think leaks.
How much urine do you usually leak (whether you wear
protection or not)? (Cross one box)
6 Overall, how much does leaking urine interfere with your everyday life?
Please cross a number between 0 (not at all) and 10 (a great deal)
not a great
at all deal
0123456789 10
7 When does urine leak? (Please cross all that apply to you) never – urine does not leak
leaks before you can get to the toilet
leaks when you cough or sneeze
leaks when you are asleep
leaks when you are physically active/exercising
leaks when you have finished urinating and are dressed
leaks for no obvious reason
leaks all the time
8 Did you leak urine BEFORE you had your prostate surgery? Yes No
PTO
Copyright © “ICIQ Group” ICIQ-UI SF Version 4 November 2004
Men After Prostate Surgery
MAPS
none
a small amount
a moderate amount
a large amount© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
179   Health Technology Assessment 2011; Vol. 15: No. 24 DOI: 10.3310/hta15240
9 Have you lost control of your bowel or leaked bowel motion (stool) Yes No
at an inappropriate time or place SINCE your prostate operation?
10 Please write here the name of the type of prostate surgery you had if you know it:
.......................................................................................................................................................................
THANKYOU
Thank you very much for your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us carry out research into men‘s health
after prostate surgery. It will be treated with the strictest confidence.
We are planning to carry out further research into men’s health after prostate surgery. We would like to contact
you again in the future with information about what this might involve. Please could you give us your contact
details for this purpose?
My phone number is: ..........................................................................................................................................
My email address is: ...........................................................................................................................................
If you do not have a phone number, we will send everything by post or email.
You will not commit yourself to taking part in any research until you are satisfied that you want to.
If we have sent this questionnaire to the wrong address, please could you give us your correct details in the box
below?
Please tick here if you do NOT want us to contact you again about any further research
Please send the questionnaire back to us in Aberdeen
in the envelope provided.
Thank you again for your help180 Appendix 3
Appendix 3.2  MAPS baseline questionnaire
Study Number
CONFIDENTIAL
MAPS TRIAL
MEN’S HEALTH
AFTER PROSTATE SURGERY
Thank you for helping us with our research into urinary incontinence after prostate surgery.
We would be very grateful if you could complete and return this questionnaire.
After you have answered the questions,
we can allocate you to a treatment group.
Version 6 February 2005 Baseline Q
Men After Prostate Surgery
MAPS
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HOW TO FILL IN THIS QUESTIONNAIRE
Most questions can be answered by putting numbers or a tick in the appropriate box or boxes. Please print
your answers carefully within the boxes like this:
27 OR MIKE OR ￿
If you make a mistake, shade out the wrong box completely and tick the correct one like this
e.g. If you ticked often but meant to answer sometimes:
OFTEN ￿ SOMETIMES ￿ NEVER
Please try to complete the whole questionnaire.
There are no right or wrong answers.
Sometimes the box you tick tells you to skip forward so that you miss out questions which do not apply to
you.
In some questions we would like you to think about different time periods, such as during the last week,
during the last 4 weeks or since your prostate operation. Please check the time periods carefully.
Some of the questions ask for answers in your own words, please write these in the boxes provided.
You do not have to answer any question if you do not want to.
Thank you for your help.
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SECTION A – URINE SYMPTOMS
When you answer these questions, please think about how you have been in the LAST WEEK.
A1 How often do you leak urine?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A2 We would like to know how much urine you think leaks.
How much urine do you usually leak (whether you wear protection or not)?
(Tick ONE box only) None
A small amount
A moderate amount
A large amount
A3 Overall, how much does leaking urine interfere with your everyday life?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
In the following questions (A4 to A8), we would like to find out when you leak urine.
When you answer these questions, please think about how you have been in the LAST WEEK.
A4 Does urine leak when you cough, sneeze, or are physically active or exercising?
(Tick ONE box only)
Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
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When you answer these questions, please think about how you have been in the LAST WEEK.
A5 When you feel the need to urinate, do you have to rush urgently to the toilet?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A6 Does urine leak when you have to rush urgently to the toilet?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A7 Does urine leak when you have finished urinating and are dressed?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A8 Does urine leak at times other than shown in your answers to questions A4, A6 or A7?
(Tick ONE box only)
Yes Go to A8a No Go to A9
A8a If you do leak at other times, please give details of when you leak:
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When you answer these questions, please think about how you have been in the LAST WEEK.
A9 Do you wear a pad or other protection because of leaking urine?
(Tick ONE box only)
Yes Go to A9a No Go to A10
A9a IfYes, how many pads do you wear in an average day (24 hours)?
Enter TOTAL number of pads you wear in 24 hours
A9b Of these pads, how many do you pay for yourself?
If you do not pay for them, please enter zero (0) in the boxes
Enter number of pads YOU PAY FOR yourself
A10 Do you use pads or protectors on your chair or bed in case you leak urine?
(Tick ONE box only)
Yes Go to A10a No Go to A11
A10a IfYes, how many chair or bed pads do you use in an average day (24 hours)?
Enter TOTAL number of chair and bed pads you use in 24 hours
A10b Of these chair or bed pads, how many do you pay for yourself?
If you do not pay for them, please enter zero (0) in the boxes
Enter number of chair and bed pads YOU PAY FOR yourself
A11 How often do you usually pass urine during the daytime?
Enter number of times
A12 How often do you usually have to get up at night to pass urine?
Enter number of times
A13 Are you using a permanent catheter (inside your bladder) to collect your urine?
Yes No
A14 Do you ever use an external (sheath) catheter to collect your urine?
Yes No
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SECTION B – CAREYOU HAVE RECEIVED
When you answer these questions, please think about the care you have received SINCE YOUR PROSTATE
OPERATION.
B1 Have you seen your family doctor (GP) since your prostate operation?
Yes Go to B1a No Go to B2
B1a If Yes, approximately how often have you seen your family doctor (GP) since your prostate
operation?
Enter number of times seen GP for leaking urine
Enter number of times seen GP for any other reason
B2 Have you seen a nurse (from your doctor’s practice) since your prostate operation?
Yes Go to B2a No Go to B3
B2a If Yes, approximately how many times have you seen a nurse from your doctor’s practice since
your prostate operation?
Enter number of times seen nurse for leaking urine
Enter number of times seen nurse for any other reason
B3 Since your prostate operation, have you seen NHS HOSPITAL staff for leaking urine?
If yes, enter number of visits
I have seen a hospital doctor Yes Number of visits
about leaking urine
No
I have seen a hospital nurse Yes Number of visits
about leaking urine
No
I have seen a hospital physiotherapist Yes Number of visits
about leaking urine
No
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When you answer these questions, please think about the care you have received SINCE YOUR PROSTATE
OPERATION.
B4 Since your prostate operation, have you received any PRIVATE TREATMENT (which you had to
pay for yourself) for leaking urine?
If Yes, enter number of visits
I have seen a private doctor Yes Number of visits
about leaking urine
No
I have seen a private nurse Yes Number of visits
about leaking urine
No
I have seen a private physiotherapist Yes Number of visits
about leaking urine
No
B5 Since your prostate operation, have you been admitted to hospital because of leaking urine?
Yes Go to B5a No Go to B6
B5a If you were admitted since your prostate operation, how many nights did you stay in hospital?
Enter number of nights in hospital
B5b Since your prostate operation, have you had an operation for leaking urine?
Yes Go to B5c No Go to B6
B5c IfYes, please give the name or type of operation and the date:
B6 Since your prostate operation, have you taken any medications (from a doctor, or direct from the
chemist’s) for leaking urine?
Yes Go to B6a No Go to B7
B6a IfYes, please give details of medication received since your prostate operation for leaking urine.
Please give drug names (e.g. detrusitol, duloxetine):
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When you answer these questions, please think about the care you have received SINCE YOUR PROSTATE
OPERATION.
B7 Have you had any other treatment or advice for leaking urine since your prostate operation
(other than the operation you named in B5c or the drugs you listed in B6a)?
Yes Go to B7a No Go to B8
B7a IfYes, please give details of other treatment or advice received since your prostate operation
for leaking urine:
B8 Are you in paid employment?
Yes Go to B8a No Go to Section C
B8a If Yes, approximately how many days off sick have you had for any reason since your prostate
operation?
days
SECTION C – OTHER HEALTH PROBLEMS
C1 Do you have any health or medical problems (such as heart, chest or kidney problems, diabetes,
stroke or high blood pressure) other than those to do with your prostate operation?
Yes No
C2 Do you take any medications (such as drugs or prescriptions from your doctor, or direct from the
chemist’s) for these health problems?
Yes No
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SECTION D – BOWEL SYMPTOMS
This section is about your bowel symptoms and control of your stool (also called bowel motions or faeces).
Many people experience bowel symptoms some of the time. When you answer these questions, please think
about how you have been in the LAST WEEK.
D1 How often do you lose control of or leak stool?
(Tick ONE box only) Never
Occasionally
Sometimes
Most of the time
All of the time
D2 If you do, how much does this bother you?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
D3 When you feel the need to open your bowels, do you have to rush urgently to the toilet?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
D4 When you have to rush urgently, do you ever lose control of or leak stool?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
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When you answer these questions, please think about how you have been in the LAST WEEK.
D5 Do you ever lose control of or leak stool WITHOUT first feeling that you have to rush urgently?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
D6 If stool leaks, is this usually solid, liquid or both? (Tick ONE box only)
Doesn’t leak
Liquid only
Solid only
Liquid and solid
D7 Are you currently receiving ANY treatment or advice for leaking stool?
Yes Go to D7a No Go to D8
D7a IfYes, please give details of treatment or advice received for leaking stool:
D8 Did you ever lose control of or leak stool BEFORE your prostate surgery?
Yes No
D9 Do you have any of these other bowel problems?
(Tick ALL boxes that apply to you) Ulcerative colitis
Crohn’s disease
Irritable bowel syndrome
Constipation
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When you answer these questions, please think about how you have been in the LAST WEEK.
D10 Are you currently receiving ANY treatment or advice for any of these other bowel problems?
Yes Go to D10a No Go to Section E
D10a IfYes, please give details of treatment or advice received for other bowel problems:
SECTION E – OTHER HEALTH ISSUES
This section is about exercise, weight and other issues to do with your health. When you answer these
questions, please think about how you have been in the LAST WEEK.
E1 Have you done any general exercise or fitness activity?
Yes Go to E2 No Go to E3
E2 IfYes, what sort of exercise have you done? (Tick all boxes that apply)
Walking Swimming
Gardening Running
Going to the gym Other (please give details in E2a)
E2a Please give details of other exercise:
E3 Have you done any pelvic floor exercises over the last week?
Yes Go to E4 No Go to E5 Don’t know what these are Go to E6
E4 IfYes, on how many days in the last week did you do pelvic floor exercises?
(Tick ONE box only) Every day
5 to 6 days
3 to 4 days
1 to 2 days
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When you answer these questions, please think about how you have been in the LAST WEEK.
E5 How do you know about pelvic floor exercises? (Tick ALL boxes that apply to you)
Yes No
From a doctor
From a nurse / continence advisor
From a physiotherapist
From leaflets or books
From the internet
From friends or family
From another source (please give details in E5a)
E5a If from another source, please give details:
E6 Were you able to achieve an erection BEFORE your recent prostate surgery?
Yes No
E7 Have you ever had a prostate operation BEFORE your recent prostate surgery?
Yes No
E8 Please could you enter your weight and height?
If you are not sure what they are, please give your best guess.
(Please use whichever units you are familiar with)
Stones Pounds OR Kilograms
What is your average weight now?
Feet Inches OR Centimetres
What is your height?
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SECTION F – DESCRIBINGYOUR OWN HEALTH TODAY
The next two sections are about your general health.
By placing a tick in one box in each group below, please indicate which statements best describe your own
health state today.
F1 Mobility I have no problems in walking about
I have some problems in walking about
I am confined to bed
F2 Self-care I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
F3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
F4 Pain/discomfort I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
F5 Anxiety/depression I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
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SECTION G – GENERAL HEALTH SF12 ©
The following questions ask for your views about your health in the last 4 weeks, how you feel and how well
you are able to do your usual activities.
Answer every question by selecting the answer as indicated. If you are unsure about how to answer a question
please give the best answer you can.
G1 In general, would you say your health is:
(Tick ONE box only) Excellent
Very good
Good
Fair
Poor
G2 During a typical day does your health limit you in moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(Tick ONE box only) Yes, limited a lot
Yes, limited a little
No, not limited at all
G3 During a typical day does your health limit you in climbing several flights of stairs? If so, how
much?
(Tick ONE box only) Yes, limited a lot
Yes, limited a little
No, not limited at all
G4 During the past 4 weeks, how often have you accomplished less than you would have liked in
your work or other regular daily activities as a result of your physical health?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
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G5 During the past 4 weeks, how often have you been limited in performing any kind of work or
other regular daily activities as a result of your physical health?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G6 During the past 4 weeks, how often have you accomplished less than you would have liked in
your work or any other regular daily activities as a result of any emotional problems (such as
feeling depressed or anxious)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G7 During the past 4 weeks, how often have you done work or other activities less carefully than
usual as a result of any emotional problems (such as feeling depressed or anxious)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G8 During the past 4 weeks how much did pain interfere with your normal work (both outside the
home and housework)?
(Tick ONE box only)
Not at all
A little bit
Moderately
Quite a bit
Extremely
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G9 How much during the past 4 weeks have you felt calm and peaceful?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G10 How much during the past 4 weeks did you have a lot of energy?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G11 How much during the past 4 weeks have you felt downhearted and depressed?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
G12 During the past 4 weeks how much of the time has your physical health or emotional problems
interfered with your social activities (like visiting friends, relatives, etc.)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
SF-12v2(tm) Health Survey (c) 2000 by QualityMetric Incorporated - All rights reserved
SF-12v2(tm) is a trademark of QualityMetric Incorporated
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Sometimes we lose touch with our participants (for example if they move house). Would you please give us the
name and contact details of someone such as a family member or close friend (a ‘best contact’) who might be
able to give us your new address?
This ‘best contact’ should be someone who does NOT live at your own home.
BEST CONTACT
Title (Mr, Mrs etc) Surname
First Names
Address
Postcode Telephone Number (including code)
Relationship to yourself
Please could you let this person know that you have given us their details.
We would also like to tell your GP that you are helping with our MAPS study. Please could you give us his or
her contact details
MY GENERAL PRACTITIONER:
Surname
First Name(s) (if known)
Address
Postcode Telephone Number (including code)
PTO
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Finally:
DD MM YY Y Y
Date you filled in this questionnaire //
DD MM YY Y Y
Your date of birth //
THANKYOU
Thank you very much for your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us carry out research into men’s health
after prostate surgery.
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen
in the envelope provided.
When we receive it, we will contact you to tell you which type of treatment
you will receive, and to tell you what to do next.
Please could you confirm your
phone number:
Thank you again for your help
If you would like any further information or have any queries about the study, please contact:
The MAPS Study Office in Aberdeen (Tel: 01224 551103)
This study is taking place in centres across the UK but the questionnaires are being processed in Aberdeen
at the Health Services Research Unit, Polwarth Building, Foresterhill, ABERDEEN, AB25 2ZD.
20198 Appendix 3
Appendix 3.3  MAPS 12-month questionnaire
Study Number
CONFIDENTIAL
MAPS TRIAL
MEN’S HEALTH
AFTER PROSTATE SURGERY
Thank you for helping us with our research into urinary incontinence after prostate surgery.
We would be very grateful if you could complete and return this questionnaire.
Thank you for taking the time to help us with our research.
12m Q
Men After Prostate Surgery
MAPS
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HOW TO FILL IN THIS QUESTIONNAIRE
Most questions can be answered by putting numbers or a tick in the appropriate box
or boxes. Please print your answers carefully within the boxes like this:
27 O R MIK E O R ￿
If you make a mistake, shade out the wrong box completely and tick the correct one
like this
e.g. If you ticked often but meant to answer sometimes:
OFTEN ￿ SOMETIMES ￿ NEVER
Please try to complete the whole questionnaire.
There are no right or wrong answers.
Sometimes the box you tick tells you to skip forward so that you miss out questions
which do not apply to you.
In some questions we would like you to think about different time periods, such as
during the last week, during the last 4 weeks or since your prostate operation. Please
check the time periods carefully.
Some of the questions ask for answers in your own words, please write these in the
boxes provided.
You do not have to answer any question if you do not want to.
Thank you for your help.
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SECTION A – URINE SYMPTOMS
When you answer these questions, please think about how you have been in the LAST WEEK.
A1 How often do you leak urine?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A2 We would like to know how much urine you think leaks.
How much urine do you usually leak (whether you wear protection or not)?
(Tick ONE box only) None
A small amount
A moderate amount
A large amount
A3 Overall, how much does leaking urine interfere with your everyday life?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
A4 If you have not leaked urine in the last week, in which month did you last leak urine?
MM Y Y Y Y
(Please enter month and year): /
If you do not leak urine now, please go to question A12
Otherwise, please go to question A5
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In the following questions (A5 to A9), we would like to find out when you leak urine.
When you answer these questions, please think about how you have been in the LAST WEEK.
A5 Does urine leak when you cough, sneeze, or are physically active or exercising?
(Tick ONE box only)
Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A6 When you feel the need to urinate, do you have to rush urgently to the toilet?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A7 Does urine leak when you have to rush urgently to the toilet?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
A8 Does urine leak when you have finished urinating and are dressed?
(Tick ONE box only) Never
About once a week or less often
Two or three times a week
About once a day
Several times a day
All the time
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When you answer these questions, please think about how you have been in the LAST WEEK.
A9 Does urine leak at times other than shown in your answers to questions A5, A7 or A8?
(Tick ONE box only)
Yes Go to A9a No Go to A10
A9a IfYes, please give details of when you leak:
A10 Do you wear a pad or other protection because of leaking urine?
(Tick ONE box only)
Yes Go to A9a No Go to A10
A10a IfYes, how many pads do you wear in an average day (24 hours)?
Enter TOTAL number of pads you wear in 24 hours
A10b Of these pads, how many do you pay for yourself?
If you do not pay for them, please enter zero (0) in the boxes
Enter number of pads YOU PAY FOR yourself
A11 Do you use pads or protectors on your chair or bed in case you leak urine?
(Tick ONE box only)
Yes Go to A11a No Go to A12
A11a IfYes, how many chair or bed pads do you use in an average day (24 hours)?
Enter TOTAL number of chair and bed pads you use in 24 hours
A11b Of these chair or bed pads, how many do you pay for yourself?
If you do not pay for them, please enter zero (0) in the boxes
Enter number of chair and bed pads YOU PAY FOR yourself
A12 How often do you usually pass urine during the daytime?
Enter number of times
A13 How often do you usually have to get up at night to pass urine?
Enter number of times
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When you answer these questions, please think about how you have been in the LAST WEEK.
A14 Are you using a permanent catheter (inside your bladder) to collect your urine?
Yes No
A14 Do you ever use an external (sheath) catheter to collect your urine?
Yes No
SECTION B – CAREYOU HAVE RECEIVED
When you answer these questions, please think about the care you have received IN THE LAST 3 MONTHS.
B1 Have you seen your family doctor (GP) in the last 3 months?
Yes Go to B1a No Go to B2
B1a IfYes, approximately how often have you seen your family doctor (GP) in the last 3 months?
Enter number of times seen GP for leaking urine
Enter number of times seen GP for any other reason
B2 Have you seen a nurse (from your doctor’s practice) in the last 3 months?
Yes Go to B2a No Go to B3
B2a IfYes, approximately how many times have you seen a nurse from your doctor’s practice
in the last 3 months?
Enter number of times seen nurse for leaking urine
Enter number of times seen nurse for any other reason
B3 In the last 3 months, have you seen NHS HOSPITAL staff for leaking urine?
If yes, enter number of visits
Yes Number of visits
No
Yes Number of visits
No
Yes Number of visits
No
Study Number 5 12m Q
I have seen a hospital doctor
about leaking urine
I have seen a hospital nurse
about leaking urine
I have seen a hospital physiotherapist
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When you answer these questions, please think about the care you have received IN THE LAST 3 MONTHS.
B4 In the last 3 months, have you received any PRIVATE TREATMENT
(which you had to pay for yourself) for leaking urine?
If Yes, enter number of visits
Yes Number of visits
No
Yes Number of visits
No
Yes Number of visits
No
B5 In the last 3 months, have you been admitted to hospital because of leaking urine?
Yes Go to B5a No Go to B6
B5a If you were admitted in the last 3 months, how many nights did you stay in hospital?
Enter number of nights in hospital
B5b In the last 3 months, have you had an operation for leaking urine?
Yes Go to B5c No Go to B6
B5c IfYes, please give the name or type of operation and the date:
B6 In the last 3 months,have you taken any medications (from a doctor,or direct from the chemist’s)
for leaking urine?
Yes Go to B6a No Go to B7
B6a IfYes, please give details of medication received in the last 3 months for leaking urine.
Please give drug names (e.g. detrusitol, duloxetine):
6
I have seen a private doctor
about leaking urine
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When you answer these questions, please think about the care you have received IN THE LAST 3 MONTHS.
B7 Have you had any other treatment or advice for leaking urine in the last 3 months
(other than the operation you named in B5c or the drugs you listed in B6a)?
Yes Go to B7a No Go to B8
B7a IfYes, please give details of other treatment or advice received in the last 3 months for
leaking urine:
B8 Are you in paid employment?
Yes Go to B8a No Go to Section C
B8a IfYes, approximately how many days off sick have you had for any reason in the last 3 months?
days
SECTION C – BOWEL SYMPTOMS
This section is about your bowel symptoms and control of your stool (also called bowel motions or faeces).
Many people experience bowel symptoms some of the time. When you answer these questions (C1 to C6),
please think about how you have been in the LAST WEEK.
C1 How often do you lose control of or leak stool?
(Tick ONE box only) Never
Occasionally
Sometimes
Most of the time
All of the time
C2 If you do, how much does this bother you?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
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When you answer these questions, please think about how you have been in the LAST WEEK.
C3 When you feel the need to open your bowels, do you have to rush urgently to the toilet?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
C4 When you have to rush urgently, do you ever lose control of or leak stool?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
C5 Do you ever lose control of or leak stool WITHOUT first feeling that you have to rush urgently?
(Tick ONE box only)
Never
Occasionally
Sometimes
Most of the time
All of the time
C6 If stool leaks, is this usually solid, liquid or both?
(Tick ONE box only)
Doesn’t leak
Liquid only
Solid only
Liquid and solid
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C7 Are you currently receiving ANY treatment or advice for leaking stool?
Yes Go to C7a No Go to C8
C7a IfYes, please give details of treatment or advice received for leaking stool:
C8 Do you have any of these other bowel problems?
(Tick ALL boxes that apply to you) Ulcerative colitis
Crohn’s disease
Irritable bowel syndrome
Constipation
C9 Are you currently receiving ANY treatment or advice for any of these other bowel problems?
Yes Go to C9a No Go to Section D
C9a IfYes, please give details of treatment or advice received for other bowel problems:
SECTION D – OTHER HEALTH ISSUES
This section is about exercise, weight and other issues to do with your health. When you answer these
questions, please think about how you have been in the LAST WEEK.
D1 Have you done any general exercise or fitness activity?
Yes Go to D2 No Go to D3
D2 IfYes, what sort of exercise have you done? (Tick all boxes that apply)
Walking Swimming Gardening
Running Going to the gym Other (please give details in D2a)
D2a Please give details of other exercise:
Study Number 9 12m Q208 Appendix 3
When you answer these questions, please think about how you have been in the LAST WEEK.
D3 Since your prostate operation, have you changed how you exercise?
(Tick ONE box only) No, I have made no changes
I take LESS exercise than I did
I take MORE exercise than I did
D4 Have you done any pelvic floor exercises over the last week?
Yes Go to D5 No Go to D6 Don’t know what these are Go to D9
D5 IfYes, on how many days in the last week did you do any pelvic floor exercises?
(Tick ONE box only) Every day
5 to 6 days
3 to 4 days
1 to 2 days
D5a On average, how many contractions did you do each day
when you did any pelvic floor exercises?
Enter number of contractions Don’t Know
D6 Do you deliberately contract your pelvic floor a little while you are walking about?
(Tick ONE box only)
No Rarely Sometimes Often Always
D7 Do you deliberately contract your pelvic floor before you do something that would cause you
to leak urine? (e.g. cough, sneeze, exercise, lift etc)
(Tick ONE box only)
No Rarely Sometimes Often Always
D8 If you do, does contracting your pelvic floor stop leakage of urine?
(Tick ONE box only)
Yes, completely Reduces the amount No
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When you answer these questions, please think about how you have been in the LAST WEEK.
D9 Please could you enter your current weight?
If you are not sure what it is, please give your best guess.
(Please use whichever units you are familiar with)
Stones Pounds OR Kilograms
What is your average weight now?
D10 Since your prostate operation (one year ago), have you made any changes to the amount of fluid
you drink? (Please tick ALL that apply)
I have made no changes Go to D11
Yes No
I drink more fluids
I drink more cranberry juice
I take fewer drinks with caffeine
I drink less fluid in the evenings
I have made other changes (please give details in D10a)
D10a I have made these other changes to the amount of fluid I drink: (please give details)
D11 Since your prostate operation, have you made any changes to your diet or the sort of food you
eat? (Please tick ALL that apply)
I have made no changes Go to D12
Yes No
I eat a more balanced diet
I eat more fruit and vegetables
I eat more foods containing fibre eg. wholemeal bread or brown rice
I eat less food containing lots of fat or sugar
I have made other changes (please give details in D11a)
D11a I have made these other changes to my diet: (please give details)
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When you answer these questions, please think about how you have been in the LAST WEEK.
D12 Since your prostate operation, have you tried to lose any weight?
No, I do not need to lose weight Go to D13
No, I haven’t tried to lose weight Go to D13
Yes No
I do extra exercise to help me lose weight
I went on a weight reducing diet
I have tried to lose weight in other ways (please give details in D12a)
D12a I have tried these other ways of losing weight: (please give details)
D13 Since your prostate operation, have you avoided or reduced the amount of heavy lifting you do
(e.g. lighter gardening, less heavy shopping or lifting less)?
Yes No
D14 Do you smoke?
Yes Go to D14b No Go to D15
D14b IfYes, have you changed your smoking habit?
(Please tick ALL that apply)
No, I have not changed my smoking habit Go to D15
Yes No
I have stopped smoking
I have reduced the amount I smoke
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When you answer these questions, please think about how you have been in the LAST WEEK.
D15 Are you affected by any chest / respiratory symptoms (e.g. cough, asthma, bronchitis)?
Yes Go to D16 No Go to E1
D16 Since your prostate operation, have you tried to reduce your chest / respiratory symptoms?
(Please tick ALL that apply)
No, I have not tried to reduce my symptoms Go to E1
Yes No
I have made sure that I am taking the correct medication for my condition(s)
I have spoken to my doctor to make sure that that my treatment is up-to-date
I have made other changes (please give details in D16a)
D16a I have made other changes to help problems related to my chest symptoms: (please give details)
SECTION E – DESCRIBINGYOUR OWN HEALTH TODAY
The next two sections (E and F) are about your general health.
By placing a tick in one box in each group below, please indicate which statements best describe your own
health state TODAY.
E1 Mobility I have no problems in walking about
I have some problems in walking about
I am confined to bed
E2 Self-care I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
E3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
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By placing a tick in one box in each group below, please indicate which statements best describe your own
health state TODAY.
E4 Pain/discomfort I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
E5 Anxiety/depression I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
SECTION F – GENERAL HEALTH SF12 ©
The following questions ask for your views about your health in the LAST 4 WEEKS, how you feel and how
well you are able to do your usual activities.
Answer every question by selecting the answer as indicated.
If you are unsure about how to answer a question please give the best answer you can.
F1 In general, would you say your health is:
(Tick ONE box only) Excellent
Very good
Good
Fair
Poor
F2 During a typical day does your health limit you in moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(Tick ONE box only) Yes, limited a lot
Yes, limited a little
No, not limited at all
F3 During a typical day does your health limit you in climbing several flights of stairs?
If so, how much?
(Tick ONE box only) Yes, limited a lot
Yes, limited a little
No, not limited at all
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F4 During the past 4 weeks, how often have you accomplished less than you would have liked
in your work or other regular daily activities as a result of your physical health?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
F5 During the past 4 weeks, how often have you been limited in performing any kind of work or
other regular daily activities as a result of your physical health?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
F6 During the past 4 weeks, how often have you accomplished less than you would have liked in
your work or any other regular daily activities as a result of any emotional problems (such as
feeling depressed or anxious)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
F7 During the past 4 weeks, how often have you done work or other activities less carefully
than usual as a result of any emotional problems (such as feeling depressed or anxious)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
15214 Appendix 3
F8 During the past 4 weeks how much did pain interfere with your normal work
(both outside the home and housework)?
(Tick ONE box only)
Not at all
A little bit
Moderately
Quite a bit
Extremely
F9 How much during the past 4 weeks have you felt calm and peaceful?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
F10 How much during the past 4 weeks did you have a lot of energy?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
F11 How much during the past 4 weeks have you felt downhearted and depressed?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
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F12 During the past 4 weeks how much of the time has your physical health or emotional problems
interfered with your social activities (like visiting friends, relatives, etc)?
(Tick ONE box only)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
SF-12v2(tm) Health Survey (c) 2000 by QualityMetric Incorporated - All rights reserved
SF-12v2(tm) is a trademark of QualityMetric Incorporated
SECTION G – SEXUAL MATTERS
We would also like to find out about your sexual function and activity. When you answer these questions, please
think about how you have been in the LAST 4 WEEKS.
You do not have to answer any question if you do not want to.
G1 Do you get erections? (Tick ONE box only)
Yes, with normal stiffness
Yes, with reduced stiffness
Yes, with severely reduced stiffness
No, erection not possible
G1a If you have a problem with erection, how much does this bother you?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
G2 Do you ejaculate? (Tick ONE box only)
Yes, normal quantity of semen
Yes, but reduced quantity of semen
Yes, but significantly reduced quantity of semen
Yes, but no semen comes out
No ejaculation
G2a If you have a problem with ejaculation, how much does this bother you?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
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When you answer these questions, please think about how you have been in the LAST 4 WEEKS.
G3 Do you have pain or discomfort during ejaculation? (Tick ONE box only)
No pain or discomfort
Yes, slight pain or discomfort
Yes, moderate pain or discomfort
Yes, severe pain or discomfort
G3a If you have pain or discomfort, how much does this bother you?
Please choose a number between 0 (not at all) and 10 (a great deal)
(Tick ONE box only)
Not at all 0123456789 10 A great deal
G4 Have you taken any medications for sexual problems?
Yes No
G5 Have you used a vacuum device for sexual problems?
Yes No
G6 Do you have an active sex life (with or without a partner)?
Yes Go to G8 No Go to G9
G7 Do you leak urine during sex?
Yes No Don’t Know
G8 Has your sex life changed compared with before your prostate operation one year ago?
(Tick ONE box only)
It has stayed the same
It is better
It is worse
Now go to Section H
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When you answer these questions, please think about how you have been, in the LAST 4 WEEKS.)
G9 If you DO NOT have an active sex life, is this for any of these reasons?
(Please tick ALL boxes that apply)
Because of my urinary symptoms
Because of my bowel symptoms
Because of my prostate operation
Because of medical treatment (e.g. drugs or medication)
For another reason
SECTION H – FINALLY…
H1 How satisfied were you with the treatment you received for leaking urine since your prostate
operation?
Please choose a number between 0 (very unsatisfied) and 10 (very satisfied)
(Tick ONE box only)
Very Very
unsatisfied 0123456789 10 satisfied
H2 Do you have any other comments about the MAPS Study, or the care you have received
for leaking urine?
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DD MM YY Y Y
Date you filled in this questionnaire //
DD MM YY Y Y
Your date of birth //
THANKYOU
Thank you very much for your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us carry out research
into men’s health after prostate surgery.
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen
in the envelope provided.
Please could you confirm your
phone number:
Thank you again for your help
If you would like any further information or have any queries about the study, please contact:
The MAPS Study Office in Aberdeen (Tel: 01224 551103)
This study is taking place in centres across the UK but the questionnaires are being processed in Aberdeen
at the Health Services Research Unit, Polwarth Building, Foresterhill, ABERDEEN, AB25 2ZD.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Appendix 3.4  MAPS participants’ cost questionnaire
Study Number
CONFIDENTIAL
MAPS TRIAL
MEN’S HEALTH
AFTER PROSTATE SURGERY
Thank you for helping us with our research into urinary incontinence after prostate surgery.
We would be very grateful if you could complete and return this questionnaire.
Thank you for taking the time to help us with our research.
Participant Costs Questionnaire
Men After Prostate Surgery
MAPS
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ISRCTN: 87696430
Version 1 February 2005220 Appendix 3
This questionnaire will help us to find out how much it costs you to use health
services. We wish to ask about your most recent admission to hospital,
your most recent outpatient appointment and your most recent
appointment with a GP. We wish to know how much money and time were
spent by you and any companion in attending these appointments and as a
result of any hospital admission you may have had.
It may have been a long time ago and we understand that you are unlikely
to remember the exact details. Please just give us your best guess.
If you have a problem in answering any question
please telephone the MAPS Study Office on 01224 551103.
Please return the questionnaire in the enclosed pre-paid envelope.
HOW TO FILL IN THIS QUESTIONNAIRE
Most questions can be answered by putting numbers or a tick in the appropriate box or boxes. Please print
your answers carefully within the boxes like this:
27 O RM IKEO R ￿
If you make a mistake, shade out the wrong box completely and tick the correct one like this
e.g. If you ticked often but meant to answer sometimes:
OFTEN ￿ SOMETIMES ￿ NEVER
Please try to complete the whole questionnaire.
There are no right or wrong answers.
Sometimes the box you tick tells you to skip forward so that you miss out questions which do not apply to
you.
In some questions we would like you to think about different time periods, such as during the last week,
during the last 4 weeks or since your prostate operation. Please check the time periods carefully.
Some of the questions ask for answers in your own words, please write these in the boxes provided.
You do not have to answer any question if you do not want to.
Thank you for your help.
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SECTION A -YOUR MOST RECENT ADMISSION TO HOSPITAL
If you were NOT admitted to hospital in the last 12 months, please go to SECTION B
A1 How did you travel to hospital?
If you used more than one form of transport please indicate the way you travelled for the main (longest in terms
of distance) part of your journey. Please tick the box that best describes how you travelled.
Bus Taxi Ambulance
Train Hospital car Private car
Other (please specify)
A2 If you travelled by bus, train or taxi to hospital, what was the total cost of the (one-way) journey?
Please write the cost in the box below. Please put zero if you did not travel by bus, train or taxi at all or if you
did not pay a fare.
Cost of (one-way) fare (£) - pence
A3 If you travelled by private car, about how many miles did you travel one-way?
Please write the number of miles in the box below. Please put zero if you did not travel by private car at all.
Number of miles one-way
A4 If you travelled by private car and you or your companion had to pay a parking fee, how much did this
cost? Please write the cost in the box below. Please put zero if you did not pay for parking.
Cost of parking fee (£) - pence
A5 When you were admitted to the hospital, how long did you spend there?
Please write the number of days in the box below.
Number of days
A6 What would you otherwise have been doing as your main activity if you had not had to be admitted to
hospital? Please tick the box that best applies to you.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
A7 When you were admitted to hospital, did anyone come with you? Please tick one box only.
Yes Go to A8 No Go to Section B
Study Number 3 Participant Costs Questionnaire222 Appendix 3
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A8 Who came with you to the hospital?
Please tick the box that best describes the main person who accompanied you to the hospital.
Partner/spouse Paid caregiver Other relative Friend
Other (please specify)
A9 What would your main companion otherwise have been doing as their main activity if they had not gone
with you to the hospital? Please tick the box that best applies.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
A10 Did your main companion take time off from paid work (or business activity if self-employed)?
Please tick one box only.
Yes Go to A11 No Go to Section B
A11 Please write the number of hours you companion took off from paid work (or business activity if self-
employed) in the box below. Please put zero if your main companion did not take time off from paid work (or
business) to accompany you to the hospital.
Number of hours
A12 While you were in hospital, approximately how many times did your main companion come to visit you?
Number of times
SECTION B -YOUR MOST RECENT OUTPATIENT VISIT
If you did not have an outpatient visit in the last 12 months, please go to Section C
B1 How did you travel to the Outpatient Department?
If you used more than one form of transport please indicate the way you travelled for the main (longest in terms
of distance) part of your journey. Please tick the box that best describes how you travelled.
Bus Taxi Ambulance
Train Hospital car Private car
Other (please specify)
B2 If you travelled by bus, taxi or train to hospital, what was the total cost of the (one-way) journey?
Please write the cost in the box below. Please put zero if you did not travel by bus, train or taxi at all or if you
did not pay a fare.
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B3 If you travelled by private car, about how many miles did you travel one-way?
Please write the number of miles in the box below. Please put zero if you did not travel by private car at all.
Number of miles one-way
B4 If you travelled by private car and you or your companion had to pay a parking fee, how much did this
cost? Please write the cost in the box below. Please put zero if you did not pay for parking.
Cost of parking fee (£) - pence
B5 When you visited outpatients, how long did it take to travel there?
Please write the number of hours and minutes in the box below.
Number of hours - minutes
B6 When you visited outpatients, how long did you spend there?
Please write the number of hours and minutes in the box below.
Number of hours - minutes
B7 What would you have otherwise been doing as your main activity if you had not been visiting
outpatients? Please tick the box that best applies to you.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
B8 When you visited outpatients, did anyone come with you? Please tick one box only.
Yes Go to B9 No Go to Section C
B9 Who came with you to outpatients?
Please tick the box that best describes the main person who accompanied you to outpatients.
Partner/spouse Paid caregiver Other relative Friend
Other (please specify)
B10 If your main companion travelled with you by bus or train, approximately how much did they pay (one-
way) in fares? Please write the approximate cost in the box below. Please put zero if your main companion
did not travel by bus or train at all.
Cost of (one-way) fare (£) - pence
B11 What would your main companion otherwise have been doing as their main activity if they had not gone
with you to outpatients? Please tick the box that best applies.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
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SECTION C -YOUR MOST RECENT GP APPOINTMENT
If you did not visit your GP in the last 12 months, please go to C12.
C1 How did you travel to your GP’s surgery?
If you used more than one form of transport please indicate the way you travelled for the main (longest in terms
of distance) part of your journey. Please tick the box that best describes how you travelled.
Walked Private car Taxi
Cycled Bus
Other (please specify)
C2 If you travelled by bus or taxi, what was the cost of the (one-way) fare? Please write the cost in the box
below. Please put zero if you did not travel by bus or taxi or if you did not pay a fare.
Cost of (one-way) fare (£) - pence
C3 If you travelled by private car, how many miles did you travel one-way?
Please write the number of miles in the box below. Please put zero if you did not travel by private car at all.
Number of miles one-way
C4 If you travelled by private car and you or a companion had to pay a parking fee, how much did this
cost? Please write the cost in the box below. Please put zero if you did not pay for parking.
Expenditure on parking fee (£) - pence
C5 When you visited your GP, how long did it take to travel there?
Please write the number of minutes in the box below.
Number of minutes
C6 When you visited your GP, how long did you spend there?
Please write the number of minutes in the box below. Please include in your answer the time spent waiting and
also the time spent with the doctors and nurses.
Number of minutes
C7 What would you otherwise have been doing as your main activity if you had not visited your GP?
Please tick the box that best applies to you.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
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C8 When you visited your GP did anyone come with you? Please tick one box only.
Yes Go to C9 No P.T.O. to back page
C9 Who came with you to your GP?
Please tick the box(es) that best describe the person(s) who accompanied you to your GP's surgery.
You may tick more than one box if appropriate.
Partner/spouse Paid caregiver Other relative Friend
Other (please specify)
C10 If your main companion travelled with you by bus, how much approximately did they pay (one-way) in
fares?
Please write the cost in the box below. Please put zero if your main companion did not travel by bus at all.
Cost of (one-way) fare (£) - pence
C11 What would your main companion otherwise have been doing as their main activity if they had not gone
with you to your GP's surgery? Please tick the box that best applies.
Housework Unemployed Leisure activities Childcare
Paid work Caring for a relative or friend Voluntary work
Other (please specify)
C12 If you wish to provide any further information please do so here.
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THANKYOU
Thank you very much for your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful
in helping us carry out research into men’s health after prostate surgery.
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen
in the envelope provided.
Please could you confirm your
phone number:
Thank you again for your help
If you would like any further information
or have any queries about the study, please contact:
The MAPS Study Office in Aberdeen (Tel: 01224 551103)
This study is taking place in centres across the UK but the questionnaires are being processed in Aberdeen
at the Health Services Research Unit, University of Aberdeen, Foresterhill, ABERDEEN, AB25 2ZD.
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Appendix 3.5  MAPS urinary diary
Time Day 1 Night 1
Mark with cross each time XXXXX XX
you go to toilet to pass urine X
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small X
Moderate X
Large
Pad X
Clothing X
Bedding X
Time Day 3 Night 3
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
Urinary Diary
Please keep this diary to record how your bladder is functioning.
Please could you fill in the diary for the NEXT 3 DAYS.
Please mark a cross in the appropriate box for every time you:
• Go to the toilet to pass urine,
• Leak urine (show if it was a small, moderate or large amount),
• Change your pad, clothing or bedding due to leaking urine.
The number of crosses in each box will show how often each event
occurred either during the day or after you have gone to bed at
night.
For example, if you went to the toilet to pass urine 6 times during
the day, but also leaked a moderate amount and changed your pad
once; woke twice at night to go to the toilet to pass urine; leaked a
small amount at night and changed your pyjamas and bedding, you
would enter:
Thank you very much for filling in this diary.
Please return it in the stamped addressed envelope enclosed,
along with your questionnaire, to the MAPS study office.
Version 1 March 2005
Men After Prostate Surgery
MAPS Study Number
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Time Day 1 Night 1
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
Time Day 2 Night 2
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
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Time Day 1 Night 1
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
Time Day 2 Night 2
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
Date today_____________________________ Date today_____________________________230 Appendix 3
Time Day 1 Night 1
Mark with cross each time XXXXX XX
you go to toilet to pass urine X
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small X
Moderate X
Large
Pad X
Clothing X
Bedding X
Time Day 3 Night 3
Mark with cross each time
you go to toilet to pass urine
Mark with cross
each time you
leak urine (small,
moderate or
large amount)
Mark with cross
each time you
change pads,
clothing or
bedding because
they are wet
Small
Moderate
Large
Pad
Clothing
Bedding
Urinary Diary
Please keep this diary to record how your bladder is functioning.
Please could you fill in the diary for the NEXT 3 DAYS.
Please mark a cross in the appropriate box for every time you:
• Go to the toilet to pass urine,
• Leak urine (show if it was a small, moderate or large amount),
• Change your pad, clothing or bedding due to leaking urine.
The number of crosses in each box will show how often each event
occurred either during the day or after you have gone to bed at
night.
For example, if you went to the toilet to pass urine 6 times during
the day, but also leaked a moderate amount and changed your pad
once; woke twice at night to go to the toilet to pass urine; leaked a
small amount at night and changed your pyjamas and bedding, you
would enter:
Thank you very much for filling in this diary.
Please return it in the stamped addressed envelope enclosed,
along with your questionnaire, to the MAPS study office.
Version 1 March 2005
Men After Prostate Surgery
MAPS Study Number
Date today_____________________________© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 4  
Therapy documentation and 
participants’ advice leaflets232 Appendix 4
Appendix 4.1  Therapy documentation used during therapy 
appointments
MAPS No:  1 RADICAL – Therapy Documentation 
Version 1 February 2005               1
Date:
Urinary Incontinence in Men After Prostate Surgery (MAPS)
Assessment at First visit
Unit No:
Patient Details
Name Date of Birth: 1 9
Address
Telephone No Occupation
Hobbies & activities:
Consultant GP
Surgical History Yes No
Radical Date: Previous TURP
Complications of recent prostate surgery.
Other relevant surgical history
Medical history Yes No Yes No
Cystitis / UTI (Acute) Cough /chest problems
Cystitis / UTI (Chronic) Smoker
Latex allergy Neurological disease (please give details)
Other medical problems (heart, BP, 
diabetes etc) 
(details)
Medication / drugs
Body Mass Measurements (if blank, please fill in)
Height Metres OR Feet Inches
Weight Kilograms OR Stones Pounds© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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MAPS No:  1 RADICAL – Therapy Documentation 
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Visit No. 1st X 2nd 3rd 4th Date:
Name of Therapist
Physiotherapist Continence Nurse Other Nurse
HISTORY
Yes No Comments
Did urine leak BEFORE prostate surgery?
If Yes, type of incontinence and amount BEFORE prostate surgery
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*
Urinary incontinence symptoms NOW (in last week)
   If incontinent, amount?
Yes No Small Moderate Large
Any urinary incontinence 
Frequency of incontinence (tick one box only)
never two or three times a week several times a day
about once a week or less often about once a day all the time
Overall, how much does leaking urine interfere with everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
Not at all 01234 56789 10 A great deal
Type of incontinence and amount NOW (in last week)
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*234 Appendix 4
MAPS No:  1 RADICAL – Therapy Documentation 
Version 1 February 2005               3
Visit No. 1st X 2nd 3rd 4th
Other Symptoms Yes No
Sensation when bladder is full? Comments
Sensation when urine is leaking?
Use of external sheath catheter
Use of penile clamp
Pain passing urine (dysuria)
Urinary frequency by day (enter no. of 
urinations)
Comments
Nocturia (enter no. of times up at night)
Number of pads used during day 
Number of pads used at night
Use of other aids (eg chair pads, bed pads, mattress protectors etc) (please give brief details)
Bowel problems NOW (in last week) Yes No Yes No
Faecal incontinence Irritable bowel syndrome
Faecal urgency Ulcerative colitis
Faecal incontinence WITH urgency Crohn’s disease
Faecal incontinence WITHOUT urgency Constipation
Comments
Sexual problems NOW (in last week) Yes No
Difficulty gaining erection now
Difficulty maintaining erection now
Premature ejaculation now
Nocturnal erection now
Ability to achieve an erection BEFORE prostate surgery
Comments© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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MAPS No:  1 RADICAL – Therapy Documentation 
Version 1 February 2005               4
Visit No. 1st X 2nd 3rd 4th
EXAMINATION
Informed consent to examination obtained Yes
Chaperone Accepted
Declined
Relationship of chaperone:
External examination
(in crook lying, i.e. supine, knees bent and separated, feet apart, with paper towel over the pelvis)
Yes No
Evidence of skin damage (excoriation/ ulcers) (penis, perineum, anal area)
Evidence of infection of skin
Able to tighten anus
Able to perform penile retraction and testicular lift
Leakage on coughing
Able to prevent leakage on coughing
Comments
Dermatomes Left Right
Normal Abnormal Normal Abnormal
S 2 Lateral buttocks and thigh, posterior calf and plantar heel
S 3 upper two-thirds of medial thigh
S 4 Penis and perineal area
Comments236 Appendix 4
MAPS No:  1 RADICAL – Therapy Documentation 
Version 1 February 2005               5
Visit No. 1st X 2nd 3rd 4th
Digital anal examination
1. External anal sphincter (insert finger to first joint)
Strength of contraction of external anal sphincter (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Anal sphincter endurance (enter number of seconds)
Yes No
Able to contract anal sphincter quickly
2. Puborectalis muscle (insert finger to second joint)
Strength of contraction of puborectalis muscle  (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Puborectalis muscle endurance (enter number of seconds)
Yes No
Able to contract puborectalis muscle quickly
If digital anal examination is not performed, please give reason:
Biofeedback
Yes No
Biofeedback is available in this centre 
Biofeedback is clinically indicated for this man
This man has had biofeedback
If biofeedback is used:
Either:   Anal pressure biofeedback
Maximum reading in cm H2O from best of 3 contractions   
Or:  EMG with anuform probe
Maximum reading in V from best of 3 contractions © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Summary of Management
Diagnoses Yes No
1 Stress urinary incontinence
2 Urge urinary incontinence   
3 Post micturition dribble
4 Faecal incontinence
5 Erectile dysfunction (unable to gain or maintain erection)
6 Other diagnoses (please give details)
Treatment Yes No
1 Given and explained PFMT leaflet
2 Number of seconds agreed with man to hold contraction (also enter in leaflet)
3 Given (or has got) and explained Lifestyles Advice Leaflet   
4 3 sets of contractions in three positions twice a day
5 Lift (tighten) pelvic floor muscles before exertion (eg coughing, lifting, rising from sitting)
6 Lift (tighten) pelvic floor muscles 50% while walking
7 Lift (tighten) pelvic floor muscles after urinating (to squeeze out last drops)
8 Lift (tighten) pelvic floor muscles during sexual activity
9 Urge suppression techniques (bladder training) 
10 Other treatment (please give details)
Advice
Plan Make appointment in two weeks
Questions for next time
Medication/other treatment for urinary incontinence or sexual problems?
At the end of the session, ask the man if he has any pain anywhere as a result of the examination.  If 
so, document it and if it is severe or it does not resolve advise him to see his GP.  Also remind man to 
keep his travel receipts.
Signed:238 Appendix 4
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Visit No. 1st 2nd X 3rd 4th Date:
Name of Therapist
Physiotherapist Continence Nurse Other Nurse
HISTORY
Yes No Comments
Did urine leak BEFORE prostate surgery?
If Yes, type of incontinence and amount BEFORE prostate surgery
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*
Urinary incontinence symptoms NOW (in last week)
   If incontinent, amount?
Yes No Small Moderate Large
Any urinary incontinence 
Frequency of incontinence (tick one box only)
never two or three times a week several times a day
about once a week or less often about once a day all the time
Overall, how much does leaking urine interfere with everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
Not at all 01234 56789 10 A great deal
Type of incontinence and amount NOW (in last week)
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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MAPS No:  1 RADICAL – Therapy Documentation 
Version 1 February 2005               8
Visit No. 1st 2nd X 3rd 4th
Other Symptoms Yes No
Sensation when bladder is full? Comments
Sensation when urine is leaking?
Use of external sheath catheter
Use of penile clamp
Pain passing urine (dysuria)
Urinary frequency by day (enter no. of 
urinations)
Comments
Nocturia (enter no. of times up at night)
Number of pads used during day 
Number of pads used at night
Use of other aids (eg chair pads, bed pads, mattress protectors etc) (please give brief details)
Bowel problems NOW (in last week) Yes No Yes No
Faecal incontinence Irritable bowel syndrome
Faecal urgency Ulcerative colitis
Faecal incontinence WITH urgency Crohn’s disease
Faecal incontinence WITHOUT urgency Constipation
Comments
Sexual problems NOW (in last week) Yes No
Difficulty gaining erection now
Difficulty maintaining erection now
Premature ejaculation now
Nocturnal erection
Ability to achieve an erection BEFORE prostate surgery
Comments240 Appendix 4
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Visit No. 1st 2nd X 3rd 4th
EXAMINATION
Informed consent to examination obtained Yes
Chaperone Accepted
Declined
Relationship of chaperone:
External examination
(in crook lying, i.e. supine, knees bent and separated, feet apart, with paper towel over the pelvis)
Yes No
Evidence of skin damage (excoriation/ ulcers) (penis, perineum, anal area)
Evidence of infection of skin
Able to tighten anus
Able to perform penile retraction and testicular lift
Leakage on coughing
Able to prevent leakage on coughing
Comments
Dermatomes Left Right
Normal Abnormal Normal Abnormal
S 2 Lateral buttocks and thigh, posterior calf and plantar heel
S 3 upper two-thirds of medial thigh
S 4 Penis and perineal area
Comments© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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MAPS No:  1 RADICAL – Therapy Documentation 
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Visit No. 1st 2nd X 3rd 4th
Digital anal examination
1. External anal sphincter (insert finger to first joint)
Strength of contraction of external anal sphincter (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Anal sphincter endurance (enter number of seconds)
Yes No
Able to contract anal sphincter quickly
2. Puborectalis muscle (insert finger to second joint)
Strength of contraction of puborectalis muscle  (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Puborectalis muscle endurance (enter number of seconds)
Yes No
Able to contract puborectalis muscle quickly
If digital anal examination is not performed, please give reason:
Biofeedback
Yes No
Biofeedback is available in this centre 
Biofeedback is clinically indicated for this man
This man has had biofeedback
If biofeedback is used:
Either:   Anal pressure biofeedback
Maximum reading in cm H2O from best of 3 contractions   
Or:  EMG with anuform probe
Maximum reading in V from best of 3 contractions 242 Appendix 4
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Version 1 February 2005               11
Summary of Management
Diagnoses Yes No
1 Stress urinary incontinence
2 Urge urinary incontinence   
3 Post micturition dribble
4 Faecal incontinence
5 Erectile dysfunction (unable to gain or maintain erection)
6 Other diagnoses (please give details)
Treatment Yes No
1 Given and explained PFMT leaflet
2 Number of seconds agreed with man to hold contraction (also enter in leaflet)
3 Given (or has got) and explained Lifestyles Advice Leaflet   
4 3 sets of contractions in three positions twice a day
5 Lift (tighten) pelvic floor muscles before exertion (eg coughing, lifting, rising from sitting)
6 Lift (tighten) pelvic floor muscles 50% while walking
7 Lift (tighten) pelvic floor muscles after urinating (to squeeze out last drops)
8 Lift (tighten) pelvic floor muscles during sexual activity
9 Urge suppression techniques (bladder training) 
10 Other treatment (please give details)
Advice
Plan Make appointment in four weeks
Questions for next time
Medication/other treatment for urinary incontinence or sexual problems?
At the end of the session, ask the man if he has any pain anywhere as a result of the examination.  If 
so, document it and if it is severe or it does not resolve advise him to see his GP.  Also remind man to 
keep his travel receipts.
Signed:© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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MAPS No:  1 RADICAL – Therapy Documentation 
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Visit No. 1st 2nd 3rd X 4th Date:
Name of Therapist
Physiotherapist Continence Nurse Other Nurse
HISTORY
Yes No Comments
Did urine leak BEFORE prostate surgery?
If Yes, type of incontinence and amount BEFORE prostate surgery
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*
Urinary incontinence symptoms NOW (in last week)
   If incontinent, amount?
Yes No Small Moderate Large
Any urinary incontinence 
Frequency of incontinence (tick one box only)
never two or three times a week several times a day
about once a week or less often about once a day all the time
Overall, how much does leaking urine interfere with everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
Not at all 01234 56789 10 A great deal
Type of incontinence and amount NOW (in last week)
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*244 Appendix 4
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Visit No. 1st 2nd 3rd X 4th
Other Symptoms Yes No
Sensation when bladder is full? Comments
Sensation when urine is leaking?
Use of external sheath catheter
Use of penile clamp
Pain passing urine (dysuria)
Urinary frequency by day (enter no. of 
urinations)
Comments
Nocturia (enter no. of times up at night)
Number of pads used during day 
Number of pads used at night
Use of other aids (eg chair pads, bed pads, mattress protectors etc) (please give details)
Bowel problems NOW (in last week) Yes No Yes No
Faecal incontinence Irritable bowel syndrome
Faecal urgency Ulcerative colitis
Faecal incontinence WITH urgency Crohn’s disease
Faecal incontinence WITHOUT urgency Constipation
Comments
Sexual problems NOW (in last week) Yes No
Difficulty gaining erection now
Difficulty maintaining erection now
Premature ejaculation now
Nocturnal erection now
Ability to achieve an erection BEFORE prostate surgery
Comments© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Visit No. 1st 2nd 3rd X 4th
EXAMINATION
Informed consent to examination obtained Yes
Chaperone Accepted
Declined
Relationship of chaperone:
External examination
(in crook lying, i.e. supine, knees bent and separated, feet apart, with paper towel over the pelvis)
Yes No
Evidence of skin damage (excoriation/ ulcers) (penis, perineum, anal area)
Evidence of infection of skin
Able to tighten anus
Able to perform penile retraction and testicular lift
Leakage on coughing
Able to prevent leakage on coughing
Comments
Dermatomes Left Right
Normal Abnormal Normal Abnormal
S 2 Lateral buttocks and thigh, posterior calf and plantar heel
S 3 upper two-thirds of medial thigh
S 4 Penis and perineal area
Comments246 Appendix 4
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Visit No. 1st 2nd 3rd X 4th
Digital anal examination
1. External anal sphincter (insert finger to first joint)
Strength of contraction of external anal sphincter (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Anal sphincter endurance (enter number of seconds)
Yes No
Able to contract anal sphincter quickly
2. Puborectalis muscle (insert finger to second joint)
Strength of contraction of puborectalis muscle  (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Puborectalis muscle endurance (enter number of seconds)
Yes No
Able to contract puborectalis muscle quickly
If digital anal examination is not performed, please give reason:
Biofeedback
Yes No
Biofeedback is available in this centre 
Biofeedback is clinically indicated for this man
This man has had biofeedback
If biofeedback is used:
Either:   Anal pressure biofeedback
Maximum reading in cm H2O from best of 3 contractions 
Or:  EMG with anuform probe
Maximum reading in V from best of 3 contractions © Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Summary of Management
Diagnoses Yes No
1 Stress urinary incontinence
2 Urge urinary incontinence   
3 Post micturition dribble
4 Faecal incontinence
5 Erectile dysfunction (unable to gain or maintain erection)
6 Other diagnoses (please give details)
Treatment Yes No
1 Given and explained PFMT leaflet
2 Number of seconds agreed with man to hold contraction (also enter in leaflet)
3 Given (or has got) and explained Lifestyles Advice Leaflet   
4 3 sets of contractions in three positions twice a day
5 Lift (tighten) pelvic floor muscles before exertion (eg coughing, lifting, rising from sitting)
6 Lift (tighten) pelvic floor muscles 50% while walking
7 Lift (tighten) pelvic floor muscles after urinating (to squeeze out last drops)
8 Lift (tighten) pelvic floor muscles during sexual activity
9 Urge suppression techniques (bladder training) 
10 Other treatment (please give details)
Advice
Plan Make appointment in six weeks
Questions for next time
Medication/other treatment for urinary incontinence or sexual problems?
At the end of the session, ask the man if he has any pain anywhere as a result of the examination.  If 
so, document it and if it is severe or it does not resolve advise him to see his GP.  Also remind man to 
keep his travel receipts.
Signed:248 Appendix 4
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Visit No. 1st 2nd 3rd 4th X Date:
Name of Therapist
Physiotherapist Continence Nurse Other Nurse
HISTORY
Yes No Comments
Did urine leak BEFORE prostate surgery?
If Yes, type of incontinence and amount BEFORE prostate surgery 
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*
Urinary incontinence symptoms NOW (in last week)
   If incontinent, amount?
Yes No Small Moderate Large
Any urinary incontinence 
Frequency of incontinence (tick one box only)
never two or three times a week several times a day
about once a week or less often about once a day all the time
Overall, how much does leaking urine interfere with everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
Not at all 01234 56789 10 A great deal
Type of incontinence and amount NOW (in last week)
Yes No Small Moderate Large * If other incontinence please give details
Stress incontinence 
Urgency
Urge incontinence
Post micturition dribble
Incontinence at other times*© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Visit No. 1st 2nd 3rd 4th X
Other Symptoms Yes No
Sensation when bladder is full? Comments
Sensation when urine is leaking?
Use of external sheath catheter
Use of penile clamp
Pain passing urine (dysuria)
Urinary frequency by day (enter no. of 
urinations)
Comments
Nocturia (enter no. of times up at night)
Number of pads used during day 
Number of pads used at night
Use of other aids (eg chair pads, bed pads, mattress protectors etc) (please give brief details)
Bowel problems NOW (in last week) Yes No Yes No
Faecal incontinence Irritable bowel syndrome
Faecal urgency Ulcerative colitis
Faecal incontinence WITH urgency Crohn’s disease
Faecal incontinence WITHOUT urgency Constipation
Comments
Sexual problems NOW (in last week) Yes No
Difficulty gaining erection now
Difficulty maintaining erection now
Premature ejaculation now
Nocturnal erection now
Ability to gain and maintain an erection BEFORE prostate surgery
Comments250 Appendix 4
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Visit No. 1st 2nd 3rd 4th X
EXAMINATION
Informed consent to examination obtained Yes
Chaperone Accepted
Declined
Relationship of chaperone:
External examination
(in crook lying, i.e. supine, knees bent and separated, feet apart, with paper towel over the pelvis)
Yes No
Evidence of skin damage (excoriation/ ulcers) (penis, perineum, anal area)
Evidence of infection of skin
Able to tighten anus
Able to perform penile retraction and testicular lift
Leakage on coughing
Able to prevent leakage on coughing
Comments
Dermatomes Left Right
Normal Abnormal Normal Abnormal
S 2 Lateral buttocks and thigh, posterior calf and plantar heel
S 3 upper two-thirds of medial thigh
S 4 Penis and perineal area
Comments© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Visit No. 1st 2nd 3rd 4th X
Digital anal examination
1. External anal sphincter (insert finger to first joint)
Strength of contraction of external anal sphincter (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Anal sphincter endurance (enter number of seconds)
Yes No
Able to contract anal sphincter quickly
2. Puborectalis muscle (insert finger to second joint)
Strength of contraction of puborectalis muscle  (tick one only)
0 (no flicker) 3 (moderate movement) 6 (very strong, unable to withdraw finger)
1 (flicker) 4 (good resistance)
2 (weak) 5 (strong resistance)
Puborectalis muscle endurance (enter number of seconds)
Yes No
Able to contract puborectalis muscle quickly
If digital anal examination is not performed, please give reason:
Biofeedback
Yes No
Biofeedback is available in this centre 
Biofeedback is clinically indicated for this man
This man has had biofeedback
If biofeedback is used:
Either:   Anal pressure biofeedback
Maximum reading in cm H2O from best of 3 contractions   
Or:  EMG with anuform probe
Maximum reading in V from best of 3 contractions 252 Appendix 4
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Summary of Management
Diagnoses Yes No
1 Stress urinary incontinence
2 Urge urinary incontinence   
3 Post micturition dribble
4 Faecal incontinence
5 Erectile dysfunction (unable to gain or maintain erection)
6 Other diagnoses (please give details)
Treatment Yes No
1 Given and explained PFMT leaflet
2 Number of seconds agreed with man to hold contraction (also enter in leaflet)
3 Given (or has got) and explained Lifestyles Advice Leaflet   
4 3 sets of contractions in three positions twice a day
5 Lift (tighten) pelvic floor muscles before exertion (eg coughing, lifting, rising from sitting)
6 Lift (tighten) pelvic floor muscles 50% while walking
7 Lift (tighten) pelvic floor muscles after urinating (to squeeze out last drops)
8 Lift (tighten) pelvic floor muscles during sexual activity
9 Urge suppression techniques (bladder training) 
10 Other treatment (please give details)
Advice
Plan
At the end of the session, ask the man if he has any pain anywhere as a result of the examination.  If 
so, document it and if it is severe or it does not resolve advise him to see his GP.  Also remind man to 
keep his travel receipts.
As this is your patient’s last visit, please advise him as follows:
 Thank him for his help with the MAPS Study
 If he needs further treatment please contact the MAPS Study Office
 Encourage him to keep doing the exercises for the rest of his life – regularly and forever
Signed:© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 4.2  Lifestyle advice leaflet
Men After Prostate Surgery
MAPS
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
Version 2 February 2005
LIFESTYLE ADVICE LEAFLET
For men taking part in the MAPS Study
Please take time to read this information leaflet and discuss it
with your family and friends if you wish. Do not hesitate to
contact us if there is anything you do not understand
or if you would like more information.
Your notes:254 Appendix 4
Lifestyle advice
Leaking urine is quite common after prostate surgery but usually gets
better with time. It is affected by many sorts of daily activities. This
leaflet contains suggestions for things you could do for yourself which
may help you get better faster. Even small changes may make your
urine symptoms better.
What you drink
It is important to drink enough each day. If you do not drink enough,
it makes your urine too concentrated. This could make bladder
problems worse or cause a urine infection. Try to drink at least six
cups or glasses of fluid during the day. Drinking less in the evening
may reduce the number of times you urinate at night.
Some people find that drinking cranberry juice helps bladder
problems. However, if you are taking warfarin you should not drink
cranberry juice.
Caffeine
Sometimes bladder problems are made worse by caffeine (for
example in coffee, tea and cola drinks). Try reducing your caffeine
intake gradually over three weeks. You could drink water,
decaffeinated coffee, decaffeinated tea, herb tea, fruit juice or milk
instead.
What you eat
Eating a balanced diet is important, including five helpings of fruit or
vegetables a day. Being overweight can put extra pressure on the
bladder.If you are overweight, think about going on a weight reducing
diet.Try to avoid foods that contain lots of fat or sugar.
Constipation
Constipation may make incontinence worse. Straining to empty your
bowel may weaken the muscles which hold the bladder closed.You
can help prevent constipation by eating some food that contains fibre
every day – such as fruit and vegetables, wholemeal bread or brown
rice.
Fitness
Try to take regular exercise and keep as active and mobile as you
can. Regular exercise can include walking, using the stairs,
swimming, cycling or gardening. Drink extra fluids if you exercise a
lot. Taking extra exercise may also help you to lose weight if you are
overweight.
Heavy lifting
Incorrect or heavy lifting can weaken the muscles which hold the
bladder closed.Try to avoid it if you can, or be careful how you lift. If
you cannot avoid heavy lifting, try to lift less often or for shorter
periods of time. Think about what you could do – can you lift two
lighter loads rather than one heavy one?
Chest problems
Coughing can cause you to leak urine by putting extra strain on the
muscles which keep the bladder closed. If you smoke or have chest
problems, you are more likely to cough or have chest infections. Try
to reduce or stop smoking. If you have asthma, bronchitis or hay
fever, you should ensure you are taking the correct treatment. You
could ask your doctor to make sure that your treatment is up to date.
Urine infections
Sometimes a urine infection can make bladder problems worse.
Symptoms of a urine infection are:
• pain or burning while urinating
• fever or chills
• the urine becomes dark, cloudy, blood-stained or begins to smell,
or
• you suddenly start urinating more often than normal for you or in
smaller amounts
If you think you might have a urine infection, you should tell your GP,
who will test your urine and may give you an antibiotic.
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Lifestyle advice
Leaking urine is quite common after prostate surgery but usually gets
better with time. It is affected by many sorts of daily activities. This
leaflet contains suggestions for things you could do for yourself which
may help you get better faster. Even small changes may make your
urine symptoms better.
What you drink
It is important to drink enough each day. If you do not drink enough,
it makes your urine too concentrated. This could make bladder
problems worse or cause a urine infection. Try to drink at least six
cups or glasses of fluid during the day. Drinking less in the evening
may reduce the number of times you urinate at night.
Some people find that drinking cranberry juice helps bladder
problems. However, if you are taking warfarin you should not drink
cranberry juice.
Caffeine
Sometimes bladder problems are made worse by caffeine (for
example in coffee, tea and cola drinks). Try reducing your caffeine
intake gradually over three weeks. You could drink water,
decaffeinated coffee, decaffeinated tea, herb tea, fruit juice or milk
instead.
What you eat
Eating a balanced diet is important, including five helpings of fruit or
vegetables a day. Being overweight can put extra pressure on the
bladder.If you are overweight, think about going on a weight reducing
diet.Try to avoid foods that contain lots of fat or sugar.
Constipation
Constipation may make incontinence worse. Straining to empty your
bowel may weaken the muscles which hold the bladder closed.You
can help prevent constipation by eating some food that contains fibre
every day – such as fruit and vegetables, wholemeal bread or brown
rice.
Fitness
Try to take regular exercise and keep as active and mobile as you
can. Regular exercise can include walking, using the stairs,
swimming, cycling or gardening. Drink extra fluids if you exercise a
lot. Taking extra exercise may also help you to lose weight if you are
overweight.
Heavy lifting
Incorrect or heavy lifting can weaken the muscles which hold the
bladder closed.Try to avoid it if you can, or be careful how you lift. If
you cannot avoid heavy lifting, try to lift less often or for shorter
periods of time. Think about what you could do – can you lift two
lighter loads rather than one heavy one?
Chest problems
Coughing can cause you to leak urine by putting extra strain on the
muscles which keep the bladder closed. If you smoke or have chest
problems, you are more likely to cough or have chest infections. Try
to reduce or stop smoking. If you have asthma, bronchitis or hay
fever, you should ensure you are taking the correct treatment. You
could ask your doctor to make sure that your treatment is up to date.
Urine infections
Sometimes a urine infection can make bladder problems worse.
Symptoms of a urine infection are:
• pain or burning while urinating
• fever or chills
• the urine becomes dark, cloudy, blood-stained or begins to smell,
or
• you suddenly start urinating more often than normal for you or in
smaller amounts
If you think you might have a urine infection, you should tell your GP,
who will test your urine and may give you an antibiotic.
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LIFESTYLE ADVICE LEAFLET
For men taking part in the MAPS Study
Please take time to read this information leaflet and discuss it
with your family and friends if you wish. Do not hesitate to
contact us if there is anything you do not understand
or if you would like more information.
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Appendix 4.3  Pelvic floor exercises for men taking part in the 
MAPS study
Men After Prostate Surgery
MAPS
Suppressing the urge
Some men have a sudden strong urge to urinate and feel they have to
rush to the toilet. They may leak urine after they feel this urge. Most
men can overcome this urge using the following tips.
1 Stay CALM (panic makes things worse)
2 Sit down or stand still for ONE MINUTE until the urge disappears
3 THINK of something to distract your thoughts
4 Try NOT to rush to the toilet when you feel the urge
5 Continue normal activity or visit the toilet once the urge has
disappeared
You are trying to train your bladder to hold more urine. Some people
find that it helps to drink less caffeine (coffee, cola, tea).
With practice you will overcome the urge…and the need to urinate so
often.
Bladder training is a method of controlling the bladder
instead of the bladder controlling you.
Thank you for reading this
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
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PELVIC FLOOR EXERCISES
For men taking part in the MAPS Study
Please take time to read this information leaflet and discuss it
with your therapist if you wish. Do not hesitate to contact us if
there is anything you do not understand
or if you would like more information.258 Appendix 4
The Pelvic Floor
The pelvic floor is made up of muscles which hold the bladder and
bowel in place. The pelvic floor muscles help to stop leaks from the
bladder and bowel.
After prostate surgery some men leak urine. Exercises may help.These
exercises are called PELVIC FLOOR EXERCISES. They may help
prevent urine from leaking.
Pelvic floor exercises
Please practise these exercises (numbered 1 to 3) every day
• one set in the morning, and
• one set in the afternoon or evening
1 Lying down
• Lie on your back with your knees bent, and your feet comfortably
apart on the bed.
• Tighten (contract) your pelvic floor as if you are trying to stop wind
escaping.
• Hold the pelvic floor contraction as strongly as you can.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions lying down. Hold each one for ……
seconds.
2 Sitting
• Sit on a chair with your knees apart.
• Tighten (contract) your pelvic floor as if you are trying to stop wind
escaping.
• Hold the pelvic floor contraction as strongly as you can.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions sitting down. Hold each one for ……
seconds.
3 Standing
• Stand with your feet apart. Tighten your pelvic floor strongly. You
should see the base of your penis move in and your testicles lift.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions while standing. Hold each one for ...…
seconds.
During other activities
• while walking
Tighten your pelvic floor a little while you are walking.
• after urinating
Tighten your pelvic floor strongly to ‘squeeze out’ the last few drops
before leaving the toilet.
• during sexual activity
Tighten your pelvic floor to help keep the penis firm.
Important tip
Tighten your pelvic floor quickly just before and during activities such as:
• coughing
• sneezing
• lifting
• shouting
• rising from sitting.
Do your exercises regularly to keep your pelvic floor strong
Pubic Bone
Prostate
Urethra
Spine
Anus
Pelvic Floor Muscles
Bladder Rectum
Scrotum© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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The Pelvic Floor
The pelvic floor is made up of muscles which hold the bladder and
bowel in place. The pelvic floor muscles help to stop leaks from the
bladder and bowel.
After prostate surgery some men leak urine. Exercises may help.These
exercises are called PELVIC FLOOR EXERCISES. They may help
prevent urine from leaking.
Pelvic floor exercises
Please practise these exercises (numbered 1 to 3) every day
• one set in the morning, and
• one set in the afternoon or evening
1 Lying down
• Lie on your back with your knees bent, and your feet comfortably
apart on the bed.
• Tighten (contract) your pelvic floor as if you are trying to stop wind
escaping.
• Hold the pelvic floor contraction as strongly as you can.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions lying down. Hold each one for ……
seconds.
2 Sitting
• Sit on a chair with your knees apart.
• Tighten (contract) your pelvic floor as if you are trying to stop wind
escaping.
• Hold the pelvic floor contraction as strongly as you can.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions sitting down. Hold each one for ……
seconds.
3 Standing
• Stand with your feet apart. Tighten your pelvic floor strongly. You
should see the base of your penis move in and your testicles lift.
• Try to avoid holding your breath, pulling in your abdomen or tensing
your buttocks.
Perform 3 strong contractions while standing. Hold each one for ...…
seconds.
During other activities
• while walking
Tighten your pelvic floor a little while you are walking.
• after urinating
Tighten your pelvic floor strongly to ‘squeeze out’ the last few drops
before leaving the toilet.
• during sexual activity
Tighten your pelvic floor to help keep the penis firm.
Important tip
Tighten your pelvic floor quickly just before and during activities such as:
• coughing
• sneezing
• lifting
• shouting
• rising from sitting.
Do your exercises regularly to keep your pelvic floor strong
Pubic Bone
Prostate
Urethra
Spine
Anus
Pelvic Floor Muscles
Bladder Rectum
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Suppressing the urge
Some men have a sudden strong urge to urinate and feel they have to
rush to the toilet. They may leak urine after they feel this urge. Most
men can overcome this urge using the following tips.
1 Stay CALM (panic makes things worse)
2 Sit down or stand still for ONE MINUTE until the urge disappears
3 THINK of something to distract your thoughts
4 Try NOT to rush to the toilet when you feel the urge
5 Continue normal activity or visit the toilet once the urge has
disappeared
You are trying to train your bladder to hold more urine. Some people
find that it helps to drink less caffeine (coffee, cola, tea).
With practice you will overcome the urge…and the need to urinate so
often.
Bladder training is a method of controlling the bladder
instead of the bladder controlling you.
Thank you for reading this
MAPS Study Office
Health Services Research Unit
University of Aberdeen
Polwarth Building, Foresterhill
Aberdeen, AB25 2ZD
Tel: 01224 551103
Fax: 01224 554580
Email: maps@abdn.ac.uk
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PELVIC FLOOR EXERCISES
For men taking part in the MAPS Study
Please take time to read this information leaflet and discuss it
with your therapist if you wish. Do not hesitate to contact us if
there is anything you do not understand
or if you would like more information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the 
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Appendix 5  
Health economics
Resource use tables: radical prostatectomy and transurethral 
resection of the prostate
TABLE 88  Satisfaction with treatment for urinary incontinence at 12 months after randomisation: radical prostatectomy
Intervention [mean (SD) n] Control [mean (SD) n]
Mean difference (95% CI), 
p-value
Satisfaction scorea 7.5 (2.7) 175 6.6 (3.3) 158 0.83 (0.19 to 1.48), 0.012
a  0 = ‘very unsatisfied’ to 10 = ‘very satisfied’.262 Appendix 5
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PROTOCOL SUMMARY 
QUESTION ADDRESSED  Does conservative (physical) treatment improve 
urinary incontinence in men who have had prostate 
surgery? 
   
CONSIDERED FOR ENTRY  Men who have urinary incontinence after prostate 
surgery, approached initially when inpatients having 
surgery. 
   
POPULATIONS  1.  Radical 
     Prostatectomy (RP) 
2.  Transurethral 
Resection of                                      
Prostate (TURP) 
   
STUDY ENTRY  Information about all men having prostate surgery 
collected by recruitment officers in centres, sent to 
MAPS Study Office.   
 
Screening postal questionnaire sent from MAPS 
Study Office at 3 weeks after surgery.   
 
Consent to RCT obtained from incontinent men 
after written and oral information, and after 
completing Baseline Questionnaire and Urinary 
Diary.   
   
INTERVENTIONS  Active group attend four treatment sessions during 
3-month period after randomisation (pelvic floor 
muscle training with biofeedback, bladder training) 
Control group do not have active treatment 
Both groups receive Lifestyles Advice Leaflet 
   
OUTCOME ASSESSMENT  Postal questionnaires at 6 and 12 months after 
randomisation 
Urinary diaries (incontinent episodes and pad use) 
and health care utilisation questions at 3, 6, 9 and 
12 months 
   
CO-ORDINATION  Local: by local lead Urologist and Recruitment 
Officer.   
Central: by Study Office in Aberdeen  
(telephone 01224 551103).   
Overall: by the Project Management Group, and 
overseen by the Steering Committee and the Data 
Monitoring Committee.   
   
FUNDING  NHS R&D National Coordinating Centre for Health 
Technology Assessment (NCCHTA).   
Start date:  
Planned finish date:  
Planned reporting date: 
December 2004 
February 2010 
February 2010 
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MAPS PERSONNEL 
 
 
Grant Holders / MAPS Project Management Group 
Cathryn Glazener, Adrian Grant, Grace Dorey, James N’Dow, Suzanne Hagen, 
Katherine Moore, Craig Ramsay, Luke Vale, John Norrie, Brian Buckley, Alison 
McDonald, Gladys McPherson 
 
 
Steering Committee Independent Members 
Chair    Paul Abrams, Urologist, Bristol 
Others   David Torgerson, Economist, York 
    Jane Dixon, Senior Physiotherapist, St Ives, Cambridgeshire 
    John Verrier-Jones, Patient Representative, Bristol 
 
 
Data Monitoring Committee Members 
Chair    Peter Langhorne, Professor of Stroke Care, Glasgow 
Others   Julia Brown, Methodologist, Leeds 
    Thomas McNicholas, Urologist, Stevenage, Herts 
    Chris Norton, Nurse Consultant, Harrow, London 
 
 
MAPS Study Office Team in Aberdeen 
Cathryn Glazener, Alison McDonald, Gladys McPherson, Adrian Grant, James 
N’Dow, John Norrie, Craig Ramsay, Luke Vale, Claire Cochran, Louise Campbell. 
 
Other Information 
 
International Standard Randomised  
Controlled Trial Number (ISRCTN)     ISRCTN87696430 
 
MREC Reference Number      MREC/04/10/01 
 
MREC Version Number      Version 6,  01 07 07 
  
HTA Project Number        03/14/03 
 
Trial Registrations 
 
The NHS HTA Programme website  http://www.hta.nhsweb.nhs.uk/projectdata 
 
The CancerHelp UK website: www.cancerhelp.org.uk 
 
INVOLVE   www.invo.org.uk 
 
National Cancer Research Network Trials Portfolio: NCRN Trial ID  1459 
 
Current Controlled Trials website:  ISRCTN87696430 
 
NIH website:  ClinicalTrials.gov Identifier:  NCT00237029 
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CONSERVATIVE TREATMENT FOR URINARY INCONTINENCE IN MEN AFTER 
PROSTATE SURGERY 
 
Known as MAPS (Men After Prostate Surgery) 
 
Title of trial:  Conservative treatment for urinary incontinence in men after prostate 
surgery (MAPS):  multicentre randomised controlled trial of pelvic 
floor muscle training, biofeedback and bladder training 
 
This protocol describes a major multicentre UK trial to establish whether conservative 
physical treatment delivered personally by a trained health professional results in 
better urinary and other outcomes compared with standard management in men who 
are incontinent after prostate surgery.  The study is designed to be as simple as 
possible both for those participating and for those involved in clinical care.   
 
Recruitment officers in each centre will identify and recruit men undergoing prostate 
surgery and collect descriptive information.  Those who are incontinent will be invited 
to enter a randomised trial of conservative treatment.  They will be followed up at 6 
and 12 months.   
 
1.  THE REASONS FOR THE TRIAL 
 
1.1  The burden of the problem 
Prostate surgery is an iatrogenic cause of male urinary incontinence.  Urinary 
incontinence is defined as the complaint of any involuntary leakage of urine.
1  It is a 
debilitating condition that has a greater effect on quality of life than erectile 
dysfunction (which is another consequence of prostate surgery).
2  The economic 
costs include personal (such as need to use pads or devices, and deleterious effect 
on quality of life) and societal ones (use of health services and need for residential or 
nursing home care).   
 
Based on a population audit of over 3000 men, an estimated 11% of men needed to 
use pads at 3 months after endoscopic resection of prostate.
3  The prevalence of 
urinary incontinence after radical prostatectomy is more widely reported, ranging 
from 5% to 45%, albeit at varying times after operation.
4  Estimates of incontinence 
soon after radical operation are much higher (e.g. 82% in 1013 men
5).  We have 
used estimates of 5% and 50% respectively in calculation of sample sizes (which 
may be conservative, based on data from a feasibility study).   
 
1.2  The decision to test conservative treatment 
A recent Cochrane review has identified that, although conservative treatment based 
on pelvic floor muscle training may be offered to men with urinary incontinence after 
either type of prostate surgery, there is insufficient evidence to evaluate its 
effectiveness, cost-effectiveness and effect on quality of life.
6  Data from three trials 
involving 232 men provided estimates of the effects of pelvic floor muscle training on 
the chance of incontinence after radical prostatectomy at 1 year:  relative risk (RR) 
for incontinence, pelvic floor muscle training plus biofeedback versus control, 0.55, 
95% CI 0.24 to 1.23.
7–9  However, not all of the men included in the trials were 
incontinent at baseline, and the trials were all small.  Thus the data suggest (but do 
not provide conclusive evidence) that conservative treatment may reduce 
incontinence at 1 year after operation.   
 
Data available from these trials suggest that, amongst men incontinent at around 6 
weeks after surgery, about 30% will still be incontinent at 1 year.  The Cochrane 
review therefore suggests that this might be reduced to 15%, and this is the basis for 
the sample size in the proposed trial (70% ‘dry’ increased to 85% ‘dry’). 
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In one small trial of pelvic floor muscle training started before surgery amongst men 
having endoscopic resection of prostate, the RR for incontinence at 4 weeks after 
surgery was 0.31, 95% CI 0.03 to 2.82
10 although again the trial included some men 
who were not incontinent at baseline.  After the first 4 weeks, there were no trial data 
about expected incontinence rates or effect sizes amongst men having endoscopic 
resection of prostate.   
 
1.3  The questions which this study will address 
The following questions will be addressed, primarily in terms of regaining urinary 
continence at 12 months after recruitment: 
 
(a) For men with urinary incontinence 6 weeks after radical prostatectomy, what 
is the clinical and cost-effectiveness of active conservative treatment 
delivered by a specialist continence physiotherapist or a specialist continence 
nurse compared with usual management? 
(b) For men with urinary incontinence 6  weeks after transurethral resection of 
prostate, what is the clinical and cost-effectiveness of active conservative 
treatment delivered by a specialist continence physiotherapist or a specialist 
continence nurse compared with usual management? 
 
The hypothesis being tested in each group of men (in two parallel but separate trials) 
is that active conservative management will increase the proportion of continent men 
by 15% at 1  year after recruitment.  The two groups are being considered 
independently because the rates of incontinence are expected to be different.   
 
2.  TRIAL RECRUITMENT AND ALLOCATION 
2.1  Men considered for trial entry 
The trial will involve men who have urinary incontinence after prostate surgery.  Two 
parallel but separate trials will be conducted, amongst: 
(i)  men having a radical prostatectomy usually for prostate cancer, and 
(ii)  men having a transurethral resection of prostate, usually for benign prostatic 
hypertrophy.   
 
Inclusion criteria: 
•  Urinary incontinence at 6 weeks after prostate surgery (incontinence defined as a 
response indicating a loss of urine to either of two questions in the screening 
questionnaire: ‘how often do you leak urine’ and ‘how much urine do you leak’).   
•  Informed consent.   
•  Ability to comply with intervention.   
 
Exclusion criteria:  
•  Referral for formal therapy (teaching of pelvic floor muscle training) because of 
prostate surgery. 
•  Radiotherapy planned or given during the first 3 months after surgery for men 
with prostate cancer.   
•  Endoscopic resection of prostate carried out as palliation for outflow obstruction 
in advanced prostate cancer.   
•  Inability to complete study questionnaires.   
 
Men with prostate cancer diagnosed at TURP: 
Around 15% of men may be found to have incidental prostate cancer when the 
prostatic chips removed at TURP are examined for pathology.  If he is not going to 
have formal treatment (wait and see policy), he will be eligible for the RCT.   
 
If the cancer is identified before he is randomised and either radiotherapy or radical 
prostatectomy are planned, he will not  be eligible for the RCT (TURP group).   
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eligible to be recruited as a new participant to the Radical group.  He would sign a 
new consent form and be sent a new screening questionnaire.   
 
If the cancer is only diagnosed once he has been randomised, even if radiotherapy or 
radical prostatectomy are planned, he will remain in the group to which he was 
allocated, and be followed up as normal.   
 
The study consists of two stages: Stage 1 (Section 2.2) concerns the screening 
survey used to identify eligible men, and Stage 2 (Section 2.3) the randomised 
controlled trial.   
 
2.2  Screening for postoperative urinary incontinence (Stage 1 of study)  
Potential participants will be identified by Recruitment Officers in each clinical centre 
from amongst all men admitted to the urological ward(s) for prostate surgery.  A log 
will be kept of men meeting the inclusion criteria, describing reasons if they do not 
agree to receive a screening questionnaire (Appendix 1).   
 
Each man will be given the Hospital Patient Information Sheet by the Recruitment 
Officer.  After reading it and having the opportunity to discuss all aspects of the 
study, each man will be asked for his consent to be sent the Screening Questionnaire 
at 3 weeks after surgery.  The patient information sheet, the consent form and the 
questionnaire all refer to the possibility of being contacted about further research if 
the men are willing.  If he agrees, his signed contact details (address, phone number, 
date of birth, Study Number and Hospital Number) will be sent to the Study Office in 
Aberdeen (Appendix I).   
 
The questionnaire (Appendix VI) will be sent to men from the Study Office in 
Aberdeen at 3  weeks after the date of operation (together with a covering letter, 
Appendix II).  A reminder letter will be sent after 2 weeks if there is no response 
(Appendix II).  If the returned questionnaire indicates that a man has urinary 
incontinence, he will be eligible for Stage 2.   
 
2.3  Recruitment to the RCT of conservative treatment (Stage 2, the trial) 
Each man with urinary incontinence will be sent a Patient Information Sheet (PIS, 
Appendix III) by the Study Office in Aberdeen to inform him about the trial.   
 
•  For men who have a phone    
The Aberdeen Recruitment Co-ordinator will send the man a Patient 
Information Sheet (Appendix III)  by post, with a consent form, Baseline 
Questionnaire and Urinary Diary.  About a week after sending the trial 
information and documents, she will contact the man by telephone using a 
Standard Instruction Sheet (Appendix III).  She will ask if he has received the 
Patient Information Sheet, answer any questions or concerns, and ask whether 
he might be interested in entering the trial.  She will explain what would happen 
in the two groups, that allocation would be randomised and what follow-up is 
involved.  If he agrees orally, he  will be asked to complete and return: a 
Consent Form (Appendix III); a Baseline Questionnaire (Appendix VI); and a 
Urinary Diary (Appendix VI).  Optionally, the man may fill in the Baseline 
Questionnaire over the phone but written consent is still required before 
randomisation.   
•  For men who do not have a phone:  
All the documents [the Patient Information Sheet (Appendix III), a Consent 
Form (Appendix III), a Baseline Questionnaire (Appendix VI) and a Urinary 
Diary (Appendix VI)]  will be sent by mail.  The  man will be able to ring a 
helpline (to the Aberdeen Recruitment Officer) if he has any queries.  If he 
decides to enter the trial, he will complete and return the last three documents.   
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The man would keep the Information Sheet and the bottom (fourth) copy of the 
consent form (returning the top three to the Study Office in Aberdeen).   
 
If the three documents are not returned by 3 weeks after posting (no phone contact), 
or 2 weeks after oral consent was given over the phone, men will be sent a postal 
reminder with duplicate documentation.  If they are not returned after another 2 
weeks, they will be phoned (if possible) or sent a further reminder letter (if no phone).   
 
Oral Withdrawal Consent will be obtained from men who initially agree to enter the 
trial but later decide to withdraw to enable us to maintain their existing data and 
access NHS data.   
 
2.4  Randomisation and allocation to management group 
When the baseline documents are received, the Aberdeen MAPS Study Office will 
randomise the man to active or standard management.   
 
Randomisation will be by computer allocation using the service that already exists at 
the Health Service Research Unit.  Allocation will be stratified by type of operation 
(radical prostatectomy or transurethral resection of prostate), and minimised using 
centre, age and pre-existing urinary incontinence.   
 
The Study Office will send out an allocation letter to all men with details of their 
allocation (Appendix IV) and the Lifestyle Advice Leaflet (Appendix V).  If the man is 
allocated to the Active Group, the Study Office will arrange for the local Therapist 
(physiotherapist or continence nurse) to send him the necessary appointments (the 
first, for an hour, as soon as possible, followed by a three-quarter-hour appointment 
on three occasions at 2, 6 and 12 weeks) (letter to Therapist, Appendix IV).   
 
A letter and GP Information Sheet (Appendix IV) will be sent to the man’s GP.  A 
copy of the GP letter and the consent form will be sent to the hospital urological 
consultant for filing in the man’s hospital notes.   
 
3.    TRIAL INTERVENTIONS (Appendix V) 
3.1  Intervention arm 
The men in the intervention group will receive a physiotherapist or continence nurse 
assessment of their symptoms at about 6 weeks after surgery.  They will be taught 
pelvic floor muscle training, with bladder training for men with urgency or urge 
incontinence.
11  The men will be taught:  
•  to carry out three maximum pelvic floor contractions in three positions 
(standing, sitting and lying down) twice per day;  
•  to ‘lift’ their pelvic floors while walking;  
•  to tighten their pelvic muscles before activities which may cause them to leak, 
such as coughing;  
•  and to tighten after urinating to ‘squeeze out’ any last drops.   
 
Biofeedback involves monitoring the strength of a pelvic floor contraction (by digital 
anal assessment) and relaying the information back to the men, in order that they 
know when they are performing contractions correctly and to inform them when they 
are increasing the strength or duration of their contractions.  Therapists may use 
machine-mediated biofeedback with an anal biofeedback probe at their clinical 
discretion (if they feel it is clinically indicated) in centres where this is available in 
addition to digital anal assessment.  Bladder training involves gradually delaying 
urination (by pelvic floor muscle contraction and distracting activities) to teach the 
bladder to hold increasing volumes of urine.   
 
The men will also receive a booklet describing pelvic floor muscle training (Pelvic 
Floor Exercise Booklet, Appendix V) in addition to the one giving general lifestyle 
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sessions on three more occasions over 3 months – at around 2 weeks, 6 weeks and 
12 weeks after the first appointment.   
 
Ensuring standardisation of intervention 
All the staff delivering the intervention will receive training to ensure consistency of 
their method of teaching and delivery of the pelvic floor muscle training, bladder 
training and biofeedback.  Both specialist continence physiotherapists and 
continence nurse specialists will be eligible for training, thus extending the 
generalisability of the trial.   
 
The therapists will record their assessments and treatment programmes on standard 
study forms (Appendix V).  Data from these forms will be collected centrally.   
 
3.2  Control arm 
Men in the control group will receive a booklet containing supportive lifestyle advice 
only (without reference to pelvic floor muscle training) by post after randomisation 
(Lifestyle Advice Booklet, Appendix V).  Men will not receive any formal assessment 
or treatment but will be able to access usual care and routine NHS services if they 
feel they need help.  This may include written advice if this is part of routine hospital 
care. 
 
Use of NHS services, use of pads and practice of pelvic floor muscle training will be 
documented in both groups using information from questionnaires and Urinary 
Diaries.  The lifestyle and pelvic floor muscle training booklets will be customised for 
each group.   
 
4.  SUBSEQUENT ARRANGEMENTS 
4.1  Informing key people 
Following formal trial entry, the Study Office will contact: 
i)  The General Practitioner (by letter enclosing an information sheet, with the 
MAPS phone number in case of queries or notifiable events)   
ii)  The Hospital Urologist (by copy of letter sent to GP, and copy of consent form 
for filing in hospital notes) 
 
4.2  Monitoring the men  
Men will be contacted by phone, post or email as appropriate.  In case of non-return 
of questionnaires or diaries, or non-attendance at therapy appointments, attempts will 
be made by staff at the Study Office to trace the men directly using these means or 
indirectly by contacting the therapist, the GP or the ‘Best Contact’.   
 
Notification by GPs 
GPs are asked to phone the Study Office if one of the participants moves, becomes 
too ill to continue or dies, or any other notifiable event or possible adverse effect 
occurs.  Alternatively, staff at the Study Office may contact the GP.   
 
Notification by ‘best contact’ 
If the MAPS Study Office loses touch with a participant (e.g. questionnaires, diaries 
or phone calls not returned), we will try to establish why via the ‘Best Contact’.  Men 
will be asked (in their trial Baseline Questionnaire) to nominate someone, who will be 
informed (Appendix IV).   
 
Flagging at Office for National Statistics 
All men recruited to the RCT will be flagged at the Office for National Statistics for 
notification of death.   
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5.  DATA COLLECTION AND PROCESSING 
Men will be recruited for a median period of 2 years (range 1–3).  Follow-up will 
continue for 15 months from the date of the last operation (allowing 3 months for 
recruitment and 12 months for follow-up after randomisation).  It is not part of this 
protocol or the current study to follow  up the men beyond this time.  However, 
consent will be sought to make this possible in the future.   
 
5.1  Questionnaires (Appendix VI) 
Men will be sent questionnaires at baseline, 6 and 12 months (Appendix VI).  Content 
will include: 
i)  Urinary outcome questions [leakage of urine, amount, effect on QOL 
(http://www.iciq.net/), pad use, catheter use] 
ii)  Bowel function outcome questions
 
iii)  Sexual function   
iv)  Health care utilisation questions 
v)  Exercise, weight and height, including pelvic floor exercises 
vi)  EQ-5D
12  
vii)  SF-12
13 
 
and additionally at baseline only: 
i)  Date of operation, type of operation and reason for operation  
ii)  GP address and phone number 
iii)  ‘Best Contact’ at another address for follow-up (not wife or partner) 
iv)  Other medical problems   
 
and additionally at 6 months only: 
i)  Health Care Unit Cost Questionnaire 
 
and additionally at 12 months only: 
i)  Need for further treatment for incontinence  
ii)  Further treatment for prostate planned? 
 
5.2  Urinary diaries  (Appendix VI) 
Men will be asked to keep diaries at 3, 6, 9 and 12 months, kept for 3 days at each 
time period.  Content will include: 
i)  Frequency of urination (day and night) 
ii)  Daily episodes of incontinence, quantity of loss 
ii)  Daily use of pads, need to change clothing or bedding 
 
and additionally at 3 and 9 months only: 
iii)  Health care utilisation questions (Appendix VI) 
 
5.3  ISD Data (Scotland only) 
At 6 months after the last man has been recruited we will run a check for Scottish 
men only to compare self-reported operations, diagnoses and hospital admissions 
with centrally collected data to validate a proportion of the data.   
 
5.4  Data processing  
Data from the various sources outlined above will be sent to the Study Office in 
Aberdeen for processing.  Staff in the Study Office will work closely with local 
Recruitment Officers to ensure that the data are as complete and accurate as 
possible.  Extensive range and consistency checks will further enhance the quality of 
the data.   
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6.  ANALYSIS PLANS 
 
6.1  Ground rules for the statistical analysis 
The statistical analysis will be based on all men as randomised, irrespective of 
subsequent compliance with the treatment allocated.  The principal comparisons will 
be: 
1.  After radical prostatectomy 
i)  men allocated to active therapy (four visits to therapist plus Lifestyle Advice 
Leaflet), compared with 
ii)  men allocated to control group (Lifestyle Advice Leaflet only) 
 
2.  After transurethral resection of prostate 
i)  men allocated to active therapy (four visits to therapist plus Lifestyle Advice 
Leaflet) , compared with 
ii)  men allocated to control group (Lifestyle Advice Leaflet only) 
 
6.2  Measures of outcome 
The primary clinical outcome is: 
•  Subjective report of urinary continence at 12 months (http://www.iciq.net/) 
 
The primary measure of cost-effectiveness is: 
•  Incremental cost per quality-adjusted life-year 
 
Secondary outcome measures include: 
Clinical 
•  Subjective report of continence or improvement of urinary incontinence at 3, 6 
and 9 months after randomisation, and improvement at 12 months 
•  Number of incontinent episodes in previous week (objective, from diary) 
•  Duration of incontinence (based on time of resolution relative to time of 
operation and randomisation)
* 
•  Use of absorbent pads, penile collecting sheath, bladder catheter or bed/chair 
pads 
•  Number and type of incontinence products used 
•  Co-existence, cure or development of urgency or urge incontinence  
•  Urinary frequency 
•  Nocturia 
•  Faecal incontinence (passive or urge) 
•  Other bowel dysfunction (urgency, constipation, other bowel diseases) 
•  Sexual function at 12 months (including information about erection,   
ejaculation, retrograde ejaculation, pain, change in sex life and reason for 
change) 
Quality of life 
•  Incontinence-specific quality of life outcome measure (10-point scale, ICI 
questionnaire (http://www.iciq.net/)  
•  General health measures (SF-12,
13 EQ-5D
12)  
Use of health services for urinary incontinence  
•  Need for alternative management for incontinence (e.g. surgery, drugs)  
•  Use of GP, nurse, consultant urologist, physiotherapist 
Other use of health services  
•  Visits to GP 
•  Visits to practice nurse 
                                                 
* We will obtain an estimate from the men who become dry of when they became dry – both by asking 
them to name the month they were last wet, and for how many months after their operation were they 
wet, as well as by the change in the 3-monthly diaries, from wet to dry. 280 Appendix 6
Effects of interventions 
•  Use of PFMT 
•  Lifestyle changes (weight, constipation, lifting, coughing, exercise)  
Economic measures 
•  Patient costs [e.g. self-care (e.g. pads, laundry), travel to health services, sick 
leave] 
•  Cost of conservative trial treatment  
•  Cost of alternative or additional NHS treatments [e.g. pads, catheters, drugs 
(e.g.  adrenergic agonists, anticholinergics, oral medication for erectile 
dysfunction), hospital admissions or further surgery]  
•  Other measures of cost-effectiveness (e.g.  incremental cost per additional 
man continent at 12 months) 
 
The ways in which these data will be analysed are set out in Appendix VII  (Dummy 
Tabulations).   
 
It is anticipated that the data generated by the study, along with other focused data 
collection sets, may be used as a basis for exploratory or epidemiological research, 
but these will be described in separate protocols.   
 
6.3  Timing and frequency of analyses 
A single principal analysis is anticipated at 15 months after the last man is recruited 
(at month 48).  The Data Monitoring Committee will determine the frequency of 
confidential interim analyses, but at present these are planned on three occasions 
during the data collection period (at months 16, 28 and 35).   
 
6.4  Planned secondary subgroup analyses 
The two populations of men (having radical prostatectomy or transurethral resection) 
will be analysed as separate trials as shown above in section 6.1.   
 
Subgroup analyses (separately for  the two populations) will explore the effect on 
urinary incontinence at 12 months after randomisation of:  
1.  pre-existing urinary incontinence (before prostate surgery) 
2.  age (up to 70, 71 and over) 
3.  type of incontinence at trial entry (stress, urge, mixed, other) 
4.  body mass index up to 30, 30–34.9, 35 or greater 
5.  centres with and without biofeedback machines 
6.  type of therapist (physiotherapist or nurse) 
7.  other morbidity/treatment for other morbidity 
 
Stricter levels of statistical significance (2p<0.01) will be sought, reflecting the 
exploratory nature of these analyses.   
 
All study analyses will be according to a statistical analysis plan that will be agreed in 
advance by the MAPS Steering Committee.   
 
6.5  Economic analysis 
Both trials (radical prostatectomy or transurethral resection of prostate) will include a 
formal economic evaluation.   Resource use and costs will be estimated for every trial 
participant.  Resource-use data collected will include the intervention and the use of 
primary and secondary NHS services  by the men including referral for specialist 
management.  Personal costs to the men (such as use of pads or work/social 
restrictions) will also be described.  Thus the point of view adopted is that of the NHS 
and the patient.   
 
6.5.1  Collection of data 
At each time point of contact during the study (baseline and 3, 6, 9 and 12 months 
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(via the health care utilisation questions,  Appendix VI).  At baseline, 6 and 12 
months, they will complete the SF-12 and EQ-5D.  Midway through the trial (at 6 
months after randomisation), a questionnaire survey of all men will be used to 
ascribe costs to typical episodes of such health service use (the Health Care Unit 
Cost Questionnaire, Appendix VI).  The underlying aim is to keep economic data 
collection as parsimonious as possible to minimise the burden on the men and the 
effect on response rates.   
 
6.5.2  Participant costs of urinary incontinence  
Participant costs will comprise three main elements: self-purchased health  care; 
travel costs for making return visit(s) to NHS health care; and time costs of travelling 
and attending NHS health care.   
•  Self-purchased health care is likely to include items such as pads bought by 
the participant, prescription costs and over-the-counter  medications.  
Information about these will be collected through the health care utilisation 
questions (see 6.5.1 above).   
•  Estimation of travel costs requires information from participants about the 
number of visits to, for example, their GP or physiotherapist (estimated from 
the health care utilisation questions) and the unit cost of making a return 
journey to each type of health care provider (from the Participant Unit Cost 
Questionnaire, Appendix VI).    
•  The cost  of participant time will be estimated in a similar manner.  The 
participant will be asked, in the Participant Unit Cost Questionnaire, how long 
they spent travelling to and attending their last visit to each type of health care 
provider.  Participants will also be asked what activity they would have been 
undertaking (e.g. paid work, leisure, housework) had they not attended the 
health care provider.  These data will be presented in their natural units, e.g. 
hours, and also costed using standard economic conventions, e.g. the 
Department of Transport estimates for the value of leisure time.  These unit 
time costs, measured in terms of their natural and monetary terms, will then 
be combined with estimates of number of health care contacts derived from 
the health care utilisation questions. 
 
6.5.3  Costs of intervention 
Health service costs incurred as the consequence of the intervention will be recorded 
prospectively for every participant in the study.  Main areas of costs will be: staffing 
(four sessions with the therapist), capital costs (buildings and equipment), and 
consumables (probes for biofeedback, pads).   
 
6.5.4  NHS costs of other health services used 
•  Consumables (drugs, pads, etc.) 
•  Staff time (GP, nurse, consultants) 
•  Outpatient visits 
•  Hospital admissions (operations, other) 
 
6.5.5  Cost-effectiveness 
Effectiveness within the trials will be measured in terms of quality-adjusted life-years 
(QALYs) and subjective continence at 12 months (assessed using data from the ICI 
questionnaire).  QALYs will be estimated by combining estimated quantity of life, with 
quality of life derived from the EQ-5D questionnaire (administered at baseline, 6 and 
12 months) and UK tariffs.  The estimation of QALYs will take account of the mortality 
of study participants.  Participants who die within the study follow-up will be assigned 
a zero utility weight from their death until the end of the study follow-up.  QALYs 
before death will be estimated using linear extrapolation between the QALY scores at 
baseline and all available EQ-5D scores up to death.  The method of eliciting QALYs 
described is one commonly adopted in economic evaluation.   
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The primary analysis is based on the 1-year follow-up of the trial and two outcomes 
have been specified.  These are incremental cost per additional man continent and 
incremental cost per QALY.  The former outcome has been chosen to facilitate 
understanding of the findings amongst health care professionals while the second 
measure, the primary economic outcome, has been chosen to reflect a societal 
decision-making perspective.  The results will be presented as point estimates of 
mean incremental costs, proportion of men continent, QALYs, and cost per man 
continent or per QALY.  Measures of variance for these outcomes are likely to 
involve bootstrapping estimates of costs, proportion of men continent, QALYs, and 
incremental cost per additional man continent and per QALY.  Incremental cost-
effectiveness data will be presented in terms of cost-effectiveness acceptability 
curves (CEACs).   
 
Other forms  of uncertainty, e.g. concerning the unit cost of a resource, will be 
addressed using standard deterministic sensitivity analysis.  The results of the 
sensitivity analyses will also be presented as CEACs.  Further sensitivity analysis will 
be conducted to consider the effect of differential timing over which treatments may 
be given.  These data are likely to prove useful for the economic model. 
 
6.5.6  Modelling 
While the within study results will prove useful it is important to note that incontinence 
is a chronic condition and the effects of treatment on costs and outcomes may persist 
into the future.  Therefore, assuming that one intervention is not dominant (less costly 
but more effective at 12 months), additional useful information for policy makers will 
be derived from an economic model that considers a longer time horizon.  In the 
model, the findings of the trial will be extrapolated to the patient’s lifetime.  The model 
will describe the change in levels of incontinence over the patient's lifetime following 
the start of treatment.  The structure of the model will be developed in collaboration 
with clinicians and trial collaborators, and parameter estimates for costs and utilities 
will be derived from the trial data.   
 
In order to extrapolate estimates of cost-effectiveness to a longer time horizon (e.g. 
the participant’s lifetime) than that considered by the trial, a modelling exercise will be 
developed. The model will be populated using individual patient data from the study 
as well as both published and unpublished evidence in the field.  The methods used 
to assemble additional data will follow recognised methodology, which will vary 
according to the type of parameter, extent of uncertainty and role within the model.  
Therefore, comprehensive systematic searching will be limited to those parameters 
to which the results of the model are likely to be particularly sensitive.  The modelling 
exercise will comply with recent recommendations on good practice for modelling
14 
and the results will be presented in terms of incremental cost per continent man and 
incremental cost per QALY gained.   
 
Estimates of mortality will be based on data from life tables.  As the model will be 
constructed to estimate outcomes both for men with benign disease and for men with 
prostate cancer, mortality rates will be adjusted, where necessary, using relative risks 
of mortality for prostate cancer.  These data will be obtained from the literature and 
from an on-going study within the Health Economics Research Unit in Aberdeen that 
is looking at the cost-effectiveness of screening for prostate cancer.  
 
Outcomes in the model will be expressed in terms of an incremental cost per QALY.  
Parameter uncertainty will be integrated by the incorporation of probability 
distributions into the model and involving Monte Carlo simulation.  Other forms of 
uncertainty such as that associated with choices made about the structure of the 
model, discount rate, etc., will be addressed though sensitivity analysis.  The base-
case and sensitivity analyses will be presented as CEACs.   
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7.  SAMPLE SIZE AND FEASIBILITY 
7.1  Sample size sought  
Based on the aim to detect a difference between intervention and control groups of 
15% (70% to 85%) in the number of men no longer incontinent, we will need 174 
men per arm of the trial to give 90% power to detect a significant difference at the 5% 
level.  This will allow detection of a difference of 0.30 of a standard deviation at 80% 
power for continuous measures such as quality of life.  Should the proportion of men 
no longer incontinent be less than 70% we shall still have 80% power to detect a 
15% change from 60% to 75%.   
 
Table 1 below is an extrapolation to show the number of men who will need to be 
approached and hence the number of ‘typical sized’ clinical centres that will be 
required.  Allowing for a 13% dropout rate after enrolment in the RCT, we plan to 
recruit 200 men per arm.  There will thus be 400 men in each of the two parallel trials 
who would come from 615 incontinent men assuming that 65% agree to join the trial.  
Based on conservative assumptions of 50% and 5% incontinent at 6 weeks after 
radical prostatectomy and endoscopic resection of prostate, respectively, and 80% 
response rates to the screening questionnaire, 1,540 and 15,400 men will need to be 
approached.    If a typical centre undertakes 30 radical prostatectomies and 300 
endoscopic resections of prostate each year, about 26 centres will be required for 
each trial recruiting over an average of 2 years.   
 
In summary, Table 1 shows that we will need to screen around 17,000 men in Stage 
1 of the study, making conservative assumptions about likely response and 
participation rates.  Based on these figures, a 2-year recruitment period in 26 centres 
will be needed.   
 
Table 1    Recruitment numbers needed 
 
  Radical prostatectomy  Transurethral 
resection 
Men needed per arm (minimum)  174  174 
Allowing for 13% dropout  200  200 
Total men needed in two arms  400  400 
Assuming 65% willing to enter RCT, 
no. incontinent men needed 
615  615 
% incontinent at 6 weeks (Stage 2)  50%  5% 
No. of men needed to reply to 
survey 
1230  12,300 
Assuming 80% response to survey, 
no. needed for survey (Stage 1) 
1540 (approx)  15,400 (approx) 
No. of operations per typical centre  30  300 
No. of typical centres needed in 2 
years 
26  26 
     
 
7.2  Recruitment rates 
Figure 1 shows the projected recruitment of centres and participants, and projected 
number of men who would be approached.  Three centres will be established 
relatively early in the project (by 5 months) followed by roll-out to the others over the 
subsequent 10 months.   
 
The participant recruitment graph in Figure 1 has been modelled to take into account: 
the phased roll-out to the centres over the first 15 months; that there will be lags 
between the approach to men when they are in hospital and the despatch of the 
‘screening’ questionnaire and between the despatch of the screening questionnaire 
and trial recruitment; and that there are likely to be fewer prostatectomies around 
August and over Christmas (due to holidays).  Recruitment continues after the final 284 Appendix 6
screening questionnaires have been sent out because of these ‘lags’.  The lines for 
the two trials (radical prostatectomy and endoscopic resection of prostate) are 
superimposed because their rates of recruitment are expected to be similar.   
 
 
Figure 1    Projected recruitment chart 
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In summary, we originally aimed to recruit an average of 8 men to the randomised 
trial per week over a 2-year period.  We estimated that if we had 26 centres, that 
would have amounted to 30 men per centre in 2 years, half of whom (around 15 in 2 
years, or 8 per year) will be randomised to active therapy.  In order to achieve this, 
we estimated that approximately 7 men per centre will need to be screened each 
week for 2 years.  As the recruitment period was extended by 9 months in May 2007 
(by the HTA) recruitment targets have altered since these original projections –the 
graph above therefore now reflects both the original and the extended recruitment 
periods.   
 
8  ORGANISATION 
A detailed plan and timetable of study organisation is given in the Gantt chart 
(Appendix VIII).  In summary, it is as follows – 1–4 months: set up office, assemble 
team, and establish first centre; 5–15 months: establish study in all 26 centres; 5–36 
months: identify and recruit 800 men with urinary incontinence (average 24 months in 
each centre); 13–48 months: follow up at 6 and 12 months after randomisation;   
49–54 months: complete data collection, analysis and dissemination. In the light of 
the revised recruitment period (the 9-month extension) the Gantt chart has also been 
revised (Version 6 protocol). 
 
The Gantt chart also shows when we expect the major study events to occur, 
including recruitment, study progress and meetings.  There will be 3-monthly project 
management meetings, five meetings of the Steering Committee and four of the Data 
Monitoring Committee.  Two meetings are planned for collaborators (including 
urologists, therapists, local recruitment officers and consumer participants), the first 
timed to occur when all the sites have been identified and the second when results 
are available.  Four Training Meetings will be held to train the therapists during the 
course of the first year. Remote training of any other thepaists unable to attend these 
days will occur as and when applicable.  
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Based on this chart, the specific, time-related milestones given in Appendix VII will be 
used to allow close monitoring of progress. 
 
8.1  Local organisation in centres  
i)  Lead Urologist (Local Principal Investigator) 
Each collaborating centre will identify a Lead Urologist who will be the point of 
contact for that centre.  The responsibilities of this person will be to: 
•  establish the study locally [for example by getting agreement from clinical 
colleagues; facilitate local research ethics committee approval (LREC); liaise 
with R&D department; identify and appoint a local Recruitment Officer; and 
inform all relevant local staff about the study (e.g. secretaries, ward staff)] 
•  take responsibility for clinical aspects of the study locally (for example if any 
particular concerns occur) 
•  notify the Study Office of any unexpected clinical events which might be 
related to study participation 
•  provide support and supervision for the local Recruitment Officer 
•  represent the centre at the collaborators’ meeting 
 
ii)  Local Recruitment Officer 
Each collaborating centre will appoint a local Recruitment Officer to organise the day-
to-day recruitment of men to Stage 1 of the study (the Screening Survey).  The 
responsibilities of this person will be to: 
•  keep regular contact with the local Lead Urologist, with notification of any 
problem or unexpected development 
•  maintain regular contact with the Study Office 
•  keep local staff informed of progress in the study 
•  contact potential participants by: organising  mailing out of  the Patient 
Information Sheet to men being admitted electively for prostate surgery; 
identifying all eligible men on the ward while they are in hospital for their 
prostate surgery; explaining the screening study and the potential for 
participation in a trial if they are incontinent after surgery; explaining what is 
intended by research access to their NHS data; and describing the possibility 
of long-term follow-up whether or not they are incontinent 
•  obtain the men’s written consent to being sent a screening questionnaire 
•  keep a log of whether eligible men are recruited or not (with reasons for non-
participation) (Appendix I) 
•  collect baseline data describing the men (Appendix I), and send these to the 
Study Office along with the signed consent forms (Appendix I) 
•  organise and supervise alternative recruiters in case of holiday or absence 
•  represent the centre at the collaborators’ meeting 
 
iii)  Therapists and training  
Each collaborating centre will identify a Lead Therapist who will be responsible for 
co-ordinating the active intervention at a local level.  (S)he will identify the local 
therapist who will carry out the intervention, or may assume this role personally.  The 
therapist may be a specialist physiotherapist or continence nurse specialist.  The 
therapist will attend a Training Day (led by Professor Grace Dorey) to ensure 
consistency of training and intervention in each centre.  There will be four Training 
Days at a range of locations throughout the UK during the setting-up phase of the 
study.   
 
The therapist will use standard study instruction materials and documentation, which 
will be provided by the Study Office.  The Study Office will also be the first point of 
contact for the therapist in case of problems, concerns, adverse effects or need for 
advice.   
 
The responsibilities of the therapist will be to: 286 Appendix 6
•  attend a training day to become familiar with the standard method of teaching 
the men and the standard study documentation  
•  contact men allocated to the active arm by sending them an initial 
appointment (for one hour), and repeat three-quarter-hour appointments at 2, 
6 and 12 weeks thereafter 
•  notify the Study Office if men fail to attend: a phone number will be provided 
for this purpose  
•  notify the Study Office of any unexpected clinical events which might be 
related to study participation 
•  teach all the men pelvic floor muscle training, using digital anal biofeedback to 
reinforce correct contractions 
•  use machine biofeedback with an anal probe if, in their opinion, it is clinically 
indicated (and a machine is available) 
•  teach bladder training to men who have urge incontinence 
•  provide other lifestyle advice as appropriate  
•  record the details of the treatment and response to treatment at each visit 
using standard study documentation (assessment and treatment forms, 
Appendix V) 
•  return the assessment and treatment forms to the Study Office at the end of 
each man’s 3-month treatment period 
•  support the men in adhering to treatment  
•  represent the centre at the collaborators’ meeting 
 
iv)  Other training materials 
We hope also to provide an interactive CD-rom instruction and reminder package 
both to supplement the main Training Day teaching, and in case some therapists 
cannot attend or if staff changes result in new therapists being appointed.   
 
It may be possible to amend this material for use in training other NHS staff after the 
trial is finished if the intervention is effective.   
 
8.2  Study co-ordination in Aberdeen 
i)  The Study Office Team 
The Study Office is in the Health Services Research Unit in Aberdeen and provides 
day-to-day support for the clinical centres.  It is responsible for all data collection 
(such as mailing questionnaires), follow-up, data processing and analysis.  It is also 
responsible for randomisation, despatch of Lifestyle Booklets and communicating 
with the therapists about men allocated to active treatment.  Finally, we intend to 
produce a yearly MAPS Newsletter for participants and collaborators to inform 
everyone of progress and maintain enthusiasm.   
 
The MAPS Study Office Team will meet formally at least monthly during the course of 
the study to ensure smooth running and trouble-shooting.   
 
ii)  The Project Management Group 
The study is supervised by its Project Management Group.  This consists of the grant 
holders and representatives from the Study Office.  Observers may be invited to 
attend at the discretion of the Project Management Group.  We plan to meet every  
3 months on average.   
 
iii)  The Steering Committee 
The study is overseen by an independent Steering Committee.  The Chairman is 
Professor Paul Abrams, with  Mrs Jane Dixon and Professor David Torgerson as 
other independent members appointed by the HTA.  The other members are the 
grant  holders.  Observers or members of the host university (Aberdeen) and the 
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Management Group or members of other professional bodies at the invitation of the 
Chair.   
 
8.3  Research Governance, EU Directives, Data Protection and Sponsorship 
 
i)  Research Governance, EU Directive 
The trial will be conducted in compliance with the EU Clinical Trials Directive (EU-
CTD, 1 May 2004) although it does not come within the scope of the Directive.  Other 
studies associated with the trial will either be conducted in compliance with the EU 
Clinical Trials Directive (1 May 2004) or in line with local implementation of Research 
Governance to at least the standard of the Aberdeen University policy on Research 
Governance (http://www.abdn.ac.uk/iahs/research-governance/index.shtml).   
 
ii)  Sponsorship 
Before April 2007 the sponsorship for these studies (RCT and observational) was the 
Department of Health, UK. Their duties as sponsors were co-ordinated through the 
National Coordinating Centre for Health Technology Assessment (NCCHTA) in 
Southampton. In April 2007 sponsorship responsibility was transferred from the 
NCCHTA to the host institution, the University of Aberdeen. 
 
Responsibility for transacting Part 3 of the EU-CTD (study initiation and finance), Part 
IV (Compliance with Good Clinical Practice) and Part V (Pharmacovigilance) will be 
delegated to the Chief Investigators, Dr James N’Dow and Dr Cathryn Glazener at 
Aberdeen University.  They will ensure, through the Steering Committee, that 
adequate systems are in place for monitoring the quality of the study (compliance 
with GCP) and appropriate expedited and routine reports of adverse effects, to a 
level appropriate to the risk–benefit assessment of the trials.   
 
iii)  Data Protection 
All data collected and stored within the study will comply with the Data Protection Act.   
 
8.4  Data and safety monitoring  
i)  Data Monitoring Committee 
A Data Monitoring Committee (DMC) will be established.  This will be independent of 
the study organisers.  During the period of recruitment to the study, interim analyses 
will be supplied, in strict confidence, to the Data Monitoring Committee, together with 
any other analyses that the committee may request.  This may include analyses of 
data from other comparable trials.  In the light of these interim analyses, the Data 
Monitoring Committee will advise the Steering Committee if, in its view:   
a)  the active intervention has been proved, beyond reasonable doubt,
*  to be 
different from the control (standard management) for all or some types of 
men, and  
b)  the evidence on the economic outcomes is sufficient to guide a decision from 
health care providers regarding recommendation of this service development.   
 
The Steering Committee can then decide whether or not to modify intake to the trial.  
Unless this happens, however, the Steering Committee, Project Management Group, 
clinical collaborators and study office staff (except those who supply the confidential 
analyses) will remain ignorant of the interim results.   
 
The frequency of interim analyses will depend on the judgement of the Chairman of 
the Committee, in consultation with the Steering Committee.  However, we anticipate 
that there might be three interim analyses and one final analysis.   
 
                                                 
* Appropriate criteria for proof beyond reasonable doubt cannot be specified precisely.  A difference of 
at least three standard deviations in the interim analysis of a major end point may be needed to justify 
halting, or modifying, such a study prematurely (Peto R et al., Br J Cancer 1976;34:548–612).   288 Appendix 6
The Chairman is Professor Peter Langhorne, with Mrs Julia Brown, Mr Thomas 
McNicholas and Professor Christine Norton as other independent members, to be 
appointed after confirmation by the HTA.   
 
 
ii)  Safety concerns 
The MAPS trial involves conservative interventions which are well established in 
clinical practice, although unproven regarding effectiveness for men after 
prostatectomy.  We do not anticipate any adverse effects, but would respond 
appropriately to any notification.   
 
Collaborators and participants may contact the chairman of the Steering Committee  
through the Study Office about any concerns they may have about the study.  If 
concerns arise about procedures, participants or clinical or research staff (including 
risks to staff) these will be relayed to the Chairman of the Data Monitoring 
Committee.   
 
As the trial arm to which men are allocated cannot be blind after randomisation has 
occurred, unblinding is not an issue in this trial.   
 
The Multicentre Research Ethics Committee for Scotland has approved the study for 
the UK (ref MREC/04/10/01).  The study will be conducted according to the principles 
of good practice provided by Research Governance Guidelines.   
 
9.  FINANCE 
The study is supported by a grant from the NHS R&D National Coordinating Centre 
for Health Technology Assessment (NCCHTA) (ref 03/14/03).   
 
10.  EXPLANATORY STUDIES 
The funds provided by the NCCHTA are to conduct the screening survey (Stage 1) 
and the randomised controlled trial (Stage 2) as described in this protocol.  It is 
recognised, however, that the value of the study will be enhanced by smaller ancillary 
studies of specific aspects.  Plans for some of these are being submitted to other 
grant funding bodies.  Further suggestions would be welcome and should be 
discussed in advance with the Project Management Group and agreed with the 
NCCHTA.  MREC approval will be sought for any new proposals.   
 
11.  INDEMNITY 
The Patient Information Sheet provides the following statement regarding indemnity 
for negligent and non-negligent harm: 
 
‘We do not expect any harm to come to you by taking part in this study.   
However, if you are harmed by taking part in this research project, there are 
no special compensation arrangements.  If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms (which includes professional indemnity insurance) would be 
available to you.’   
 
In addition, the universities involved with this study hold and maintain a ‘no fault’ 
insurance policy.  This policy covers all employees of the universities and those 
working under their direction.   
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12.  PUBLICATION 
The success of the study depends entirely on the wholehearted collaboration of a 
large number of men undergoing prostate surgery, as well as therapists, nurses and 
doctors.  For this reason, chief credit for the study will be given, not to the 
committees or central organisers, but to all those who have collaborated in the study.  
The study’s publication policy is described in detail in Appendix IX.  The results of the 
study will be reported first to study collaborators.  The main report will be drafted by 
the Project Management Group and circulated to all clinical co-ordinators for 
comment.  The final version will be agreed by the Steering Committee before 
submission for publication, on behalf of all the MAPS collaborators.    
 
To safeguard the integrity of the main trial, reports of explanatory or satellite studies 
will not be submitted for publication without prior agreement from the Project 
Management Group.   
 
We intend to maintain interest in the study by publication of MAPS Newsletters at 
intervals for participants, staff and collaborators.  Once the main report has been 
published, a lay summary of the findings will be sent in a final MAPS Newsletter to all 
involved in the trial.   
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